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Abstract 
Synovial fibroblasts and macrophages are incriminated in rheumatoid arthritis 
(RA) but the interactions between these cells and the roles of cellular subsets are 
only partially understood. To address this, fibroblasts isolated from normal, 
resolving arthritis, very early RA, established RA, and longer duration RA patients 
were co-cultured in vitro with myeloid cells; synovial fibroblast and macrophage 
subsets were identified, and the transcriptomes of synovial cells were analysed. 
Co-culture of fibroblasts and monocytes elicited an increase in IL-6 release and 
a reduction in CCL2/CCL4 levels. No difference in response was elicited by 
fibroblasts from different stages of RA. 
Fibroblast and macrophage markers were defined in frozen tissue sections. A 
synovial tissue digestion protocol was then developed and used to isolate 
synovial cells. Fibroblast and macrophage populations were identified and the 
proportions of fibroblast subsets correlated with clinical variables. Transcriptional 
analysis identified differentially expressed genes between fibroblast subsets and 
one distinct macrophage population. 
Analysis of previously generated transcriptome data for fibroblasts from RA 
stages identified cassettes of genes differentially expressed at each disease 
stage. 
This work expands previous findings on fibroblast function by beginning to assign 
functions to subsets and demonstrating that fibroblasts from stages of RA have 
distinct gene expression. 
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1 INTRODUCTION 
1.1  Rheumatoid Arthritis 
1.1.1 Clinical manifestations 
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial 
joints of the body causing damage and destruction of articular cartilage and the 
underlying bone and manifesting itself as morning stiffness, fatigue, and swelling 
and tenderness of affected joints. Due to the presence of autoantibodies directed 
against immune complexes and citrullinated proteins in around two thirds of 
patients with the disease, RA is frequently classified as an autoimmune disease 
(Schellekens et al., 1998). RA has a prevalence in the UK population of 
approximately 1% with the disease being 3 times more likely to affect women 
than men (Symmons et al., 2002). Patients also suffer from systemic 
comorbidities with an increased prevalence of cardiovascular disease being one 
of the most common, occurring in around 6% of people with RA (Dougados et al., 
2013). Additionally, due to the immunosuppressive nature of treatments for RA, 
patients are at an increased risk of infection (Listing.,Gerhold and Zink, 2013). 
 
The progression of RA is heterogeneous with some patients suffering a low-level 
of inflammation and joint damage while others suffer a highly inflammatory, 
aggressive disease rapidly leading to joint destruction (Wolfe and Sharp, 1998). 
This heterogeneity is reflected in the broad range of criteria used to classify 
inflammatory arthritis as definite RA and in the difficulty in diagnosing newly 
presenting arthritis (Table 1) (Aletaha et al., 2010; Machold et al., 2002).Indeed 
it may be more appropriate to view RA as a syndrome with several distinct 
pathologies as evidenced by the variability of autoantibody status, genetic risk 
factors, and in the distinct differences in disease manifestations visible in 
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histological samples of RA synovial tissue (Dennis et al., 2014; Van Der Helm-
Van Mil, Annette Hm and Huizinga, 2008; Van Oosterhout et al., 2008). 
 
 Score 
Target population (who should be tested?): patients who 
 1) have at least one joint with definite clinical synovitis (swelling) 
 2) with the synovitis not better explained by another disease 
Classification criteria for RA (score-based algorithm: add score of categories A–D 
a score of ≥6/10 is needed for classification of a patient as having definite RA)  
 A. Joint involvement 
  1 large joint 0 
  2−10 large joints 1 
  1−3 small joints (with or without involvement of large joints)  2 
  4−10 small joints (with or without involvement of large joints) 3 
  >10 joints (at least one small joint)  5 
 B. Serology (at least 1 test result is needed for classification)  
  Negative RF and negative ACPA 0 
  Low-positive RF or low-positive ACPA 2 
  High-positive RF or high-positive ACPA 3 
 C. Acute-phase reactants (at least one test result is needed for classification)  
  Normal CRP and normal ESR 0 
       Abnormal CRP or abnormal ESR 1 
 D. Duration of symptoms  
  <6 weeks 0 
  ≥6 weeks 1 
Table 1: ACR/EULAR 2010 classification criteria for Rheumatoid Arthritis  adapted 
from (Aletaha et al., 2010). RA = rheumatoid arthritis, RF = rheumatoid factor, 
ACPA = anti-citrullinated protein antibody, CRP = C-reactive protein, ESR = 
erythrocyte sedimentation rate. 
 
The primary sites in which the signs of RA manifest are the synovial joints of the 
body such as knees and elbows and also the smaller joints of the hands and feet 
(Smolen, Aletaha and Mcinnes, 2016). Healthy synovial joints consist of a fluid-
filled space into which the two bones of the joint protrude, the termini of which are 
capped in a protective layer of articular cartilage (Figure 3). The joint space is 
enclosed within a fibrous capsule lined on the interior by a thin synovial tissue 
(synovium) which interfaces around the margin of the joint at the junction of the 
bone and articular cartilage. Under homeostatic conditions the synovium 
produces and maintains a small volume of synovial fluid rich in lubricants such as 
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hyaluronic acid and regulates extracellular matrix turnover to facilitate normal joint 
function (Smith, 2011).  
 
1.2 Treatment 
The treatment of RA is complex with no single treatment being suitable for all 
patients reflecting the heterogeneity of the disease. The current treatment 
approach recommended by the European League Against Rheumatism (EULAR) 
is to start treatment as early as possible with the disease modifying anti-rheumatic 
drugs (DMARDs) methotrexate or leflunomide/sulfasalazine possibly in 
combination with glucocorticoids (Figure 1 (Smolen et al., 2017)). Early treatment 
is particularly important for RA patients as several studies have found that early 
treatment of RA, possibly within 3 months of symptom onset, results in an 
improvement in disease course with patients showing less joint damage 
(radiological progression) and taking a longer time to the point of requiring 
surgical joint replacement (Kyburz et al., 2011; Moura et al., 2015; Nell et al., 
2004; Van Aken et al., 2004). 
 
If patients do not respond to treatment with DMARDs then it is recommended that 
patients move onto one of the biological DMARDs available such as infliximab or 
entanercept (tumour necrosis factor (TNF)-inhibitors) or rituximab (targeting B 
cells) (Smolen et al., 2017). Unfortunately, not all patients respond adequately to 
treatment with biologics and often treatment becomes an approach of trialing 
different biologics which is an inadequate method by which to treat patients and 
as such finding biomarkers that predict response to treatment is a current priority 
of research (Chen, Y. F. et al., 2006; Greenberg et al., 2008; Hyrich et al., 2006; 
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Smolen et al., 2017). 
 
Figure 1: ‘Algorithm based on the 2016 European League against Rheumatism 
(EULAR) recommendations on rheumatoid arthritis (RA) management’ taken from 
Smolen et al. (2017). RF = rheumatoid factor, ACPA = anti-citrullinated protein 
antibody, DMARD = disease modifying anti-rheumatic drug, csDMARD = 
conventional synthetic DMARD, bDMARD = biological DMARD, tsDMARD = 
targeted synthetic DMARD, IL-6 = interleukin-6, TNF = tumour necrosis factor, Jak 
= Janus kinase. 
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New treatments targeting epigenetic aspects are being researched as an 
alternative to the traditional DMARDs and biological DMARDs in an attempt to 
not just limit inflammation but possibly reverse any epigenetic changes elicited by 
RA. Treating fibroblasts in vitro with Trichostatin A, a histone deacetylase 
inhibitor, inhibits progression through the cell cycle and also sensitises the 
fibroblasts to apoptosis induced by TNF-related apoptosis-inducing ligand 
(Jungel et al., 2006). In the murine collagen-induced arthritis model treatment 
with Trichostatin A significantly reduced arthritis as measured by a clinical score 
and synovial inflammation and cartilage damage measured by histology (Nasu et 
al., 2008). In humans the histone deacetylase inhibitor givinostat was used to 
treat juvenile idiopathic arthritis patients and successfully reduced swollen and 
tender joint counts but unfortunately had many adverse effects on patients such 
as vomiting, nausea, and fatigue (Vojinovic et al., 2011). 
 
1.3 Pathophysiology 
1.3.1 Aetiology 
The aetiology of RA is unknown however genetic and environmental factors are 
known to increase predisposition for the disease. For example, tobacco smoking 
is associated with an increased risk of developing RA with anti-cyclic citrullinated 
peptide (anti-CCP) antibodies present in the circulation whereas obesity is 
associated with anti-CCP negative RA (Pedersen et al., 2006; Silman, Newman 
and Macgregor, 1996). There are also suggestions of a link between infections 
with organisms such as Porphyromonas gingivalis and the development of RA 
(Mikuls et al., 2014; Totaro et al., 2013). 
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Anti-CCP antibodies are a subset of anti-citrullinated protein antibodies (ACPA) 
(Ioan-Facsinay et al., 2011). During tissue damage and immune cell activation 
there is an increase in citrullination, the conversion of arginine residues to 
citrulline, of native proteins such as fibrinogen and α-Enolase. In RA patients an 
autoimmune response occurs targeting these neoepitopes with the production of 
ACPAs which can in turn drive bone loss through the differentiation of osteoclasts 
(Harre et al., 2012; Kinloch et al., 2005; Lundberg et al., 2008; Masson-Bessiere 
et al., 2001). The risk of developing ACPA-positive RA is associated with the 
presence of human leukocyte antigen (HLA) class II ‘shared-epitope’ alleles and 
this is believed to be due to an increased affinity of the MHC II proteins encoded 
by the shared epitope for citrullinated peptides which leads to the activation of the 
adaptive arm of the immune system (Gibofsky et al., 1978; Gregersen, Silver and 
Winchester, 1987; Hill et al., 2003; James et al., 2010; Stastny, 1978; Van Der 
Helm-Van Mil et al., 2006). 
 
The contribution of genetic factors to RA is estimated to be around 60% with 
approximately 37% of this genetic contribution being attributable to HLA alleles 
(Deighton et al., 1989; Macgregor et al., 2000). However the impact of identified 
risk factors such as the presence of shared epitope alleles is not uniform across 
all subtypes of RA with the presence of one or more HLA-DRB1 shared epitope 
alleles in a patient being significantly associated with an increased risk for anti-
CCP positive RA but not anti-CCP negative RA and having no significant 
association with the presence or absence of Rheumatoid Factor (RF), another 
autoantibody implicated in RA (Bukhari et al., 2002; Huizinga et al., 2005; Van 
Der Helm-Van Mil et al., 2006). Another genetic risk factor, the PTPN22 R620W 
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single nucleotide polymorphism, is associated with an increased risk of 
developing all types of RA and has been shown to enhance neutrophil activation 
in all people regardless disease status as well as potentially altering the signalling 
threshold required for T lymphocyte activation (Bayley et al., 2014; Begovich et 
al., 2004; De La Puerta et al., 2013; Källberg et al., 2007; Michou et al., 2007; 
Taylor et al., 2013; Van Oene et al., 2005; Vang et al., 2012). These alterations 
could possibly prime the immune system increasing the propensity to develop 
autoimmune reactions. 
 
There have been several studies providing evidence for the existence of further 
genetic risk factors associated with RA albeit often with conflicting findings 
between studies possibly due to the differences in methods and cohorts. Single 
nucleotide polymorphisms in the genomic region of the TRAF1 and C5 genes are 
significantly associated with an increased risk of developing anti-CCP positive RA 
in Dutch, North American, and Swedish cohorts and may also promote a more 
destructive disease course (Kurreeman et al., 2007; Plenge  et al., 2007). 
Interestingly, in the murine collagen-induced arthritis model knockout of the C5 
gene or prophylactic/therapeutic blocking of the function of C5 using an anti-C5 
antibody results in both a significant reduction in the incidence and the severity 
of arthritis to the point that there are no apparent histological differences between 
the synovium of healthy mice and those in which C5 was knocked out (Grant et 
al., 2002; Wang et al., 2000; Wang et al., 1995). Several prospective treatments 
are in development to target C5 or the C5a receptor in inflammatory diseases 
(Horiuchi et al., 2009). 
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Given the presence of autoantibodies targeting citrullinated peptides it is perhaps 
unsurprising that PADI4, an enzyme capable of citrullinating peptides, has been 
identified as another genetic risk factor for RA. Single nucleotide polymorphisms 
in the region of the PADI4 gene are significantly associated with an increased risk 
of developing RA in several Asian and European cohorts (Hoppe et al., 2006; 
Kang et al., 2006; Suzuki et al., 2003). Mechanistically, Suzuki et al. (2003) 
demonstrated that a single nucleotide polymorphism in the PADI4 gene that is 
particularly strongly associated with RA increases the stability of PADI4 
messenger ribonucleic acid (mRNA) offering a possible explanation for 
associations found. 
 
It is clear that RA is a multifactorial disease and that the aetiology is complex. It 
is also clear that the syndrome of signs and symptoms of RA defines a family of 
closely related disorders under the umbrella title of Rheumatoid Arthritis; it is 
important to be aware of this heterogeneity 
 
1.3.2 Physical manifestations 
The structure of the synovium can be divided into the intimal or lining layer, which 
is in juxtaposition with the synovial fluid, and an underlying subintimal or sublining 
layer (Figure 2). The cellular composition of these two regions within the 
synovium differ in that the sublining layer consists of loosely associated 
extracellular matrix, vascular structures, resident tissue macrophages, and 
synovial fibroblasts, whereas the lining layer forms a cellular membrane (although 
lacking a classical basement membrane) that consists of type-A synoviocytes 
(macrophage-like synoviocytes) and type-B synoviocytes (fibroblast-like 
synoviocytes) (Barland, Novikoff and Hamerman, 1962; Smith, 2011). 
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Figure 2: Schematic of the structure of normal synovium. The lining layer consists 
of tightly assocated fibroblasts and macrophages and is in juxtaposition with the 
joint space. The sublining layer is a loosely associated tissue consisting of 
fibroblasts and macrophages but is also penetrated by vessels. 
 
In RA the aforementioned structure of the synovial tissue is disturbed as the 
tissue enters a chronically inflamed state (Figure 3).The synovial sublining 
becomes increasingly vascularised with an accompanying increase in 
inflammatory infiltrate consisting of cells of both the innate and adaptive immune 
system. Additionally the thickness of the lining layer, normally 2-3 cells, becomes 
greatly increased leading to the formation of an invasive pannus tissue that 
damages the articular cartilage and the underlying bone (Barland, Novikoff and 
Hamerman, 1962; Fassbender and Simmling-Annefeld, 1983; Smith, 2011). 
 
 
Vessel 
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layer 
Sub-lining  
layer 
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Figure 3: Schematic of a synovial joint comparing normal joint status with an 
inflamed joint in RA. Adapted from Strand.,Kimberly and Isaacs (2007) 
 
 
1.3.3 Cellular Innate immunity 
Of the members of the innate immune system neutrophils are one of the cell types 
highly incriminated in the pathogenesis of RA. Neutrophil extracellular traps 
(NETs) are known to be elicited from neutrophils in the peripheral blood and 
synovial fluid of RA patients at an increased efficacy than from healthy controls 
or osteoarthritis patients and induce interleukin-6 (IL-6) and IL-8 expression in 
synovial fibroblasts (Khandpur et al., 2013; Sur Chowdhury et al., 2014). 
Interestingly in RA neutrophils higher nuclear levels of PADI4 are found along 
with increased levels of histone H3 citrullination and NETosis correlates with 
ACPA levels found in the patients indicating that neutrophils may be tightly 
involved with auto-antigen generation in RA. 
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Of the members of the innate immune cell family antigen-presenting cells (APCs) 
are of particular interest as they bridge the gap between the innate and adaptive 
immune system. Macrophages (and as macrophage progenitors, monocytes) are 
important APCs and as they are central to the work in this thesis will be discussed 
in more detail below. Due to their prominent role as antigen presenting cells and 
the auto-immune aspect of RA dendritic cells (DCs) are thought to be involved in 
RA. Both differentiated myeloid- and plasmacytoid-DCs and DC precursors have 
been found to accumulate in the synovial fluid of RA patients with the 
concentration of DCs being increased compared to the circulating DC 
concentration (Jongbloed et al., 2006; Zvaifler et al., 1985). DC progenitors in the 
synovial fluid can be differentiated into mature DCs with a potent ability to 
stimulate T helper 1 cell (Th1) responses using a combination of granulocyte-
macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF), 
stem cell factor (SCF), and IL-4 (Santiago-Schwarz et al., 2001). In addition to 
the accumulation in synovial fluid DCs also infiltrate the synovium and form 
perivascular clusters (Pettit et al., 2000). A point of particular interest is that DCs 
provided with synovial fluid from RA patients present collagen type II and cartilage 
gp39 and elicit responses from T cells (Tsark et al., 2002). 
 
1.3.4 Adaptive immunity 
With regards to the adaptive immune system both T and B lymphocytes have 
been implicated in RA pathogenesis. T and B cells are involved in the formation 
and maintenance of tertiary lymphoid organs; structures resembling germinal 
centres that develop in the synovium of a subset of RA patients and are thought 
to contribute to the autoimmune response in RA (Hjelmstrom et al., 2000; Wagner 
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et al., 1998; Young, et al., 1984). B lymphocytes may ultimately play a role in RA 
through differentiation into plasma cells which produce autoantibodies and B cells 
are also effective APCs. However a recently discovered subset of Fc receptor 
like protein 4 (FcRL4) expressing B cells present in the synovial fluid and tissue 
of RA patients may contribute to bone erosion through expression of the 
osteoclast differentiating cell surface molecule receptor activator of nuclear factor 
kappa-B ligand (RANKL) (Massey and Flanagan, 1999; Shipman, Dasoveanu 
and Lu, 2017; Yeo et al., 2015b; Yeo et al., 2011).  
 
A subset of IL-17 producing T cells termed Th17 cells are thought to contribute 
to the pathogenesis of RA as the cytokine is produced at higher levels in RA 
compared to osteoarthritis (OA) synovium and is known to induce IL-6 gene 
expression and also induce NETosis in neutrophils (Chabaud et al., 1999; 
Khandpur et al., 2013; Onishi and Gaffen, 2010; Veldhoen et al., 2006; Zrioual et 
al., 2008). IL-17 also increases the expression of Toll-like receptors (TLRs) 2, 3, 
and 4 on RA synovial fibroblasts (Lee et al., 2014). In the murine collagen-
induced arthritis model genetic knockout of IL-23 prevents the development of 
arthritis and results in a reduction in the number of Th17 cells, probably through 
an indirect reduction of circulating IL-6 and tissue growth factor beta (TGFβ) 
levels (Bettelli et al., 2006; Murphy et al., 2003). 
 
The anti-inflammatory regulatory T cell (Treg) population has also been 
implicated in RA. Treg cells normally act to restrain inflammation through the 
production of IL-10 and expression of the immune checkpoint protein cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) which inhibits APC activation 
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(Sakaguchi, 2004). Treg cells specific to heat shock protein 70 can suppress 
murine proteoglycan-induced arthritis demonstrating a therapeutic potential (Van 
Herwijnen et al., 2012). However CTLA-4 is downregulated on RA peripheral 
blood Treg cells and these cells respond inadequately to stimulation and are poor 
inhibitors of activated T cells and monocytes (Ehrenstein et al., 2004; Flores-
Borja et al., 2008). Anti-TNF treatment restores the regulatory capacity of the 
Treg cells and increases Treg cell counts in the peripheral blood of RA patients 
that respond to treatment. 
 
1.4 Monocytes, Macrophages, and Synovial Fibroblasts in Rheumatoid 
Arthritis 
1.4.1 Monocytes and Macrophages 
Monocytes and macrophages are cells of myeloid lineage of the innate arm of the 
immune system. Both are intricately linked to each other as certain subsets of 
macrophages are known to differentiate from monocytes. However, there are 
important differences in their phenotypes and differentiation potential that make 
it clear that they serve different functions in the body. 
 
Monocytes are peripheral blood borne mononuclear cells that patrol the 
vasculature and to some extent tissues as sentinels aiming to rapidly detect and 
respond to injury or infection (Meerschaert and Furie, 1994; Priller and Bottcher, 
2017; Sumagin et al., 2010). They are capable of producing a range of 
proinflammatory factors such as IL-1β, TNFα, and C-X-C motif ligand 8 (CXCL8) 
in response to stimuli inducing toll-like receptor 4 (TLR4) engagement and so are 
capable of initiating the immune response to invading organisms (De Waal 
Malefyt et al., 1991; Muller-Alouf et al., 1994). One of the most important functions 
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of monocytes lies in their capability to differentiate into cells such as 
macrophages and dendritic cells upon encountering stimuli such as GM-CSF, M-
CSF, and IL-4 allowing monocytes to act as a circulating pool of progenitor cells 
differentiating into other cells of the myeloid lineage as and when needed 
(Fleetwood et al., 2009; Fleetwood et al., 2007; Sallusto and Lanzavecchia, 
1994). 
 
Macrophages are mononuclear phagocytic cells, with key roles as professional 
antigen presenting cells, found in the tissues of the body. They are often one of 
the first cell types to encounter and respond to an insult, be it a pathogen or injury. 
They are capable of rapidly responding to damage and infection, recognising 
damage-associated molecular patterns (DAMPs) and pathogen-associated 
molecular pathogens (PAMPs) respectively through pattern recognition receptors 
(PRRs), triggering immune sentinel responses such as elaboration of cytokines 
(TNF-α, IL-1β) and chemokines (CXCL8, a hallmark neutrophil chemoattractant 
in early inflammation), the production of antimicrobial substances such as 
reactive oxygen species, phagocytosis, and ultimately bridging innate to adaptive 
immune responses through antigen presentation (Apostolopoulos, Davenport 
and Tipping, 1996; Ribeiro et al., 1991; Takeuchi and Akira, 2010). 
 
1.4.2 Monocyte and macrophage subsets 
Much is known regarding the phenotype and function of monocytes and 
macrophages but newer molecular biology techniques are revealing the 
existence of increasing numbers of cellular subsets, often with distinct functions, 
within both of these populations 
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1.4.2.1 Monocytes 
Monocytes are not a homogeneous population and were thought to consist of 
three subsets identified by levels of CD14 and CD16 expression, the proportions 
of which are altered in certain disease states, for example in active RA the 
intermediate CD14++CD16+ subset is expanded and is associated with an 
increase in the number of IL-17 producing T lymphocytes (Rossol et al., 2012; 
Wahl et al., 1992; Wong et al., 2011; Ziegler-Heitbrock et al., 2010; Ziegler-
Heitbrock and Hofer, 2013). The majority of published studies on human 
monocytes have used CD14 and CD16 to identify classical (CD14++CD16-), 
intermediate (CD14++CD16+), and non-classical (CD14+CD16++) subsets of 
monocytes (Figure 4) (Ziegler-Heitbrock et al., 2010; Ziegler-Heitbrock and Hofer, 
2013). In fact, recent single-cell RNA sequencing of human peripheral blood 
populations by Villani et al. (2017) has identified four distinct monocyte 
populations and indicates that the intermediate subset consists of two distinct 
monocyte populations along with classical and non-classical monocytes. 
 
 
Figure 4: A representative plot demonstrating three major human peripheral 
blood monocyte populations identified using CD14 and CD16 staining. A 
CD14++CD16- classical population, CD14++CD16+ intermediate population, and 
CD14+CD16++ population can be identified. Adapted from Ziegler-Heitbrock and 
Hofer (2013). 
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In homeostatic conditions classical monocytes constitute the majority of the 
circulating monocyte pool (approximately 92%) (Nockher and Scherberich, 
1998). Evidence indicates that the different monocyte subsets may represent 
progression from a less to a more terminally differentiated state from classical 
through to non-classical monocytes respectively (Wong et al., 2011). This is 
supported by a shift in the expression of genes towards less proliferation 
promoting genes and more pro-apoptotic genes which results in a 3-fold higher 
level of apoptosis in CD16+ monocytes than in the CD16- subset after 4 hours of 
in vitro culture with no additional stimuli or growth factors added (Malavez et al., 
2015). 
 
As well as the differences in surface CD14 and CD16 expression and the 
expression of proliferation and apoptosis associated genes, monocyte subsets 
also differ in the chemokines and cytokines that they express that hint at the 
different roles they may play in the immune response. In humans, nonclassical 
monocytes are thought to be a pro-inflammatory population as highlighted by their 
increased expression of genes associated with inflammation (TNF-α, IL-1β) in 
response to lipopolysaccharide when compared with the other monocyte 
subpopulations (Wong et al., 2011). Additionally, the CD14++CD16+ intermediate 
and nonclassical populations are found to be expanded in response to bacterial 
infections in haemodialysis patients and fall to baseline numbers concurrently 
with a reduction in symptoms (Nockher and Scherberich, 1998). The 
CD14++CD16+ population also has a higher level of expression of MHC-II, higher 
phagocytic activity, higher TLR2 expression, and higher levels of CD54 and CD86 
than the CD14++CD16- population (Nockher and Scherberich, 1998; 
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Skrzeczynska-Moncznik et al., 2008). Other proteins expressed differentially 
include colony stimulating factor receptor 1 (CSFR1), complement component 3a 
receptor 1 (C3AR1), CXCL16, CD43, and CX3C chemokine receptor 1 
(CX3CR1), expressed at higher levels on non-classical monocytes, and colony 
stimulating factor 3 receptor (CSF3R), CD93, CD1d, and CCR2, with greater 
expressed on the classical subset (Ancuta et al., 2009; Wong et al., 2011). 
Additionally both subsets express similar levels of mRNA for TLR-1, 2, 4, and 5. 
The intermediate subset expresses levels of surface markers which are in 
between those expressed by the CD14++CD16- or the CD14+CD16++ subsets 
again hinting at progressive differentiation from the classical to the non-classical 
subset. 
 
With regards to soluble factor production the classical subpopulation expresses 
the widest range of cytokines and chemokines including IL-6, CCL5, IL-10, and 
TNFα whereas the non-classical subset produces the highest levels of TNF-α in 
response to lipopolysaccharide (Skrzeczynska-Moncznik et al., 2008; Wong et 
al., 2011). Functional differences of these subpopulations can be seen when 
genes are grouped according to their involvement in biological processes. 
Classical monocytes express genes involved in functions ranging from tissue 
repair and remodelling to host defence and inflammation, the intermediate 
subpopulation is enriched for genes involved in antigen presentation and 
costimulatory molecules (i.e. major histocompatibility complex 2 (MHC-II) and 
CD40), and nonclassical monocytes show gene expression associated with 
motility, phagocytosis, and antibacterial responses (Ancuta et al., 2009; Wong et 
al., 2011). 
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Classical Intermediate Non-classical 
TNFa + ++ +++ 
CSF3R (G-CSF-R) +++ ++ + 
CD93 +++ ++ + 
CD1d +++ ++ + 
CCR2 +++ ++ + 
CSF1R (M-CSF-R) + ++ +++ 
C3AR1 + ++ +++ 
CXCL16 + ++ +++ 
CD43 + ++ +++ 
CX3CR1 + ++ +++ 
Biological function 
Tissue 
repair, 
inflammation 
Antigen 
presentation, 
costimulation 
Phagocytosis, 
antibacterial 
responses 
Table 2: Summary of the differences in protein expression and biological function 
between the three monocyte subsets in humans. Expression levels are relative to 
the other subsets. +++ = relative high expression, ++ = relative intermediate 
expression, + = relative low expression. 
 
The differentiation of monocytes into dendritic cells or macrophages has been 
intensively studied, however due to a lack of consistency between publications 
there are many approaches taken to generate these cell types some of which 
arguably reflect more of an activation phenotype due to the stimulus used than 
true differentiation. Additionally the in vivo situation is likely to be significantly 
different to the approach taken in vitro as cells typically encounter a milieu of 
stimuli consisting of many factors derived from differing sources whereas the in 
vitro approach normally consists of the use of one or two factors in combination 
for several days duration, a situation unlikely to occur during a dynamic immune 
response. Nethertheless, studies have successfully demonstrated the ability of 
monocytes to differentiate into various subpopulations and, particularly in the 
case of macrophages, that the phenotypes of these cells are highly plastic. 
 
One of the most common methods for differentiating both human peripheral blood 
monocytes and also murine bone marrow cells into two subsets of macrophages 
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is to culture the cells in the presence of GM-CSF or M-CSF for approximately 6 
days (Fleetwood et al., 2007; Jaguin et al., 2013). Treatment with GM-CSF results 
in higher expression of the IL-12 p35 subunit (IL-12p35), CXCL10, CXCL11, 
CCL5, CCR7, indolamine-pyrrole 2,3-dioxygenase (IDO), and TNFα mRNA 
which indicates a pro-inflammatory phenotype whereas treatment with M-CSF 
results in higher levels of mRNA for TGFβ, scavenger receptor class B member 
1 (SRB-1), peroxisome proliferator-activated receptor gamma (PPARG), CCL14, 
mannose receptor C-type 1 (MRC1), heme oxygenase 1 (HO-1), CD36, CCL2, 
and IL-10 indicating an anti-inflammatory scavenging phenotype. The two 
macrophage populations that can be differentiated in this manner express 87% 
of genes at a similar level in humans and 80% in mice with 3044 genes 
differentially expressed in humans at a fold change greater than two (Lacey et 
al., 2012). Interestingly, GM-CSF treatment of the murine macrophage subset 
differentiated with M-CSF prior to stimulation with lipopolysaccharide results in 
an increase in the production of TNFα from these cells above that of those only 
differentiated with M-CSF, albeit at lower levels than those cells initially 
differentiated with GM-CSF. Treatment with M-CSF prior to stimulation results in 
decreased TNFα and IL-12 p70 subunit (IL-12p70) production demonstrating the 
plasticity inherent in macrophage subsets (Fleetwood et al., 2007). 
GM-CSF 
differentiated 
M-CSF 
differentiated 
IL-12p35 TGFB 
CXCL10 SRB-1 
CXCL11 PPARG 
CCL5 CCL14 
CCR7 MRC1 
IDO CCL2 
TNFa IL-10 
Table 3: Key genes expressed by either GM-CSF differentiated or M-CSF 
differentiated macrophages generated from peripheral blood monocytes. 
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In addition to the well characterised differentiation of monocytes to macrophages 
it has also been demonstrated that monocytes can be terminally differentiated 
into functional dendritic cells through the combined action of GM-CSF and IL-4 
(Chapuis et al., 1997; Sallusto and Lanzavecchia, 1994). This method of 
differentiation produces competent antigen-presenting cells with the 
characteristic veiled morphology and dendritic processes associated with 
dendritic cells. Interestingly, although the dendritic cells differentiated in this 
manner are incapable of differentiation towards a macrophage phenotype, 
treatment of M-CSF differentiated macrophages with IL-4 and M-CSF does 
convert these cells to a dendritic cell phenotype and approximately 50% of the 
macrophages differentiated with GM-CSF can also be converted by this 
treatment, demonstrating a difference in plasticity between these cell types. 
Monocytes are also the source of osteoclasts which are differentiated using a 
treatment of RANKL, M-CSF, IL-4, and 1,25-dihydroxy-vitamin D3 (Massey and 
Flanagan, 1999). 
 
1.4.2.2 Macrophages 
Macrophages are known to develop from at least two sources. In early foetal life 
yolk-sac derived macrophages populate the tissues of the embryo and eventually 
give rise to tissue-resident macrophages such as microglia (Mizutani et al., 2012; 
Schulz et al., 2012). The early progenitors of the haematopoietic system reside 
in the foetal liver before migrating to the bone marrow and developing into 
haematopoietic stem cells (HSCs) (Sasmono et al., 2003; Tavian and Peault, 
2005). HSCs are the source of many of the cells of the immune system including 
monocytes which are known progenitors of macrophages. Upon encountering 
specific inflammatory chemokines such as CCL2 and CX3CR1, monocytes exit 
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the blood stream and infiltrate the tissues, where signals such as GM-CSF and 
M-CSF may drive predetermined pathways in order to fight specific pathogen 
groups. 
 
Most studies investigating the origin of tissue-resident macrophages are 
undertaken in mice as fate mapping and knockout studies and can be used to 
test hypotheses that cannot be tested in humans. A population of macrophages 
which can develop independent of the transcription factor Myb, which is required 
for the differentiation of macrophages from peripheral blood monocytes, were 
found to originate from the yolk sac during embryogenesis and seeded several 
long lived tissue resident macrophage populations during the ongoing maturation 
of the embryo, although precisely how long these cells persist in tissues is as yet 
unclear (Perdiguero et al., 2014). However, intricate work has demonstrated that 
microglia derived from a precursor shared with yolk sac macrophages and not 
from haematopoiesis are capable of self-renewal without hematopoietic input 
(Ginhoux et al., 2010). Using either sublethal irradiation of a mouse before a bone 
marrow transplant or parabiosis experiments in which the circulatory systems of 
two mice are surgically joined, these investigators found that although circulating 
leukocytes consist of roughly 30% donor-derived cells 1 month after transplant or 
initiation of parabiosis, only 5% of microglia are donor derived and that even 21 
months after the procedures the contribution of donor cells to the microglia 
population is only 10-20%. These findings indicate that tissue-resident microglia 
are seeded during embryogenesis, are capable of self-renewal, and persist into 
adulthood. However the contribution of embryologically derived macrophages to 
other tissue-resident macrophage populations and the longevity of these 
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populations is yet to be defined but initial work indicates that lung, peritoneal, 
spleen, and bone marrow macrophage populations may all be long-lived tissue-
resident populations capable of self-renewal without hematopoietic input 
(Hashimoto et al., 2013). 
 
Several studies have demonstrated that tissue-resident macrophages, such as 
microglia in the central nervous system, cardiac macrophages, or red pulp 
macrophages, require distinct transcription factors for development and function 
and yet show shared expression of markers specific for all tissue-resident 
macrophages; CD64 and MerTK (Gautier et al., 2012). A striking example of the 
tissue tropism of tissue-resident macrophages can be found in the splenic 
macrophage populations. Red pulp macrophages are dependent on Spi-C 
expression, which is specific to this population and not found in other tissue-
resident macrophages, monocytes, or dendritic cells, whereas marginal zone 
macrophages require Liver X receptor alpha (LXRα) expression (A-Gonzalez et 
al., 2013; Kohyama et al., 2008). As previously mentioned tissue-resident 
macrophages appear to be capable of self-replenishment and thus maintain 
population integrity without input from peripheral blood monocytes, however 
during inflammation cardiac macrophages undergo not only self-replenishment 
but are aided in reconstituting the resident population by peripheral blood 
monocytes again highlighting the disparity between resident macrophage 
populations (Epelman et al., 2014). Regarding the features responsible for driving 
the differences between resident macrophage populations tissue-specific factors 
appear to be critical rather than terminal differentiation of the macrophages as 
transfer of one resident population into the niche of another results in the 
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transferred macrophage assuming a phenotype similar to that of the tissue-
resident macrophages found in the destination tissue (Gosselin et al., 2014; Lavin 
et al., 2014). 
 
The other more well defined source of macrophages is through differentiation 
from monocytes. The current paradigm of monocyte to macrophage 
differentiation defines two broad classes of macrophages with the M1 class 
regarded as proinflammatory and the M2 class anti-inflammatory (Buechler et al., 
2000; Jaguin et al., 2013; Lacey et al., 2012; Mantovani et al., 2004; Mantovani 
et al., 2002; Strauss-Ayali, Conrad and Mosser, 2007). M1 macrophages are 
characterised by the expression of CD86 and MHC-II; they produce cytokines 
involved in driving inflammation such as TNF-α and IL-1β along with monocyte 
and activated T lymphocyte recruiting chemokines such as CXCL10, CXCL11, 
and CCL5 (Ambarus et al., 2012a; Angiolillo et al., 1995; Cole et al., 1998; Dufour, 
Jennifer H. et al., 2002b; Jaguin et al., 2013; Mantovani et al., 2004; Rey-Giraud, 
Hafner and Ries, 2012; Verreck et al., 2004). The functions of these markers and 
soluble factors lead to the portrayal M1 macrophages as a proinflammatory 
subset. 
 
M2 macrophages have been split into M2a, M2b, and M2c subsets depending 
upon the repertoire of markers and soluble factors being produced (Mantovani et 
al., 2004). Broadly speaking M2 macrophages are considered to have anti-
inflammatory roles and are important in tissue remodelling and homeostasis. This 
is exemplified in the markers and factors used to identify the M2 phenotype, 
including the scavenger receptor CD163, the mannose receptor (CD206), and 
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key anti-inflammatory mediators such as IL-10 (Ambarus et al., 2012a; Mantovani 
et al., 2004; Mikita et al., 2011; Verreck et al., 2004). 
 
The limitations of such an artificial paradigm have become apparent with 
discordance between the various methods of in vitro differentiation of M1 and M2 
macrophage phenotypes. Furthermore the phenotypes of in vivo macrophages 
are rarely as extremely polarised as in vitro differentiated populations, suggesting 
that macrophages exist across a wide functional and phenotypic spectrum. 
Efforts to clarify studies on in vitro differentiation and functions of macrophages 
have been made with the publication of guidelines on macrophage activation 
nomenclature (Murray et al., 2014). 
  
 
1.4.3 Roles in disease 
1.4.3.1 Monocytes 
As with other immune cell types the subset distribution and function of monocytes 
can become skewed during the pathogenesis of several diseases. In the 
cardiovascular field a raised intermediate monocyte count is significantly 
associated with a higher risk of adverse outcomes from strokes and myocardial 
infarctions (Rogacev et al., 2012). In patients suffering from carotid artery disease 
the levels of mRNA for high mobility group box 1 (HMGB1), plasminogen activator 
inhibitor 1 (PAI-1), matrix metalloproteinase 9 (MMP9), TNFα, and TGFβ are 
significantly higher in monocytes and T cells within plaques than in the peripheral 
blood, suggesting that these cells may aid in the rupture of plaques (Sternberg et 
al., 2013). Monocytes isolated from patients suffering from systemic sclerosis, a 
disease in which fibrosis occurs in the skin and vasculature of patients, have 
higher levels of the transcription factor Fra-2 which has been implicated in pro-
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fibrotic pathways and drives increased expression of tissue inhibitor of 
metalloproteinase 1 (TIMP-1) in these cells (Ciechomska et al., 2016; Reich et 
al., 2010). 
 
Early work investigating the role played by monocytes in RA found a significantly 
higher number of monocytes in the synovial fluid of RA patients expressed CD16 
on their surface than monocytes in the peripheral blood from the same patients 
indicating a shift in the balance of monocyte subsets in the inflammatory joint 
environment (Wahl et al., 1992). Further work showed that the increase in CD16 
expression was mediated mostly but not entirely by TGFβ as this effect is greatly 
reduced but not completely abrogated by blocking antibodies against TGFβ in 
vitro. Subsequently an increase in the number of CD16+ monocytes in the 
circulation of RA patients has been shown particularly in active disease; the 
CD16+ cell count positively correlated with c-reactive protein levels (CRP), a 
measurement of systemic inflammation. This study showed that not only TGFβ, 
but also M-CSF and IL-10 can increase CD16 expression on monocytes and that 
M-CSF levels are significantly higher in the peripheral blood of RA patients than 
controls (Kawanaka et al., 2002). Interestingly the duration of disease also 
appears to affect the number of CD16+ monocytes present as higher numbers 
are found in longer duration RA than in early disease. Although CD16+ monocyte 
numbers decrease with successful therapy, patients who do not respond well to 
methotrexate or steroids have a higher proportion of intermediate monocytes 
relative to the other subsets when compared to good responders (Cooper et al., 
2012; Kawanaka et al., 2002). More evidence that the intermediate population is 
involved in RA pathogenesis was provided by Rossol et al who found significantly 
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expanded intermediate populations in the peripheral blood of RA. In vitro the 
intermediate monocyte subsets induces significantly greater Th17 cell 
differentiation, a T cell subset implicated in RA, from memory T cells than the 
other monocyte subsets and in RA the frequency of Th17 cells positively 
correlates with the intermediate monocyte population (Rossol et al., 2012). 
 
Regarding the activation of monocytes in RA both synovial macrophages and 
monocytes in RA have significantly higher basal and interferon gamma (IFNγ) or 
TNFα stimulated levels of neopterin, which can be used as a marker of monocyte 
or macrophage activation, compared to monocytes isolated from healthy controls 
(Hahn et al., 1993). The levels of Siglec-1, a scavenger and phagocytosis 
receptor, mRNA and protein are also higher in peripheral blood monocytes 
isolated from RA patients than from patients with osteoarthritis or healthy 
controls; this expression positively correlates with the DAS28 composite-disease 
activity score, rheumatoid factor levels, erythrocyte sedimentation rate (a 
measure of global inflammation levels, ESR), and CRP (Crocker and Gordon, 
1986; Jones, Virji and Crocker, 2003; Xiong et al., 2014). Siglec-1 expression on 
monocytes can be upregulated by several pro-inflammatory stimuli such as IFNγ, 
TNFα, and also collagen-II. Monocytes and T cells isolated from the peripheral 
blood of RA patients have significantly higher signal transducer and activator of 
transcription (STAT3) levels than in healthy controls and significantly higher 
levels of phosphorylated STAT3 in monocytes and CD4+ T cells (Isomäki et al., 
2015). Levels of IL-6 and TNFα found in the plasma of patients and controls 
significantly correlate with the number of monocytes and CD4+ T cells positive for 
phosphorylated STAT3, while levels of IFNγ are significantly correlated with the 
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number of phosphorylated STAT3 positive monocytes. Taken together, this 
indicates that RA monocytes shift their expression and activation of STAT family 
members depending on the cytokine milieu to which they are exposed. 
 
1.4.3.2 Macrophages 
Macrophages have been shown to play significant roles in RA. The count of 
CD68+ cells (CD68 being a marker of macrophages) in the sublining region of the 
synovium is highly correlated with DAS28 score. Falls in DAS28 score due to 
successful treatment is associated with a concurrent decrease in the sublining 
CD68+ cell count (Haringman et al., 2005; Kunisch et al., 2004; Micklem et al., 
1989; Pulford et al., 1990). For example, the successful RA treatment infliximab 
which targets TNF-α, the signature cytokine of M1 macrophages, causes a 
decrease in CD68+ lining layer cells. In another study, treatment with the 
glucocorticoid prednisolone decreased synovial IL-1β and TNF-α levels and the 
sublining CD68+ cell count (Gerlag et al., 2004; Haringman et al., 2005; Smeets 
et al., 2003). Furthermore, the number of CD14 positive sublining cells and the 
thickness of the lining layer both correlate with the radiological progression of 
joint damage (Mulherin, Fitzgerald and Bresnihan, 1996). 
 
Differences in the number and marker expression of synovial macrophage 
subsets between different disease states have been investigated. Ambarus et al. 
(2012b) investigated synovial macrophage populations using immunofluorescent 
staining of tissue sections and found that although expression of the pan 
macrophage marker CD68 was similar between RA and spondyloarthritis in both 
lining and sublining layers of the synovium, expression of CD163 was significantly 
higher in the lining layer of spondyloarthrtis than RA. In general lining layer 
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macrophages expressed higher levels of CD163 and CD32 but little or no CD64, 
CD80, CD200R, CD14, or CD16 whereas sublining macrophages expressed 
CD163, CD32, and CD64. However, such findings are not consistent in the 
literature, it has also been shown that there are an increased number of CD163+ 
and CD68+ cells in the lining layer of spondyloarthritis patients and an increase 
in CD163+ cell numbers in the sublining of spondyloarthritic synovium (Baeten et 
al., 2002; Baeten et al., 2004). Interestingly, the number of CD163+ sublining cells 
was shown to correlate with CRP and ESR values. In addition to the difference in 
phenotype between lining and sublining macrophages Fonseca et al. (2002) 
found that CD163+cells were not in proximity with lymphocyte rich clusters 
whereas CD68+cells not expressing CD163 were found in and around these 
clusters in RA synovium. 
 
Studies investigating the levels of soluble CD163 in the plasma of RA patients 
have shown that CD163 levels are significantly higher in patients with 
longstanding RA than in healthy controls and in patients who have had a 
symptom duration of less than 6 months, soluble CD163 levels are correlated 
with CRP, ESR, and DAS28 (Greisen et al., 2011; Greisen et al., 2015). In 
patients with the shorter symptom duration the levels of soluble CD163 were not 
significantly higher than healthy controls, however levels dropped significantly 
during treatment for 9 months with methotrexate, betamethasone, and 
cyclosporine and post-treatment levels correlated with radiological progression 
over a 5 year period. Differences between early and later stage RA have also 
been observed in the cytokine profile in macrophages with CXCL4 and CXCL7 
being expressed at higher levels in the synovium of early RA patients compared 
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to longer duration RA or healthy controls and with the expression of these 
cytokines co-localising with the macrophage marker CD68 in synovium as 
identified by immunofluorescent staining (Yeo et al., 2015a). 
 
In addition to the above markers, activated macrophages present in the skin, 
lung, liver, spleen, kidneys, intestines, lymph nodes, and synovium all express 
folate receptor beta (FRβ) (Nagayoshi et al., 2005; Van Der Heijden et al., 2009; 
Xia et al., 2009). Macrophage FRβ expression is only present in sublining 
macrophages distant from T cell infiltrate in inflamed synovium. Murine FRβ+ 
macrophages express higher levels of CD80 and CD86 than FRβ- macrophages, 
indicating an increased co-stimulatory capability in this macrophage subset and 
FRβ+ macrophages also have intracellular TNFα pools and higher levels of 
reactive oxygen species than FRβ- macrophages. Curiously, FRβ expression on 
macrophages differentiated from human peripheral blood monocytes using M-
CSF was not elicited when these cells were stimulated with a range of typical 
stimuli used in in vitro experimentation, so the mechanism by which FRβ is 
upregulated on macrophages in inflamed synovium is as yet unclear. 
 
Subsets of monocytes or macrophages may have disparate roles in the 
progression of RA as highlighted in the K/BxN serum-transfer mouse model of 
arthritis. In this model resident synovial macrophages and infiltrating 
macrophages could be identified on the basis of MHC-II absence or presence 
respectively (Misharin et al., 2014). Although both of these subsets of 
macrophage could differentiate from non-classical monocytes, resident 
macrophages dampened the severity of arthritis and were required for resolution 
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of the inflammation whereas infiltrating macrophages exacerbated the 
inflammation. This highlights the complexity of the macrophage subset field which 
often does not conform to the current M1-M2 paradigm of macrophage 
polarisation. 
 
1.4.4 Summary 
Macrophages are derived from at least two sources with tissue-resident 
macrophages believed to be derived from yolk sac progenitors during 
embryogenesis and infiltrating populations differentiated from peripheral blood 
monocytes. Macrophages and monocytes are thought to act as sentinels 
monitoring tissue and the circulation for signs of injury or infection and responding 
both directly and indirectly. Monocytes respond to pathogens with the production 
of proinflammatory cytokines and are capable of differentiating into macrophage 
and dendritic cell subsets. Macrophages are important both in the 
initiation/propagation of inflammation through the production of cytokines such as 
TNFα and in limiting inflammation through IL-10 production and are important in 
clearing infections through phagocytosis and scavenger functions and the 
production of reactive oxygen species. Macrophages also bridge the innate and 
adaptive arms of the immune system as they are capable antigen presenting cells 
and express costimulatory cell surface molecules. Although it is clear 
macrophage subsets exist within the synovium and that these subsets play 
different roles during RA the precise function of each macrophage marker and/or 
subpopulation is yet to be clarified.  
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1.5 Fibroblasts 
1.5.1 Development 
Fibroblasts are stromal cells that give structure and support to the tissues of the 
body but also are critically involved in the immune response. During adult life, 
mesenchymal stem cells and peripheral-blood fibrocytes may contribute to 
fibroblast populations present in tissues of the body however it is certain that 
during embryogenesis fibroblasts develop from the primary mesenchyme 
(Parsonage et al., 2005). Fibrocytes are classified on the basis of CD45, collagen-
I, and alpha smooth muscle actin (αSMA) expression and on their contractile 
ability, are derived from circulating CD14+ precursors in a tissue growth factor β1 
(TGF-β1) dependent manner, and play a role in wound healing but their 
contribution to fibroblast populations is uncertain (Abe et al., 2001; Pilling et al., 
2009). Multipotent mesenchymal stromal cells are present in many connective 
tissues in the body and have the ability to differentiate into several stromal 
lineages such as fibroblasts, adipocytes, and osteoblasts (Lee et al., 2010; 
Uccelli, Moretta and Pistoia, 2008). Identification of mesenchymal stem cells is 
complex and relies on the exclusion of cells expressing CD45, CD11b, CD19, 
and HLA-DR and on the use of a suite of markers expressed on the stem cells 
such as CD73, CD90, and CD105. Fibroblasts can be differentiated from 
mesenchymal stem cells through the action of connective tissue growth factor 
which results in cells expressing fibroblast markers such as vimentin and 
collagen-I. However, the difference between fibroblasts and MSCs is unclear, 
partially due to the heterogeneity of fibroblasts, and some authors hypothesise 
that fibroblasts are actually activated MSCs as opposed to a unique cell type 
(Kalluri, 2016). 
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Synovial fibroblasts have traditionally been viewed as merely providing tissue-
specific structure and function to the synovium and joint (Lee et al., 2010). 
Maintaining the synovial tissue extra-cellular matrix and synovial fluid to permit 
normal mechanistic function of the joint is achieved through the production of 
hyaluronan, amongst other products, which helps maintain the correct viscosity 
of the joint fluid, and through the production of a range of matrix-
metalloproteinases (MMPs) and tissue-inhibitors of metalloproteinases (TIMPs) 
that allow the fibroblast to respond to the high levels of tissue remodelling 
required in a high trauma environment such as the joint (Aicher et al., 2003; 
Huang et al., 2011; Vuorio et al., 1982). Due to these functions, fibroblasts were 
viewed as having a passive role in the immune response. However this viewpoint 
is changing as emerging evidence shows fibroblasts not only as active players in 
the immune system with an immune sentinel role similar to macrophages but also 
as key players in the progression of RA. 
 
1.5.2 Role in orchestrating the immune response 
It is now clear that fibroblasts do not simply provide the backdrop against which 
immune and inflammatory responses carry out their play but are critically involved 
in the immune response and this is apparent in the viewpoints expressed in 
recent publications (Filer, 2013; Juarez, Filer and Buckley, 2012; Naylor, Filer 
and Buckley, 2013; Turner and Filer, 2015). Simple evidence that the stroma 
responds to and supports the inflammatory response can be seen in the ability of 
fibroblasts to proliferate in response to the key pro-inflammatory cytokines IL-1β 
and TNFα, however this is not an unremitting response and the same two 
cytokines trigger the release of prostaglandin E2 from fibroblasts which acts in an 
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autocrine manner to inhibit proliferation (Gitter et al., 1989). This demonstrates 
the existence of regulatory networks in fibroblasts that respond to inflammatory 
cues. 
 
More direct evidence that fibroblasts are key sentinel cells, in a similar manner to 
macrophages, is apparent in the fact that pattern recognition receptors are 
expressed by these cells (Kim et al., 2007b; Kim et al., 2009; Ospelt et al., 2008). 
Toll-like receptors (TLRs) 1, 3, 4, 5, and 6 are all expressed by synovial 
fibroblasts, with TLR3 and TLR4 at the highest levels allowing fibroblasts to detect 
and mount a response to pathogen associated molecular patterns (PAMPs) such 
as bacterial lipoprotein, double-stranded RNA, lipopolysaccharide (LPS), and 
flagellin. Upon stimulation with poly(I:C) (synthetic double-stranded RNA), LPS, 
flagellin, or bacterial lipoprotein synovial fibroblasts release higher levels of IL-6 
than dermal fibroblasts. Furthermore, synovial fibroblasts isolated from the 
afflicted joints of RA patients (RA-FLS) basally express mRNA for immune 
mediators such as IL-6, IL-11, and oncostatin M (OSM) which are increased upon 
stimulation with TNF-α or IL-1α, highlighting the ability of fibroblasts to respond 
not only to pathogens but also in response to factors elicited from other immune 
cells (Okamoto et al., 1997). 
 
In addition to being able to react to PAMPs fibroblasts also produce a range of 
proinflammatory cytokines and chemokines such as IL-23p19, and IL-6, and also 
CCL2, CCL3, CCL4, CXCL8, CXCL10, and CXCL12 which promote the 
recruitment of neutrophils, monocytes, and T lymphocytes (Bradfield et al., 2003; 
Gitter et al., 1989; Hayashida et al., 2001; Hwang et al., 2004). IL-17, a cytokine 
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frequently implicated in the pathogenesis of RA elicits an increase in IL-6 and 
CXCL8 production from RA-FLS and acts in synergy with TNFα to increase GM-
CSF production (Al-Saadany et al., 2016; Hwang et al., 2004; Lubberts, 2015; 
Parsonage et al., 2008). Furthermore, fibroblasts can also respond to IL-1α and 
IL-1β with an increase in GM-CSF production. Taken together the ability of 
fibroblasts to produce and respond to many factors involved in the immune 
response indicates the degree to which they are involved in orchestrating the 
immune response. 
 
As fibroblasts are involved in the recruitment and activation of cells in the tissue 
they can also act to retain leukocytes in the tissue. Through the constitutive 
expression of CXCL12, CCL2, and CXCL8 RA-FLS can promote the ingress of B 
cells, T cells, monocytes, and neutrophils through signals mediated by CXCR4, 
CCR2, CCR4, CXCR1, and CXCR2 on the surface of these populations. When 
stimulated with peptidoglycan, which signals via TLR2, RA-FLS upregulate 
CXCL8, CCL5, and CCL8 leading to recruitment of neutrophils, monocytes, and 
CD4+ T cells to sites of inflammation (Bradfield et al., 2003; Burger et al., 2001; 
Pierer et al., 2004; Scaife et al., 2004). The repertoire and magnitude of cytokine 
release from RA-FLS is modified compared to control synovial fibroblasts 
highlighted by higher levels of CCL2 and CXCL8 that RA-FLS secrete leading to 
greater monocyte migration compared to osteoarthritis synovial fibroblasts (OA-
FLS) or dermal fibroblasts (Hayashida et al., 2001). In addition RA-FLS release 
more CXCL12 when co-cultured with CD4+ T lymphocytes, mediated by 
CD40/CD40L interactions and IL-17 signalling; furthermore higher levels of 
CXCL12 can be found in the synovial fluid of RA patients compared to that of 
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osteoarthritis patients (Kim et al., 2007a). 
 
In vitro pseudoemperipolesis assays have provided evidence that the range of 
chemokines produced by synovial fibroblasts is capable of retaining leukocytes 
within an environment which could possibly facilitate an inappropriate chronic 
immune response. Pseudoemperipolesis is the migration and retention of cells 
underneath a monolayer of cells and in the case of monolayers of RA-FLS or OA-
FLS these cells facilitate the pseudoemperipolesis of B cells, activated T cells, or 
natural killer (NK) cells isolated from peripheral blood compared to dermal 
fibroblasts (Bradfield et al., 2003; Burger et al., 2001; Chan et al., 2008). 
Interestingly both B and T cells require CXCL12-CXCR4 interactions for this 
process however B cells also require additional VCAM-1-VLA-4 interactions for 
successful pseudoemperipolesis. It is important to note that the 
pseudoemperipolesis process is not simply a method of leukocyte retention but 
the co-culture of fibroblasts with another cell type results in the modulation of 
factors produced by both cell types, in the case of NK cells IL-6, IL-15, CCL2, 
CXCL8, and GM-CSF release is increased in the pseudoemperipolesis assay. 
 
To further exacerbate the effect that inappropriate leukocyte retention may have 
on immune responses, co-culture of fibroblasts with B cells, T cells, and NK cells 
also results in increased survival of these cell types which could allow prolonged 
exposure of tissues to damaging and pro-inflammatory factors. RA-FLS mediate 
the increased survival of B cells and NK cells through the expression of IL-15 and 
B-cell activating factor and, when stimulated via TLR3, the expression of a 
proliferation-inducing ligand (APRIL) and increased B-cell activating factor 
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(BAFF) expression (Benito-Miguel et al., 2012; Bombardieri et al., 2011; Burger 
et al., 2001; Chan et al., 2008). IL-15 engages the IL-15 receptor on NK and B 
cells, the expression of which on B cells is increased by BAFF stimulation, to 
increase survival of these cells over 6 days from 3% viable cells in monoculture 
to 50% in co-culture with RA-FLS, an increase which is significantly higher than 
that elicited by OA-FLS or dermal fibroblasts. APRIL and BAFF released during 
co-culture also promotes B cell class switching as evidenced by an increase in 
cytidine deaminase and increases in immunoglobulin A (IgA) and IgG expression. 
Finally, activated T cells also survive for longer in co-culture with synovial 
fibroblasts which is facilitated in part by an IFNβ dependent mechanism (Filer et 
al., 2006). 
 
In addition to aiding and abetting an inappropriate immune response, RA-FLS are 
thought to be indirectly involved in the bone erosions present in the joints of RA 
patients through manipulation of the osteoblast/osteoclast axis. This is mediated 
through the expression of the pro-osteoclast differentiation factor RANKL which 
is expressed in the lining layer at significantly higher levels in RA synovium than 
in osteoarthritis and can be induced in RA-FLS but not OA-FLS or dermal 
fibroblasts through TLR2, TLR3, or TLR4 stimulation and subsequent autocrine 
IL-1β signalling (Kim et al., 2007b; Kim et al., 2009). Stimulation of these TLRs 
on RA-FLS with peptidoglycan, lipopolysaccharide, or poly(I:C) and co-culture of 
these cells with monocytes directly drives the differentiation of monocytes into 
osteoclasts demonstrating that RANKL expression on RA-FLS can interfere with 
the balance of osteoclasts within tissues. 
 
59 
 
1.5.3 Direct role in joint damage 
There is compelling evidence that RA-FLS play a direct and key role in driving 
the progression and the chronicity of the disease. Significantly, RA-FLS are a key 
cellular constituent of the invasive pannus tissue that actively erodes into 
cartilage and bone in severe disease. Current evidence incriminates lining layer 
fibroblasts as being the subset involved in forming and driving pannus invasion 
into cartilage as fibroblasts in the pannus tissue express the lining layer marker 
cadherin-11 (Kiener et al., 2009; Lee et al., 2007). Additionally, modulating the 
expression of cadherin-11 affects the invasiveness of fibroblasts into cartilage 
with lower expression resulting in lower invasion and vice versa. 
 
In vitro cultured RA-FLS are capable of directly invading and damaging ex vivo 
articular cartilage through the production of MMP9, and cathepsins B, D, and L, 
and retain this aggressive behaviour after transfer into a leukocyte free 
environment, namely a severe combined immunodeficiency (SCID) mouse, 
whereas OA-FLS invasion in this model is minimal (Allard, Maini and Muirden, 
1988; Muller-Ladner et al., 1996; Pap et al., 2001; Unemori, Hibbs and Amento, 
1991; Xue et al., 1997). Additionally, RA-FLS appear to be capable of migrating 
from cartilage in one site to cartilage at another, offering a possible explanation 
for the progressive involvement of additional joints in RA (Lefevre et al., 2009). 
The tumour suppressor gene p53 is also implicated in RA with studies 
demonstrating the upregulation of the protein in RA-FLS invading cartilage and 
that the forced upregulation of p53 increases the invasiveness of normal 
fibroblasts (Inazuka et al., 2000; Muller-Ladner et al., 1996; Pap et al., 2001; 
Seemayer et al., 2003). These findings have led to the postulation that the 
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behaviour of RA-FLS is permanently altered from the normal and maintains the 
disease state, suggesting possible involvement of epigenetic mechanisms. 
 
1.5.4 Epigenetic and genetic regulation of fibroblasts 
Accumulated evidence suggests that RA-FLS have an ‘imprinted’ aggressive 
phenotype that may be mediated through disturbances in the epigenetic 
regulation of these cell types. Epigenetic regulation controls the expression of 
genes by limiting or encouraging the access of deoxyribonucleic acid (DNA) 
transcription factors to gene promoters and common mechanisms by which 
access is regulated include covalent modification of DNA-binding histones 
including acetylation, methylation, and phosphorylation, and the direct 
methylation of CpG islands of DNA (Portela and Esteller, 2010). These 
modifications are mediated by regulatory complexes containing enzymes such as 
histone acetylases (HATs), histone deacetylases (HDACs), and DNA 
methyltransferases (DNMTs), that are known to be involved the addition and 
removal of histone and DNA epigenetic modifications (Wu and Zhang, 2010). 
 
There is evidence that global levels of DNA methylation, an epigenetic 
modification implicated in the silencing of gene expression, are different in RA-
FLS when compared to levels in osteoarthritis (Portela and Esteller, 2010). When 
comparing total methylation levels RA-FLS have significantly lower levels of 
methylation than OA-FLS, even after a period of in vitro culture (Karouzakis et 
al., 2009). Several attempts have been made to assess the number of genes 
regulated by methylation with one study investigating RA-FLS and OA-FLS and 
finding 575 genes associated with hypomethylated sites and 714 genes 
associated with hypermethylated sites and an alternative study demonstrating 
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that treatment of healthy synovial fibroblasts with 5-azacytidine, a demtheylating 
agent, for 3 months results in a greater than 2-fold upregulation in more than 180 
genes and that genes implicated in RA are within this upregulated set (De La 
Rica et al., 2013; Karouzakis et al., 2009). 
 
Other methods of gene regulation have also become of interest as possible 
methods by which RA-FLS are imprinted with a phenotype. With the relatively 
recent developments in the field of microRNAs (miRNAs), small non-coding RNA 
sequences that can regulate the stability and expression of multiple coding mRNA 
species, investigations into the possible function of these molecules in the RA-
FLS phenotype have begun (He and Hannon, 2004). miR-155, miR-146a, and 
miR-22 are all differentially expressed between RA-FLS and OA-FLS with miR-
155 and miR-146a being higher in RA-FLS than OA-FLS and miR-22 lower (Lin 
et al., 2014; Long et al., 2013; Stanczyk et al., 2008). miR-155 downregulates the 
expression of MMP3 and MMP1 upon TLR or IL-1β stimulation and in synovial 
tissue miR-155 expression is 8-fold higher in RA than osteoarthritis which may 
reflect an attempt to restrain the chronic inflammatory state whereas miR-22 
inhibits proliferation and IL-6 production by downregulating Cry61 but is 
expressed at lower levels in RA than osteoarthritis synovial tissue and hence may 
be aiding the aggressive phenotype of RA-FLS. 
 
1.5.5 Subsets 
As with other tissue resident cell types, such as macrophages, fibroblasts differ 
in the phenotype and genes expressed depending on the tissue from which they 
were isolated. Microarray analysis of fibroblast populations by Parsonage et al. 
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(2003) has demonstrated variation in basal and stimulated expression of genes 
related to inflammatory processes and work by Filer et al demonstrated a 
hierarchy to factors that influence the gene expression in dermal, synovial, and 
bone marrow fibroblasts with the largest effect being dependent on anatomical 
location from which the fibroblasts were isolated, the response to serum levels in 
culture media second, and the disease status of the donor, RA or osteoarthritis, 
last (Filer et al., 2015).  
 
Fibroblast gene expression is not limited to inter-tissue differences but actually 
varies across tissues of the same type that are distributed throughout the body. 
When investigating the transcriptome of fibroblasts isolated from 43 anatomical 
locations, most of which were taken from dermal tissue at different sites of the 
body, differences in gene expression were apparent and fibroblasts clustered on 
the basis of these differences with fibroblasts from similar regions of the body 
clustering together (Chang et al., 2002; Rinn et al., 2006). Differentially expressed 
genes between fibroblasts isolated from different sites included homeobox (HOX) 
genes which are known to be involved in embryological patterning and 
development but perhaps the most interesting finding of this work is that the 
variance between fibroblasts from the same site in two distinct donors is less than 
that found between two different sites in the same donor (Chang et al., 2002; 
Frank-Bertoncelj et al., 2017). The evidence for stromal heterogeneity has 
resulted in the hypothesis that the stroma and endothelial tissue function together 
to present a stromal address code through chemokine and adhesion molecule 
expression that regulates the influx of certain leukocytes from the vasculature into 
tissues and the persistence of these cells within the tissue or the efflux into the 
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lymphatics (Parsonage et al., 2005). It is postulated that expression of an 
improper postcode leading to the retention of pro-inflammatory immune cells and 
the prevention anti-inflammatory/pro-resolution cells from entering the afflicted 
tissue for example increased CXCL13 and CCL19 expression could lead to an 
increase in B lymphocyte infiltration and retention (Rupprecht et al., 2009; Sellam 
et al., 2013). 
 
In addition to the heterogeneity between fibroblasts from different sites 
differences can also be seen between cells isolated from different geographical 
areas within the same tissue. As mentioned earlier the synovium can be stratified 
into the lining or sublining layer and the fibroblasts present in these two regions 
not only differ in location but also in the markers they express, indicating several 
subsets of fibroblasts are present in synovial tissue with the potential for varying 
roles in RA progression (Turner and Filer, 2015). For example lining layer 
fibroblasts express cadherin-11 which facilitates adhesion of the lining layer 
fibroblasts to one another in a tissue which lacks a basal lamina and in RA has 
been shown to promote cartilage invasion (Assefnia et al., 2014; Kiener et al., 
2009; Lee et al., 2007; Valencia et al., 2004). A monoclonal antibody against this 
target is now entering clinical trials. 
 
Lining layer fibroblasts also express GP38, particularly in inflamed RA tissue, the 
expression of which is upregulated by TNF-α and IL-1β and downregulated by 
anti-TNF-α therapy. Lining layer cells have been shown to express markers 
including CD55 and fibroblast activation protein (FAP) which sublining fibroblasts 
express at lower or negligible levels except in very early RA disease (Bauer et 
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al., 2006; Choi et al., 2017; Croft et al., 2016; Del Rey et al., 2014; Ekwall et al., 
2011). Sublining fibroblasts express a different set of markers that can be used 
to identify alternative synovial fibroblast subsets which consists of CD90 (THY1) 
and CD248 (Endosialin) (Bauer et al., 2006; Macfadyen et al., 2005; Maia et al., 
2010; Saalbach et al., 1996; Saalbach et al., 1998). Recent single cell RNA 
sequencing of human synovial fibroblasts has expanded the number of core 
subsets to three with a seemingly lining layer subset identified as CD90-GP38+ 
and a CD90+GP38+ sublining layer subset actually consisting of two subsets that 
are either CD34+ or CD34- the second of which appears to expand concurrent 
with an increase in systemic and local inflammatory markers such as ESR or 
CD45+ cell influx into the synovium (Mizoguchi et al., 2017). 
 
1.5.6 Summary 
In summary, RA-FLS are involved in the recruitment, retention, and activation of 
many cells of the immune system within the synovium (Figure 5). RA-FLS can 
drive the differentiation of immune cell subsets which, in the case of monocyte to 
osteoclast differentiation, can push the balance of bone remodelling towards 
degradation and erosion. In addition, RA-FLS are capable of directly damaging 
articular cartilage through the production of matrix remodelling enzymes and do 
not require continued stimulation from cells of the immune system to maintain this 
behaviour. The maintenance of this aggressive phenotype even after prolonged 
in vitro culture is believed to be enforced through a combination of genetic and 
epigenetic factors. However, the exact number and function of fibroblast subsets 
within the synovium is still unclear. 
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Figure 5: Synovial fibroblasts involvement in inflammation. Chemokines such as 
CCL2, CCL5, CXCL8, CXCL12, and CXCL13 attract leukocytes into the tissue 
where fibroblast release of factors such as IL-6 and GM-CSF propagate 
inflammation. Interactions of B cells and T cells with fibroblasts via CXCL12-
CXCR4 and VCAM-1-VLA-4 interactions retains leukocytes in the tissue and 
provides survival signals reinforced by a positive feedback loop with IL-15 
released from fibroblasts. Binding of fibroblast expressed RANK to RANKL on 
monocytes in combination with M-CSF drives osteoclast differentiation. MMP and 
cathepsin release damages extracellular matrix and articular cartilage in joints. 
 
 
1.6 Interactions between macrophages and synovial fibroblasts result in 
increased invasiveness, and cytokine and growth factor production. 
Early studies have highlighted the importance of macrophage/fibroblast 
interactions in cartilage degradation through the use of in vitro assays which 
found co-culture stimulated the production of cartilage degrading MMPs (Janusz 
and Hare, 1993; Scott et al., 1997). A subsequent study using in vitro 
fibroblast/macrophage co-cultures highlighted the influence of intercellular 
adhesion molecule 1 (ICAM-1) and free oxygen radicals on CCL3 production 
(Steinhauser et al., 1998). Chomarat et al. (1995) demonstrated that co-culture 
of fibroblasts and macrophages increases IL-6, GM-CSF, leukaemia inhibitory 
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factor (LIF), and CXCL8 release with the mechanism dependent on IL-1β 
signalling. During the work undertaken in this thesis it has been published that 
co-culture of fibroblasts with M-CSF differentiated macrophages modulated gene 
expression elicited in macrophages by TNFα (Donlin et al., 2014). A set of genes 
normally increased indirectly in macrophages by TNFα through autocrine IFNβ 
signalling were suppressed by co-culture with fibroblasts, partially through 
inhibition of macrophage IFNβ production, however the full mechanism is still 
unclear. Additionally 34% of the genes normally down-regulated by TNFα in 
macrophages were upregulated by greater than 2-fold during co-culture. Pathway 
enrichment analysis of the genes modulated in macrophages by co-culture found 
enrichment in interferon and MYC related pathways in the downregulated genes 
and enrichment of growth factor and colony stimulating pathways in the 
upregulated genes. 
 
Despite these findings the interactions between synovial fibroblasts and 
macrophages have not been explored in great depth, and the key molecules 
mediating communication between these cells have not been established. This 
study aimed to address this issue through the development of a suitable in vitro 
system to allow detailed analysis of the interactions between synovial fibroblasts 
and macrophages. 
 
An advantage this study has over others that may aim to investigate fibroblast 
macrophage interactions is access to fibroblasts from samples within the 
Birmingham Early Arthritis Cohort (BEACON). Samples are donated by patients 
within this cohort at different stages of disease progression, ranging from early 
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undifferentiated arthritis through to destructive RA that requires joint replacement, 
and includes a group of patients with actively inflamed joints whose disease 
subsequently resolves during follow-up, providing a unique “inflamed control” 
group. Tissue samples are obtained either at surgery or via minimally invasive, 
imaging guided procedures. Synovial fibroblasts are routinely isolated and 
cultured from tissue samples which will allow this study to investigate any 
differences in interactions between macrophages and fibroblasts that may arise 
between different disease states, and at different stages of the progression of 
RA. Additionally, monocytes/macrophages will be readily available throughout 
the study through the use of peripheral blood apheresis cones commercially 
available from the NHS Blood and Transplant Service (NHSBT). Peripheral blood 
monocytes will be used in this study due to the ease of obtaining large numbers 
of these cells. 
 
1.7 Birmingham Early Arthritis Cohort (BEACON) 
BEACON is a well characterised cohort recruiting treatment naïve patients 
presenting with inflammatory arthralgia or new inflammatory arthritis. The 
patients are followed longitudinally allowing those presenting with 
undifferentiated arthritis to be assigned an exact diagnosis and for sequential 
blood, urine, and tissue samples to be collected during this period along with 
detailed clinical data. The key outcome groups in the BEACON include treatment 
naïve new onset very early RA (up to 3 months symptoms, VeRA), treatment 
naïve resolving arthritis (up to 3 months symptoms, Res), longer duration 
treatment naïve RA (>three months symptoms, EstRA) and long duration RA 
disease (from joint replacement surgery, JRep) in addition to control tissue from 
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patients with musculoskeletal symptoms but no macroscopic or microscopic 
evidence of joint inflammation (normal, Norm) (Figure 6). 
 
 
Figure 6: Schematic of patient outcomes included in the Birmingham Early 
Arthritis Cohort.  BEACON recruits patients presenting with undifferentiated 
arthritis and collects serum, peripheral blood, urine, synovial fluid, and synovial 
tissue from the patients before following disease progression and assigning 
patients to disease outcome groups. In addition to BEACON patients synovial 
tissue is collected from patients undergoing arthroplasty and also from patients 
with arthralgia in the absence of macro- or microscopic signs of inflammation in 
the synovium. 
 
1.8 Technologies 
Whole transcriptome RNA-sequencing and cytometry by time of flight (CyTOF) 
are two advanced technologies that will be used to investigate synovial fibroblasts 
and macrophages within this thesis. RNA-sequencing facilitates the untargeted 
measurement of the transcriptome of cells as opposed to the probe-based 
approached offered by microarray and also has a lower limit of detection and 
higher dynamic range than microarrays (Wang, Gerstein and Snyder, 2009). 
Briefly, RNA-sequencing requires the conversion of isolated RNA into 
complementary-DNA (cDNA) libraries either with or without amplification 
depending on the amount of RNA isolated. Before library preparation RNA not of 
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interest is removed, for example ribosomal RNA or immature RNA species, and 
during library synthesis adapters are ligated to the ends of sequences to prepare 
for next generation sequencing (NGS). Depending on the technology variations 
in the approach to NGS exist but in most approaches the cDNA sequences act 
as templates upon which nucleotides are bound and sequences generated by 
polymerases (Holt and Jones, 2008). In the fluorescence based approach 
nucleotides labelled with fluorophores to facilitate identification are incorporated 
into the new sequence generated and the fluorphore, which corresponds with the 
base added, is released allowing measurement. In the luminescence based 
approach a solution consisting of one type of nucleotide bound to pyrophosphate 
is added to the sequences, if the nucleotide is incorporated by polymerases the 
pyrophosphate is released and used to generate a luminescent signal. The 
excess solution is then washed away before addition of a solution containing 
another nucleotide and the process is repeated. In this manner the cDNA library 
is sequenced and the resulting sequences produced, or reads, are aligned with 
the genome and quantified. 
 
CyTOF results in similar data to those obtained by traditional flow cytometry but 
adds the possibility to analyse a much higher number of variables than previously 
possible. In short, rather than fluorescently labelling antibodies pure metals are 
conjugated to antibodies and cells are stained using these antibody-metal 
conjugates (Bandura et al., 2009). The cells are then nebulised, metals ionised, 
and analysed using time-of-flight mass spectroscopy, all embedded within 
equipment known as a mass cytometer. CyTOF can simultaneously analyse a 
higher number of markers than flow cytometry due to the distinct peaks produced 
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by the metal ions and the lack of spectral overlap seen with fluorophores. 
 
1.9 Hypotheses 
This work aims to test two hypotheses: 
 
During the later stages of rheumatoid arthritis synovial fibroblasts develop a 
chronic inflammatory phenotype which, through the production of soluble and 
membrane bound factors, drives the pro-inflammatory response/differentiation of 
monocytes and macrophages to perpetuate disease progression. 
 
Distinct subsets of synovial fibroblasts and macrophages exist within the 
synovium with a lining subset responsible for driving cartilage and bone 
destruction in rheumatoid and the regulation of inflammation and leukocyte 
infiltration driven by a sublining subset. 
 
 
Although published work has previously investigated differences between RA and 
healthy controls or osteoarthritis the RA samples used to isolate fibroblasts 
typically are isolated from longer duration patients who have received multiple 
different treatments and undergone arthroplasty which immediately limits the 
findings of these studies to later stage, destructive RA from which extrapolation 
to the earlier stages of disease may not be appropriate. This work is uniquely 
positioned due to access to the Birmingham Early Arthritis Cohort which provides 
a range of samples from different stages of RA and undifferentiated arthritis which 
allows a more longitudinal approach to investigating the pathogenesis of RA. This 
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cohort will allow expansion of the current knowledge on fibroblast and 
macrophage interactions into the interactions during the progression of 
rheumatoid arthritis (Figure 7). 
 
Figure 7: Current knowledge on the interactions between fibroblasts and 
macrophages. Although information is known regarding the cross-talk between 
fibroblasts and macrophages (left-hand side of the figure) the influence fibroblasts 
may have upon monocytes and macrophages during RA progression is unclear 
(right-hand side of figure). 
 
In addition to addressing the issue of fibroblast-monocyte interactions the 
BEACON provides a rich source of synovial tissue from the different stages of RA 
and resolving arthritis which will be used to expand the current model of synovial 
fibroblast and macrophage subsets in RA and other arthritides by identifying and 
characterising subpopulations within the tissue (Figure 8). 
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Figure 8: Schematic of the synovium highlighting the current understanding of 
fibroblast and macrophage populations within the tissue.  Although fibroblasts are 
known to separate into the lining and sublining layers it is not known if the 
fibroblasts differ in function or if other subsets, represented here by different 
colours, exist in both regions of the tissue. Additionally, it is not known if different 
subsets of macrophage are present in the synovium 
 
The three key aims that will be addressed to test the hypotheses are: 
 
Fibroblasts isolated from different stages of RA progression maintain differential 
gene expression during in vitro co-culture and respond to stimuli in different ways. 
 
Fibroblasts isolated from different stages of RA progression differentially 
modulate monocyte or macrophage phenotype in vitro. 
 
Discrete fibroblast and macrophage subsets exist within the synovium with 
distinct functions. 
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2 MICROARRAY ANALYSIS OF IN VITRO CULTURED SYNOVIAL 
FIBROBLASTS 
2.1 Introduction 
To address the first aim a cDNA microarray dataset generated by a previous PhD 
student was used to analyse gene expression in in vitro unselected cultured 
synovial fibroblasts from the BEACON cohort allowing interrogation of the 
differences between disease stages (Juárez Pérez, 2014). Previously this 
dataset was limited to fibroblasts cultured in 10% FBS in the presence or absence 
of TNFα. Subsequent to Dr Juarez’s PhD this dataset was expanded to include 
samples cultured in 0.1% FBS with no TNFα, an important group given the known 
impact of serum on the transcriptome of cultured fibroblasts and the possibility 
that this effect may mask disease specific differences (Filer et al., 2015). Longer 
duration treatment naïve RA patients were also added to the samples in all 
treatment groups. In this part of my PhD, this larger dataset was reanalysed, from 
scratch, including all quality control and data preparation steps, to test the 
hypothesis that fibroblasts isolated from different stages of RA progression 
maintain differential gene expression during in vitro co-culture and respond to 
stimuli in different ways. For this analysis specific comparisons were focused on 
within each treatment group; (1) the differences between Jrep samples and all 
other outcomes, (2) the differences between very early RA and resolving 
samples, and (3) the differences between normal samples and all other outcome 
groups. 
 
It is known that fibroblasts isolated from late stage RA patients undergoing joint 
replacment retain an ‘imprinted aggressor’ phenotype (Bottini and Firestein, 
2013). However it is not known at which stage these fibroblasts become imprinted 
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or if the imprinted phenotype remains the same from early to late RA. This chapter 
aimed to address this knowledge gap using the aforementioned microarray 
dataset on cultured synovial fibroblasts from the BEACON. The key questions 
that were addressed were: 
1. Do synovial fibroblasts isolated from RA patients undergoing joint 
replacement differ in gene expression from those from early RA and non-
arthritic fibroblasts? 
2. Do synovial fibroblasts from very early RA show differential gene 
expression compared to fibroblasts from resolving arthritis and hence 
demonstrate features specific to RA compared to other arthritides? 
3. Do synovial fibroblasts from non-arthritic patients differ from all other 
BEACON groups and what knowledge does this impart regarding 
important inflammatory pathways in RA synovial fibroblasts? 
 
2.2 Materials and methods 
The wet lab work and running of the microarray technology discussed herein was 
completed as a component of a PhD thesis completed by a previous student, 
Maria Juárez Pérez (Juárez Pérez, 2014) with the microarray processing and raw 
data delivery completed as a commercial service by Oxford Gene Technologies. 
 
2.2.1 Culture of synovial fibroblast cell lines 
Synovial tissue collected from BEACON patients was used to generate synovial 
fibroblast cell lines via an outgrowth protocol. From a patient 8 small tissue 
biopsies were taken, to account for heterogeneity within the synovium, and 
suspended in 6 ml of complete fibroblast medium (Roswell Park Memorial 
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Institute 1640 (RPMI 1640, Sigma), 10% v/v foetal bovine serum (FBS, Labtech), 
[0.87X] minimal essential medium non-essential amino acids (Sigma), 0.87mM 
sodium pyruvate (Sigma), 1.75mM L-glutamine, 87U/ml penicillin, 87µg/ml 
streptomycin (added as a mixed L-glutamine-penicillin-streptomycin solution, 
Sigma)). The suspension was then transferred to a T25 flask and incubated at 
37oC 5% CO2 for 1 week after which the medium was replaced with fresh medium 
weekly. Cells begin to grow out from the tissue within 1-2 weeks and reach 80% 
confluency within a period of 6 months. The weekly feeding cycle was continued 
with 33% of the medium (conditioned medium) kept in the flask at each feed and 
66% replaced with fresh complete fibroblast medium. Upon reaching 80% 
confluency the cells were passaged by removing the medium, washing in 
phosphate buffered saline (PBS, Oxoid), and trypsinising by incubating with 10x 
Trypsin ethylenediaminetetraacetic acid (EDTA) solution (Sigma) diluted to 2x 
with PBS for 5 minutes at 37oC. The Trypsin was then inhibited by adding 
complete fibroblast medium to the suspension before centrifuging at 300g for 6 
minutes. The cell suspension was then seeded into two T75 flasks and again 
cultured until 80% confluent. The cells were then split in a 1:3 ratio with vials of 
cells frozen in 10% dimethyl sulphoxide (DMSO, Sigma) with 90 % FBS and 
stored at -140°C when possible. Cells were used for experiments between 
passages 3 and 7. 
 
2.2.2 Treatment of fibroblasts 
The protocol used by Maria Juárez Pérez to generate samples for analysis of 
gene expression by microarray analysis is as follows: fibroblasts were cultured 
(section 2.2.1) until an 80% confluent monolayer was reached during passage 
76 
 
three with three flasks of the same fibroblast line. The medium was then removed 
from the cells before washing with PBS and adding new medium to each flask; 
one flask with 6ml of complete fibroblast medium (10% FBS v/v), one flask with 
6ml of complete fibroblast medium (10% FBS v/v) containing 10ng/ml TNFα, and 
one flask with 6ml fibroblast medium containing FBS of 0.1% v/v. All flasks were 
incubated at 37oC 5% CO2 for 24 hours before another PBS wash, removal of the 
cells by incubating with 2xTrypsin EDTA for 5 minutes, and producing cell pellets 
at a concentration of 0.5x106 cells/pellet. Cell pellets were then stored at -80oC 
until RNA isolations were performed. RNA was subsequently isolated using the 
RNeasy and QIAshredder kits (Qiagen), and RNA clean and concentrator 25 kit 
(Cambridge biosciences) all according to the manufacturer’s instructions. RNA 
quantity and quality were assessed using a Nanodrop 2000 spectrophotometer 
(Thermo Fisher Scientific). Clinical details of the fibroblast lines used are 
presented in Table 4. 
  
 
7
7
 
ID Group Disease 
classification 
Site CCP 
+/- 
RF 
+/- 
Disease 
duration 
(Weeks) 
Age Sex DMARD Prednisolone DAS28 
ESR 
baseline 
ESR 
(mm/
hr) 
CRP 
(mg/l) 
BX003 VeRA RA Knee + + 4 50 M None None 5.7 31 26 
BX004 Res UA Knee - - 3 33 M None None 3.6 9 6 
BX005 VeRA RA Knee - - 5 70 F None None 6.0 68 26 
BX008 Res UA Knee - - 6 64 M None None 4.5 24 15 
BX010 Res Parvovirus Knee - - 4 40 F None None 3.9 5 0 
BX011 VeRA RA Knee - - 2 49 F None None 4.7 12 8 
BX013 VeRA RA Knee - - 10 45 F None None 3.8 24 12 
BX015 VeRA RA Knee - - 2 48 F None None 3.5 4 102 
BX016 RA RA Knee + + 150 46 M None None 6.7 34 7 
BX020 VeRA RA Knee - - 6 59 M None None 5.0 14 22 
BX024 Res Reactive Knee - - 7 32 M None None 2.9 10 10 
BX028 Res RA Knee - - 5 74 M None None 4.8 45 13 
BX030 Res RA Knee - - 8 72 M None None 3.6 5 0 
BX031 VeRA RA Knee - - 9 43 M None None 6.9 58 0 
BX032 RA RA Ankle + - 30 46 F None None 5.2 24 32 
BX033 Res Pseudogout Ankle - - 7 81 F None None 6.7 60 52 
BX038 Res Parvovirus Knee - - 1 45 F None None 4.0 4 0 
BX040 VeRA RA MCP - + 10 56 M None None 5.2 5 0 
BX042 VeRA RA Knee + - 4 55 M None None 3.5 58 45 
BX045 VeRA RA Ankle + + 2 42 F None None 8.3 54 40 
BX048 Res Reactive/post 
strep 
Knee - - 2 35 M None None 4.1 51 7 
BX049 VeRA RA Ankle + + 3 48 F None None 3.9 10 0 
BX054 Res UA Ankle - - 6 55 M None None 3.5 2 6 
BX055 RA RA Knee - - 26 64 M None None 5.4 13 17 
BX063 VeRA RA Knee + - 9 74 F None None 4.4 20 32 
BX064 Res UA Knee - - 1 35 M None None 1.6 2 9 
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BX065 Res UA Knee - - 7 37 F None None 3.3 7 0 
BX066 RA RA  Knee + + 38 67 M None None 4.2 29 48 
BX070 Normal Normal Knee - - NA 44 M None None NA NA NA 
BX071 Res Parvovirus Ankle - - 4 41 F None None 1.7 5 9 
BX072 Res UA Knee - - 10 32 M None None 3.6 15 0 
BX075 RA RA Knee - - 52 22 F None None 6.4 81 79 
BX076 Res Reactive Knee - - 6 28 M None None 4.5 18 8 
BX077 RA RA Knee - - 38 72 M None None 7.4 53 43 
BX081 Normal Normal Knee - - NA 59 F None None NA NA NA 
BX082 Normal Normal Knee - - NA 49 F None None NA NA NA 
BX083 Normal Normal Knee - - NA 42 M None None NA NA NA 
BX084 VeRA RA MCP + + 6 49 M None None 6.8 25 18 
BX085 Normal Normal Knee - - NA 38 M None None NA NA NA 
BX086 RA RA Ankle + + 38 52 F None None 6.5 26 52 
BX087 Res Reactive Ankle - - 4 27 M None None 3.8 37 28 
BX088 Normal Normal Knee - - NA 34 M None None NA NA NA 
BX089 Normal Normal Knee - - NA 38 F None None NA NA NA 
BX092 VeRA RA MCP + + 4 48 M None None 6.0 63 38 
BX093 RA RA Knee + + 156 65 F None None 5.3 72 81 
BX094 Normal Normal Knee - - NA 46 F None None NA NA NA 
BX113 RA RA Ankle - - 53 65 M None None 5.0 50 10 
BX118 RA RA MCP + + 114 64 F None None 6.1 46 10 
RA06SY Jrep RA Knee NA + 1560 60 M SSA None 6.399599 54 75 
RA15SY Jrep RA Knee NA - 1144 37 M MTX, 
Leflunomide 
None 5.055023 46 50 
RA20SY Jrep RA Knee NA + 1040 72 M Leflunomide None 4.83098 18 3 
RA23SY Jrep RA Knee NA + 572 58 F MTX None 6.726424 23 32 
RA25SY Jrep RA Knee NA + 1560 53 F HCQ 10mg 3.6 NA NA 
RA28SY Jrep RA Knee NA - 1040 41 F Gold 10mg 3.3 20 26 
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RA29SY Jrep RA Knee + + 364 67 F Etanercept, 
MTX 
7.5mg 6.6 57 66 
RA37SY Jrep RA Knee + + 1196 54 F None 5mg 5.9 45 57 
Table 4: Clinical characteristics of the patients from which fibroblast lines were isolated and used for the microarray experiments. NA 
= Not available, MTX = Methotrexate, DAS28 = Disease activity 28 score, ESR = Erythrocyte sedimentation rate, CRP = C-reactive protein, 
CCP = Anti-cyclic citrullinated peptide, RF = Rheumatoid factor, MCP = Metacarpophalangeal, UA = Undifferentiated arthritis, HCQ = 
Hydroxychloroquine, SSA = Sulfasalazine. 
 
 
 80 
 
2.2.3 Microarray preparation and data generation 
Two-colour Sure Print G3 gene expression 8x60k v2 (Agilent) microarrays were 
completed by Oxford Gene Technologies. The RNA isolates generated in 4.2.1 
were converted to cDNA using the Low Input Quick Amp Two-Colour Labelling 
kit (Agilent) and in parallel Stratagene universal human reference RNA (Agilent) 
was also converted to cDNA and the sample and reference cDNA were labelled 
with Cy3 and Cy5 fluorophores respectively. Sample and reference cDNA were 
mixed in equal ratios and hybridised to the microarrays before reading the slides 
using an Agilent G2505C scanner and generating data for further analysis using 
Agilent Feature Extraction version 10.7.3.1. During generation of the data pre-
processing steps were completed consisting of locally weighted scatterplot 
smoothing (LOESS) normalisation to correct for dye-bias and background 
correction using the subtract method of subtracting background values from the 
relevant foreground values. 
 
2.2.4 Analysis of microarray data 
All quality control and analysis from this point onwards was completed by the 
author of this thesis. Analysis was completed using R 3.4.1 and RStudio 1.0.153. 
Feature extraction files generated during imaging of the arrays were loaded into 
the R session and analysed using the limma package (Ritchie et al., 2015). Due 
to the functions which generate log2 ratio data requiring the reference sample to 
be in the green channel and the test sample in the red channel, the data in the 
columns was swapped before any further analysis. The data was subjected to 
within-array normalisation using the LOESS method and background correction 
using the ‘normexp’ method before a final between-array normalisation step using 
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the ‘G-quantile’ method. Following normalisation, quality checks were completed 
using the arrayQualityMetrics package which automates the production of several 
quality metrics for all of the arrays and additionally through the generation of 
heatmaps for all log2 ratios for the probes in the original layout of the array 
(allowing the identification of artefacts such as fibres on the arrays) (Kauffmann, 
Gentleman and Huber, 2009) . Samples showing abnormal MA-plots or that were 
highlighted as outliers by the arrayQualityMetrics package were excluded from 
further analysis leaving 148 samples. Replicate probes were then averaged and 
all probes were non-specifically filtered by calculating the standard deviation of 
each probe across arrays and keeping the top 60% of probes ranked according 
to variation. Differential expression analysis was completed using the limma 
package by fitting a linear model. Due to the lack of an array annotation package 
for the Agilent arrays with ID AMADID039494 the packages human.db0 and 
AnnotationForge were used to generate an AMADID039494.db package using 
the annotation information obtained from the Agilent website. 
 
2.3 Results 
2.3.1 Data preparation and exploration 
The data used in this chapter were generated from 165 two-colour Agilent 
microarrays with the green colour of each array corresponding to a universal 
control hybridised to all arrays and the red colour to an individual sample for each 
array. Individual samples were divided amongst three treatment groups; TNFα 
and high-serum stimulated, high-serum stimulated, and low-serum stimulated 
(see section 2.2.2). The 5 BEACON disease outcome groups were joint 
replacement (Jrep), established RA (EstRA), very early RA (Early), resolving 
arthritis (Res), and normal non-inflamed control (Norm) (see section 1.7). 
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As any large datasets, it was important to explore the structure of the microarray 
dataset and filter out poor quality samples as the presence of these could lead to 
spurious results when investigating biological differences. A total of 165 arrays 
were normalised using a two-step process, first the arrays were corrected for 
background noise and probes normalised within arrays by fitting locally weighted 
scatterplot smoothing (LOESS) (Figure 9 A and B). The arrays were then 
normalised between each other by aligning the distribution of the green channel 
intensities and adjusting the red channel accordingly using quantile 
normalisation. This approach rests on the assumption that the same reference 
cDNA was used on the green channel of every array, such that the intensity of 
this channel on each array should have the same distribution (Figure 9 C). 
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Figure 9: Density plots of the intensity of Red and Green channel fluorescence for 
all probes on each array (left-hand side) and plots of the log2 ratios of green and 
red fluorescence against the mean red and green log2 intensity for each probe in 
the array (known as MA-plots, right-hand side) for sample BX003 grown in high 
serum with no additional stimuli. Plots A (top row) show the raw non-normalised 
data, B (middle row) show the LOESS normalised within array data, and C (bottom 
row) show the within array and G-quantile between array normalisation. The 
horizontal line on the MA-plots is to aid visualisation of the shape of the plotted 
data. 
 
Following normalisation, quality control of the array data using the 
arrayQualityMetrics package was completed. This package calculates distances 
between arrays, calculated as the mean absolute difference between the arrays 
when comparing all probes, and flags arrays as outliers when the sum of 
distances of one array to all others is exceptionally large, compares the 
distribution of the log2 red and green channel intensity ratios (referred to as log2 
ratio from here onwards) to the pooled log2 ratio distribution of all arrays and flags 
arrays as outliers based on the Kolmogorov-Smirnov statistic of these 
comparisons, and compares the joint distribution of both the M and A values of 
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MA-plots for each array using Hoeffding’s statistic for outlier detection. In addition 
to the automatic outlier detection all MA-plots were manually checked for unusual 
distributions and arrays with concerning MA-plots were flagged. Using this 
combination of manual and automated outlier detection 17 arrays were detected 
as outliers and excluded from further analysis leaving 148 arrays. 
 
In a previous analysis of this dataset (Juárez Pérez, 2014) it was found through 
examination of log2 ratios of sex-specific genes that several samples appeared 
to have expression levels inconsistent with the biological sex recorded in the 
clinical data for the patient from which the sample was derived. This analysis was 
repeated here through comparison of the log2 ratios of XIST, a gene which is 
involved in X-inactivation and expressed at higher levels in females, between 
arrays (Herzing et al., 1997). As several of the probes on the arrays target XIST 
the mean log2 ratio of these probes was calculated for each array and the results 
plotted as a frequency histogram (Figure 10). The resulting distribution is bimodal 
as expected with a higher population representing the female samples and a 
lower population representing the male samples. In order to compare the sex 
according to gene expression with that recorded in the clinical data a cutoff of -
1.2 for mean XIST expression was used as the separation between male and 
female samples, samples with mean XIST log2 ratios below this value were 
classified as males and those with mean XIST log2 ratios above classified as 
females and the resulting classification compared with that present in the clinical 
data. Using this approach RA29SY, BX113, BX093, BX084, BX077, and BX072 
were identified as having an incorrect sex. As it is unknown if the samples were 
mislabelled during experiments or the expression of XIST does not match the 
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expected pattern due to an unknown chromosomal abnormality the samples were 
excluded from further analysis leaving 132 arrays after removal of the 16 
abnormal arrays. 
 
Figure 10: Frequency distribution of the mean log2 ratio of probes targeting XIST 
on each array. The distribution was clearly bimodal as would be expected of a 
dataset containing male and female samples. The samples with high XIST 
expression are biological females and the samples with low expression are 
biological males. 
 
As a final quality control step the log2 ratios of each probe on an array were 
plotted as a heatmap according to the original layout of the probes on the array. 
This technique allowed visualisation of any gross artefacts that may have been 
present on the arrays to see if any compromised arrays had passed the quality 
control steps. Using this approach three arrays were found to have small artefacts 
affecting the log2 ratios of a small number of probes (an example can be seen in 
Figure 11). As the number of probes affected on each array appeared to be small 
it was decided to keep the arrays in the final dataset. 
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Figure 11: Heatmap of log2 ratios plotted according position of the probes on the 
array. Green represents a low log2 ratio whereas red represents high. The array 
shown is for the sample BX031 grown in low serum with no stimuli. Small artefacts 
could be seen affecting some probes as small red or green ‘threads’ visible on the 
array. 
 
As final steps of data preparation replicate probes identified using the Agilent 
probe ID were averaged (mean) reducing 62,976 probes to 50,739 and these 
probes were then subjected to non-specific filtering by calculating the standard 
deviation of each probe across the arrays and keeping the top 60% of the probes 
when ranked from largest to smallest standard deviation. All these quality control 
and data preparation steps resulted in a final probe count of 30,443 with the 
number of samples remaining in each biological group of interest shown in Table 
5. 
 
 
TNF High serum Low serum 
Jrep 6 7 6 
EstRA 6 6 5 
Early 12 12 9 
Res 14 15 12 
Norm 7 8 7 
Table 5: Number of samples remaining in each biological group of interest after 
quality control and data preparation 
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Principal component analysis (PCA) of the curated microarray dataset found the 
largest sources of variation to be the treatments the synovial fibroblasts were 
subjected to prior to the microarray procedure (Figure 12). The first two principal 
components accounted for 40% of the variation in the dataset and clearly 
separated the data into three clusters consisting of the TNF/serum treated 
samples as would be expected. As hypothesised the diagnostic groups of the 
patient from which the fibroblast lines were isolated also contributed to the 
variation in the dataset albeit across several different principal components 
(Figure 13). The normal samples were separated from other samples along 
principal components four and five whereas the joint replacement samples 
separated along components eight and nine. Interestingly, three or four rough 
clusters could be visualised in principal components 5 and 6 consisting of the 
Norm samples, the Early and Res samples, and the Jrep and EstRA samples 
respectively. 
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Figure 12: Principal component analysis of the prepared synovial fibroblast 
microarray dataset. Principal components one and two clearly separated the 
treatment groups with approximately 40% of variance in the dataset accounted for 
in these two components. Three clear clusters could be seen which accounted for 
the TNF stimulated samples (red), the samples grown in high serum (10% FBS) 
with no additional stimuli (green), and the samples grown in low serum (0.1% FBS) 
with no additional stimuli (blue). Ellipses are 95% confidence intervals for each 
cluster. TNF.High = TNF stimulated high-serum samples, Unstim.High = 
Unstimulated high-serum samples, Unstim.Low = Unstimulated low-serum 
samples. 
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Figure 13: Principal component analysis of the prepared synovial fibroblast 
microarray dataset. Separation of the dataset on the basis of diagnosis was not 
clear, however the normal and Jrep samples appeared to separate on principal 
components four and five or eight and nine respectively. Principal components 
five and six appeared to slightly separate three broad clusters consisting of the 
Norm samples, the Early and Res samples, and the Jrep and EstRA samples 
respectively. Early = very early RA, EstRA = established RA, Jrep = joint 
replacement RA, Norm = normal controls, Res = resolving arthritis. 
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Investigating other relevant and potentially confounding biological variables found 
variation dependent on the sex of the patient from which the samples were 
generated and the joint from which the biopsy was collected. The sex of the 
patient from which the fibroblasts were isolated contributed to the variation in the 
dataset with subtle separation of samples visible in principal components seven, 
eight, and nine (Figure 14). However, the amount of variation accounted for by 
sex was less than that between the treatments, with approximately 6% of 
variation being contributed by this variable; this was similar to that due to the 
disease grouping of the samples. Site dependent differences between samples 
(principal component seven, 2.32% of variance) separated the ankle from the 
knee and metacarpophalangeal (MCP) samples (Figure 15). Some separation 
could be seen between the MCP and the other samples in other principal 
components however the low number of MCP samples made it difficult to 
ascertain if a separate cluster was truly present. 
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Figure 14: Principal component analysis of the prepared synovial fibroblast 
microarray dataset. Separation of the data on the basis of donor sex can be found 
in the principal components 7, 8, and 9 with approximately 6% of the variance in 
the dataset accounted for by these components. 
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Figure 15: Principal component analysis of the prepared synovial fibroblast 
microarray dataset. Separation of the samples on the basis of site/joint from which 
the fibroblasts were isolated could be seen on the seventh principal component 
which accounted for 2.32% of the variance in the data. 
 
Using this approach of analysing variance within each diagnostic outcome group 
across treatments did not provide any clearer clustering in the TNF treated 
samples however the normal samples still formed a subtly separated group of 
samples (Figure 16). Investigating the high serum unstimulated samples the 
normal, established RA, and joint replacement samples could each be seen 
forming subtly separated clusters in the second and third, fifth and sixth, sixth, 
and seventh principal components respectively mirroring the behaviour seen 
when running PCA on all of the samples (Figure 17). In the low serum samples 
separation between the disease groups could be seen in principal components 3 
and 4 with the Jrep, Early and Res, and Norm and EstRA broadly forming 
separate clusters (Figure 18). 
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Figure 16: Principal component analysis of the TNF treated, high serum treated, 
synovial fibroblast microarray dataset. Although not a clear separation a tendency 
of the normal samples to cluster separately from the other samples could be seen 
in principal component 2. 
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Figure 17: Principal component analysis of the high serum treated, unstimulated 
synovial fibroblast microarray dataset. The normal, established RA, and joint 
replacement samples could each be seen forming slightly separate clusters in the 
second and third, fifth and sixth, sixth, and seventh principal components 
respectively. 
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Figure 18: Principal component analysis of the low serum treated, unstimulated 
synovial fibroblast microarray dataset. Jrep samples, Early and Res samples, and 
EstRA and Norm samples broadly form separate clusters. 
 
2.3.2 Differences between disease outcomes in each treatment 
Due to the presence of unwanted (at least for the hypothesis being addressed) 
sex and site dependent variation within the dataset, a linear model was fitted to 
each probe using sex and site as the independent variables. The residuals were 
then taken from this model and a second model was fitted to the residuals using 
diagnosis and treatment as the independent variables. This strategy reduces the 
unwanted variation that may obfuscate the results of interest and was 
implemented after discussions and in collaboration with Kamil Slowikowski 
(Soumya Raychaudhuri lab, Brigham and Women’s Hospital, Boston). The effect 
of this approach was apparent when looking at the principal components in which 
sex and site differences were visible in the original dataset. For example Figure 
19 and Figure 20 show the clustering of TNF treated samples according to site 
and sex respectively both before and after the correction. 
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Figure 19: Principal component analysis of the TNF treated prepared synovial 
fibroblast microarray data in A, and of the dataset after fitting a model using sex 
and site as the independent variables and taking the residuals of the model for 
each probe in B. The effect of this approach was apparent as the separate clusters 
of knee and ankle samples present in principal components 6 and 7 in A were no 
longer visible in the ‘corrected’ data in B. 
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Figure 20: Principal component analysis of the TNF treated prepared synovial 
fibroblast microarray data in A, and of the dataset after fitting a model using sex 
and site as the independent variables and taking the residuals of the model for 
each probe in B. The effect of this approach was apparent as the separate clusters 
of female and male samples present in principal components 4 and 5 in A were no 
longer visible in the ‘corrected’ data in B. 
 
Returning to the biological question of interest, how the fibroblasts from different 
disease stages differ in the different treatment groups, analyses of differentially 
expressed genes were made to address this question however a large number 
of differentially expressed genes were detected in many of the comparisons. 
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Whilst this indicated differences exist between the fibroblasts from different 
disease stages, the number of differentially expressed (DE) genes made 
interpretation complex. To expedite the analysis in each treatment group the DE 
genes from all comparisons were manually curated to select genes that may be 
of particular interest to RA and the immune system or genes that appear to be 
consistently expressed in one disease group compared to the others and only 
these selected genes were further investigated. Full tables of the selected 
differentially expressed genes are available in appendices 8.6, 8.7, and 8.8. 
 
2.3.2.1 TNFα stimulated 
Complete linkage hierarchical clustering of the TNF stimulated samples using 
Pearson’s correlation distance calculated on the top 400 most variable genes 
between the samples did not provide clear separation of the samples depending 
on disease state (Figure 21). A cluster of resolving arthritis and very early RA 
samples could be found on the left-hand side of the dendrogram however the 
remaining samples appeared to be mixed throughout the plot. 
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Figure 21: Dendrogram showing complete linkage hierarchical clustering of the 
TNF stimulated samples using Pearson’s correlation distance calculated on the 
top 400 most variable genes between the samples after correction for sex and site 
influence. Clustering by diagnosis was unclear however possible clustering of 
resolving arthritis and very early RA samples was visible on the left-hand side of 
the plot. 
 
Analysis of differentially expressed genes between the diagnosis groups in the 
TNF stimulated samples found a considerable number of DE genes in all 
comparisons with the exception of between very early RA and resolving arthritis 
samples in which no DE genes were detected (Table 6). The lack of DE genes 
between the Res and Early samples may reflect a lack of differences between 
these two disease outcomes in the fibroblasts during very early disease, a fact 
which is reflected by the clustering seen in PCA plots in Figure 13 and Figure 16. 
 
 
Jrep EstRA Early Res 
Norm 1013 1755 1951 1168 
Res 58 992 0 
 
Early 262 2200 
  
EstRA 656 
   
Table 6: Number of differentially expressed genes between each disease group in 
the TNF stimulated samples 
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The lists of DE genes were manually curated as aforementioned and the resulting 
gene lists were investigated to find genes in each disease group that were 
consistently up- or down-regulated across the comparisons with other disease 
outcome groups and may represent an identifying phenotype. In the TNF 
stimulated Jrep samples this identified two upregulated and two downregulated 
genes that were expressed at higher or lower levels than all or most of the other 
disease groups. The upregulated genes were HAS3, encoding hyaluronan 
synthase 3, and IL-6, which was expressed at higher levels in the Jrep than 
EstRA, Early, and Norm samples. The genes downregulated in the Jrep samples 
were FOS and FOSB, downregulated when compared to all but Norm samples, 
which encode c-Fos and FosB respectively.  
 
Using the same approach to investigate genes in the EstRA samples found five 
upregulated genes of interest and three downregulated that may represent a 
phenotype specific to the disease group. Of the upregulated genes XIST was 
detected as differentially expressed between EstRA and all other groups except 
the Jrep samples indicating that the approach taken to reduce the influence of 
sex and site on the dataset did not completely remove the variation contributed 
by these aspects (Figure 22). Investigating the number of male and female 
samples in each group clearly showed an imbalance particularly in the EstRA and 
Jrep samples (Table 7). 
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Figure 22: Expression of XIST in the TNF stimulated microarray samples after 
fitting a linear model to reduce the variation contributed by sex and site to the 
dataset. It is clear XIST expression remained higher in the EstRA samples than in 
the other groups. 
 
 Male Female 
Jrep 2 4 
EstRA 2 4 
Early 5 7 
Res 5 9 
Norm 3 4 
Table 7: Number of male and female samples in each disease group of the TNF 
stimulated microarray samples 
 
The comparison of Norm samples with the other disease groups found several 
up- and down-regulated genes consistent across the comparisons. Both CCL8 
and CCL20 were expressed at higher levels in Norm samples compared to all 
others, indicating differential regulation of leukocyte migration mediated by 
normal fibroblasts and fibroblasts from an inflammatory state, an unsurprising 
finding. This is further confirmed by the higher expression of CXCL10 in Norm 
samples than in all other states except EstRA. The gene encoding cathepsin K, 
CTSK, was expressed at higher levels in the Norm samples than Res, EstRA, 
and Jrep samples and normal synovial fibroblasts also expressed higher levels 
of the gene encoding CD44, a receptor for hyaluronan that also may be involved 
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in process of activating and secreting TGF-β (Acharya et al., 2008; Aruffo et al., 
1990). The expression of a reported fibroblast subset marker, CD34, was higher 
in Norm samples than Jrep or EstRA and the expression of another fibroblast 
subset marker, PDPN, was higher in Norm samples than all other groups except 
Early indicating that either the fibroblasts in each disease state had a 
homogenous population with different levels of subset markers between disease 
stages or that each disease group consisted of different proportions of fibroblast 
subsets (Mizoguchi et al., 2017). Of the genes downregulated in the Norm 
samples compared to other disease groups HIST1H4C and HIST1H4L were 
consistently lower expressed in the Norm samples. 
 
Investigating the expression of known stromal markers showed differences in 
expression between disease stages such as the already mentioned higher CD34 
expression in the normal samples and also increased PDPN (GP38) expression 
in Norm and EstRA samples (albeit not detected as DE in EstRA samples) (Figure 
23) (Choi et al., 2017; Mizoguchi et al., 2017). Expression of THY1 (CD90) 
showed no clear modulation whereas FAP expression appeared highest in the 
Early samples. 
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Figure 23: Expression of genes encoding markers of stromal populations in the 
TNF stimulated microarray data. 
 
2.3.2.2 Unstimulated high serum. 
As with the TNF stimulated samples complete linkage hierarchical clustering of 
the unstimulated high serum samples using Pearson’s correlation distance 
calculated on the top 400 most variable genes between the samples did not find 
clear clusters according to diagnosis (Figure 24). However six of the eight Norm 
samples could be found in the cluster on the right hand side of the plot indicating 
some degree of clustering was occurring. The remaining samples were spread 
throughout the plot with no clear clustering apparent. 
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Figure 24: Complete linkage hierarchical clustering of the unstimulated high 
serum samples using Pearson’s correlation distance calculated on the top 400 
most variable genes between the samples after correction for sex and site 
influence. Clustering by diagnosis was unclear however a concentration of Norm 
samples could be seen in the right hand clusters. 
 
When comparing different disease groups large numbers of DE genes were 
detected for all comparisons except Early versus Res, in which no DE genes were 
detected again, and Jrep versus Res, in which 46 genes were detected as DE 
(Table 8). These findings were similar to those in the TNF stimulated samples 
indicating that with or without the stimulus the disease groups maintained a 
degree of similarity. 
 
 
Jrep EstRA Early Res 
Norm 1063 3093 3466 2730 
Res 46 2035 0 
 
Early 299 2348 
  
EstRA 1110 
   
Table 8: Number of differentially expressed genes between each disease group in 
the unstimulated high serum samples. 
 
To investigate the large number of DE genes the same approach was taken to 
manually select relevant genes and then to investigate these genes for a 
conserved pattern of expression across comparisons that may aid in assigning a 
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phenotype or function to samples in each disease grouping. Jrep samples had 
significantly higher expression of MOK, encoding a protein kinase, than any other 
disease groups. WNT16 was higher in Jrep samples compared to Res and Norm 
samples but not EstRA or Early samples. The increased expression of HAS3 
seen in the TNF stimulated samples was preserved in the unstimulated high 
serum samples with expression being higher in Jrep compared to Early, Res, or 
Norm. Considering genes downregulated in the Jrep samples, FOS and FOSB 
were both expressed at lower levels in the Jrep than the EstRA, Early and Norm 
samples or the EstRA, and Early samples respectively continuing the similarities 
with the TNF stimulated samples but with slight differences in which disease 
groups have lower expression. Jrep samples also had lower expression of the 
gene encoding hyaluronidase-1, HYAL1, than EstRA or Norm samples. 
 
Investigating the Norm samples again highlighted similarities between this subset 
in the unstimulated high serum samples and TNF stimulated samples. The subset 
marker CD34 was expressed at higher levels in the Norm samples compared to 
all other disease groups as was CTSK. CTSH which encodes cathepsin H was 
also higher in Norm compared to all other groups. Expression of the 
monocyte/macrophage chemoattractant CXCL14 was also higher in Norm 
samples as was the expression of MMP2 and CCR3 (Augsten et al., 2009). 
VEGFB was expressed at higher levels in the Norm samples than all other groups 
perhaps indicating this gene is downregulated in response to inflammation. FIGF, 
also known as VEGFD was also higher expressed in the Norm samples which 
may indicate differences in vascularisation between normal and inflamed 
samples. Finally, Norm samples expressed higher levels of the IL1 receptor 
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encoding gene IL1R1, of TLR5 which has been implicated in joint damage, and 
CSF1 encoding the macrophage differentiation factor M-CSF (Fleetwood et al., 
2007; Kassem et al., 2015). 
 
Considering the genes downregulated in the Norm samples several keratin 
genes, KRT14, KRT16, and KRT19 were expressed at lower levels in Norm 
compared to the other disease groupings along with HAS2 and SERPINE1 again 
hinting at differences in matrix constituents in between inflamed and non-inflamed 
tissues. CDH13, encoding cadherin-13, has been shown to inhibit proliferation 
and to be downregulated in tumours and is downregulated in the Norm samples 
(Sato et al., 1998; Takeuchi et al., 2002; Takeuchi et al., 2000). Expression of 
serine/threonine kinase 24 and integrin alpha-3 and TGFB1 were all 
downregulated in the Norm samples also. Finally, as in the TNF stimulated 
samples several histone genes were downregulated in the Norm samples 
compared to the EstRA, Early, and Res samples. HIST1H3H, HIST1H3G, 
HIST2H3D, HIST2H2BF, and HIST3H4C all showed this downregulated pattern 
of expression. 
 
Investigating the expression of fibroblast subset markers as with the TNF 
stimulated samples found similar patterns (Figure 25). The higher expression of 
PDPN (GP38) in the Norm samples seen in the TNF stimulated dataset was 
reduced in the unstimulated high serum samples however the higher level of 
CD34 expression was maintained as was the increased expression of FAP in the 
Early samples. 
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Figure 25: Expression of genes encoding markers of stromal populations in the 
unstimulated high serum microarray data. 
 
2.3.2.3 Unstimulated low serum. 
As with the previous samples hierarchical clustering did not find any clear 
clustering of clinical outcome groups in the unstimulated low serum dataset 
(Figure 26). EstRA samples in particular were spread throughout the dendrogram 
whereas some degree of clustering for Norm and Res samples could be seen in 
the middle region of the plot and some Jrep samples had clustered on the left-
hand side of the plot. 
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Figure 26: Complete linkage hierarchical clustering of the unstimulated low serum 
samples using Pearson’s correlation distance calculated on the top 400 most 
variable genes between the samples after correction for sex and site influence. 
Clustering by diagnosis was unclear, some clustering of Norm and Res samples 
could be found towards the centre of the dendrogram with some Jrep clustering 
to the left hand-side but no clearly separated clusters. 
 
The number of DE genes found in the comparisons of low serum samples was 
smaller than those found when investigating the TNF stimulated or unstimulated 
high serum samples (Table 9). In these samples comparisons with the EstRA 
group consistently found the lowest numbers of DE genes with only comparisons 
with EstRA versus Norm or Jrep v EstRA finding any DE genes (43 and two 
respectively). The comparison of Early and Res in the low serum dataset found 
only 1 DE gene following the pattern of no clear differences between these groups 
as in the previous datasets. 
 
 
Jrep EstRA Early Res 
Norm 868 2 369 30 
Res 579 0 1 
 
Early 1134 0 
  
EstRA 43 
   
Table 9: Number of differentially expressed genes between each disease group in 
the unstimulated low serum samples. 
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Investigating the gene signature of Jrep samples found 14 genes that showed 
consistent regulation across the comparison of the different disease groups. 
TAGLN, encoding transgelin which is involved in cytoskeletal rearrangements, 
was higher in Jrep than in all other disease groups (Thompson et al., 2012). 
Another gene, POGZ, was upregulated in Jrep samples compared to the other 
disease groups and could be involved in the IL-1β signalling pathway (Ainscough 
et al., 2015). The final gene that was higher in Jrep samples than all others was 
ADH4, encoding alcohol dehydrogenase 4 pi subunit. There were several genes 
that were higher in Jrep samples than Early, Res, or Norm samples such as 
ALDH3A1; encoding aldehyde dehydrogenase 3 family member A1, IL16, 
encoding pro-interleukin-16, AHRR, encoding the aryl hydrocarbon receptor 
repressor, and ZFAT. No genes were found to be consistently downregulated in 
Jrep compared to all other samples. However NFKBIZ, COL4A3BP, MAPK6, 
IRAK1, BCL2, DUSP14, CTSA were all expressed at lower levels in the Jrep 
samples compared to the Early, Res and Norm samples. Expression of the 
subset marker FAP was lower in the Jrep samples when compared to Early 
samples. The genes involved in matrix regulation MMP11 and COL4A1 were both 
lower in Jrep samples than in Early or Res samples 
 
Moving on to the Norm samples, FIGF was expressed at higher levels than in all 
other disease subsets and the related gene VEGFB was higher than in Jrep or 
Early samples. The gene LGI1 was higher in the Norm samples than in EstRA, 
Early, or Res samples. As previously mentioned CD34 was higher in this disease 
group than in the Early samples. With regards to genes downregulated in the 
Norm subset two patterns of expression were found, genes lower in Norm 
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samples compared to Jrep, Early, and Res samples, and genes lower in Norm 
samples compared to Jrep and Early samples. TAGLN and CDH11 followed the 
first pattern of expression whereas SERPINE2, ITGA10, SERPINI1, and 
ADAMTS4 showed the second pattern. 
 
The expression of subset markers in the low serum samples highlighted the key 
differences found in the previous TNF stimulated and unstimulated high serum 
samples (Figure 27). Namely CD34 expression was highest in Norm samples and 
FAP was increased in the Early samples. 
 
 
Figure 27: Expression of genes encoding markers of stromal populations in the 
unstimulated low serum microarray data. 
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2.4 Discussion 
The first steps of analysis in big data approaches are normalisation/correction of 
the data followed by quality control and subsequent exploratory data analysis. 
Background correction and normalisation of the data acts to reduce unwanted 
variation, a very important step given the numerous sources of noise, and to 
prepare the data from each array to allow for comparisons between arrays 
(Coller, 2009). Many background correction and normalisation techniques are 
available for use on these kind of data each with advantages and disadvantages 
depending on the scenario. The normexp plus offset background correction was 
used here along with LOESS normalisation within arrays and G-quantile 
normalisation between arrays. The normexp plus offset has previously been 
shown to give a good consistent level of results with various datasets and a low 
false discovery rate (Ritchie et al., 2007). LOESS is a commonly used method to 
normalise microarray data removing technical variation (Cleveland, 1979; Smyth 
and Speed, 2003; Yang et al., 2002). The final normalisation step, G-quantile, is 
designed specifically for arrays in which a common reference was used on every 
array, which was the case here. The normalisation adjusts the distribution of the 
reference channels to match across all arrays and then adjusts the sample 
channel relative to the reference channel adjustment (see the documentation for 
the function normalizeBetweenArrays in the R Biocondutor package limma 
(Ritchie et al., 2015)). The normalisation successfully adjusted the distribution of 
the red and green fluorescence intensities and removed technical variation in the 
data as shown by a straightening in the curvature seen in some MA-plots. One 
additional benefit of the G-quantile normalisation method is that it could have 
helped to reduce batch effects introduced during the running of the arrays 
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although due to the lack of replicate samples in this dataset it was not possible to 
test how well this approach has worked. 
 
Comparisons of differentially expressed genes between disease stages in all 
treatment groups detected a large number of genes leading to a targeted 
approach to the analysis in order to make the data more manageable. This 
approach had obvious caveats such as overlooking possibly important genes, 
overlooking new DE genes which may be of interest but have not previously been 
studied, and the reliance upon the knowledge of the operator to select genes of 
interest. However the advantage, particularly in time constrained situations, was 
that the differentially expressed gene lists were reduced to a more manageable 
and easily interpretable size and the genes being explored were easier to explore 
in the context of RA pathogenesis. 
 
The comparison of most interest due to the possible benefits to early RA patients 
was between the very early RA and resolving arthritis group. As discussed in 
section 1.2 early treatment of RA is beneficial to patients and decreases joint 
damage over a substantial time period. However it is difficult to identify which 
patients are suffering from very early RA or from resolving arthritis and as such 
identification and treatment of RA patients during this early window is complex 
and improved biomarkers able to differentiate between resolving arthritis and 
persistent RA are still required. Unfortunately in the comparisons of these two 
disease stages in both the TNFα stimulated and unstimulated high serum 
samples no differentially expressed genes were detected and in the low serum 
samples only 1 differentially expressed gene, RIIAD1, was detected the 
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significance of which is unclear in the context of RA. The lack of differential gene 
expression between fibroblasts in the first three months of clinically evident 
arthritis is surprising given that functional differences have been found between 
fibroblasts from resolving arthritis and very early RA (Filer et al., 2017). In this 
publication fibroblasts from very early RA were found to recruit lymphocytes to 
stimulated endothelial cells whereas fibroblasts from resolving RA inhibited 
recruitment. This indicates functional assays may be required to understand the 
differences between cells from these outcome groups. Transcriptional analysis of 
freshly isolated fibroblasts may find more differences between these groups as 
long term culture is known to result in significant changes to gene expression 
(Zimmermann et al., 2000). 
 
The Jrep sample signature defined as genes consistently found to be higher in 
most if not all of the comparisons with other samples included HAS3, encoding 
hyaluronan synthase 3, and IL-6 which were upregulated and FOS and FOSB 
which were downregulated. Hyaluronan synthase 3 is responsible for the 
production of the synovial fluid constituent hyaluronic acid which is produced at 
higher levels in RA patients however doesn’t lead to a difference in synovial fluid 
concentrations as the volume of synovial fluid also increases in RA patients 
(Ragan and Meyer, 1949). Additionally, the expression of hyaluronan synthase in 
endothelial cells and skin fibroblasts is known to be induced by proinflammatory 
mediators such as IL-1β and hyaluronan is known to interact with the immune 
system and also correlated with RA disease activity in early RA (Campo et al., 
2006; De La Motte et al., 1999; Majeed et al., 2004; Mohamadzadeh et al., 1998). 
Increased expression of IL-6 in the Jrep samples compared to the others is 
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unsurprising given the well-known involvement of IL-6 in the pathogenesis of RA 
(Srirangan and Choy, 2010). FOS and FOSB are members of the FOS gene 
family which are capable of dimerizing with members of the Jun family of proteins 
to form the transcription factor AP-1 (Chiu et al., 1988). c-FOS has been found to 
be expressed in RA synovial fibroblasts producing collagenases and is 
constitutively expressed in RA fibroblasts even after in vitro culture (Dooley et al., 
1996; Trabandt et al., 1992). 
 
In the normal samples CTSK and CTSH were at higher levels than in all other 
disease stages. The activity of cathepsin H has previously been shown to be 
unchanged in leukocytes from RA patients and the serum levels of cathepsin H 
are not correlated with disease activity or radiographic progression (Jorgensen et 
al., 2011; Sohar, Hammer and Sohar, 2002). However these findings do not 
exclude the possibility that levels and activity of cathepsin H in fibroblasts are 
affected in RA. MMP2 and CCR3 were both found at higher levels in the normal 
samples than all others, an interesting finding given that MMP2 has been linked 
to erosive arthritis and CCR3 is thought to be expressed at higher levels in RA 
synovial fibroblasts (Goldbach-Mansky et al., 2000; Liu et al., 2017; Xue et al., 
2014b; Zhou et al., 2014). Interestingly, normal samples expressed higher levels 
of M-CSF which could be of importance given the role of this factor in 
differentiating anti-inflammatory macrophages (Fleetwood et al., 2007; Jaguin et 
al., 2013). Of the downregulated genes in the normal samples several can be 
linked to maintenance of matrix and synovial fluid. Three keratin genes, KRT14, 
KRT16, and KRT19 were all lower as was HAS2. The gene SERPINE1, which 
encodes PAI-1, was also reduced and has been associated with both pro-fibrotic 
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responses and poor prognosis in cancers (Durand et al., 2004; Ghosh and 
Vaughan, 2012; Marudamuthu et al., 2015). TGFB1 was lower in the normal 
samples which is in line with published data finding higher levels of TGF-β 
signalling in the synovium in RA (Gonzalo-Gil et al., 2013). Additionally the 
expression of the genes HIST1H3H, HIST1H3G, HIST2H3D, HIST2H2BF, and 
HIST3H4C which encode histone proteins was lower in the normal samples. 
 
In the low serum samples an immediate difference was apparent simply by 
examining the number of differentially expressed genes in each comparison. In 
the other treatment groups the established RA samples demonstrated a decent 
number of differentially expressed genes in line with the magnitude of differences 
seen in comparisons of other disease groups. In the low serum samples either 
no or few differentially expressed genes were found in all comparisons with this 
disease stage. As all of the established RA samples in all treatment groups were 
generated in a separate experimental batch and also run in a separate batch of 
arrays with the low serum samples rather than the high serum samples an 
immediate concern is that the previously discussed signatures for this disease 
group in the stimulated and unstimulated high serum samples were actually an 
artefact of batch effects and not actually a true biological finding. Unfortunately 
no replicate samples were run between groups and so it was not possibly to easily 
test for this kind of noise in these datasets. The signatures present in all of the 
low serum samples were considerably different than those shown the stimulated 
and unstimulated high serum samples. The differences were unlikely to be due 
to different experimental batches as no comparisons between batches were 
made in the low serum samples. The differences in signature may be a biological 
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finding as the two treatment groups displaying similar signatures were grown in 
high serum with or without stimulation. 
 
Of particular interest is that several subset markers were detected as differentially 
expressed between the disease stages. Across all treatment groups a pattern 
was seen in that CD34 expression was highest in the normal samples and FAP 
highest in the very early RA samples. The cultured synovial fibroblasts used for 
the microarrays had not been examined for the expression of these markers so it 
is unclear if the protein expression in culture follows the pattern seen here. 
Several possibilities exist that may explain the differences in subset marker in the 
cultures. As the fibroblasts were isolated using the outgrowth method no selection 
of particular subsets was implemented meaning the fibroblasts isolated could be 
a heterogeneous population consisting of different proportions of fibroblasts from 
different subsets depending on the disease stage from which they were isolated 
which are maintained through culture and result in detection of different levels of 
expression of the genes encoding the markers between disease stages. 
Alternatively once isolated fibroblasts may become a homogenous population all 
expressing similar levels of subset marker genes that vary between disease 
stages. 
 
The attempt to correct for variation contributed by sex using the linear modelling 
approach did not appear to completely eliminate confounding, as XIST was 
detected as differentially expressed in comparisons with the EstRA samples due 
to an imbalance in male and female samples. If the analysis was repeated 
techniques to correct for unwanted variation such as comBat or surrogate 
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variable analysis should be used and the results compared with the analysis in 
this thesis (Johnson, Li and Rabinovic, 2007; Leek and Storey, 2007). The risk of 
using these techniques is that some variation introduced by the biological 
differences of interest could also be removed. However, given the large number 
of differentially expressed genes detected this may not be a large issue with this 
dataset. As several samples were possibly mislabelled leading to the mismatch 
between sex and XIST expression it could also be possible that other samples 
may have been mislabelled but swapped with samples from the same sex donor 
meaning it is not possible to identify these samples. 
 
The analysis of this dataset improves on the previous analysis due to rigorous 
quality control steps and exploration of confounding sources of variation (Juárez 
Pérez, 2014). The major sources of unwanted variation were sex and site, 
unsurprising given the known transcriptional differences between fibroblasts 
isolated from different sites (Chang et al., 2002; Frank-Bertoncelj et al., 2017; 
Rinn et al., 2006). The data appeared robust with the differentially expressed 
genes making intuitive sense given the origin of the fibroblasts and in the context 
of published work. If the work was to be completed again there is a convincing 
argument to use only samples from one sex and site thus reducing variation from 
unwanted sources without the need for computational correction. In addition, 
analysis of freshly sorted and treated fibroblasts would avoid the influence of 
prolonged in vitro culture upon gene expression and possibly uncover findings 
masked by this effect.  
 
In summary the results of this chapter find that gene expression varied 
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significantly between different stages of RA but that resolving and very early RA 
are not significantly different. Gene signatures could be found in most disease 
stages in each treatment group that identified the stage of disease from which the 
fibroblasts were isolated. The expression of genes encoding previously identified 
subset markers varied between disease stages hinting that in vitro cultured 
fibroblasts may not be a homogeneous population. The expression of FAP could 
be a possible biomarker of very early RA allowing stratification of patients with 
early synovitis. 
 
The work in this chapter supported the first alternative hypothesis stated in this 
body of work; fibroblasts isolated from different stages of RA progression 
maintain differential gene expression during in vitro co-culture and respond to 
stimulation in different ways. The finding of differential gene expression between 
late stage RA and early stages of RA progression changes the viewpoint with 
which one should approach the literature. Most studies in the field use synovial 
fibroblasts isolated from patients undergoing joint replacements and therefore 
use a highly selected for group of patients with destructive RA that is likely to 
have encountered many treatment regimes. Differential gene expression 
between fibroblasts from this late stage RA and early stages indicates that the 
‘imprinted aggressor’ phenotype commonly referred to in the literature may be an 
artefact specific to destructive end stage RA (Bottini and Firestein, 2013). 
Additionally the lack of differential gene expression between fibroblasts from 
patients with resolving arthritis and patients with very early RA indicates that the 
imprinted changes that characterise RA fibroblasts do not occur during the first 
three months of apparent symptoms. These data could signpost that changes in 
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synovial fibroblasts are not the first features to occur in RA and instead occur 
subsequent to inappropriate activation and targeting of the immune system. This 
could explain why early therapeutic treatment has been shown to be alter overall 
disease progression and prevent joint damage more effectively than later 
treatment (Kyburz et al., 2011; Moura et al., 2015; Nell et al., 2004; Van Aken et 
al., 2004). 
 
The differences in gene expression between fibroblasts from different stages of 
RA adds to the knowledge in this field. As differences were detected it could be 
that these differences extend to fibroblast-monocyte crosstalk resulting in more 
pro-inflammatory monocyte phenotypes in late stage RA than early and as such 
we used in vitro assays to test this hypothesis.
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3 INVESTIGATING FIBROBLAST/MACROPHAGE INTERACTIONS: IN 
VITRO CO-CULTURES 
3.1 Introduction 
Given the sparsity of knowledge regarding the interaction between synovial 
fibroblasts and monocytes or macrophages, work was undertaken to address this 
using several different methods. Firstly, the technical aspects of co-culturing two 
cell types together including seeding density, removal and deconvolution, and 
optimal methods of monocyte isolation from peripheral blood were investigated. 
The effects of monocyte:fibroblast co-culture on cytokine release was 
interrogated to test the hypothesis that fibroblasts isolated from different 
BEACON outcome groups can differentially modulate monocyte phenotypes. 
Monocyte to macrophage differentiation was elicited with either M-CSF or GM-
CSF during co-culture with BEACON fibroblast lines to assess if fibroblasts are 
capable of differentially modulating monocyte to macrophage differentiation and 
drive a more pro- or anti-inflammatory phenotype. Finally, M-CSF differentiated 
macrophages were co-cultured with fibroblasts in the presence of TNFα to test 
the ability of BEACON fibroblasts to differentially modulate a set of interferon 
stimulated genes previously shown to be regulated by co-culture with synovial 
fibroblasts (Donlin et al., 2014). 
 
This chapter aimed to address the gap in knowledge regarding the influence of 
fibroblasts upon monocyte phenotype during RA progression using an in vitro 
system. As the previous chapter demonstrated fibroblasts from different stages 
of RA maintain differential gene expression it was hypothesised that this would 
translate into differences in protein expression that results in late stage RA 
fibroblasts driving a more pro-inflammatory phenotype in monocytes and 
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macrophages than fibroblasts from earlier stages. To test this hypothesis three 
questions were asked: 
1. Do fibroblasts isolated from different stages of RA progression 
differentially modulate cytokine/chemokine release from peripheral blood 
monocytes? 
2. Do fibroblasts isolated from different stages of RA progression 
differentially modulate monocyte-to-macrophage differentiation? 
3. Do fibroblasts isolated from different stages of RA progression 
differentially modulate macrophage response to stimulation? 
 
3.2 Materials and methods 
3.2.1 Fibroblast and RAW264.7 co-cultures 
Co-cultures of human synovial fibroblast lines and the murine 
monocyte/macrophage-like cell line RAW264.7 were investigated as an easy 
method for identifying the source of cytokines released during the co-culture by 
using species specific assays with the caveat that the species difference may 
also prevent or modify the interactions between the cell types (Raschke et al., 
1978). 45,000 fibroblasts were seeded into wells of a 24 well plate and rested for 
2 days before removal of the media and seeding either 50,000 or 600,000 
RAW264.7 cells on top of the fibroblasts and culturing for various timepoints. Co-
cultures were completed in standard complete fibroblast medium as specified in 
2.2.1. 
 
3.2.2 Monocyte isolation 
For all experiments except the stimulated co-cultures in section 3.3.6 peripheral 
blood was obtained from apheresis cones provided as a commercial product by 
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the NHSBT. This facilitated the easy isolation of large numbers of monocytes for 
each experiment. 
 
3.2.2.1 Method 1: Density gradient separation followed by subsequent 
negative selection using magnetic microbeads 
Monocytes were isolated from whole blood via density gradient separation using 
Ficoll-Paque PLUS (GE Healthcare) followed by negative selection using a pan-
human monocyte magnetic bead labelling kit (MiltenyiBiotec). The blood was 
emptied from a blood cone and any remaining blood flushed out with Hank’s 
balanced Salt solution (HBSS, No Ca or Mg, Life Technologies). The total volume 
of the blood was made up to 40ml with HBSS and gently mixed before being 
layered onto Ficoll-Paque PLUS at a 1:1 ratio and centrifuged. The isolated 
peripheral blood mononuclear cells (PBMCs) were then labelled with the pan-
human monocyte magnetic bead labelling kit and monocytes isolated by 
sequentially passing the labelled cell suspension through two MACs LS columns 
(MiltenyiBiotec). The purity and subset bias of isolated monocytes was 
determined by flow cytometric analysis of CD14(-PE) and CD16(-FITC) (BD 
Biosciences, clones MφP9 and 3G8) cell-surface expression using a Dako Cyan-
ADP.  
 
3.2.2.2 Method 2:  Double density gradient separation followed by 
adherence to tissue culture plastic 
The second method of monocyte isolation consisted of density gradient 
separation using Ficoll-Paque PLUS with a subsequent density gradient 
separation using Percoll PLUS (GE Healthcare) followed by seeding of the 
obtained cell suspension onto tissue culture plastic and washing off the non-
adherent cells with PBS. The blood was collected from the blood cone and the 
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PBMCs isolated using Ficoll-Paque PLUS as in method 1. The washed PBMCs 
were diluted using RPMI 1640 containing 10% FBS to a concentration of 20x106 
cells/ml. A Percoll solution was made using 23ml Percoll PLUS, 4.75ml 10x 
Dulbecco’s PBS (Gibco), and 26.25ml of distilled H2O, and the solution was 
dispensed into 15ml Falcon tubes (5ml/tube). The cell suspension was then 
gently layered onto the Percoll solution (5ml/tube) and tubes were centrifuged at 
400g for 30 minutes with minimum break and acceleration. The interphase was 
removed from the tubes and washed in RPMI 1640 containing 10% FBS and 
centrifuged at 650g for 5 minutes. The cells were resuspended in RPMI 1640 
containing 10% FBS and seeded into 10cm diameter tissue-culture treated petri 
dishes at a density of 20x106 cells/dish. The cells were allowed to adhere for 1h 
at 37oC after which contaminating non-adherent cells were removed by washing 
twice with PBS with the remaining population being monocytes. The purity and 
subset bias of isolated monocytes was determined by flow cytometric analysis as 
in method 1. 
 
3.2.3 Unstimulated monocyte:fibroblast co-cultures 
Fibroblasts and heterologous peripheral blood monocytes were co-cultured 
together for 5 days, 24 hours, or less as follows. 0.2x105 fibroblasts/well were 
seeded into a 24 well plate (Corning) and cultured for 2 days at 37oC 5% CO2 in 
complete fibroblast medium. Monocytes were isolated as in 3.2.2.1 and seeded 
onto the fibroblasts, after the fibroblasts had been washed once in PBS, at a 
density of 3x105 monocytes/well in co-culture medium which is constructed as 
complete fibroblast medium with the adjustment of the foetal bovine serum 
concentration to 5% v/v. Fibroblast only and monocyte only control cultures were 
 124 
 
subjected to the same protocol but omitting the relevant cell type at its addition 
and adding medium only. Supernatants were harvested at the end of co-culture 
and immediately stored at -80oC. Clinical details of the fibroblast lines used are 
presented in Table 14. 
 
3.2.4 Unstimulated macrophage:fibroblast co-cultures 
Unstimulated macrophage:fibroblast co-cultures were completed in the presence 
of GM-CSF and M-CSF (PeproTech) with no additional stimuli. For these co-
cultures monocytes were isolated as in 3.2.2.1 and were seeded at a density of 
3x105 monocytes/filter onto inverted Transwell filters for 24 well plates with 0.4μm 
pores in either co-culture medium containing 50ng/ml GM-CSF, 100ng/ml M-
CSF, or neither and incubated at 37oC 5% CO2 for 1 hour. After 1 hour the filters 
were righted and placed into a 24 well plate and 200μl or 500μl of co-culture 
medium containing GM-CSF, M-CSF, or neither factor at the aforementioned 
concentrations was added above or below the filter respectively. The monocytes 
were left to differentiate for 2 days before gently washing once with PBS and 
adding 0.2x105 fibroblasts into the upper chamber of the filters in 200μl of co-
culture medium containing GM-CSF, M-CSF, or neither at the aforementioned 
concentrations and adding 600μl of the co-culture medium with the growth factors 
below the filter. After two days of co-culture all cells were washed once in PBS 
and removed by incubating with [2x] trypsin for 5 minutes at 37oC 5% CO2 before 
inhibiting the trypsin with co-culture medium with no added GM-CSF or M-CSF 
and centrifuging the cells at 300g for 6 minutes. Clinical details of the fibroblast 
lines used are presented in Table 15. 
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3.2.5 Removal and deconvolution of co-culture populations 
In order to isolate RNA or assess cells by flow cytometry after direct co-culture 
methods to extract pure populations from the co-culture were compared. After 
five days in direct co-culture cells were removed from tissue culture plastic using 
three different treatments. The co-cultures were gently washed once with PBS 
and 500µl of either trypsin (used at 2x concentration), Accutase (Sigma), or cell-
dissociation buffer (CDB) (Gibco) was added to the wells and plates were 
incubated for 15 minutes at 37oC. 500µl of co-culture medium was then added to 
all wells. The co-cultures treated with CDB were scraped and all treatments were 
further disrupted by pipetting. The ability of the removal methods to isolate two 
clean populations of fibroblasts and monocytes with minimal disruption of surface 
markers was assessed via flow cytometry panels as in Table 10 and Table 11. 
Target Conjugate Clone Isotype Supplier 
CD16 FITC 3G8 Mouse IgG1, κ BD Biosciences 
CD14 PE MφP9 Mouse IgG2b, 
κ 
BD Biosciences 
CD163 PE-CF694 GHI/61 Mouse IgG1, κ BD Biosciences 
CD68 Alexor Fluor 647 Y1/82A Mouse IgG2b, 
κ 
BD Biosciences 
CD86 BV510 FUN-1 Mouse IgG1, κ BD Biosciences 
CD45 V450 2D1 Mouse IgG1, κ BD Biosciences 
CD90 PerCP-Cy5.5 eBio5E10 Mouse IgG1, κ eBioscience 
FAP Biotin  Sheep IgG R & D Systems 
Biotin Streptavidin PE-Cy7 N/A N/A Invitrogen 
Table 10: Antibody panel used to assess the efficacy of co-culture separation and 
the effect of removal techniques on cell-surface markers 
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Isotype Clone Conjugate Supplier 
Mouse IgG1, κ MOPC-21 FITC BD Biosciences 
Mouse IgG2b, κ 27-35 PE BD Biosciences 
Mouse IgG1, κ X40 PE-CF594 BD Biosciences 
Mouse IgG2b, κ 27-35 Alexa Fluor 647 BD Biosciences 
Mouse IgG1, κ X40 BV510 BD Biosciences 
Mouse IgG1, κ MOPC-21 V450 BD Biosciences 
Mouse IgG1, κ P3.6.2.8.1 PerCP-Cy5.5 eBioscience 
Sheep IgG  Biotin Southern 
Biotech 
N/A N/A Streptavidin PE-Cy7 Invitrogen 
Table 11: Isotype controls used in conjunction with the antibody panel in Table 10 
 
3.2.6 Intracellular cytokine staining 
Direct co-cultures were established in which the fibroblasts were labelled with 
1µM of DDAO-SE (Life Technologies) prior to seeding. Cells were harvested from 
these 5 day co-cultures using Accutase (Sigma) then stained for CD45. Some co-
culture wells were treated with 2μg/ml Brefeldin A (Sigma) for 12 hours before 
staining for intracellular TNF-α and IL-10 using a fixation and permeabilization kit 
(BD Biosciences). All samples were analysed on a MoFlowAstrios EQ (antibody 
panel used in Table 12). 
 
 
Target Conjugate Clone Isotype Supplier 
CD45 V450 2D1 Mouse IgG1, κ BD Biosciences 
TNF-α Alexa Fluor® 700 MAb11 Mouse IgG1, κ BD Biosciences 
IL-10 DyLight 350 JES3-9D7 Rat IgG1 Novus Biologicals 
Table 12: Antibodies used for analysis of intracellular cytokines 
 
Isotype Clone Conjugate Supplier 
Mouse IgG1, κ MOPC-21 V450 BD Biosciences 
Mouse IgG1, κ MOPC-21 Alexa Fluor® 700 BD Biosciences 
Rat IgG1, kappa L 
Chain 
KLH/G1-2-2 DyLight 350 Novus 
Biologicals 
Table 13: Isotype control antibodies used in conjunction with those in Table 12. 
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3.2.7  Blocking CD18 interactions 
An anti-CD18 blocking antibody (Biolegend clone TS1/18) was added to direct 5 
day co-cultures to investigate the role of common membrane-bound protein 
interactions between fibroblasts and monocytes. The direct co-cultures were 
completed as in 3.2.3 with the addition of a single treatment with 5μg/ml at the 
beginning of the co-culture when the monocytes are combined with the 
fibroblasts. An isotype control (Biolegend clone MOPC-21) was used as 
appropriate to control for non-specific effects of the anti-CD18 antibody. 
 
3.2.8 Stimulated macrophage:fibroblast co-cultures 
TNFα stimulated macrophage:fibroblast co-cultures were completed following a 
similar protocol as used by Donlin et al. (2014). 0.2x105 fibroblasts were seeded 
into the upper chamber of a Transwell filter with 0.4μm pores in a 24 well plate 
with 200μl and 600μl of complete fibroblast medium above and below the filter 
respectively and were incubated at 37oC 5% CO2 for two days. Monocytes were 
isolated from peripheral blood as in 3.2.2.1 and were seeded at a density of 
0.5x105 monocytes/well in a 24 well plate in complete fibroblast medium 
supplemented with 10ng/ml M-CSF and were cultured at 37oC 5% CO2 for 2 days 
to induce monocyte to macrophage differentiation. After the 2 days of culture both 
cell types were washed twice in PBS and the Transwell filters containing the 
fibroblast cultures were placed into the 24 well plate above the macrophage 
cultures before adding 200μl or 600μl of complete fibroblast medium 
supplemented with 20ng/ml TNFα above and below the filter respectively. The 
cells were then co-cultured at 37oC 5% CO2 for 16 hours. Both cell types were 
then separated and washed once with PBS, the fibroblasts were removed by 
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treatment with 600μl 2x Trypsin for 15 minutes before inhibiting the enzyme with 
an equal volume of complete fibroblast medium. The macrophages were 
removed by adding fresh PBS to the wells, putting the entire plate on ice and 
scraping the cells with cell scrapers. Clinical details of the fibroblast lines used to 
generate samples in preparation for RNA-sequencing are presented in Table 16.
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ID Group Disease 
classification 
Site CCP 
+/- 
RF 
+/- 
Disease 
duration 
(Weeks) 
Age Sex DMARD Prednisolone DAS28 
ESR 
baseline 
ESR 
(mm/
hr) 
CRP 
(mg/l) 
BX013 VeRA RA Knee - - 10 45 F None None 3.8 24 12 
BX033 Res Pseudogout Ankle - - 7 81 F None None 6.7 60 52 
BX049 VeRA RA Ankle + + 3 48 F None None 3.9 10 0 
BX071 Res Parvovirus Ankle - - 4 41 F None None 1.7 5 9 
BX076 Res Reactive Knee - - 6 28 M None None 4.5 18 8 
BX084 VeRA RA MCP + + 6 49 M None None 6.8 25 18 
BX087 Res Reactive Ankle - - 4 27 M None None 3.8 37 28 
BX092 VeRA RA MCP + + 4 48 M None None 6.0 63 38 
BX119 VeRA RA MCP - - 6 61 M None None 5.3 20 25 
RA11SY Jrep RA Knee  NA + 1040 62 F None None 6.1 63 34 
RA18SY Jrep RA Knee NA + 1196 47 F Etanercept None 3.8 57 NA 
RA20SY Jrep RA Knee NA + 1040 72 M Leflunomide None 4.8 18 3 
RA28SY Jrep RA Knee NA - 1040 41 F Gold 10mg 3.3 20 26 
RA29SY Jrep RA Knee + + 364 67 F Etanercept, MTX 7.5mg 6.6 57 66 
Table 14: Clinical characteristics of the patients from which fibroblast lines were isolated and used for the unstimulated 
monocyte:fibroblast co-cultures. NA = Not available, MTX = Methotrexate, DAS28 = Disease activity 28 score, ESR = Erythrocyte 
sedimentation rate, CRP = C-reactive protein, CCP = Anti-cyclic citrullinated peptide, RF = Rheumatoid factor, MCP = 
Metacarpophalangeal, UA = Undifferentiated arthritis. 
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ID Group Disease 
classification 
Site CCP 
+/- 
RF 
+/- 
Disease 
duration 
(Weeks) 
Age Sex DMARD Prednisolone DAS28 
ESR 
baseline 
ESR 
(mm/
hr) 
CRP 
(mg/l) 
BX005 VeRA RA Knee - - 5 70 F None None 6.0 68 26 
BX013 VeRA RA Knee - - 10 45 F None None 3.8 24 12 
BX033 Res Pseudogout Ankle - - 7 81 F None None 6.7 60 52 
BX063 VeRA RA Knee + - 9 74 F None None 4.4 20 32 
BX071 Res Parvovirus Ankle - - 4 41 F None None 1.7 5 9 
BX072 Res UA Knee - - 10 32 M None None 3.6 15 0 
BX076 Res Reactive Knee - - 6 28 M None None 4.5 18 8 
BX084 VeRA RA MCP + + 6 49 M None None 6.8 25 18 
BX092 VeRA RA MCP + + 4 48 M None None 6.0 63 38 
RA11SY Jrep RA Knee  NA + 1040 62 F None None 6.1 63 34 
RA25SY Jrep RA Knee NA + 1560 53 f HCQ 10mg 3.6 na na 
RA28SY Jrep RA Knee NA - 1040 41 F Gold 10mg 3.3 20 26 
RA29SY Jrep RA Knee + + 364 67 F Etanercept, MTX 7.5mg 6.6 57 66 
Table 15: Clinical characteristics of the patients from which fibroblast lines were isolated and used for the unstimulated 
macrophage:fibroblast co-cultures. NA = Not available, MTX = Methotrexate, DAS28 = Disease activity 28 score, ESR = Erythrocyte 
sedimentation rate, CRP = C-reactive protein, CCP = Anti-cyclic citrullinated peptide, RF = Rheumatoid factor, MCP = 
Metacarpophalangeal, UA = Undifferentiated arthritis, HCQ = Hydroxychloroquine. 
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ID Group Disease 
classification 
Site CCP 
+/- 
RF 
+/- 
Disease 
duration 
(Weeks) 
Age Sex DMARD Prednisolone DAS28 
ESR 
baseline 
ESR 
(mm/
hr) 
CRP 
(mg/l) 
BX005 VeRA RA Knee - - 5 70 F None None 6.0 68 26 
BX010 Res Parvovirus Knee - - 4 40 F None None 3.9 5 0 
BX011 VeRA RA Knee - - 2 49 F None None 4.7 12 8 
BX017 RA RA Knee - - 30 61 F None None 4.9 8 9 
BX018 RA RA Knee - - 52 69 F None None 4.6 11 0 
BX033 Res Pseudogout Ankle - - 7 81 F None None 6.7 60 52 
BX038 Res Parvovirus Knee - - 1 45 F None None 4.0 4 0 
BX049 VeRA RA Ankle + + 3 48 F None None 3.9 10 0 
BX063 VeRA RA Knee + - 9 74 F None None 4.4 20 32 
BX071 Res Parvovirus Ankle - - 4 41 F None None 1.7 5 9 
BX072 Res UA Knee - - 10 32 M None None 3.6 15 0 
BX075 RA RA Knee - - 52 22 F None None 6.4 81 79 
BX081 Normal Normal Knee - - NA 59 F None None NA NA NA 
BX089 Normal Normal Knee - - NA 38 F None None NA NA NA 
BX095 Normal Normal Knee - - NA 47 F None None NA NA NA 
BX097 Normal Normal Knee - - NA 41 F None None NA NA NA 
BX098 Normal Normal Knee - - NA 41 F None None NA NA NA 
BX121 VeRA RA Ankle + + 11 60 F None None 4.3 32 45 
BX125 RA RA Knee + + 16 56 F None None 5.5 48 47 
BX130 VeRA RA Ankle - + 12 61 F None None 5.4 43 18 
BX143 Res UA Knee - - 16 45 F None None 3.0 8 4 
BX157 Res UA Knee - - 2 45 F None None 2.6 8 17 
RA05SY Jrep RA Knee NA + 1040 62 F None None 6.8 63 62 
RA07SY Jrep RA Knee NA + 52 71 F MTX 10mg 7.2 31 54 
RA16SY Jrep RA Knee NA + 780 30 F Azathioprine 3mg 6.5 37 33 
RA18SY Jrep RA Knee NA + 1196 47 F Etanercept None 3.8 57 NA 
  
 
1
3
2
 
RA19SY Jrep RA Knee NA + 1040 62 F Etanercept None 4.1 8 8 
RA22SY Jrep RA Knee NA + 1560 70 F Adalimumab None 4.419537 20 NA 
Table 16: Clinical characteristics of the patients from which fibroblast lines were isolated and used for the stimulated 
macrophage:fibroblast co-cultures. NA = Not available, MTX = Methotrexate, DAS28 = Disease activity 28 score, ESR = Erythrocyte 
sedimentation rate, CRP = C-reactive protein, CCP = Anti-cyclic citrullinated peptide, RF = Rheumatoid factor, MCP = 
Metacarpophalangeal, UA = Undifferentiated arthritis. 
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3.2.9 Enzyme-linked immunosorbent assay (ELISA) of co-culture 
supernatants 
IL-6 levels present in the supernatants harvested from all co-cultures were 
measured by ELISA (Thermo Fisher Scientific). After thawing supernatants for 
use in an ELISA the remaining supernatant was aliquoted into working volumes 
before storing at -20oC to prevent any further freeze/thaw cycles. 
 
3.2.10  Luminex of co-culture supernatants 
Supernatants from co-cultures were used in a Bio-Plex Pro™ Human Cytokine 
27-plex Assay (BIORAD) as per the manufacturer’s instructions. The full panel of 
factors assessed can be found in appendix 8.2. 
 
3.2.11  Quantitative real-time polymerase chain reaction (qRT-PCR) 
RNA was isolated from the cells using the PicoPure® RNA Isolation Kit (Thermo 
Fisher Scientific). The PicoPure RNA Isolation Kit was used according to the 
manufacturer’s protocol with the modifications specified in the protocol appendix 
VI for isolation from cell pellets and DNase treatment and with the following 
additional modification; after step h the columns were left open to air dry for 5 
minutes before elution of the isolated RNA in 11μl of elution buffer. Eluted RNA 
was stored at -80oC. RNA was converted to complementary DNA (cDNA) using 
the iScript™ cDNA Synthesis Kit (Bio-Rad). cDNA was then used for various 
qRT-PCR reactions depending on the experiment. The primer sequences were 
designed using Primer-BLAST (NCBI) or obtained from John O’Neil (both 
synthesised by Eurofins) and are listed in Table 17. The reaction mix consisted 
of 2.4μl of sample, 0.3μl (0.05pmol/µl final concentration) of forward primer, 0.3μl 
(0.05pmol/µl final concentration) of reverse primer, and 3μl of SYBR® Premix Ex 
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Taq™ II (Tli RNase H Plus) (Takara) or 3μl of Absolute qPCR SYBR Green ROX 
Mix (Thermo Scientific). The thermocycler used was a LightCycler® 480 II 
(Roche) and the reaction parameters were 15 minutes at 95oC before 40 cycles 
of 15 seconds at 95oC followed by 30 seconds at 55oC and finally 30 seconds at 
72oC. 
Target Forward primer 5`->3` Reverse primer 5`->3` 
GAPDH GTCAGCCGCATCTTCTTTTGC AATCCGTTGACTCCGACCTT
CC 
UBC CGGGATTTGGGTCGCAGTTC
TTG 
CGATGGTGTCACTGGGCTCA
AC 
STAT1 GCGCGCAGAAAAGTTTCATTT TGAGACATCCTGCCACCTTG 
IL-6 GAGGCACTGGCAGAAAACAA TGGCATTTGTGGTTGGGTCA 
IL-8 CAGAGACAGCAGAGCACACA GGCAAAACTGCACCTTCACA 
TNF CCCCAGGGACCTCTCTCTAA
T 
TCTCTCAGCTCCACGCCATT 
IL-10 GCCTAACATGCTTCGAGATC TGATGTCTGGGTCTTGGTTC 
Table 17: Primers used for qPCR reactions 
 
3.3 Results 
3.3.1 Co-cultures of human synovial fibroblasts with the murine 
RAW264.7 cell line 
Initial co-cultures were undertaken in order to establish a suitable protocol to 
allow interrogation of monocyte:fibroblast co-cultures. A starting co-culture 
duration of 5 days was used, the reasoning behind this decision being that many 
monocyte-macrophage differentiation protocols, including one commonly used 
in-house, culture monocytes for 5 days in the presence of M-CSF or GM-CSF to 
allow for full differentiation of the cells and in order to capture any potential 
differentiation effects that fibroblast:monocyte co-culture may have it was decided 
to co-culture for a similar amount of time. 
 
The murine monocyte/macrophage cell line RAW264.7 was used during pilot 
qualitative experiments for two reasons. First, due to the high proliferative rate of 
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the cell line it provided a plentiful source of monocytic cells without the need for 
isolation from peripheral blood. Secondly, if the co-culture proved functional then 
the species difference may have allowed for easy identification of the source of 
soluble factors released during the co-culture. However, the obvious caveat to 
this experiment is that the species difference may result in spurious interactions 
and results that fail to represent the situation in human co-cultures. 
 
Seeding fibroblasts at an initial density of 45,000 cells/well and resting the cells 
for 2 days prior to co-culture resulted in an over-confluent monolayer of cells 
before the co-culture had begun (Figure 28 A and C). Regardless of if 600,000 
or 50,000 RAW cells were seeded into the co-culture by day five the cells had 
aggressively proliferated and obscured the underlying fibroblasts making any 
observations of these cells difficult. The qualitative analysis of co-culture images 
informed the choice of seeding density for fibroblasts in future co-cultures with 
20,000 cells/well giving a reasonable level of confluence within the wells. The 
RAW264.7 co-cultures were discontinued in favour of human monocyte:fibroblast 
co-cultures due to (a) the difficulties of using a murine cell line and (b) the 
difficulties in managing proliferation of the RAW264.7 cell line. 
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Figure 28: Microscopy analysis of 5 day co-cultures of RAW264.7 cells with 
synovial fibroblasts  Rapid proliferation of the monocyte/macrophage line and a 
seeding density of 45,000 fibroblasts (A and C) resulted in an over-confluent 
monolayer of cells at the start of co-culture. All images were taken using 
differential interference contrast at 200x magnification. A 50,000 RAW264.7 cells 
on 45,000 fibroblasts cells at the start of the co-culture and B after 5 days of co-
culture, and C 600,000 RAW264.7 cells on 45,000 fibroblasts at the start of the co-
culture and D after 5 days of co-culture 
 
3.3.2 Negative selection from blood cones using magnetic microbeads 
isolates unbiased monocyte subsets at a high purity 
Two methods to isolate human monocytes from peripheral blood commonly used 
in the literature were assessed in three ways, the yield produced from total 
PBMCs, the purity of the isolated cells as assessed by flow cytometric analysis 
of CD14 and CD16 surface expression, and any bias for isolating one or two 
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monocyte subsets over others. Isolating monocytes using density-gradient 
separation followed by subsequent negative selection using MiltenyiBiotec MACs 
magnetic bead technology consistently resulted in a much higher yield and purity 
of monocytes compared to double density-gradient separation with subsequent 
adherence to tissue culture plastic for one hour with the average purity of the 
negative selection approach being 82.71% ± 4.96 (Mean ± 95% confidence 
interval (CI), n=6) and for the adherence approach being 30.51% ± 6.99 (Mean ± 
95% CI, n=3) (Figure 29, representative figure). Both approaches isolated 
monocyte subsets in similar proportions in-keeping with those published in the 
literature; using the negative selection approach as a representative the 
proportion of classical monocytes was 87.39% ± 3.35 (Mean ± 95% CI, n=6), the 
proportion of intermediate monocytes was 3.79% ± 2.20 (Mean ± 95% CI, n=6), 
and the proportion of non-classical monocytes was 8.83% ± 1.91 (Mean ± 95% 
CI, n=6) (Ziegler-Heitbrock et al., 2010; Ziegler-Heitbrock and Hofer, 2013). 
 
Figure 29: Representative dot plots of A monocytes isolated using negative 
selection, and B monocytes isolated using the adherence method. The gating 
demonstrates the method used to assess the purity of the monocyte populations 
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As density-gradient separation of peripheral blood using Ficoll-Paque followed by 
negative isolation of monocytes from PBMCs using magnetic bead technology 
provided a higher yield and purity of monocytes compared to the adherence 
method this technique was used for all future monocyte isolations both for direct 
co-culture and macrophage differentiation. 
 
3.3.3 Accutase and trypsin remove co-cultures from culture vessels with 
similar efficacy whereas cell-dissociation buffer performs worse 
As it was planned to isolate separate populations post co-culture for downstream 
analysis, the efficacy of different methods of cell removal was tested. Three 
methods of removal; trypsinisation, treatment with accutase, and treatment with 
CDB, were used to remove fibroblasts and monocytes from 24 well plates after 5 
days of co-culture. 
 
Treatment with trypsin or Accutase removed similar populations of fibroblasts 
from monoculture with the presence of two broad forward-scatter (FSC) low or 
FSC high populations visible by flow cytometry (Figure 30). However, the FSC 
high population was absent when the cells were removed from culture using CDB 
indicating this method does not remove all fibroblasts from tissue culture 
plasticware with equal effectiveness. With regards to the isolation of monocytes 
from monoculture all three methods remove similar populations from culture with 
the population isolated using trypsin displaying a reduction in variation in both the 
FSC and the side-scatter (SSC) channel. When assessing the number of 
doublets present in the samples isolated from monocyte-only cultures, trypsin 
produced an almost pure population of single cells whereas accutase and CDB 
both produced samples with a population of doublets with CDB producing the 
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largest doublet population. In the co-culture samples the FSC SSC profile 
resembled a combination of the fibroblast and monocyte monoculture profiles 
with the co-culture profile of the cell-dissociation buffer sample still showing a 
reduction in the number of FSC high cells in-keeping with that found in the 
fibroblast-only culture. It was apparent that the FSC SSC profiles of monocytes 
and fibroblasts overlap negating the possibility of using FSC SSC profiles to cell 
sort pure populations of each cell type post co-culture without the use of further 
surface marker staining, intracellular labelling of cells, or physically separated co-
culture. 
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Figure 30: Representative dot plots of flow cytometric analysis of co-cultured cells 
removed from co-culture using Trypsin, Accutase, or Cell-dissociation buffer 
(CDB). It was not possible to identify clear populations of fibroblasts or monocytes 
from co-cultures due to the overlapping nature of the forward and side scatter 
profiles of the two cell types. 
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3.3.4 Direct and separated monocyte:fibroblast co-cultures stimulate a 
synergistic increase in IL-6 release 
Co-cultures of freshly isolated human monocytes with fibroblasts from the 
BEACON cohort, specifically: (1) fibroblasts isolated from tissue removed during 
arthroplasty of RA patients (Joint replacement fibroblasts, Jrep), (2) fibroblasts 
isolated from treatment naïve patients who either presented with or would 
subsequently develop persistent RA but who had had symptoms for less than 3 
months (Very early RA fibroblasts, VeRA), and (3) fibroblasts isolated from 
treatment naïve patients who were suffering from arthritis symptoms for less than 
3 months which spontaneously resolved (Resolving fibroblasts, Res), were 
completed. Three techniques were used to co-culture the cells in order to 
interrogate the role of cell contact in the interactions between fibroblasts and 
monocytes (Figure 31). In direct co-culture fibroblasts and monocytes were 
seeded into the same well enabling full contact between cell types. In the 
Transwell co-cultures fibroblasts were seeded and allowed to adhere onto the 
underside of a filter with 0.4µm pores. The filter was then placed into a well with 
monocytes seeded in the upper chamber allowing the fibroblasts suspended 
below and the monocytes above a limited amount of contact. In separate co-
cultures the fibroblasts were seeded into the upper chamber of a Transwell filter 
whereas the monocytes were seeded into the plate below thus preventing cell to 
cell direct contact. 
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Figure 31: Schematic of the three different assay setups used to investigate the 
contribution of contact-dependent and contact-independent interactions to the 
release of soluble factors. In direct co-culture fibroblasts and monocytes were 
seeded into the same well enabling full contact between cell types, Transwell co-
cultures allowed a reduced level of contact whereas separate co-cultures 
prevented all direct cell contact.  
Monocytes cultured alone for 5 days with no stimuli typically release basal levels 
of IL-6 with median levels released in these controls being 29.26pg/ml ± 33.45 
(Median ± 95% CI) (Figure 32). Unstimulated fibroblast monocultures also results 
in low levels of IL-6 release, albeit higher than monocyte monoculture, with levels 
in direct monoculture being 120.28pg/ml ± 69.07 (Median ± 95% CI). Direct and 
separate co-culture of synovial fibroblasts with monocytes elicited a synergistic 
and statistically significant increase in the concentration of IL-6 released into the 
culture media regardless of the disease outcome group from which the fibroblast 
line was isolated (direct co-culture IL-6 levels 3116.578pg/ml ± 2824.02 (Median 
± 95% CI), separate co-culture IL-6 levels 931pg/ml ± 892.83 (Median ± 95% CI)). 
The increase in transwell co-culture IL-6 levels did not reach statistical 
significance (461.22pg/ml ± 153.03 (Median ± 95% CI)). 
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Figure 32: IL-6 release from monocyte and fibroblast cultures after 5 days as 
assessed by ELISA. Statistical analysis was performed using a Kruskal-Wallis test 
with Dunn’s multiple comparisons test. **** = p<0.0001. Bars show the median. DC 
= Direct co-culture, TW = Transwell co-culture, Sep = Separate co-culture, Mono = 
monocyte, FLS = Fibroblast-like synoviocyte. 
 
When the results of the co-cultures are stratified according to the disease group 
of the fibroblast line it becomes apparent that regardless of the type of co-culture 
IL-6 levels are similar (Figure 33). This finding favours the null hypothesis that 
fibroblasts isolated from different clinical outcome groups all modulate monocyte 
phenotype similarly. However, as it was possible that factors other than IL-6 
produced by monocytes and/or fibroblasts could be differentially modulated but 
not detected by this approach, a 27-plex luminex assay was performed on 
supernatants from the direct co-cultures. 
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Figure 33: Co-culture of monocytes with fibroblasts from different disease 
outcome groups did not induce differential IL-6 release regardless of if the cells 
were in contact or not. Tested using Kruskal-Wallis test with Dunn’s multiple 
comparisons test. * = p<0.05, ** = p<0.01. Bars show the median. Mono = 
monocyte, FLS = Fibroblast-like synoviocyte, Coc = Co-culture. 
 
Results from the luminex assay found several factors that were either up- or 
down-modulated by direct co-culture. However, the concentration of many of the 
cytokines, chemokines, or growth factors often remained low making the 
interpretation of the biological significance of the findings questionable (Figure 
34, Table 18, full results in 8.2). Also, as CCL2 and CCL4 are both monocyte 
chemoattractants it could be argued that the decrease in the extracellular 
concentration of these chemokines is due to uptake of these factors by 
monocytes. Regardless of the biological significance of the results it appeared 
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that no differential modulation of soluble factors by disease group of the fibroblast 
line in co-culture could be seen. The factors with the highest levels of production 
were IL-6 (1583.54 ± 1343.67 (Median ± 95% CI)) and CXCL10 (1478.98 ± 
917.96 (Median ± 95% CI)) with VEGF being the next highest (437.51 ± 126.91 
(Median ± 95% CI)) but considerably lower than both IL-6 and CXCL10. 
 
 
Figure 34: Co-culture of monocytes and fibroblasts resulted in the up- and down-
regulation of the release of several soluble factors as assessed by a Luminex 
assay but not differential modulation dependent on the disease group from which 
the fibroblast line was isolated. (A) Cytokines and chemokines upregulated by co-
culture, (B) cytokines and chemokines decreased or unregulated by co-culture. 
Although the concentration of some factors were increased or decreased by co-
culture the levels often remained low making the biological significance of these 
findings questionable. No significant differences between any of the co-cultures 
as tested by a Kruskal-Wallis test with Dunn’s multiple comparison test. Bars 
show the median. 
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Mediator Direction of 
regulation 
Median concentration 
in co-culture (pg/ml) 
Statistically 
significant? 
IL-1Ra Up 50.835 FLS v Coc 
IL-6 Up 1583.54 Mo v Coc 
IL-10 Up 8.11 Mo v Coc 
TNFα Up 6.255 FLS v Coc 
IFNγ Up 41.26 Mo or FLS v Coc 
VEGF Up 437.51 Mo v Coc 
CXCL10 Up 1478.98 FLS v Coc 
CCL5 (RANTES) Down 7.755 Mo v FLS 
CCL2 (MCP1) Down 87.585 FLS v Coc 
CCL4 (MIP-1β) Unregulated 81.425 Mo v FLS, FLS v 
Coc 
Table 18: Summary of the luminex results plotted in Figure 34 with IL-6 luminex 
results added and with disease stages pooled. FLS = fibroblast like synoviocyte 
only, Coc = co-culture. Tested using Kruskal-Wallis with Dunn’s multiple 
comparisons test. 
 
Variability between cone samples remained a problem. The blood apheresis 
cones provided by the NHSBT are not provided with information on the time of 
blood collection, the time the apheresis was completed, nor the number of 
apheresis cycles used to produce the cone. Endeavours were made to obtain 
cones at similar times and days of the week to try to reduce variability however it 
was decided to investigate whether the increase in IL-6 elicited by co-culture was 
an artefact present due to the source of monocytes or a finding consistent 
regardless of the source. To this end three to four fibroblast lines were co-cultured 
in parallel with monocytes obtained from either freshly drawn peripheral blood 
from a healthy donor or with monocytes obtained from an apheresis cone, with 
monocytes from both sources isolated in parallel. No significant difference was 
found between IL-6 levels from co-cultures (Figure 35). 
 147 
 
  
Figure 35: IL-6 levels released during 5 day co-culture of the same 3-4 fibroblast 
lines with monocytes obtained from either freshly drawn peripheral blood from a 
healthy donor (HD2) or from a peripheral blood apheresis cone (BC27). No 
significant difference existed between co-cultures with monocytes from the two 
sources. Tested using a Mann-Whitney test. Bars show median. 
 
All co-cultures were run for 5 days in a similar manner to monocyte to 
macrophage differentiation protocols to allow for any differences that may depend 
on differentiation to manifest. As such the temporal dynamics of IL-6 release 
during co-culture were unknown. To investigate the kinetics of IL-6 release co-
cultures were run for durations of 30 minutes, 1 hour, 2 hours, 4 hours, 18 hours, 
1 day, 2 days, 3 days, and 5 days and supernatants were harvested before 
measuring the concentration of IL-6 by ELISA. The results show that the IL-6 
concentration in fibroblast or monocyte monoculture increased over a 24 hour 
period with maximal levels in the monocyte monocultures approached within 24 
hours of culture and with a continuous increase in levels in the fibroblast 
monocultures over 5 days (Figure 36). IL-6 levels during co-culture increased in 
a similar manner, but with a greater magnitude, to the monocyte monocultures. 
This increased concentration of IL-6 was then maintained for a duration of at least 
5 days. 
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Figure 36: Concentration of IL-6 released into the medium during fibroblast and 
monocyte direct co-culture for varying timescales. The majority of IL-6 release 
occured within 24 hours of the initiation of co-culture and was maintained for 5 
days. No significant increase was detected between any of the daily timepoints in 
co-culture compared to monocultures presumably due to low numbers affecting 
the power of the test. Although not shown on the plot significant differences did 
exist between the timepoints earlier than 1 day of co-culture with a difference 
between 1h and 4h being the earliest detected. Significant increases in the basal 
IL-6 production by FLS were also found with a difference between 30m and 4h 
being the earliest detected. All tested using a Kruskal-Wallis test with Dunn’s 
multiple comparison test. Bars show the median. 
 
In order to assess the contribution of contact dependent or contact independent 
interactions to the increase in IL-6 release a blocking antibody against the integrin 
CD18, which is expressed by monocytes, was used (Campbell et al., 1998). 
ICAM-1 is known to be expressed on fibroblasts and ICAM-1 and CD18 are 
known to bind and interact (Liu and Piela-Smith, 2000; Yang et al., 2010; Zhou et 
al., 1994). It was attempted to block CD18 ICAM-1 interactions in 5 day co-
cultures with a single addition of 5µg/ml anti-CD18 blocking antibody at the 
initiation of co-culture and assessing the impact of treatment by measuring IL-6 
concentration in the co-culture media at the end of the co-culture. The effect of 
the blocking antibody was unclear with a seemingly inhibitory effect on IL-6 
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release in the direct co-cultures, hints of a stimulatory effect in the Transwell co-
cultures, and no effect in the separate co-cultures (Figure 37). However, the 
isotype control antibody also reduced IL-6 release in the direct co-culture, 
suggesting that the effect seen was a result of non-specific antibody binding in 
the co-culture.  
  
  
Figure 37: Blocking CD18-ICAM-1 interactions using 5µg/ml of an anti-CD18 
blocking antibody at the start of 5 day co-cultures had no clear effect on the final 
concentration of IL-6 released into the co-culture medium as assessed by ELISA. 
No significant differences were detected using a Kruskal-Wallis test with Dunn’s 
multiple comparisons test. Bars show the median. DC = direct co-culture, TW = 
transwell co-culture, Sep = separated co-culture, Bab = blocking antibody, Iso = 
isotype control. 
 
As examination of extracellular cytokine levels had not found significant 
differences in the regulation of monocyte phenotype by fibroblasts from different 
disease outcome groups it was decided to investigate the intracellular levels of 
cytokines. The advantage of such an approach in the unstimulated co-cultures is 
that although the profile of cytokines being synthesised may be altered by co-
cultures with different fibroblast lines, the release of cytokines may not be 
significantly altered without additional stimuli to elicit the effect. Therefore it was 
decided to stain for two signature intracellular macrophage cytokines, TNFα and 
IL-10 respectively, to assess if any differential modulation/differentiation was 
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driven by different fibroblast lines. Fibroblasts were labelled with an intracellular 
dye prior to co-culture to allow for easy identification of fibroblasts and monocytes 
after 5 days of co-culture. 
 
Figure 38 shows the results of the intracellular cytokine staining of co-cultured 
monocytes and fibroblasts. In both cell types the median fluorescent intensities 
(MFIs) for both cytokines were either similar to or only slightly higher than those 
of the relevant isotype controls indicating that the intracellular levels of these 
cytokines are low. The mean MFI of TNFα in co-cultured monocytes was not 
significantly higher than that of the isotype control with variation in MFIs between 
monocytes co-cultured with different fibroblasts lines being low, indicating that 
co-cultured monocytes do not express intracellular TNFα. No significant 
difference was found between either fibroblasts or monocytes in co- or mono-
culture compared to relevant isotype controls. With regards to intracellular IL-10 
levels in co-cultured monocytes the average MFI is slightly higher than that of the 
relevant isotype control but not significantly so with a similar low level of variation 
between samples indicating a lack of differential regulation by different fibroblast 
lines. Interestingly fibroblasts seem to have higher levels of IL-10 than monocytes 
with both mono- and co-cultured fibroblasts having significantly higher MFIs than 
the relevant isotype controls but not than each other when tested using a Kruskal-
Wallis test with Dunn’s multiple comparisons test. Whether IL-10 is produced by 
the fibroblasts or taken up during co-culture is unknown. 
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Figure 38: Flow cytometric identification of DDAO labelled fibroblast and CD45+ 
monocyte populations after 5 days of co-culture and measurement of intracellular 
TNFα and IL-10 levels. Levels detected remained low with median fluorescence 
intensities (MFIs) in the stained samples being in-line with or only slightly above 
the MFIs from isotype control stained samples. No differential expression of TNFα 
or IL-10 was apparent between fibroblasts from different disease outcome groups 
or from monocytes co-cultured with these fibroblasts. Tested using Kruskal-Wallis 
test with Dunn’s multiple comparisons test. Bars show the median. 
 
Considering the evidence so far it was apparent that fibroblasts isolated from 
different disease outcome groups did not appear to differentially regulate 
monocyte cytokine or chemokine expression during unstimulated 5 day co-
cultures as assessed by investigation of the cytokine profile. There were several 
caveats to the investigations so far including the fact that all co-cultures were run 
for 5 day periods and no other timepoint was investigated and that all co-cultures 
were unstimulated. It was therefore decided to address the second point using 
both differentiating and stimulating factors. 
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3.3.5  Co-culture of macrophages with fibroblasts from different disease 
outcome groups does not differentially affect macrophage 
differentiation 
To assess if fibroblasts isolated from different stages of RA could differentially 
affect the in vitro differentiation of monocytes to macrophages freshly isolated 
monocytes from apheresis cones were cultured with either 50ng/ml GM-CSF or 
100ng/ml M-CSF, to induce a pro- or anti-inflammatory phenotype respectively, 
for two days before co-culturing with fibroblasts from different outcome groups for 
a further two days still in the presence of either GM-CSF or M-CSF. At the end of 
this timepoint RNA was isolated from the macrophages and used in qRT-PCR 
experiments to analyse the expression of genes differentially expressed in pro- 
and anti-inflammatory macrophage subsets. TNF is an obvious pro-inflammatory 
gene and STAT1 has been found to drive the expression of the pro-inflammatory 
inducible-nitric oxide synthase whereas IL-10 encodes a well-known anti-
inflammatory cytokine (Ganster et al., 2001). No significant differences were 
found comparing the fold change in gene expression induced by co-culture with 
fibroblasts from different clinical outcome groups for any of the three genes 
tested: TNF, IL-10, or STAT1 (Figure 39). There was a suggestion that 
macrophages differentiated in GM-CSF co-cultured with fibroblasts from 
resolving arthritis may downregulate STAT1; increasing the number of biological 
replicates could have clarified this effect. 
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Figure 39: Fold-change in expression of the pro-inflammatory genes TNF and 
STAT1 and anti-inflammatory gene IL-10 expression in macrophages co-cultured 
with fibroblasts from different disease stages in the presence of GM-CSF or M-
CSF relative to expression in macrophage mono-cultures in the presence of these 
growth factors. Gene expression normalised to UBC expression. No significant 
difference was detected in the modulation of gene expression by fibroblasts from 
different disease stages when analysed using a Kruskal-Wallis test with Dunn’s 
multiple comparison test. However when pooling data from different disease 
stages a significant difference existed in IL-10 mRNA expression between 
treatments as assessed using a Mann-Whitney test. * = p<0.05. Bars show the 
median. Jrep = Joint replacement, VeRA = very early RA, Res = Resolving arthritis, 
Mo = Monocyte, GM = GM-CSF, M = M-CSF. 
 
As the co-culture of differentiating monocytes with fibroblasts from different 
disease stages did not appear to result in differential modulation of signature pro- 
or anti-inflammatory genes it was hypothesised that differences elicited by the 
fibroblasts may not be apparent in the absence of pro-inflammatory stimuli. 
Although no differential modulation of phenotype by fibroblasts from different 
clinical outcome groups had yet been demonstrated work on the BEACON cohort 
has demonstrated functional differences both in fibroblast-endothelial crosstalk 
and fibroblast motility (Filer, 2017; Juárez Pérez, 2014). Recent work indicated 
that fibroblasts are able to modulate the expression of genes in macrophages 
normally up- or down-regulated by stimulation (Donlin et al., 2014). It was decided 
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to adapt the approach used in this work to begin to assess if fibroblasts from 
different disease stages have different impacts upon stimulated gene expression 
in macrophages. 
 
3.3.6 Stimulated macrophage:fibroblast co-cultures 
Peripheral blood monocytes were differentiated for two days in 10ng/ml M-CSF 
before co-culturing with fibroblasts in the presence of 20ng/ml TNFα for 16 hours. 
After 16 hours of co-culture and stimulation RNA was extracted from the 
macrophages and the expression of a set of interferon stimulated genes and non-
interferon stimulated genes was assessed using qRT-PCR. Only 16 hours of co-
culture and stimulation was allowed in order to capture genes expressed in the 
early/intermediate gene response cassette as in Donlin et al. (2014). Across 4 
healthy donors results were mixed compared with the expected findings; 
downregulation was sometimes seen in the genes CXCL9, CXCL10, IFIT1, and 
MX1 and NKG7 and IL1B remained unchanged, as expected from the published 
results (Figure 40). However modulation was often seen in the two ‘control’ 
genes, NKG7 and IL1B, and no modulation seen in the interferon stimulated 
genes. Additionally there was heterogeneity in response to fibroblast co-culture 
between monocyte donors in CXCL10 expression. 
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Figure 40: Representative results of gene expression modulation in macrophages 
co-cultured with fibroblasts for 16 hours in the presence of 20ng/ml TNFα. 
Expression was normalised to GAPDH and calculated relative to expression in 
TNFα stimulated macrophages in monoculture. In the publication by Donlin et al. 
(2014) (top plots adapted from this publication, **p < 0.001) CXCL9, CXCL10, IFIT1, 
and MX1 (A) were all downregulated by co-cultured compared to macrophage 
mono-culture whereas NKG7 and IL1B (B) were both unchanged by co-culture 
however the same pattern of modulation was not always seen in the work in these 
experiments (C and D) as exemplified by NKG7 and IL1B expression. Bars in the 
bottom plots show the median. 
 
Despite the more variable findings of this work it was decided to prepare co-
culture samples for RNA-sequencing. This prepatory work was completed, but 
sequencing work was not completed as part of this thesis, other work having 
taken priority (see chapter 4). 
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3.4 Discussion 
The work in this chapter successfully established a protocol for the co-culture of 
heterologous peripheral blood derived monocytes/macrophages and synovial 
fibroblasts. Co-cultures of fibroblasts and monocytes modulated the production 
of IL-6, CXCL10, and CCL4 amongst other factors independent of the clinical 
outcome group from which the fibroblast lines were isolated. 
Macrophage:fibroblast co-cultures modulated macrophage gene expression both 
in the presence or absence of TNFα independent of fibroblast clinical outcome 
group. 
 
Regarding the choice of monocyte source peripheral blood monocytes isolated 
from commercially available apheresis cones provided by the NHSBT service 
were used for all co-cultures. There is logic to using autologous monocytes 
isolated from the peripheral blood of the same patients from which the fibroblast 
lines they were to be co-cultured with however the logistical challenges of this 
approach, given the 2-3 month duration required for the isolated fibroblasts to 
reach a useable passage, necessitated the use of other sources of monocytes. 
Additionally the use of a different monocyte donor for every fibroblast line may 
introduce a large amount of variation into the data. Furthermore it is possible that 
monocyte phenotype will change as disease progresses from early to later stages 
further confounding experimental results. For these reasons heterologous 
monocytes were used with several fibroblasts from different clinical outcome 
groups being co-cultured with each batch of monocytes. A final point of concern 
with the use of apheresis cones is that no information is provided regarding the 
length of time since blood was drawn and the cones were generated which may 
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lead to increased variation in the data or even spurious results. To address this 
question four fibroblast lines were co-cultured in direct contact with monocytes 
either from freshly drawn peripheral blood or apheresis cones, with no 
significantly different IL-6 levels found, suggesting that the true difference 
between these allogeneic approaches may not be great. 
 
During the transwell co-cultures, where cell-cell contact is reduced but not 
prevented, the increase in IL-6 in co-cultures does not reach statistical 
significance. The reasoning behind this is unclear however an obvious difference 
between the transwell co-cultures and the other co-cultures is that fibroblasts are 
suspended from the underneath of the filters whereas in the direct and separate 
co-cultures the fibroblasts are resting on either a membrane or the cell culture 
plastic. This may induce cytoskeletal changes leading to changes in the 
regulation of gene expression similar to the changes seen by Van Den Berg et 
al. (2006) in which the disruption of elements of the cytoskeleton lead to a 
decrease in translational efficacy of IL-6 mRNA in response to TNFα stimulation 
in epithelial-like cells. Additionally, the transwell membrane may modulate the 
amount of cell-cell contact in such a way as to limit the IL-6 release. Importantly 
the increase in IL-6 release in the direct and separate co-cultures did not 
significantly differ between co-cultures with fibroblasts isolated from different 
BEACON outcome groups meaning this data fails to support the alternative 
hypothesis of differential regulation. 
 
The synergistic increase in IL-6 levels elicited by monocyte:fibroblast co-culture 
is not unique to this study and has previously been demonstrated in other work. 
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Chomarat et al co-cultured synovial fibroblasts and peripheral blood monocytes 
together for 48 hours and also noted a synergistic increase in IL-6 production and 
found that this increase was comparable between co-cultures with RA synovial 
fibroblasts and normal synovial fibroblasts and was dependent on the cell 
numbers of both cell types in co-culture (Chomarat et al., 1995). This study also 
characterised a rapid increase in IL-6 levels during the first 48 hours of co-culture 
and upon extending the co-culture found that maximal IL-6 levels in the 
supernatant occurred around day 7 reaching approximately 10ng/ml. 
Furthermore, the authors began to tease apart the mechanisms behind the IL-6 
increase finding that fixing monocytes prevents the IL-6 increase and using IL-1R 
agonist, anti-CD14 or anti-CD13 blocking antibodies, or treatment with IL-4, IL-
10 or IL-13 inhibited the IL-6 release. It would be of interest to attempt similar 
experiments on future co-cultures with the BEACON fibroblast lines to assess if 
different mechanisms are involved in interactions with fibroblasts from different 
clinical outcome groups. The pre-monocytic cell line U937 co-cultured with RA 
synovial fibroblasts results in an increase in in vitro degradation of cartilage that 
is dependent on fibroblast contact with cartilage and dependent on TNF-α, IL-1β, 
IL-6, and CD44 but not ICAM-1 in the co-culture (Scott et al., 1997). Co-culture 
of RA synovial fibroblasts with the U937 monocytic cell line has also been shown 
to increase CD14 and CD11b expression on the U937 cells indicating some 
degree of differentiation may be driven by the fibroblasts (Chen et al., 1998).  
 
The increase in IL-6 elicited by co-culture of monocytes and fibroblasts is 
important in the context of RA given the multiple findings implicating this cytokine 
in the pathogenesis of the disease. The semiquantitive score of the expression 
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of sublining CD68 and IL-6 in RA synovium as measured by 
immunohistochemistry correlates with knee pain in a multivariate analysis (Tak 
et al., 1997). Additionally, IL-6 protein is constitutively expressed by RA synovial 
fibroblasts and is found at higher levels in the serum and synovial fluid of RA 
patients than in OA patients and expression in RA synovial fibroblasts can be 
increased with IL-17 stimulation, an important point given the increased IL-17 
levels present in the RA synovium (Chabaud et al., 1999; Hwang et al., 2004; 
Okamoto et al., 1997; Scaife et al., 2004). Importantly even though genes such 
as TNF, CXCL13, and basic fibroblast growth factor (FGF2) are differentially 
expressed in the published synovial phenotypes in RA IL-6 is consistently 
expressed across all phenotypes indicating the cytokine plays an essential role 
in all forms of RA (Dennis et al., 2014). 
 
Although only a few factors appearing to increase in co-culture were detected at 
biologically significant levels those detected have previously been implicated in 
RA. CXCL10 has been found to stimulate increased invasiveness of RA synovial 
fibroblasts and arthritic rat synovial fibroblasts via CXCR3 signalling (Laragione 
et al., 2011). Additionally, plasma CXCL10 levels in untreated early RA are higher 
than in healthy controls and correlate with disease activity and a polymorphism 
in the CXCL10 gene is associated with RA and extra-articular manifestations of 
the disease (Kotrych et al., 2015; Pandya et al., 2017). Genetic knockout of the 
chemokine in the murine collagen antibody induced arthritis reduced macrophage 
and CD4+ T cell infiltration into the synovium (Lee et al., 2017). Regarding the 
role of IFNγ in RA the cytokine has been found at higher levels in the RA 
synovium than in osteoarthritis and increases the motility and migration of 
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synovial fibroblasts in in vitro assays (Dolhain et al., 1996; Karonitsch et al., 
2010). In contrast to the findings regarding CXCL10, IFNγ has been found to 
reduce the increase in MMP1 and MMP3 production in RA synovial fibroblasts 
elicited by IL-1β stimulation in vitro and reduce fibroblast mediated cartilage 
damage in an in vitro assay (Page et al., 2010). The final of the three main 
upregulated cytokines, VEGF, is found at higher levels in the synovial fluid of RA 
patients than of patients with other arthritides (Fava et al., 1994; Koch et al., 1994; 
Lee et al., 2001). Additionally serum VEGF levels are elevated in RA compared 
to osteoarthritis patients, correlate with CRP levels, decrease with successful 
treatment, and are correlated with radiological progression (Ballara et al., 2001; 
Harada et al., 1998; Lee et al., 2001). Of the downregulated chemokines 
discussed CCL2 is known to be produced by synovial fibroblasts and is higher in 
both the serum and synovium of RA patients compared to healthy controls 
(Hayashida et al., 2001; Zhang et al., 2015). Also CCL5 is higher in the synovial 
fluid and serum of RA than OA patients and serum levels correlated with both 
CRP and ESR measurements (Stanczyk et al., 2005; Yang et al., 2009). 
 
Published studies have also investigated a range of other factors produced during 
fibroblast:monocyte/macrophage co-culture. Chomarat et al found significant 
synergistic increases in GM-CSF, LIF, and IL-8 during co-culture of human 
peripheral blood monocytes and RA synovial fibroblasts but also noted that 
increases in IL-10, both IL-1α and IL-1β, and TNFα were only additive indicating 
no modulation of these cytokines (Chomarat et al., 1995). In co-cultures of murine 
3T3 fibroblasts and RAW264.7 or murine bone-marrow derived macrophages 
similar results to the work in this thesis were seen (Holt, Chamberlain and 
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Grainger, 2010). The cytokines IL-2, IL-3, IL-4, IL-5, IL-9, IL-10, IL12p70, IL-13, 
IFNγ, and GM-CSF were all expressed at levels lower than 40pg/ml in co-cultures 
and so were not investigated by Holt, Chamberlain and Grainger. Co-cultures of 
the murine fibroblast cell line CL.7 with RAW264.7 cells results in an upregulation 
of CCL3 which is dependent on ICAM-1 interactions indicating that for some 
factors cell-cell contact may be required (Steinhauser et al., 1998). Another study 
successfully highlighted the importance of different aspects of the co-culture for 
the production of different chemokines as in human lung fibroblast co-cultures 
with peripheral blood monocytes both CCL3 and CCL2 were synergistically 
increased by co-culture however the CCL3 production can be inhibited by fixing 
the monocytes prior to co-culture or with antibodies targeting β3-integrins 
whereas the CCL2 increase can be inhibited by fixing the fibroblasts or using an 
anti-TNFα antibody (Zickus et al., 1998). Monocytes are not the only cell types to 
elicit responses during co-cultures with fibroblasts as fibroblast co-cultures with 
natural killer cells have been shown to increase IL-6, IL-8, GM-CSF, CCL2, TNFα, 
IL-5, IL-15, granulocyte-colony stimulating factor (G-CSF), CXCL10, MMP9, 
MMP13, and MMP3 (Chan et al., 2008). 
 
As no changes in extracellular cytokine levels between co-cultures with different 
fibroblast lines were discovered a different approach was used to assess the 
intracellular levels of cytokines based on the reasoning that cells in unstimulated 
co-cultures may not release the full spectrum of cytokines available to them and 
that fibroblasts from different disease lines may ‘prime’ monocytes by changing 
levels of cytokines maintained in intracellular stores. However, neither TNFα nor 
IL-10 were detected at levels significantly different from the isotype control in 
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monocyte samples and IL-10 was detected at similar levels in both FLS mono- 
and co-culture indicating TNFα was not being produced by either cell type and 
IL-10 may have been produced by FLS but levels were not modulated by co-
culture. 
 
The data so far indicated that co-culture of fibroblasts from different disease 
outcome groups with monocytes did not result in differential regulation of cytokine 
and chemokine release but all elicit a similar response. Regardless it is still of 
interest to investigate the mechanisms which facilitate this response. ICAM-1 and 
CD18 are known to bind each other and are expressed on fibroblasts and 
monocytes respectively (Campbell et al., 1998; Liu and Piela-Smith, 2000; Yang 
et al., 2010; Zhou et al., 1994). To test if interactions between ICAM-1 and CD18 
are involved in the interactions during co-culture a CD18 blocking antibody known 
to prevent interactions was added at the start of 5 day co-cultures and IL-6 levels 
in the co-culture medium were measured at the end of co-culture. The results of 
this work are inconclusive as in direct co-cultures the blocking antibody appears 
to reduce the IL-6 release but this reduction is also seen when the isotype control 
antibody is used which hints that the effect of the blocking antibody is non-
specific. In the separate co-cultures, which behaved similarly to the direct co-
cultures with regards to IL-6 release, neither the blocking antibody nor the isotype 
control had any impact upon IL-6 levels in the co-culture, further complicating the 
picture. Finally in the transwell co-culture blocking CD18 interactions led to an 
increase in IL-6 release and the isotype control antibody reduced levels. 
Statistical analysis was unable to confirm or refute the findings due to low sample 
numbers and inadequate power. These data are difficult to interpret and draw any 
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conclusions from however several improvements could aid in generating clearer 
data. As most of the IL-6 release occurs within 24 hours of co-culture initiation it 
would be pertinent to analyse IL-6 levels after 24 hours of co-culture with the 
blocking antibody rather than the full five days. This would also reduce the chance 
that any effects may normalise and be missed due to clearance or degradation 
of the antibody as could happen in the 5 day co-cultures. If the 5 day co-cultures 
must be used in this assay then regular additions of the antibody to the co-culture 
during the 5 day period may be required. 
 
Returning to the hypothesis that fibroblasts from different disease outcome 
groups differentially modulate monocyte/macrophage phenotype it was decided 
to test the capability of fibroblasts to skew macrophage differentiation in pro- or 
anti-inflammatory directions depending upon the disease group of the fibroblast 
line. Monocytes were cultured in the presence of either GM-CSF or M-CSF for 2 
days before co-culturing the monocytes with fibroblasts in separated co-cultures 
for a further 2 days still in the presence of the growth factors. Changes in the 
expression of genes associated with pro-inflammatory (TNF and STAT1) or anti-
inflammatory (IL-10) macrophage functions were investigated in the 
macrophages. The expression of TNF was reduced in all co-cultured monocytes 
with both GM-CSF and M-CSF relative to monocyte monocultures with the factors 
apart from in co-cultures of monocytes with resolving fibroblasts in the presence 
of GM-CSF in which expression was not altered from the monocultures. IL-10 
showed the opposite pattern of regulation with a slight increase in all co-cultures 
and STAT1 demonstrated a decrease in all GM-CSF co-cultured monocytes, with 
those co-cultured with resolving fibroblasts showing a larger decrease, and an 
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increase in all M-CSF co-cultures. Although the data show that fibroblasts can 
influence gene expression during the differentiation process no clear differences 
between disease groupings can be seen with exception of co-culture of GM-CSF 
differentiating monocytes with resolving fibroblasts which appears to 
downregulate STAT1 to a larger extent than other co-cultures but does not 
achieve statistical significance. 
 
Published work has demonstrated that fibroblasts are capable of influencing the 
monocyte differentiation process, as may be evidenced herein, by the modulation 
of gene expression compared to the differentiating monocytes alone. 
Differentiation of human peripheral blood monocytes to dendritic cells using a 
combination of GM-CSF and IL-4 can be shifted to a monocyte to macrophage 
differentiation process by co-culture with dermal fibroblasts (Chomarat et al., 
2000). This shift was assessed using CD14 expression as a 
monocyte/macrophage marker and CD1a expression as a DC marker and 
required cell-cell contact, fibroblast derived IL-6, and also M-CSF to facilitate the 
change. Also of note is that the modulation of STAT1 expression by fibroblasts 
may be relevant to RA pathogenesis as STAT1 levels are higher in monocytes 
found in the synovial fluid of RA patients than those found in the peripheral blood 
of the same patients (Isomäki et al., 2015). 
 
In summary the work in this section established a co-culture protocol that was 
used to assess the role of contact dependent and independent mechanisms in 
fibroblast:monocyte co-cultures. Co-culture resulted in increased IL-6, CXCL10, 
VEGF, and IFNγ levels and decreased CCL2 and CCL5 levels in the co-culture 
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supernatant however fibroblasts isolated from different BEACON disease 
outcome groups did not differentially modulate these factors i.e. all fibroblast lines 
elicited a similar response. The release of IL-6 during co-culture was not contact 
dependent however inducing changes in the cytoskeleton in fibroblasts may 
change IL-6 release as evidenced by co-cultures in which fibroblasts were 
suspended from a membrane. Fibroblasts were able to modulate the expression 
of genes during monocyte to macrophage differentiation however they did not 
display differential modulation dependent on the clinical outcome group from 
which the fibroblasts were taken. Therefore there is a lack of evidence to support 
the alternative hypothesis and as such the null hypothesis, that fibroblasts 
isolated from different stages of RA progression do not differentially modulate 
monocyte or macrophage phenotype in vitro, was accepted. 
 
Although the co-culture of fibroblasts and monocytes did not result in clear 
differential modulation dependent on the stage of RA from which the fibroblasts 
were isolated the variation that was observed is of interest in the context of RA. 
IL-6 is a pro-inflammatory cytokine known to be highly involved in RA 
demonstrated by the successful targeting of IL-6 signalling as a therapy for RA 
patients and also the importance of IL-6 in the murine collagen-induced arthritis 
model (Alonzi et al., 1998; Castell et al., 1988; Choy et al., 2002; Sasai et al., 
1999). The interactions between monocytes and fibroblasts in the synovium of 
RA patients may contribute to the inflammatory burden through upregulation of 
IL-6 release along with increased release of the T cell chemoattractant CXCL10 
increasing the involvement of the adaptive arm of the immune system in the 
disease (Dufour et al., 2002a). Additionally secretion of VEGF was upregulated 
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by co-culture which indicates that monocyte-fibroblast interactions could increase 
vascularisation of the synovium facilitating increased inflammatory infiltrate into 
afflicted joints. However, the modulation of secreted factors was not a blanket 
increase as the monocyte chemoattractants CCL2 and CCL5 decreased in 
concentration during co-culture which may demonstrate an feedback loop 
employed by monocytes to prevent an unrestrained influx of monocytes into 
inflammatory sites (Rollins, Walz and Baggiolini, 1991; Schall et al., 1990). In 
contrast to the pro-inflammatory effects of fibroblast-monocyte co-culture 
fibroblasts appear to dampen the differentiation of macrophages towards a pro-
inflammatory phenotype. Regardless of the fibroblast disease stage or 
macrophage differentiation factor (GM-CSF or M-CSF) co-culture resulted in 
lower levels of TNF mRNA and higher levels or IL10 mRNA in macrophages than 
in macrophages differentiated in monoculture. This highlights the complexity of 
fibroblast interactions with other cell types, although the co-cultures with 
monocytes seemingly resulted in a pro-inflammatory phenotype fibroblasts are 
capable of downregulating expression of the critical factor for RA, TNF, and 
increasing mRNA levels of the anti-inflammatory factor IL10. 
 
The lack of any significant differences in monocyte or macrophage phenotype is 
particulary interesting given that large numbers of differentially expressed genes 
were detected between fibroblasts cultured from different stages of RA in chapter 
2. It could be that the differences in gene expression are somewhat normalised 
through post-transcriptional methods leading to similar levels of protein 
expression which in turn has a similar impact on monocytes regardless of the 
fibroblast disease stage and it is known that the correlation between mRNA and 
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protein levels is complex (Edfors et al., 2016; Koussounadis et al., 2015; Liu, 
Beyer and Aebersold, 2016). Regardless, the lack of differential modulation can 
be interpreted as the interactions between fibroblasts and monocytes not being 
an initiating factor for RA. However, the work in this chapter finds limited evidence 
that fibroblasts from resolving arthritis may actually induce lower levels of IL-6 in 
co-cultures with monocytes and supress STAT1 expression during GM-CSF 
driven monocyte-to-macrophage differentiation to a higher degree than 
fibroblasts from very early or late stage RA demonstrating that resolving 
fibroblasts may indeed regulate the level of pro-inflammatory factors and 
macrophages within the joint. As monocyte/macrophage populations derived 
from peripheral blood did not appear to be differentially modulated by fibroblasts 
from different stages of RA it was decided to turn the investigation towards 
synovial populations of macrophages to eliminate the confounding factor of using 
peripheral blood derived cells.
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4 IDENTIFICATION AND ISOLATION OF SYNOVIAL FIBROBLAST AND 
MACROPHAGE POPULATIONS 
4.1 Introduction 
To address the third hypothesis, that different fibroblast and macrophage subsets 
exist within the synovium with different distinct functions, two approaches were 
used, immunofluorescent staining of tissue sections and enzymatic digestion of 
synovial biopsy material. As mentioned in section 1.5.5 different subsets of 
fibroblasts are thought to exist in the synovium, particularly between the lining 
and sublining layers. In addition macrophages are also thought to exist as 
different subsets in the synovium, possibly identified by either lining or sublining 
location or CD163 expression, as discussed in section 1.4.3.2, and may 
differentiate from infiltrating or tissue-resident populations (section 1.4.2.2). The 
expression of stromal cell markers in synovial tissue from the BEACON cohort 
were investigated along with possible macrophage markers. However, to 
investigate function and gene expression in synovial stromal and macrophage 
populations one must be able to isolate viable cells from the tissue and as such 
a protocol for the digestion of synovial tissue was developed and used to facilitate 
the flow cytometric analysis of synovial cell populations.  
 
Protocols for the isolation of cell suspensions from the synovium exist for both 
human and mouse tissue. In mouse tissues the protocols have a degree of 
standardisation presumably due to the difficultly in accessing the small amount 
of synovial tissue. Protocols typically include microdissection stages where all 
tissue is removed from bones but leaving the joint capsule intact and then, upon 
exposing the synovium by cutting the joint capsule, digestion with collagenase IV 
and in some case deoxyribonuclease I (DNaseI) (Armaka et al., 2009; Hardy et 
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al., 2013; Zhao et al., 2016). In humans, the published protocols are more varied 
with tissue source, arthroplasty material or biopsy, and enzyme used for digestion 
changing between publications e.g. hyaluronidase and collagenase IV, 0.2% 
collagenase, or clostridiopeptidase A (Chang et al., 2013; Dayer et al., 1976; 
Gullo and De Bari, 2013; Van Landuyt et al., 2010). Many collagenase 
preparations are derived from bacteria and may not have been adequately 
purified to remove endotoxin contamination. Working in collaboration with other 
members of the National Institutes of Health (NIH) accelerating medicines 
partnership (AMP) (https://www.nih.gov/research-training/accelerating-
medicines-partnership-amp) this work aimed to develop a unified digestion 
protocol using a widely available enzyme mix with low endotoxin and high 
collagenase activity. 
 
The aim of the work in this chapter was to identify fibroblast and macrophage 
subpopulations using both tissue sections and dissagregated biopsy material. To 
address this aim three questions will be addressed: 
1. Does the expression of markers identifying synovial fibroblasts vary 
depending on the stage of RA? 
2. Can subpopulations of macrophages be identified in the synovium? 
3. Can a protocol be developed to allow the isolation of pure fibroblasts and 
macrophages from synovial tissue? 
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4.2 Methods and materials 
4.2.1 Arthroplasty, biopsy material and clinical outcome groups 
Synovial tissue from patients from the BEACON clinical outcome groups was 
collected by ultrasound guided biopsy. Patients donating tissue samples 
collected by ultrasound guided biopsy in Birmingham gave written, informed 
consent under the following ethics: West Midlands Black Country REC Reference 
07/H1203/57 “Ultrasound guided synovial biopsy in patients with arthritis”. Tissue 
from patients in the Jrep group or from osteoarthritis patients was collected during 
arthroplasty at the Royal Orthopaedic Hospital NHS Foundation Trust 
(Birmingham, UK) under the following ethics: West Midlands Black Country REC 
Reference 07/H1204/191 “Origins and roles of stromal cells in chronic 
inflammatory arthritis”. To increase the number of samples for stromal marker 
staining, available tissue from the Dutch Synoviomics cohort, collected by mini-
arthroscopy, were included using the same criteria as for the BEACON samples  
(De Hair et al., 2011). Characterisitics of the patients from which tissues sections 
used for the quantification of stromal markers are presented in Table 19. 
 
  
 
1
7
1
 
ID Group Disease 
classification 
CCP 
+/- 
RF 
+/- 
Sex Age DAS28 
ESR 
baseline 
ESR 
(mm/hr) 
CRP 
(mg/l) 
58 Res UA NA NA M 57 NA 15 19 
167 EstRA RA - - F 58 NA 44 10 
389 EstRA RA - - F 18 3.8 102 5 
390 Res Gout - - F 69 3.95 38 24 
394 EstRA RA + + F 68 4.5 25 8 
573 Res Gout - - M 44 3.72 101 88 
587 EstRA RA - - M 52 6.05 20 3 
676 VeRA RA + + M 59 2.42 8 5 
760 EstRA RA - - M 74 4.07 8 12 
790 EstRA RA + + M 55 6.4 18 16 
1181 VeRA RA - - F 22 7.33 111 113.8 
1182 VeRA RA - - F 43 5.7 35 4.6 
1190 VeRA RA - + F 55 5.37 37 4.2 
1192 VeRA RA - - F 54 6.7 76 42.5 
1258 Res Gout - - M 61 3.07 8 3.6 
1262 Res Gout - - M 66 4.58 36 20.1 
1264 Res UA - - F 32 3.49 13 6.7 
1282 VeRA RA + + F 54 5.2 32 16.5 
1299 VeRA RA + + M 60 1.81 3 1.7 
1403 EstRA RA - - F 72 4.48 5 3 
1457 EstRA RA - - F 66 4.38 13 1.8 
1515 Res PsA - - F 40 2.99 11 1 
1543 VeRA RA + + M 33 
   
1554 VeRA RA + + M 38 3.62 19 6.4 
1556 Res PsA - - M 65 4.24 15 1 
1611 VeRA RA + + M 74 5.35 68 79.9 
1717 VeRA RA - - F 82 5.1 8 6.3 
1732 VeRA RA + + F 48 2.92 5 2.1 
Bx003 VeRA RA + + M 50 5.7 31 26 
  
 
1
7
2
 
Bx004 Res UA - - M 33 3.6 9 6 
BX016 RA RA + + M 46 6.7 34 7 
BX018 RA RA - - F 69 4.6 11 0 
BX024 Res Reactive - - M 32 2.9 10 10 
BX028 Res RA - - M 74 4.8 45 13 
BX032 RA RA + - F 46 5.2 24 32 
BX038 Res Parovirus - - F 45 4 4 0 
BX042 VeRA RA + - M 55 3.5 58 45 
BX048 Res Reactive/post strep - - M 35 4.1 51 7 
BX054 Res UA - - M 55 3.5 2 6 
BX063 VeRA RA + - F 74 4.4 20 32 
BX064 Res UA - - M 35 1.6 2 9 
BX065 Res UA - - F 37 3.3 7 0 
BX070 Norm Normal - - M 44 NA NA NA 
BX071 Res Parovirus - - F 41 1.7 5 9 
BX075 RA RA - - F 22 6.4 81 79 
BX076 Res Reactive - - M 28 4.5 18 8 
BX077 RA RA - - M 72 7.4 53 43 
BX082 Norm Normal - - F 49 NA NA NA 
BX083 Norm Normal - - M 42 NA NA NA 
BX084 VeRA RA + + M 49 6.8 25 18 
BX089 Norm Normal - - F 38 NA NA NA 
BX092 VeRA RA + + M 48 6 63 38 
BX093 RA RA + + F 65 5.3 72 81 
BX097 Norm Normal - - F 41 NA NA NA 
Table 19: Clinical characteristics of the patients from which samples used for the quantification of stromal markers originated. NA = 
Not available, DAS28 = Disease activity 28 score, ESR = Erythrocyte sedimentation rate, CRP = C-reactive protein, CCP = Anti-cyclic 
citrullinated peptide, RF = Rheumatoid factor, UA = Undifferentiated arthritis. 
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4.2.2 Preparation of synovial tissue sections 
Frozen tissue sections used for immunofluorescent staining of synovial cellular 
markers were cut from frozen tissue blocks by Holly Adams and Jennifer Marshall 
as follows. Ultrasound guided biopsy material was immediately mounted in 
Tissue-Tek® O.C.T™ compound (Sakura) and frozen in the gas-phase of liquid 
nitrogen. The resulting tissue block was cut into 6µm sections on a cryostat and 
the sections were subsequently acetone fixed and permeabilised at 4oC in 
histological grade acetone (J.T.Baker) for 20 minutes. Tissue sections were 
stored at -20oC until used in staining protocols. 
 
 
4.2.3 Immunofluorescent staining of fibroblast markers in synovial tissue 
sections 
Staining and imaging of tissue sections was undertaken as described in the 
supplementary methods of Misharin et al. (2014). Briefly tissue sections were 
blocked with PBS v/v 10% FBS for 10 minutes to reduce non-specific binding of 
antibodies. The primary antibodies listed in Table 20 were then used to stain the 
tissues overnight at 4oC before washing the slides in PBS and staining for 1 hour 
at room temperature using the secondary antibodies in Table 21. A nuclear 
counterstain was then added in the form of 4µg/ml Hoechst 33258, Pentahydrate 
(bis-Benzimide) for 20 minutes (Invitrogen) before washing and mounting slides 
in 2.4% w/v 1,4-diazabicyclo (2,2,2) octane (Sigma) in 90% v/v glycerol (Sigma, 
49767) in PBS (pH, 8.6). The conjugates FITC, Cy3, and Cy5 were excited with 
a 488nm argon laser, a 543nm HeNe laser, and a 633nm helium laser 
respectively and images were acquired on a LSM 510 confocal microscope using 
LSM 510 version 3.2 SP2 software (Carl Zeiss). Negative controls were stained 
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with secondary antibodies only. Each section contained 6-8 biopsy pieces and 
staining for each of the markers was assessed by calculating the number of pixels 
which have intensity measurements above the background and dividing this 
value by the pixel area of the region being assessed (giving the units pixels/unit 
area). Three batches of staining were completed with samples restained in each 
batch to account for batch effects. Analysis was completed by myself, Debbie 
Hardie, Andrew Filer, and Jennifer Marshall. 
Target Clone Isotype Supplier 
CD90 F15-42-1 Mouse IgG1 Chemicon 
FAP F11-24 Mouse IgG1 eBioscience 
GP38 D2-40 Mouse IgG1 AbD Serotec 
CD68 Y1/82A Mouse IgG2b BD Pharmingen 
Table 20: Primary antibodies used for fibroblast/macrophage staining in synovial 
tissue sections 
 
Target Conjugate Isotype Supplier 
Mouse IgG1 FITC Goat IgG SouthernBiotech 
Mouse IgG2b Cy5 Goat IgG SouthernBiotech 
Table 21: Secondary antibodies used for fibroblast/macrophage staining in 
synovial tissue sections 
 
 
4.2.4 Immunofluorescent staining of macrophage markers in synovial 
tissue sections 
Staining was completed as in section 4.2.3 but only on a small number of tissues 
using the primary antibodies listed in Table 22 and the secondary antibodies in 
Table 23.  
Target Clone Isotype Supplier 
CD163 EDHu-1 Mouse IgG1 AbD Serotec 
CD206 15-2 Mouse IgG1, κ Biolegend 
CD68 Y1/82A Mouse IgG2b, κ BD Biosciences 
HLA-DR L243 Mouse IgG2a, κ BD Biosciences 
Table 22: Primary antibodies used for macrophage staining in synovial tissue 
sections 
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Target Conjugate Isotype Supplier 
Mouse IgG1 FITC Goat IgG SouthernBiotech 
Mouse IgG2a TRITC Goat IgG SouthernBiotech 
Mouse IgG2b Cy5 Goat IgG SouthernBiotech 
Table 23: Secondary antibodies used for macrophage staining in synovial tissue 
sections 
 
4.2.5 Digest optimisation 
Several parameters were evaluated in order to establish an optimal digestion 
protocol and to assess the feasibility of cryopreservation of tissue to facilitate later 
digestion or shipment of synovial tissue samples between sites. An additional 
step of trituration in the digestion protocol was suggested by collaborators in the 
Brenner Lab (Brigham and Women’s Hospital, Boston). The final established 
protocol was as follows. Synovial tissue, either obtained during arthroscopy and 
provided without any buffer or obtained by ultrasound guided biopsy procedures 
and provided in saline solution, was minced using scalpels until the average size 
of pieces was less than 1mm3. Tissue was then transferred into 5ml 
polypropylene tubes (Falcon) containing a magnetic stirring bar at a maximum 
quantity of 0.02g of tissue/tube. 1ml of digestion buffer consisting of serum-free 
RPMI-1640 (Sigma),  0.97mM sodium orthopyruvate (Sigma), 1.94mM glutamine 
(Sigma), 97U/ml penicillin (Sigma), 97μg/ml streptomycin (Sigma), [0.97x] MEM 
non-essential amino acids (Sigma), 50μg/ml Liberase TM (Roche), and 40μg/ml 
DNaseI (Sigma) was added to each 5ml tube followed by immediate incubation 
in a 37oC water bath with stirrer agitation set to 380rpm. After 15 minutes of 
incubation the digestion buffer and tissue was triturated using a 16G needle 
before continuing the incubation and agitation at 37oC for another 15 minutes. 
The digestion mix was then passed through a 100μm filter (Greiner Bio-One) to 
remove any remaining pieces of tissue and the filter was rinsed with an equivalent 
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volume of complete fibroblast medium containing serum (see section 2.2.1) to the 
volume of digestion mix in order to inhibit the enzymatic digestion. The 
suspension was then centrifuged at 300g for 6 minutes before discarding the 
supernatant and resuspending in PBS (Oxoid). The cell suspension was 
centrifuged again at 300g for 6 minutes before resuspending in PBS containing 
LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher Scientific) at 
the manufacturers recommended concentration and incubating at 4oC for 30 
minutes. The sample was then washed twice by centrifuging at 300g for 6 minutes 
before adding 200μl of staining buffer (PBS 2% v/v heat-inactivated foetal bovine 
serum (Biosera) and 2mM Ethylenediaminetetraacetic acid (EDTA, Sigma)), 
centrifuging again at 300g for 6 minutes, and repeating the previous two steps. 
The cells were then resuspended in staining buffer containing an antibody mix 
consisting of several or all of the antibodies described in Table 24. Single colour 
controls of all antibodies in Table 24 were prepared at the same concentration as 
the full mix in staining buffer and added to VersaComp Antibody Capture Beads 
(Beckman Coulter) used as specified by the manufacturer’s instructions. Both the 
cell suspension and single colour controls were incubated at 4oC for 30 minutes 
before washing all stained cells and beads as before. Samples were resuspended 
in 200μl of staining buffer before passing the cell suspension through a 70μm 
filter (Sysmex) and rinsing the filter with 300μl of staining buffer. The cell 
suspension was then sorted into 6 populations using a MoFloAstrios EQ 
(Beckman Coulter). 
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Target Conjugate Clone Isotype Supplier 
CD1c FITC L161 Mouse IgG1, κ Biolegend 
CD11c BV650 3.9 Mouse IgG1, κ Biolegend 
CD14 BV785 M5E2 Mouse IgG2a Biolegend 
CD15 BV510 W6D3 Mouse IgG1, κ Biolegend 
CD31 FITC TP1/15 Mouse IgG2a Abcam 
CD31 PerCP 9G11 Mouse IgG1 R&D Systems 
CD34 FITC 581 Mouse IgG1, κ Biolegend 
CD45 V450 2D1 Mouse IgG1, κ BD Biosciences 
CD64 BV605 10.1 Mouse IgG1, κ Biolegend 
CD90 PerCP-Cy5.5 eBio5E10 Mouse IgG1, κ eBioscience 
CD117 FITC/PE-Cy7 104D2 Mouse IgG1, κ Biolegend 
CD163 PECF594 GHI/61 Mouse IgG1, κ BD Biosciences 
CD197 BV711 G043H7 Mouse IgG2a, κ Biolegend 
CD206 APC 15-2 Mouse IgG1, κ Biolegend 
CD235a FITC/PE-Cy7 HI264 Mouse IgG2a, κ Biolegend 
CD326 FITC/PE-Cy7 9C4 Mouse IgG2b, κ Biolegend 
GP38 PE NZ-1.3 Rat IgG2a eBioscience 
HLA-DR BV510 L243 Mouse IgG2a, κ Biolegend 
Mer Alexa Fluor 350 125518 Mouse Novus Biologicals 
Table 24: Antibodies used for fibroblast/macrophage staining in synovial tissue 
digestions 
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4.3 Results 
4.3.1 Fibroblasts and macrophages can be identified by 
immunofluorescent staining of tissue and the expression of 
fibroblast markers varies with disease stage 
The exact phenotype of fibroblast subsets in the synovium during RA is unclear 
with recent publications only beginning to address this question. However, it was 
of interest to investigate the expression of the known stromal markers, CD90, 
FAP, and GP38, in synovial tissue from different clinical outcome groups to 
assess if the markers are differentially expressed between disease stages, 
particulary given the differential expression of genes encoding these markers in 
cultured synovial fibroblasts from different disease stages (2.3.2). To this end 
synovial tissue sections obtained from patients at different stages of RA were 
stained for several prospective stromal subset markers as well as the 
macrophage marker CD68 and the levels of markers were quantified and 
compared between different disease stages the results of which formed part of a 
publication (Choi et al., 2017). Of the stromal markers assessed FAP showed a 
significant increase in expression in very early RA compared to normal, 
uninflamed controls (Figure 41). GP38 demonstrated a similar pattern to FAP 
expression but differences were not statistically significant. CD90 expression was 
significantly higher in the resolving arthritis samples compared to the normal 
samples and CD68 remained unchanged across all clinical outcome groups.  
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Figure 41: Immunofluorescent staining and quantification of fibroblast subsets 
and macrophages in the synovium of uninflamed control patients (Norm), patients 
with resolving arthritis (Res), patients with very early RA (VERA), and patients with 
established RA (RA). Representative images of staining of VERA tissue with 
regions of interest (ROIs) drawn around the lining layer present in the image 
(adapted from (Choi et al., 2017)). Quantification of staining in the tissue found 
significantly higher levels of FAP in VERA samples compared to the Norm samples 
and significantly higher CD90 expression in the Res samples than the Norm 
samples. Tested using Kruskal-Wallis tests and Dunn’s multiple comparisons 
tests. *= p<0.05, ** = p<0.01. Representative immunofluorescence images are from 
a patient with RA (left) and a patient with resolving arthritis (Res). 
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In order to identify macrophages within the synovium, synovial tissue sections 
were stained for CD68, CD163, CD206 and HLA-DR, markers reported to 
differentiate between infiltrating and resident macrophages in the literature, and 
imaged used confocal microscopy, the results of which formed part of a 
publication (Misharin et al., 2014). Two populations of CD68+CD163+ 
macrophages could be discerned using this method, a HLA-DRhiCD163lo 
population hypothesised to arise from infiltrating cells and a HLA-DRloCD163hi 
population hypothesised to arise from tissue resident cells. In addition a 
CD68+HLA-DR+CD206+ population could also be identified in the tissue. 
 
 
Figure 42: Representative images demonstrating the presence of CD68+HLA-
DR+CD163+ and CD68+HLA-DR+CD206+ populations in joint replacement RA 
synovial tissue. 
 
CD206 HLA-DR 
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Nucleus CD68 
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Due to the limited dynamic range of confocal microscopy it was technically 
challenging to image the synovial tissue populations using the same gain settings 
for the photomultiplier tube. This was due to the differences in expression of all 
the markers varying greatly between the populations with even CD68 expression 
being lower on the ‘resident’ population. Therefore quantification of imaging data 
for the macrophage populations was not attempted, however a protocol for the 
dissociation of synovial biopsy material and flow cytometric assessment of 
fibroblast and macrophage populations was developed. 
 
4.3.2 Development of a synovial digestion protocol optimised for 
recovery of cellular subpopulations 
In order to further investigate synovial fibroblast and macrophage populations a 
tissue digestion protocol was developed in collaboration with members of the NIH 
AMP to be used on arthroplasty and synovial biopsy tissue. Synovial tissue was 
minced using scalpels and two commercially available enzyme mixes, Liberase 
TM and Liberase TL which contain a medium or low concentration of thermolysin 
respectively, were used to digest the tissue for 30 minutes at 37oC with agitation 
with a magnetic stirrer with the enzymes used at a concentration of 50µg/ml and 
with DNaseI present in both digestions at a concentration of 40µg/ml. The 
resulting stromal populations were investigated by flow cytometry by investigating 
CD90 and GP38 expression in the CD31-CD45- population. Liberase TM appears 
more efficient at isolating the CD90-GP38+ and CD90+GP38- populations than 
Liberase TL but not significantly (Figure 43). Neither digestion method appears 
to isolate CD31-CD45- stromal or CD45+ hematopoietic populations in different 
proportions relative to each other indicating a similar efficacy at isolating overall 
stromal and hematopoietic populations. Perhaps most important is that although 
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Liberase TM has a higher concentration of thermolysin it does not decrease the 
viability of the cells isolated any more than that obtained by the liberase TL 
preparation with a mean viable proportion of the entire cell yield and 95% 
confidence interval of 76.5 ± 30.8 and 74.4 ± 29.3 for the liberase TM or liberase 
TL respectively. 
 
Figure 43: Comparison of digestion of synovial tissue using either Liberase TM or 
Liberase TL at 50µg/ml, with 40µg/ml DNaseI at 37oC for 30 minutes with agitation 
by a mechanical stirrer. Liberase TM appeared to isolate higher proportions of the 
CD31-CD45-CD90+GP38- and the CD31-CD45-CD90-GP38+ populations than liberase 
TL but not significantly. Both enzymes isolated similar proportions of stromal and 
hematopoietic populations, defined as CD31-CD45- or CD45+ respectively. n=3 
representative flow dot plots shown. Tested using Mann-Whitney test. Bars show 
median. 
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In order to minimise the impact of enzymatic digestion upon surface marker 
expression, mechanical disruption of synovial tissue using a gentleMACS™ 
Dissociator (MiltenyiBiotec) with gentleMACS C Tubes (MiltenyiBiotec) using the 
pre-programmed protocol m_spleen0.40 or a Stomacher® 80 Biomaster 
(Seward) for 5 minutes with or without subsequent digestion using liberase TM 
were investigated using the stromal populations identified with CD90 and GP38 
as the readout. Using only mechanical disruption resulted in a relatively poor 
isolation of stromal populations with the CD90+GP38+ population seeming to be 
completely absent (Figure 44). Using either mechanical method with a 
subsequent enzymatic digestion with magnetic stirrer agitation resulted in the 
isolation of similar stromal populations as were seen in digestions without 
mechanical disruption by stomaching or GentleMACs. 
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Figure 44: Mechanical digestion by either stomaching or GentleMACs C tube 
dissociation alone did not efficiently isolate stromal populations. When used as a 
prior step to enzymatic digestion using Liberase TM (50μg/ml and 40μg/ml DNase 
I) stomaching increased the mean proportion of CD90+GP38+ stromal cells isolated 
by 35.85% however GentleMACs increased the mean proportions of the 
CD90+GP38+ and the CD90-GP38+ stromal populations by 59.73% and 16.21% 
respectively (n=3, representative plots shown). 
 
As digesting synovial biopsy material just after collection would result in many 
small experimental batches, possibly introducing unwanted variation into 
downstream analyses, the ability to freeze tissue and digest several samples in 
one batch would be advantageous. To this end a digestion protocol using 
Cryostor 10 was optimised. As the tissue would be frozen prior to digestion there 
was a risk that the tissue would not be fully perfused by protective freezing media 
causing the death of cells present in the centre of tissue pieces. To prevent this 
from occurring freezing protocols allowing the Cryostor 10 to perfuse into the 
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tissue at 4oC for either 10 or 20 minutes before transfer to -80oC were compared 
with freshly digested tissue with regards to the viability of cells isolated by 
digestion, cell yield, and proportions of cell populations. As seen in Figure 45 
freezing the tissue with a 10 minute perfusion step did not appear to decrease 
the viability of cells isolated relative to the number of cells isolated from a 
digestion of the same tissue immediately after collection. The proportion of 
stromal subsets relative to the total of the CD90-GP38+ and CD90+GP38+ 
populations did not appear to be consistently altered by the freezing protocols; 
however when considering the proportions of the stromal and CD45+ populations 
relative to the total, it appeared that the freezing protocols increased the 
proportion of stromal cells isolated and hence decreased the proportion of CD45+ 
cells isolated. It seems unlikely that this change was due to death of CD45+ cells 
as the overall viability did not appear to be affected using the 10 minute protocol; 
the CD45+ and stromal proportions suggested that the effect could have been 
due to an increase in cell yield after freezing. 
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Figure 45: Comparison of the viability and proportion of cell populations isolated 
by digestion of either fresh synovial tissue or cryopreserved synovial tissue 
frozen in Cryostor 10 with perfusion at 4oC for either 10 or 20 minutes prior to 
freezing at -80oC. Freezing with 10 minutes of perfusion did not appear to impact 
cell viability whereas 20 minutes of perfusion did possibly reduce viability. 
Freezing did not appear to change the proportions of stromal subsets isolated 
relative to one another. The proportion of stromal cells isolated relative to the total 
stromal and CD45+ populations could possibly increase after freezing for either 10 
or 20 minutes. All digestions were completed using Liberase TL 100ug/ml and 
100ug/ml DNaseI. n = 2 for 10 minutes, 3 for fresh and 20 minutes. 
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With a functional digestion protocol optimised (full protocol in appendix 8.3) the 
stromal and macrophage populations could now be investigated in greater detail. 
 
4.3.3  Digested macrophage and fibroblast populations can be identified 
by flow cytometry 
Using the protocol developed in section 4.2.5 flow cytometric and ex vivo analysis 
of synovial stromal and macrophage populations could be attempted. The cell 
surface markers for stromal populations had been previously identified and during 
this thesis, work on single cell sequencing of synovial cells isolated by digestion 
from arthroplasty samples was completed by Mizoguchi et al. (2017) which 
identified three major stromal populations in the CD31- compartment, CD90-
GP38+ cells, CD90+GP38+CD34+ cells, and CD90+GP38+CD34- cells. Using 
these markers the same populations could be identified in synovial biopsy 
material digested herein (Figure 51).  
 
The identification of synovial macrophages was less clear, previous work having 
identified macrophage populations however one of the common markers used, 
CD68, could not be used in this work as CD68 is predominantly expressed 
intracellularly and the necessary protocols to stain for this marker would result in 
reduction of the quality of RNA (Micklem et al., 1989; Parwaresch et al., 1986; 
Pulford et al., 1989). Using CD163 and CD64 as putative macrophage markers 
CD45+CD64+CD163- and CD45+CD64+CD163+ populations could be identified 
(Figure 46). One of the caveats of using CD64 as a macrophage marker is that it 
can also be expressed on activated mast cells, however by using the mast cell 
marker CD117 these cells could be excluded (Meininger et al., 1992; Woolhiser, 
Brockow and Metcalfe, 2004). In the digestions no CD45+CD64+CD117+ 
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population was found indicating mast cells were not present in the CD45+CD64+ 
cell fraction (Figure 46, B). Using the CD45+CD163+ approach to identify possible 
macrophages, an additional CD45+CD163loGP38+ population could be found. 
 
Figure 46: Representative plots of CD45+ cells obtained from digestion of human 
synovial tissue. A, Demonstration of the gating strategy used to identify 
macrophage populations; after exclusion of debris and doublets live cells are 
identified through the use of an amine binding dye, staining for the cell surface 
markers CD45, and a combination of CD31, CD235a, and CD326 in the same 
channel allows identification of stromal populations (negative for these markers) 
and hematopoietic populations (CD45+ and either positive or negative for the other 
markers). B, two macrophage populations identified by CD64 and CD163 
expression showed a uniform level of HLA-DR expression and as such could not 
be further stratified by the use of this marker. C, A GP38hiCD163lo population was 
present in some synovial samples but not in others, the nature of this intermittent 
population was not known. 
 
Continuing the investigation of macrophage marker expression in the cell 
suspensions generated by digestion of synovial tissue, the expression of HLA-
DR and CD206 on macrophages was assessed. HLA-DR is expressed by antigen 
presenting cells and would aid in the identification of macrophages and CD206 
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had been used as a marker of less inflammatory macrophages (Ambarus et al., 
2012a; Verreck et al., 2004). In addition to these markers autofluorescence in the 
FITC channel was assessed as a potential marker, as autofluorescence had been 
shown to be high in macrophages and had previously been used as a parameter 
to identify macrophages (Aubin, 1979; Pankow et al., 1995; Umino et al., 1999). 
When investigating the expression of CD45 versus CD235a/CD326/CD117, two 
CD45+ populations could be found, a CD45+CD235a/CD326/CD117- population 
and a CD45+ population that showed a low level of fluorescence in the combined 
CD325a/CD326/CD117-PECy7 channel (Figure 47). This dimly PE-Cy7 
fluorescent population showed an increased amount of autofluorescence in the 
FITC channel when compared with the CD45+CD235a/CD326/CD117- 
population. In addition the majority of the population with higher FITC channel 
autofluorescence was positive for HLA-DR and positive for both CD163 and 
CD206 whereas the non-autofluorescent population was a mix of HLA-DR- and 
HLA-DR+ cells with most of the HLA-DR positive population being CD206-CD163-
. This indicated that the autofluorescent population consisted of a macrophage 
type population whereas the non-autofluorescent population did contain HLA-
DR+ cells but these cells lack expression of the macrophage markers CD163 and 
CD206. 
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Figure 47: Expression of macrophage markers and FITC autofluorescence profile 
of the two CD45+ populations visible. Increased autofluorescence was found in 
macrophage populations and in synovial digestions the more autofluorescent 
CD45+ population demonstrated higher levels of staining for HLA-DR, CD163, and 
CD206 in keeping with this pattern. 
 
Cell sorting the possible macrophage populations and generating cytospins can 
often aid in the identification of cell types by examining the morphological 
characteristics of the sorted cells. Using this approach CD45+HLA-DR+ cells split 
according to the amount of fluorescence in the PE-Cy7 dump channel and then 
further split according to CD206 and CD163 expression were sorted and used to 
generate cytospins (Figure 48, the dump low CD206+CD163+ population was lost 
due to equipment issues). The dump mid CD206+CD163+ cells showed 
morphological characteristics in keeping with those of macrophages, namely a 
ruffled cell membrane and oval shaped, sometimes pinched/kidney shaped 
nuclei. The dump mid CD206+CD163- population also showed a similar 
morphology however the dump low CD206+CD163- population demonstrated a 
different morphology with the presence of large vacuoles in some of the cells and 
other cells with smaller amounts of cytoplasm and dendritic 
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processes/pseudopodia. The dump low and dump mid double negative (DN) 
population both contained cells with a similar morphology to the double positive 
population, however they also contained more cells with a small amount of 
cytoplasm and more clear kidney shaped/pinched nuclei. These findings 
suggested that the CD206+CD163+ dump mid population was predominantly 
macrophage-like in appearance whereas the other populations were more 
heterogeneous, sometimes containing macrophage cells but in the presence of 
cells with various other morphological features. 
 
 
Figure 48: Cytospins of sorted putative synovial macrophage populations stained 
with Giemsa stain. The cells were sorted from the CD45+HLA-
DR+CD235a/CD326/CD117- population (dump low) or the CD45+HLA-
DR+CD235a/CD326/CD117lo population (dump mid) with further separation 
according to CD206 and CD163 expression. The CD206+CD163+ population 
appeared to have a macrophage like appearance (ruffled membrane; oval, pinched 
nucleus) and could have been slightly larger in size than the double negative 
population. The dump low CD206+CD163+ population was lost due to equipment 
failure. 
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As a final step to aid in the identification of the myeloid cells within the CD45+ 
fraction of the digested synovial tissue cells, several experiments were completed 
in which the cells were stained with a different panel of markers. A summary of 
the results of these experiments can be found in Table 25. Using this approach 
four main populations were identified. Population 1 was negative for most 
markers and could be split into a large CD11c- population and a very small 
CD11c+ population. Population 2 expressed low levels of HLA-DR but was 
positive for CD64 and also CD14 hinting at a myeloid identity. The macrophage 
markers CD163 and CD206 were absent from population 2. Population 3 had 
high expression of HLA-DR and was positive for CD64 and CD206 showing an 
increasing macrophage phenotype when compared to populations 1 and 2. 
Population 4 had slightly higher HLA-DR expression than population 3, was 
positive for CD64, CD206, CD163, GP38 and had high expression of CD14, 
CD1c, Mer, CD15, and CD197. Interestingly, expression of the putative tissue 
resident macrophage marker Mer followed a similar pattern to HLA-DR 
expression across the populations with no expression in population 1 and 
increasing expression in populations 2, 3, and 4. CD11c, a marker which is more 
highly expressed on dendritic cells was absent from all populations with the 
exception of a small subset of population 1 (Guilliams et al., 2016). CD197 
(CCR7) is normally associated with activated dendritic cells and was expressed 
on populations 2, 3, and 4 yet CD11c was absent from these population (Dieu et 
al., 1998; Sallusto et al., 1998). 
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Marker Population 1 Population 2 Population 3 Population 4 
HLA-DR   - lo hi hi+ 
CD64 - + + + 
CD206 - - + + 
CD163 - - - + 
GP38 + - - + 
CD14 - int int hi 
CD1c int - int hi 
MerTK - lo Int hi 
CD15 lo lo int hi 
CD197 - int int hi 
CD11c -/+ - - - 
Table 25: Expression of myeloid/macrophage markers in CD45+ cells isolated from 
synovial tissue. Four main populations could be identified using the markers listed 
in the table which summarises the results of several different staining panels. 
 
As part of the ongoing collaboration with partners in the AMP RA synovial biopsy 
tissue was cryopreserved and transferred to the lab of Michael Brenner (Boston, 
USA) for analysis using CyTOF, a technique combining mass spectrometry and 
flow cytometry technologies to allow the analysis of more markers than possible 
by traditional flow cytometry without the associated issues with spectral overlap 
(Bandura et al., 2009). Due to the increased dimensionality of the data 
dimensionality reduction techniques are used to visualise the relationships within 
the data. t-distributed stochastic neighbour embedding (tSNE) takes the output 
of PCA and facilitates the analysis of relationships between data without the 
limitations of the linear PCA approach (Van Der Maaten and Hinton, 2008). The 
data generated and provided by the collaborators identified clear clusters of T, B, 
myeloid, and stromal cells confirming the findings of the work above (Figure 49, 
Figure 50). CD14, CD64, and HLA-DR expression all showed a high degree of 
overlap with regards to the cluster of cells in which they were found (Figure 49). 
However CD11c staining in the CyTOF data appeared to be much higher than 
expected from the results above indicating some discordance between the two 
techniques. A possible explanation may be that the digestions completed by the 
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collaborators used the weaker Liberase TL mix as opposed to the Liberase TM 
used for the other marker work above leading one to hypothesise that CD11c 
may be cleaved from the cell surface by the harsher enzymatic mix. Alternatively, 
the antibody clone used by collaborators could have had a superior avidity.  
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Figure 49: Representative coloured tSNE plots of leukocyte (A) and myeloid (B) 
marker expression on CD45+ cells yielded by digestion of RA synovial biopsy 
material using the protocol developed in this project. Data were obtained using 
Cytometry by Time Of Flight (CyTOF) analysis by collaborators in the lab of 
Michael Brenner as part of the AMP collaboration. Colour shows normalised 
expression of the relative marker. tSNE = t-distributed stochastic neighbour 
embedding. Protocol development in collaboration with Brenner group, digestion 
and plots by Kevin Wei and adapted by the author. 
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Using the same CyTOF data but instead investigating the expression of markers 
of stromal populations provided some insight to the stromal populations (Figure 
50). Vascular endothelial cadherin (VE-cadherin), a marker specific for 
endothelium, expression could be found in a cluster negative for FAP and GP38 
indicating these markers do not label endothelial cells (Vestweber, 2008). 
However a small cluster of cadherin-11+VE-cadherin+ cells could be found and 
all of the VE-cadherin expressing cells appeared to be CD34+ reinforcing that 
caution should be exercised to exclude endothelial cells from the analysis of 
synovial fibroblast populations. Regarding the VE-cadherin negative populations 
GP38 and FAP showed a considerable amount of overlap in the populations 
labelled, with two separate clusters identified using these markers; it could be 
argued that all GP38+ cells also appeared to be FAP+. CD34 on the other hand 
only appeared to be expressed in one of the FAP+GP38+ clusters, showing a 
more restricted pattern of expression. 
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Figure 50: Representative coloured tSNE plots of stromal marker expression on 
CD45- cells yielded by digestion of RA synovial biopsy material. Data were 
obtained using Cytometry by Time Of Flight (CyTOF) analysis by collaborators in 
the lab of Michael Brenner as part of the AMP collaboration. Colour shows 
normalised expression of the relative marker. tSNE = t-distributed stochastic 
neighbour embedding. Protocol development in collaboration with Brenner group, 
digestion and plots by Kevin Wei and adapted by the author. 
 
In summary three main stromal populations recently identified in single cell 
sequencing experiments could be identified in the cells yielded by digestion of 
synovial tissue. The work above identified possible macrophage populations 
identified by HLA-DR, CD206, and CD163 expression. 
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4.4 Discussion 
The work in this chapter identified stromal populations present in the synovium 
that are modulated during different disease stages. With regards to stromal 
populations the surface marker GP38 was associated with lining layer fibroblasts, 
confirming the findings of other investigators (Bauer et al., 2006; Del Rey et al., 
2014; Ekwall et al., 2011). In addition, the expression of GP38 has been found to 
be increased by proinflammatory factors indicating expression increases in 
response to inflammation (Croft et al., 2016). Staining of synovial tissue sections 
did not find significantly increased GP38 expression in VeRA. The fibroblast 
marker FAP was significantly increased in very early RA compared to uninflamed 
controls but not compared to other stages of RA and CD90 was significantly 
increased in resolving arthritis compared to normal samples. FAP expression is 
increased in the inflamed synovium in the murine collagen-induced arthritis model 
and is highly expressed by MMP1 expressing lining layer fibroblasts that lack 
CD90 in RA synovium (Bauer et al., 2006; Laverman et al., 2015). Additionally 
increased expression of mRNA encoding FAP was found in synovial fibroblasts 
cultured from patients with very early RA in section 2.3.2 of this thesis. The lack 
of an increase in CD90+ expression in RA samples is of interest as it has been 
postulated that CD90+ stromal cells are the major source of IL-6 in cancer-
associated fibroblasts and given the prevalence of this cytokine in RA it could be 
hypothesised that the expansion of CD90+ synovial fibroblasts is involved (Huynh 
et al., 2016). 
 
Moving on to macrophage subsets, immunofluorescent staining of uninflamed 
and RA synovial tissue identified CD68+ macrophage populations in lining and 
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sublining regions of the synovium. Using additional markers such as CD163 and 
HLA-DR two broad populations were demonstrated in the synovium, HLA-
DRhiC163lo and HLA-DRloCD163hi macrophages which match the findings in a 
mouse model of arthritis that identified these two populations as infiltrating and 
resident populations respectively (Misharin et al., 2014). In the murine K/BxN 
serum-transfer model of arthritis, this work suggested that resident macrophages 
in the synovium maintain an anti-inflammatory phenotype and aid in the control 
of arthritis, however an infiltrating macrophage population was required for 
normal resolution of the arthritis despite initially expressing both pro- and anti-
inflammatory genes, with progression to a more regulatory phenotype as the 
arthritis progresses. Due to the low dynamic range of confocal microscopy, 
difficulty in quantifying data obtained using this technique, and lack of ability to 
isolate live cells for functional assays, it was decided to develop a unified 
digestion protocol in collaboration with partners in the NIH AMP which could be 
used to generate cell suspensions for flow cytometric analysis and cell sorting 
from synovial biopsy tissue. 
 
Investigation of methods for disruption of synovial tissue found that mechanical 
dissociation was not sufficient to isolate stromal cells. Enzymatic digestion with 
Liberase TM performed well at isolating stromal and macrophage populations and 
data suggested that Liberase TL was not quite as efficacious as Liberase TM, 
although these findings were not statistically significant. Freezing of the tissue did 
not result in the total loss of stromal or CD45+ populations or a reduction in 
viability, but did result in a reduction of the proportion CD45+ cells relative to the 
proportion of stromal cells. 
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It is important to mention that the number of replicates for the freezing work were 
low and should be increased to confirm or refute the findings. With this is mind 
an immediate theory regarding the change in proportion would be that the CD45+ 
cells are killed by the freezing protocols. However, given that no change in the 
viability was apparent with the 10 minute freezing protocol this hypothesis seems 
unlikely. Another possibility could be that the freezing protocols disrupt the tissue 
aiding in the recovery of cells by digestion and thus leads to an increase in the 
number of stromal cells being isolated which would result in a reduction in the 
CD45+ proportion. 
 
Regarding the populations yielded by digestion three key populations recently 
identified as the major stromal subsets in the synovium by single cell RNA-
sequencing were present in the cell suspensions (Mizoguchi et al., 2017). These 
populations were identified as CD45-CD325a/CD326/CD117-CD31- and then 
either CD90-GP38+, CD90+GP38+CD34+, or CD90+GP38+CD34- and were 
present in various proportions in the digestions. In the case of the macrophages 
three putative macrophage populations were identified as CD45+HLA-DR+ and 
then separated as CD206-CD163-, CD206+CD163-, or CD206+CD163+. It was not 
possible to use the traditional macrophage marker CD68 due to the intracellular 
nature of the antigen which lead to highly varied results (Micklem et al., 1989; 
Parwaresch et al., 1986; Pulford et al., 1989). Increased autofluorescence in the 
FITC channel has previously been used to identify macrophages which is of 
interest as the three possible macrophage populations appeared to have 
differences in this autofluorescence with the CD206+CD163+ population having 
higher levels than the CD206-CD163- population (Aubin, 1979; Pankow et al., 
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1995; Umino et al., 1999). However this feature could be due to aspects of the 
immunofluorescent staining such as interactions between the fluorophores, a 
possibility that was not tested in this work. Although a full panel of macrophage 
markers was tested HLA-DR, CD206, CD163, and CD64 remained the best 
discriminators between three macrophage populations identified. During in vitro 
differentiation of human peripheral blood monocytes into macrophage 
populations the expression of CD206 and HLA-DR was found to increase on the 
surface of all macrophage subsets compared to monocytes but CD163 
expression was absent from the pro-inflammatory M1 subset differentiated using 
GM-CSF (Rey-Giraud, Hafner and Ries, 2012). When comparing the multiple 
anti-inflammatory M2 subsets the M2a population, differentiated with M-CSF and 
IL-4, showed lower expression of CD163 and CD14 when compared to the M2c 
subset, differentiated with M-CSF and IL-10, and the M2c subset had decreased 
HLA-DR and CD206 levels. These findings mirror some of the data in this work 
indicating the macrophage populations identified in the synovial digestions may 
be similar to in vitro M2 subtypes, however some differences do exist such as no 
change in HLA-DR or CD206 levels between the populations which is probably 
due to the complex cytokine milieu surrounding the macrophages in vivo.  Finally, 
assessment of the morphology of the ex vivo macrophage populations indicated 
the CD206+CD163+ cells are indeed macrophage populations but found a higher 
degree of heterogeneity in the CD206-CD163- population hinting that this may 
represent a mixed population. 
 
The analysis of the immunofluorescent staining of synovial tissue sections had 
several limitations. Confocal microscopy is a useful tool for obtaining data on the 
 202 
 
geographic location of cells within a tissue but has a limited dynamic range. In 
the case of some markers with a broad range of expression this could result in 
the loss of data on low or high expressing cells biasing the analysis. Additionally 
the analysis method used in this work, to manually select reasonable quality 
regions of tissue, could clearly result in a bias in the analysis. The analysis of the 
data by several operators could also introduce bias however approaches were 
taken to limit this effect by comparing the results of comparisons of the same 
tissues across operators. 
 
Regarding the digestion optimisation work several improvements could be made. 
The work was completed using synovial tissue from different clinical outcome 
groups obtained by arthroscopy or ultrasound-guided biopsy. The heterogeneity 
introduced by these factors would have confounded the comparisons possibly 
leading to incorrect conclusions on the optimal digestion technique. If the work 
was to be repeated it would be sensible to use tissue obtained using one method 
and preferably from one clinical outcome group. In addition, due to the nature of 
the collaborative work the freezing protocol was optimised on digestions using 
Liberase TL even though Liberase TM was chosen as the enzyme for use in the 
optimised protocol. Ideally this work should be repeated using the appropriate 
enzyme mix and digestion protocol to reduce spurious findings. 
 
For the digest optimisation work data on the size of populations was all 
proportional meaning changes in the size of one or more populations would result 
in changes in others even if the cell count remained the same. To this end the 
experiments should be repeated using counting beads to obtain cell counts and 
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the tissue weights prior to digestion should be noted to allow the calculation of 
normalised cell counts which would clarify the results. 
 
In summary the expression of stromal markers FAP and CD90 were significantly 
different in very early RA and resolving arthritis respectively compared to normal 
samples. Macrophage populations that may correspond to resident and 
infiltrating populations could also be identified. Through work with collaborators a 
unified digestion protocol was established which can be used to isolate synovial 
cellular populations. Through the investigation of several cell markers both 
stromal and possible synovial populations could be identified in the populations 
yielded by synovial digestion. 
 
The increased expression of CD90 and FAP indicates that different fibroblasts 
subsets may be more active during different arthritic disorders. FAP, a marker 
identifying both lining and sublining fibroblasts, was higher in very early RA 
whereas CD90, a sublining specific marker, was increased in resolving arthritis. 
From this evidence it could be argued that the CD90+ synvovial population is 
beneficial, perhaps possessing a pro-resolution phenotype whereas the FAP 
expressing population could drive RA pathogenesis. However this contrasts 
somewhat with the literature given that tumour CD90 expression is associated 
with a poor prognosis in gallbladder carcinoma (Zhang, D. H. et al., 2016). The 
identification of CD206+CD163+ and CD206+CD163- macrophages contributes 
towards the knowledge on synovial macrophages. CD206 and CD163 have both 
previously been shown to be expressed by synovial macrophages and are 
thought to be expressed by macrophages with an anti-inflammatory phenotype 
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(Ambarus et al., 2012b; Fahy et al., 2014; Jablonski et al., 2015). In addition, the 
finding of MerTK expression on both of these populations could mean they 
represent tissue-resident synovial macrophages with the main function of 
maintaining homeostasis within the joint (Gautier et al., 2012). 
 
As the work in this chapter developed a protocol allowing the identification and 
isolation of pure populations of synovial fibroblasts and macrophages it was 
decided to characterise the transcriptome of these populations both in treated 
and treatment naïve RA along with arthritis with a distinct aetiology. 
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5 EX VIVO CHARACTERISATION OF SYNOVIAL FIBROBLAST AND 
MACROPHAGE POPULATIONS ISOLATED FROM BIOPSY MATERIAL 
5.1 Introduction 
To further address the third hypothesis, that different fibroblast and macrophage 
subsets exist within the synovium with distinct functions, stromal and macrophage 
populations were isolated from synovial tissue using the digestion protocol 
established in chapter 3 and the transcriptome of the cells was interrogated using 
whole transcriptome RNA-sequencing with an aim of identifying populations, 
ascribing functions, and comparing differences between disease states. RNA-
sequencing of cell populations provides data on the average gene expression for 
cells in that population and allows comparison between different populations to 
elucidate functional differences. RNA-sequencing was used rather than cDNA 
microarrays as RNA-sequencing can work with low amounts of RNA and also the 
dynamic range of RNA-sequencing is greater than microarrays and less subject 
to background noise (Hrdlickova, Toloue and Tian, 2017).  
 
Clinical samples for the RNA-sequencing experiments were dependent on clinical 
sample availability from biopsy procedures, as the procedures to freeze, digest 
and recover cells had to be determined before sample collection could 
commence. Therefore the disease groups used were not the same as those 
described previously for the BEACON cohort. The three groups used were (1) 
patients with RA who have had symptoms for longer than 3 months but have not 
yet received any treatment, (2) patients with RA who have had symptoms for 
longer than 3 months and have had an inadequate response to methotrexate and 
are therefore progressing onto biologic therapy (phase 2 in Figure 1), and (3) a 
comparison group of patients who had developed arthritis as a result of receiving 
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the anti-programmed cell death protein 1 (PD1) checkpoint inhibitors 
pembrolizumab or nivolumab to treat advanced cancer. Patients receiving 
immune checkpoint inhibitors have been found to be at risk of developing a range 
of adverse effects resulting from immune system overactivity (Weber et al., 2013). 
For example patients receiving nivolumab, an anti-PD1 agent, suffered a range 
of adverse events such as pneumonitis, allergic rhinitis, diarrhoea, rash, puritis, 
vitiligo, pruritic rash, macular rash, alopecia, hypopigmentation, hypothyroidism, 
and hyperthyroidism (Topalian et al., 2012). Most of the adverse events 
developed around 7 weeks after treatment initiation, can be successfully treated, 
and do not appear to be persistent. However, development of arthritis occurred 
later with two patients showing symptoms around 11 and 14 months after 
treatment initiation (Calabrese et al., 2017; Chan et al., 2015). It is thought that 
the issues arise due to the removal of restraints upon T lymphocyte activation by 
the anti-PD1 treatment. However it is unclear if T cells recognising relevant auto-
antigens were already present in the patients or developed subsequent to the 
treatment (Chan et al., 2015; Johnson et al., 2016). 
 
The work in this chapter aimed to investigate the phenotype of the synovial 
fibroblast and macrophage subpopulations identified in chapter 4 as these 
populations were as yet not fully characterised in the literature. Specifically RNA-
sequencing was used to characterise the transcriptome of these populations and 
address the following questions: 
1. Do the synovial fibroblast and macrophage subpopulations possess 
distinct transcriptomes? 
2. Does treatment of RA induce significant differences in the transcriptome 
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of these subpopulations? 
3. Does the transcriptome of synovial subpopulations vary between RA and 
anti-PD1 induced arthritis? 
 
5.2 Methods and materials 
5.2.1 Biopsy material and clinical outcome groups 
Synovial tissue from patients with RA and having experienced symptoms for a 
duration longer than 3 months but not yet receiving any DMARDs or biologics 
(untreated RA), patients with RA which have experienced symptoms for a 
duration longer than 3 months and have received either DMARDs alone or 
DMARDs in combination with biologics, and from patients who developed arthritis 
after receiving nivolumab or pembrolizumab to treat advanced cancer (anti-PD1) 
were obtained by ultrasound-guided biopsy and cryopreserved by freezing in 1ml 
Cryostor 10 (Sigma Aldrich) with 10 minutes incubation at 4oC before transfer to 
-80oC in a Mr Frosty (Nalgene). When required for batch processing, tissue was 
rapidly thawed in a 37oC waterbath and digested using the protocol developed in 
section 8.3. Clinical details of patients from which biopsies were taken and 
samples generated are presented in Table 26.
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ID Group Site CCP 
+/- 
RF 
+/- 
Disease 
duration 
(Weeks) 
Age Sex DMARD Prednisolone DAS28 
ESR 
baseline 
ESR 
(mm/
hr) 
CRP 
(mg/l) 
BX186 TreatedRA Knee + + 158 43 F MTX, 
Etanercept 
None  4.3 2 0 
BX189 TreatedRA Knee - - 36 66 F MTX, 
Etanercept 
None 5.5 13 5 
BX190 RA Knee + - 52 39 M None None 6.9 9 58 
BX199 RA Knee -  - 18 69 M None None 5.1 2 7 
BX200 RA Knee + + 18 57 M None None 5.4 21 10 
BX210 PD1 Knee - - 33 51 M Pembrolizumab 10mg 3.5 8 9 
BX211 RA Knee + + 79 51 M None None 5.8 21 59 
BX215 TreatedRA Knee - - 429 59 F MTX, SSA None 6.0 5 0 
BX219 PD1 Knee - - 22 51 F Pembrolizumab None 5.9 49 71 
BX224 PD1 Knee - - 10 74 F Nivolumab None 4.4 32 7 
BX225 PD1 Knee - - 21 66 F Pembrolizumab 6mg 4.3 42 9 
BX228 TreatedRA Knee + + 186 71 M MTX, HCQ None 4.9 20 4 
BX229 TreatedRA Knee + + 78 56 F MTX, HCQ None 6.3 9 11 
BX230 RA Ankle - + 43 62 M None  9mg 5.7 12 4 
BX231 RA Wrist - - 8 69 M None None 3.9 16 13 
BX233 TreatedRA Knee + + 192 43 M MTX, HCQ, LEF None 6.6 31 16 
BX235 PD1 Knee - - 22 76 F Pembrolizumab None 3.8 12 0 
Table 26: Clinical characteristics of the patients from which synovial biopsies were collected and used for the RNA-sequencing 
experiments. NA = Not available, DAS28 = Disease activity 28 score, ESR = Erythrocyte sedimentation rate, CRP = C-reactive protein, 
CCP = Anti-cyclic citrullinated peptide, RF = Rheumatoid factor, MTX = Methotrexate, SSA = Sulfasalazine, HCQ = Hydroxychloroquine, 
LEF = Leflunomide. 
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5.2.2 RNA sequencing and data analysis 
16 cryopreserved synovial tissues and 1 fresh synovial tissue, all obtained by 
ultrasound guided biopsy, were digested in three batches (2 batches of 
cryopreserved tissue and one batch with the single fresh tissue) according to the 
protocol in section 8.3, stained with the panel in Table 27, and six synovial 
populations were sorted using a MoFloAstrios EQ. RNA was isolated from the 
sorted cells as in 3.2.11 and RNA quantity and quality was assessed using RNA 
6000 Pico Kits (Agilent Technologies) as specified in the manufacturer’s 
instructions in combination with a 2100 Bioanalyzer (Agilent Technologies). 
Target Conjugate Clone Isotype Supplier 
CD31 PerCP 9G11 Mouse IgG1 R&D Systems 
CD34 FITC 581 Mouse IgG1, κ Biolegend 
CD45 V450 2D1 Mouse IgG1, κ BD Biosciences 
CD64 BV605 10.1 Mouse IgG1, κ Biolegend 
CD90 PerCP-Cy5.5 eBio5E10 Mouse IgG1, κ eBioscience 
CD117 PE-Cy7 104D2 Mouse IgG1, κ Biolegend 
CD163 PECF594 GHI/61 Mouse IgG1, κ BD Biosciences 
CD206 APC 15-2 Mouse IgG1, κ Biolegend 
CD235a PE-Cy7 HI264 Mouse IgG2a, 
κ 
Biolegend 
CD326 PE-Cy7 9C4 Mouse IgG2b, 
κ 
Biolegend 
GP38 PE NZ-1.3 Rat IgG2a eBioscience 
HLA-DR BV510 L243 Mouse IgG2a, 
κ 
Biolegend 
Live/Dead Amine binding 
dye (APC-Cy7 
emission) 
N/A N/A Life Technologies 
Table 27: Antibody panel used to stain and sort cells yielded by synovial digestion 
 
Library preparation and RNA sequencing was completed by Virginie Petitjean in 
the lab of Marc Sultan (Novartis, Basel). Library preparation was completed using 
the SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian (Takara Bio) 
using 250pg of RNA from each sample where available and for samples with less 
RNA than 250pg the total RNA available was used. 6 positive controls 
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recommended by the SEQC/MAQC-III Consortium (Consortium, 2014), intact 
SEQC A, intact SEQC B, intact SEQC C, degraded SEQC A, degraded SEQC B 
and degraded SEQC C were also used to prepare libraries in parallel with the 
other samples using 250pg of RNA as the input from each control. A negative 
control of nuclease-free water was also prepared in the same manner. All libraries 
were prepared with dual index labelling (8 base pair (bp) + 8 bp) to allow 
multiplexing of samples, were then pooled in equimolar ratios to produce 4 
multiplexes with 28-29 libraries in each, and then each multiplex was sequenced 
in quadruplicate using 4 HiSeq Paired End v4 Flow Cells (read lengths of 2 x 
76bp, Illumina) run on an HiSeq 2500 instrument (Illumina). Sequences were de-
multiplexed allowing 2bp mismatches across the index reads which produced 
between 15 and 113 million reads per library (62 million mean). 
 
The author of this thesis travelled to Novartis to view and be instructed on the 
analysis of the generated data. The sequencing data were prepared for analysis 
by Sabina Pfister (Novartis). FASTA files generated from the same samples in 
the replicate sequencing runs were merged using UNIX scripts generated by 
scripts written in the R programming language. Any possible contaminating 
adaptor and/or index sequences in the reads were trimmed using Cutadapt 
(Martin, 2011) and quality control was completed using the FastQC software 
(Babraham Bioinformatics). Reads were aligned to the transcriptome and feature 
counts were produced using Bowtie2 (Langmead and Salzberg, 2012) in the 
Exon Quantification Pipeline established at Novartis (Schuierer and Roma, 
2016). 
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Analysis from this point onwards was completed by the author of this thesis with 
supervision by Sabina Pfister, Archana Sharma-Oates, and Boris Noyvert (based 
at Novartis and University of Birmingham). Count data were analysed using R 
version 3.3.3 in the integrated development environment R Studio version 
1.0.136 using packages available from the Comprehensive R Archive Network 
(https://cran.r-project.org/) or from Bioconductor (https://www.bioconductor.org/) 
the full list of which is available in section 8.4 (Gentleman et al., 2004; Huber et 
al., 2015). Features for which weight-adjusted counts were at least one in at least 
75% of samples in group (one population from one disease group) were kept and 
other features excluded. Samples were then transformed using mean-variance 
modelling at the observational level (VOOM) to allowing linear modelling and 
normalised using the Trimmed mean of M-values (TMM) method and quantile-
normalisation both of which were performed using the edgeR and limma 
packages (Ritchie et al., 2015). Linear modelling was then used on the prepared 
dataset to test for differential expression of genes between comparisons of 
interest using the limma package(Robinson, Mccarthy and Smyth, 2010). Gene 
set enrichment and was performed using the limma package on features for 
which entrez IDs were available. Gene ontology (GO) category and Kyoto 
encyclopaedia of genes and genomes (KEGG) pathway enrichment were 
completed using the goseq package (Young et al., 2010). For all enrichment tests 
only features with ensembl IDs included in the ensembl primary assembly were 
used meaning that gene alleles, alternative sequence genes, and deprecated 
ensembl IDs were excluded from the analysis. The full R script for the analysis is 
shown in section 8.4. 
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5.3 Results 
5.3.1 The proportions of stromal and macrophage populations show 
relationships with clinical correlates and clinical outcome group 
To elucidate the phenotype and differences of synovial fibroblast and 
macrophage populations between disease groups six populations were sorted 
from treatment naïve patients with RA (referred to as RA in the RNA-sequencing 
experiments), from patients with RA who have had an inadequate response and 
may have progressed onto biologics (referred to as RA in the RNA-sequencing 
experiments), and from cancer patients who have been treated with the anti-PD1 
checkpoint inhibitor pembroluzimab and have subsequently developed arthritis 
as a result of the treatment (called anti-PD1 or PD1 in the RNA-sequencing 
experiments). Synovial biopsy material from 6 RA patients, 6 treated RA patients, 
and 5 anti-PD1 patients was digested and three fibroblast populations, all CD45-
CD235a/CD326/CD117-CD31- and either CD90-GP38+, CD90+GP38+CD34-, or 
CD90+GP38+CD34+, and three putative macrophage populations, all CD45+HLA-
DR+ and either CD206-CD163-, CD206+CD163-, or CD206+CD163+, were sorted 
and used for RNA-sequencing experiments (Figure 51). 
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Figure 51: Representative plots of fibroblast and putative macrophage populations 
identified by flow cytometric analysis of cells yielded by digestion of synovial 
tissue. Gates highlighted in red indicate populations sorted for RNA-sequencing 
experiments. 
 
When investigating the flow data obtained during cell sorting of these samples no 
significant differences in total cell viability were found between clinical outcome 
groups with the percentage of viable cells being approximately 90% in each 
disease (Figure 52). Comparing the percentage of the total viable cell population 
constituted by either stromal (CD45-CD235a/CD326/CD117-) or CD45+ cells no 
significant differences were found in the proportions of these populations 
between disease stages. Comparing the proportions of the CD90-GP38+ and the 
CD90+GP38+ populations relevant to the total of the two populations across 
clinical outcome groups, no significant differences were found when tested using 
independent Kruskal-Wallis tests and Dunn’s multiple comparisons tests for each 
population. Similarly, no significant differences were found using the same 
approach to test for differences in the proportion of CD34+ or CD34- cells in the 
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CD90+GP38+ stromal fraction, however only four replicates were available in the 
anti-PD1 group for this marker and this will have decreased the power of the test. 
No significant difference was found comparing the proportion of HLA-DR+ cells in 
the CD45+ cell fraction. Statistically significant differences did exist between the 
putative macrophage populations with the proportion of DN CD45+HLA-DR+ cells 
being higher in the RA samples than the anti-PD1 samples and the proportion of 
CD206+CD163+ cells being increased in the anti-PD1 patients compared to the 
RA patients (Figure 54). 
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Figure 52: Flow cytometry data obtained from the digestion of synovial tissue from 
untreated RA patients (RA), treated RA patients with an inadequate response 
(treated RA), and cancer patients treated with anti-PD1 immune checkpoint 
inhibitor who have subsequently developed arthritis (PD1). Data on surface 
markers is presented as relative proportions and not cell numbers. With the 
exception of the proportion CD45+HLA-DR+ cells (expanded in Figure 54) no 
significant differences were detected when tested using Kruskal-Wallis tests with 
Dunn’s multiple comparisons tests. Bars show the median. 
 
Further investigation of the stromal populations uncovered relationships between 
the proportions of stromal populations and clinical measures (Figure 53). The 
proportion of the CD90-GP38+ population positively correlated with the ESR for 
the RA and treated RA patients. The percentage of CD34- cells in the 
CD90+GP38+ population in the RA and treated RA patients positively correlated 
with both ESR and the percentage of CD45+ cells in the total viable cell 
population. When testing for correlations between the stromal and CD45+ 
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populations with CRP no significant correlations were found. However, the 
proportions of CD90+GP38+, CD34+, and CD45+ cells all correlated with synovial 
hypertrophy as measured by ultrasound. These findings indicated that the 
CD90+GP38+ and CD90+GP38+CD34- populations expand with inflammation and 
inflammatory infiltrate into the synovium. When the anti-PD1 samples were 
included in the analysis all correlations were weakened and correlations between 
stromal populations and either ESR or the CD45+ proportion lost statistical 
significance. This might indicate spurious relationships within the smaller sample, 
or that the arthritis elicited by immune checkpoint inhibition has a different 
pathology to RA. 
 217 
 
 
Figure 53: Correlations of the RA and treated RA stromal populations with CD45+ 
cell proportion, erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP). The proportion of the CD90+GP38+ population relative to the total of the 
CD90+GP38-, CD90+GP38+ and CD90-GP38+ populations positively correlated with 
ESR but not CRP and the proportion of CD90+GP38+CD34- cells relative to the total 
CD90+GP38+ population positively correlated with ESR and the percentage of 
CD45+ (relative to the total stromal and CD45+ populations) cells but not CRP in 
the total viable cell population. The CD90+GP38+, CD90+GP38+CD34-, and CD45+ 
proportions all correlated with synovial hypertrophy as measured by ultrasound. 
Including the anti-PD1 samples in this analysis weakens all correlations. All tested 
using Spearman’s correlation. 
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Performing a similar analysis on the macrophage populations did not show a clear 
relationship between ESR and population size (Figure 54). When analysing only 
the RA and treated RA samples or samples from all disease groups and testing 
for correlations between ESR and the CD163+CD206+ or the CD163-CD206- 
populations no correlations were found, although the correlation between the 
CD163+CD206+ population in the RA and treated RA samples was close to 
significance. The population sizes did not correlate with ESR but did vary 
significantly between clinical outcome groups as a higher proportion of CD163-
CD206- cells were present in RA than in anti-PD1 patients and the reverse 
relationship with was found the CD163+CD206+ population as previously 
mentioned. 
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Figure 54: Comparison of the proportion of the three putative macrophage 
populations relative to the total CD45+HLA-DR+ population across the three 
disease groups. The proportions of the CD163+CD206+ or the CD163-CD206- 
populations in the RA and treated RA samples did not correlate with the 
erythrocyte sedimentation rate (ESR, Spearman’s correlation). The proportion of 
the two populations did significantly vary between the RA and anti-PD1 samples 
with a higher proportion of double negative cells in the RA samples and a higher 
proportion of the CD163+CD206+ cells in the anti-PD1 samples. Kruskal-Wallis test 
with Dunn’s multiple comparison test, * = p value < 0.05. 
 
5.3.2 Exclusion of poor quality RNA samples following sequencing 
The synovial stromal and macrophage populations identified by flow cytometry 
were cell sorted into six populations from which RNA was then extracted (Figure 
51). Analysis of the integrity and quantity of isolated RNA using a Bioanalyzer 
provided varied results, perhaps unsurprisingly given the variation in the number 
of sorted cells between populations and samples. Of the samples for which RNA 
Integrity Numbers (RINs) were obtained (81 samples) the median RIN was 6.4, 
35 samples had RINs equal to or greater than 7, a typically used threshold for 
quality control of samples to be RNA sequenced, and 28 had a RIN score of 1 
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indicating either poor quality or an inability to accurately measure which may be 
the main reason in this case. 
 
The number of sorted events, equivalent to sorted cells, varied between samples 
with the largest number of sorted events in one sample being 163,800 and the 
smallest 10 and the median number of sorted events from which RNA was 
extracted being 3010 (Table 28). The quantity of RNA used for library preparation 
was standardised to 250pg which 69 samples were able to provide, the remaining 
32 samples had lower than 250pg of RNA available and in these samples the 
total available RNA was used to generate the libraries. 
 
 Sorted events Library RNA input (pg) 
Max 163,800 250 
3rd quartile 11,980 250 
Mean 10,900 211 
Median 3010 250 
1st quartile 446 176 
Min 10 16 
Table 28: Descriptive statistics of the number of sorted events and RNA input into 
library preparations across all 101 samples sorted from synovial tissue digestions. 
The ceiling effect apparent in the Library RNA input data was due to 250pg of RNA 
from most samples being used for the library preparation with no sample using 
more than this quantity. However approximately one third of samples had less 
than 250pg of RNA available for the library preparation. 
 
The libraries generated had varying sizes which was reflected in the distribution 
of non-normalised or transformed log2 counts per million (log2CPM) of the total 
features in each sample (Figure 55). As would be expected samples with a small 
library size had abnormal log2CPM boxplots with most values considered outliers 
and the median log2CPM residing around 0 indicating very few counts for any 
features were obtained for these samples. One would expect the samples with 
small library samples to be those derived from small numbers of cells or small 
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quantities of RNA. As seen in Figure 56 this relationship was true for these 
samples as both the concentration of RNA used for library preparations and the 
number of sorted events from each sample were significantly correlated with the 
size of libraries generated. 
 
Figure 55: The size of the library for each RNA sample sequenced and the non-
transformed/non-normalised log2 counts per million (log2CPM) of all features in 
each sample which passed filtering. Note the similarity between small library size 
and boxplots of log2CPM which were almost entirely classed as outliers. In the 
samples with reasonable library sizes the median log2CPM value showed 
substantial variation between samples highlighting the need for normalisation. 
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Figure 56: Library size is significantly correlated with the concentration of RNA 
used for the library preparation and also with the number of sorted events/cells 
from which RNA was isolated as assessed by Spearman’s correlation. 
 
Another technical aspect that must be considered with low-input RNA sequencing 
is the risk of over-representation of sequences introduced by the whole-
transcriptome amplification rather than by true biological differences. The 
amplification of RNA by the polymerase chain reaction (PCR) is non-linear with 
more abundant sequences likely to be amplified more than less abundant species 
which can lead to biases in the results (Aird et al., 2011). The FastQC software 
provides an easy automated method to estimate duplication bias in sequencing 
data and indicates which sequences may be present at higher levels due to this 
duplication bias. FastQC found a high percentage of sequences that had been 
duplicated more than 10 times relative to unique sequences indicating a bias was 
present in the dataset (Figure 57). A BLAST search of the over-represented 
sequences identified the sequences as ribosomal RNA (Table 29, Table 30). The 
protocol for library preparation contained steps for the depletion of ribosomal RNA 
from samples and as such the presence of these sequences in the samples 
indicated that the depletion did not function correctly. The efficacy of the 
ribosomal RNA depletion was dependent on the integrity and fragmentation of 
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the RNA which could have complicated the removal step leading to the 
incomplete depletion found in the samples. However, as the over-represented 
sequences were of ribosomal origin this could have indicated that the bulk of 
sequences which were of interest to this work could have been impacted to a 
lesser degree by the duplication bias. 
 
 
Figure 57: Adapted FastQC duplication plot demonstrating a high number of 
sequences which were duplicated in excess of 10 times. 
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Sequence Count Percentage 
of total 
reads 
GTCTACGGCCATACCACCCTGAACGCGCCCGATCTCGT
CTGATCTCGGAAGCTAAGCAGGGTCGGGCCTGGTT 
214223 0.348337 
GGTTTAGTGAGGCCCTCGGATCGGCCCCGCCGGGGTC
GGCCCACGGCCCTGGCGGAGCGCTGAGAAGACGGTC 
104242 0.169503 
CGACTCTTAGCGGTGGATCACTCGGCTCGTGCGTCGAT
GAAGAACGCAGCTAGCTGCGAGAATTAATGTGAAT 
97648 0.158781 
AGATCGGAAGAGCACACGTCTGAACTCCAGTCACAGC
GATAGATCTCGTATGCCGTCTTCTGCTTGAAAAAAA 
87887 0.142909 
GAGATCGGAAGAGCACACGTCTGAACTCCAGTCACAG
CGATAGATCTCGTATGCCGTCTTCTGCTTGAAAAAA 
81317 0.132225 
GTAGCCCCGGGAGGAACCCGGGGCCGCAAGTGCGTT
CGAAGTGTCGATGATCAATGTGTCCTGCAATTCACAT 
72070 0.117189 
TAGATCGGAAGAGCACACGTCTGAACTCCAGTCACAGC
GATAGATCTCGTATGCCGTCTTCTGCTTGAAAAAA 
68868 0.111983 
Table 29: Overrepresented sequences detected by FastQC in the sample as in 
Figure 57. The sequence in bold was subjected to a BLAST search to assess the 
possible source of the overrepresented sequences. 
 
Description Identity % Accession 
Homo sapiens RNA, 45S pre-ribosomal 5 
(RNA45S5), ribosomal RNA 
100% NR_046235.1 
Homo sapiens RNA, 5.8S ribosomal 5 
(RNA5-8S5), ribosomal RNA 
100% NR_003285.2 
Table 30: Results of BLAST analysis of the bold sequence in Table 29. This 
indicated that ribosomal sequences are present in the sequenced reads. 
 
Samples which could be classed as poor quality through assessment of library 
sizes and log2CPM boxplots were therefore excluded from further analysis. This 
left a mean of 4.32 samples in each experimental group (numbers in each group 
are stated in Table 31) with a median library size of 703,807 reads. Features with 
log2CPM values above 1 in at least 75% of samples in each group, i.e. Treated 
RA CD90-GP38+or anti-PD1 CD163+CD206+, were retained and all other features 
discarded due to the low level of expression or lack of expression in enough 
samples to facilitate analysis. This reduced the number of features being 
analysed from 58,510 to 17,188. The resulting samples were subjected to VOOM 
transformation, TMM normalisation, and quantile normalisation and the resulting 
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log2CPM values were plotted (Figure 58). The boxplots across samples 
displayed a similar distribution and median indicating the normalisation was 
successfully able to prepare the data for analysis. 
  
RA Treated RA Anti-PD1 
CD34+ 4 5 4 
CD34- 3 4 4 
CD90-GP38+ 3 5 5 
CD206+CD163+ 5 3 4 
CD206+CD163- 5 5 5 
Double negative 4 4 4 
Table 31: RNA sequencing samples remaining in each experimental group after 
the filtering out of poor quality samples 
 
Figure 58: Boxplots of log2CPM values of all features which passed filtering per 
sample. The samples had been VOOM transformed, TMM normalised, and quantile 
normalised. The median log2CPM values and interquartile ranges were similar 
indicating successful normalisation. 
 
After quality control and preparation of the dataset, the sources of variation within 
the data were assessed to ensure that variation from undesirable sources such 
as stochastic noise or the batch in which the tissue was digested was not the 
dominant source of variation. This was important, because such variation may 
mask variation of interest to the question being addressed. One method to 
address this issue is to use approaches that aim to reduce the many dimensions 
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of the data into a few easily interpretable dimensions (Hotelling, 1933; Kruskal, 
1964). Approaches such as principal component analysis (PCA) or 
multidimensional scaling (MDS) are commonly used for this reason. Plots of the 
first two dimensions of a MDS analysis of the dataset are shown in Figure 59 with 
each plot coloured according to a different variable. The dominant source of 
variation was cell type with a clear separation between fibroblast and 
macrophage populations. There was some possible clustering on the basis of the 
sex of the tissue donor, however neither site of biopsy nor digest batch appeared 
to show clear clustering when examining the first two dimensions. Diagnosis also 
did not appear to show clear clustering in the first two dimensions indicating that 
the differences between the disease groupings did not contribute as much to the 
variation within in the data as the cell type did. This was a reassuring finding. 
Additionally, the control samples generated from tissues formed a clear cluster 
removed from either the fibroblast or macrophage clusters, an important internal 
control. 
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Figure 59: Plots of the first two dimensions of multidimensional scaling (MDS) 
analysis of the normalised RNA sequencing data coloured according to various 
variables. The plots indicated that the largest source of variation was cell type and 
that undesirable noise from sources such as the batch in which the tissue was 
digested prior to sorting and RNA isolation was minimal.  
 
In addition to being able to identify clear fibroblast and macrophage clusters, 
additional clusters corresponding to macrophage subsets could also be identified 
(Figure 60). PCA separated the macrophage samples into two to three clusters 
that corresponded to the macrophage subsets with the CD206+CD163+ 
(206p163p) and CD206+CD163- (206p163n) showing a higher degree of overlap 
than either population did with the CD206-CD163- population, although some of 
the CD206+CD163- samples did appear to cluster with CD206-CD163- samples. 
Interestingly, the fibroblast subsets did not appear to form clear clusters in the 
first or second dimensions/components of the unsupervised clustering methods 
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reflecting a lower degree of heterogeneity between the fibroblast subsets than 
the macrophage subsets. 
 
Figure 60: Multidimensional scaling analysis and principal component analysis 
show similar results highlighting the similarity between the two techniques. The 
macrophage subpopulations formed two, possibly three, clusters indicating that 
the subsets had differential gene expression. The sorted fibroblast populations 
showed a less clear picture. Macrophage populations are CD206+CD163- 
(206p163n), CD206+CD163+ (206p163p), and CD206-CD163- (double negative, DN). 
Fibroblast populations are CD34+ (34p), CD34- (34n), and CD90-GP38+ (90n38p). 
 
Methods such as PCA also allow assessment of how much of the total variation 
in the dataset is accounted for by different variables. The first principal component 
which clearly separated the fibroblast and macrophage subsets accounted for 
17.2% of the variance within the total dataset with the second principal 
component, which separated the macrophage subsets, accounting for an 
additional 4.3% of the variance. 
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The findings so far suggested that in spite of the difficulties of working with such 
a low input of RNA the data remaining after cleaning and filtering were robust and 
the largest sources of variance were found between cell type and subsets as 
expected, and not from noise introduced by technical or stochastic elements. As 
a final quality control to determine the specificity of the sorting procedure isolating 
pure populations of cells, the expression of genes for the surface markers used 
for the sorting strategy were compared between the sorted populations. Figure 
61 shows the expression of four of the markers used for the sorting of fibroblast 
subsets in each sorted population (all clinical outcome groups pooled). As 
expected the expression of PECAM1 (CD31) was lower in the fibroblast 
populations than the macrophages as the stromal populations were sorted on the 
basis of low CD31 expression whereas the macrophages were not selected using 
CD31 expression, and are known to express surface CD31 protein (Mckenney, 
Weiss and Folpe, 2001). Expression of THY1 (CD90) was also as expected from 
the flow data as the CD34- and CD34+ samples (34n or 34p respectively), which 
were both CD90+, had higher THY1 expression than the CD90-GP38+ (90n38p) 
subset. PDPN (GP38) expression was fairly uniform across the fibroblast groups 
as expected and finally CD34 expression was clearly highest in the CD34+ (34p) 
population providing further confirmation that the sorting and sequencing 
procedures were successful. 
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Figure 61: Log2CPM of genes PECAM1, THY1, PDPN, and CD34, which encode the 
proteins used for the stromal sorting strategy , CD31, CD90, GP38, and CD34 
respectively. Macrophage populations are coloured red, fibroblast blue, and the 
sequencing controls green. 
 
Completing the same process but for the markers used for the sorting of 
macrophage populations also yielded results in keeping with the flow cytometry 
data (Figure 62). PTPRC (CD45) was expressed in all three macrophage 
populations but at low levels in the fibroblast, HLA-DRA followed a similar pattern 
but was reduced in the DN macrophage population, a finding confirmed by the 
reduction in HLA-DR surface protein levels as detected by flow cytometry. CD163 
showed the highest levels in the CD206+CD163+ (206p163p) population with 
lower levels in the CD206+CD163- (206p163n) population albeit still higher than 
the DN population indicating although CD163 surface protein was not detectable 
in this population the transcript was still expressed. Finally the levels of MRC1 
(CD206) were higher in the CD206+ populations but expressed at levels similar 
to those found in the fibroblast subsets in the DN population. 
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Figure 62: Log2CPM of genes PTPRC, HLA-DRA, CD163, and MRC1 which encode 
the proteins used for the stromal sorting strategy , CD45, HLA-DR alpha subunit, 
CD163, and CD206 respectively. Macrophage populations are coloured red, 
fibroblast blue, and the sequencing controls green. 
 
Taking the evidence presented in this section it was clear that RNA sequencing 
from low numbers of cells/low RNA input could be challenging. In this dataset 
these difficulties resulted in the loss of approximately one third of the samples 
submitted for sequencing. However, the remaining two thirds of the samples were 
of sufficient quality to continue the analysis pipeline. When considering the 
contribution of noise to the variation in the data it was apparent that noise 
introduced by technical and stochastic elements did not mask the variance of 
interest contributed by the biology of the samples. Additionally, ‘sanity’ checks of 
the expression of transcripts encoding the surface proteins used for the sorting 
procedure confirmed that the sorted populations express the panel of markers 
expected providing confidence that the sorting and sequencing procedure 
performed well for these samples. The prepared dataset was then taken forwards 
for analysis. 
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5.3.3 Macrophage populations and a mixed lymphocyte population can 
be identified from the RNA sequencing data 
As the largest sources of variation highlighted by PCA of the dataset were 
between cell type it was prudent to create fibroblast or macrophage subsets of 
the data and run PCA on these subsets as other sources of variation could have 
become more apparent due to the increased relative proportion of the variance 
for which they account. When PCA was completed on the macrophage samples 
the difference between macrophage subsets became more apparent particularly 
when investigating the second and third principal components which accounted 
for 7.23% and 3.97% of the variation in this subsetted dataset (Figure 63). The 
95% confidence intervals of the macrophage subsets make it apparent that the 
DN subset formed a clear cluster separate from either of the other subsets. 
However, whilst the CD206+CD163+ and CD206+CD163- subsets did appear to 
cluster separately the clusters were close together with a large overlap of 
confidence intervals. Importantly when assessing the first 10 principal 
components for an influence of unwanted variation such as a batch effect 
dependent on when the tissue was digested no clear pattern could be found. 
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Figure 63: Principal component analysis of the RNA sequencing data generated 
from the macrophage samples only. The data is coloured according to the 
macrophage subset from which the sample was generated. The same plot is 
shown twice, once with just the data points and once with the 95% confidence 
interval ellipses for each group. The separation between the subsets was apparent 
with the double negative population showing higher variation and further distance 
from the other clusters 
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Hierarchical clustering is another unsupervised machine learning technique that 
can be used to explore relationships between the samples in the dataset. When 
using hierarchical clustering a range of distance measures such as Euclidean or 
Manhattan can be used along with different clustering techniques which may 
allow other relationships between the data to become apparent (Jaskowiak, 
Campello and Costa, 2014). Figure 64 shows the results of complete linkage 
hierarchical clustering of the macrophage dataset using the Pearson’s correlation 
distance measure based on the top 400 most variable genes between 
macrophage subsets. As with PCA the DN macrophage subset formed a clear 
cluster irrespective of the clinical outcome group from which the sample was 
generated. The remaining two subsets were more mixed with clinical outcome 
appearing to have a larger impact, particularly with clustering of the 
CD206+CD163+ and CD206+CD163- subsets within the RA samples. The 
CD206+CD163+ and CD206+CD163- subsets from anti-PD1 and treated RA 
patients were intermingled, however each diagnosis often had the two subsets in 
the same pairs indicating that little variation between these samples existed or 
that donor specific variation could have been responsible for a significant amount 
of the variation in the dataset. Indeed when the clustering was re-annotated using 
the patient identifiers then it was apparent that the pairs were often from the same 
donor (Figure 65). 
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Figure 64: Complete linkage hierarchical clustering using Pearson’s correlation 
distance of the top 400 most variable genes of the macrophage data subset. The 
double negative macrophage subset (DN) clustered separately from the other 
samples regardless of the clinical outcome group from which they were isolated. 
The remaining two subsets were mixed with a cluster of CD206+CD163+ (206p163p) 
and CD206+CD163- (206p163n) RA samples and the same subsets from treated RA 
and anti-PD1 samples mixed among each other. 
 
 
Figure 65: Complete linkage hierarchical clustering using Pearson’s correlation 
distance of the top 400 most variable genes of the macrophage data subset as in 
Figure 64 but using patient labels as opposed to diagnosis and population labels. 
It was apparent that CD206+CD163+ and CD206+CD163- subsets from the same 
donor formed pairs within some of the clusters indicating little difference existed 
between these subsets or an influence of donor specific variation. 
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The multivariate analysis approaches so far indicated that there were significant 
differences between the gene expression profiles of the macrophage subsets, 
particularly between the DN subset and either of the CD206+ subsets. A 
commonly used approach to detect genes expressed at significantly different 
levels between experimental groups is to use univariate analysis techniques for 
each gene and to adjust the P values obtained to avoid a high number of false-
positives as a result of repeated comparisons. The approach taken with this 
dataset was to fit a linear model to the expression value of each gene and use 
the Benjamini-Hochberg method to correct for multiple comparisons (Benjamini 
and Hochberg, 1995). The number of statistically significant up- or down-
regulated genes between the CD206+CD163+ and CD206+CD163- subsets were 
relatively small whereas the differences between the CD206+CD163+ or the 
CD206+CD163- and the DN subset were larger with the same pattern found 
regardless of the disease group in which the subsets are being compared (Table 
32). The number of differentially expressed (DE) genes was largest between the 
CD206+CD163+ and the DN subsets with a mean of 428.67 DE genes. The 
differences between the CD206+CD163- and DN subsets were less with 250 DE 
genes detected and the smallest between the CD206+CD163+ and the 
CD206+CD163- subsets with only 9.3 DE genes. 
 
RA Treated RA Anti-PD1 
CD206+CD163+ vs. CD206+CD163- 3 13 12 
CD206+CD163+ vs. DN 537 214 535 
CD206+CD163- vs. DN 360 95 295 
Table 32: Number of statistically significant differentially expressed genes, both 
up- and down-regulated, between macrophage subsets in the different disease 
groupings. Tested using linear modelling, significance is classed as Benjamini-
Hochberg adjusted p value <0.05. 
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In order to investigate the differences between subsets the RA samples will be 
considered first. As predicted by the results of the unsupervised clustering 
techniques the differences between the CD206+ subsets were less than between 
the CD206+ subsets and the DN population with only 3 significantly DE genes 
detected in the RA samples all of which were downregulated in the 
CD206+CD163+ subset compared to the CD206+CD163- subset. Of these genes 
only one encoded a known protein with the remaining two being a non-coding, 
antisense transcript or encoding an as yet uncharacterised protein making 
interpretation of the biological significance of the DE genes difficult (Table 33). 
VPS37B, the single characterised protein encoding gene, encodes Vacuolar 
protein sorting-associated protein 37B which is a component of ESCRT-I, a 
complex involved in the generation of multivesicular bodies and in the budding 
and pathogenesis of HIV-1 infection (Katzmann et al., 2003; Shields et al., 2009; 
Stuchell et al., 2004). The investigation of the CD163+ and CD163- macrophage 
subsets found little difference in gene expression despite the apparent clustering 
by PCA which indicated the data could have been under-powered to detect many 
statistically significant DE genes and as such an increase in the sample size 
would be required to investigate this further. 
 
Ensembl ID HGNC symbol Log2 fold 
change 
Adjusted P 
value 
ENSG0000013
9722 
VPS37B -4.931897735 0.00581004 
ENSG0000027
3188 
(Non-coding, antisense) -4.963454639 0.008992451 
ENSG0000017
3366 
(Protein encoding, 
uncharacterised) 
-4.687845138 0.032134005 
Table 33: Significantly differentially expressed genes in the CD206+CD163+ versus 
the CD206+CD163- subsets from RA samples. Assessed using linear modelling and 
corrected for multiple comparisons using the Benjamini-Hochberg method. 
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The differences between the CD206+CD163+ and the DN subsets and also 
between the CD206+CD163- and DN subsets were more profound with 537 and 
360 significantly DE genes detected respectively in the RA samples. However 
despite the different number of genes detected only 3 genes were detected as 
differentially regulated between these comparisons indicating that the profiles of 
DE genes between either CD206+ subset and the DN subset were similar again 
reflecting the small difference between the CD206+CD163+ and the 
CD206+CD163- subsets. Examining the DE genes which were upregulated in the 
CD206+CD163+ subset confirmed the macrophage phenotype of these cells with 
the expression of complement components such as C1QB, C2, C1QA, the LPS 
co-receptor CD14, the collectin COLEC12, the scavenger receptor MARCO, 
SIGLEC1, the postulated tissue resident macrophage marker MERTK, and the 
anti-inflammatory mediator TGFB1 (Table 34) (Elomaa et al., 1998; Gautier et al., 
2012; Hartung and Hadding, 1983; Jaguin et al., 2013; Xue et al., 2014a). The 
combination of scavenger receptor and TGFB1 expression may indicate this 
subset had a regulatory phenotype. 
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Ensembl ID HGNC symbol Log 2 fold change Adjusted P value 
ENSG00000198865 CCDC152 7.940412 3.02E-07 
ENSG00000277517 
 
7.528202 1.16E-09 
ENSG00000204706 MAMDC2-AS1 7.449745 3.63E-09 
ENSG00000136235 GPNMB 7.334419 1.28E-08 
ENSG00000107643 MAPK8 6.719737 7.57E-07 
ENSG00000177575 CD163 6.592754 4.65E-06 
ENSG00000173369 C1QB 6.318715 2.47E-05 
ENSG00000279660 
 
6.304964 4.86E-05 
ENSG00000155659 VSIG4 6.177894 4.22E-09 
ENSG00000049247 UTS2 6.111618 1.66E-06 
ENSG00000153071 DAB2 6.06767 4.05E-06 
ENSG00000236467 KCNMA1-AS1 5.967043 0.000228 
ENSG00000158270 COLEC12 5.965191 2.62E-06 
ENSG00000110077 MS4A6A 5.939815 2.00E-05 
ENSG00000170458 CD14 5.887226 1.76E-07 
ENSG00000118855 MFSD1 5.773929 8.64E-05 
ENSG00000168612 ZSWIM1 5.772565 8.84E-05 
ENSG00000236581 STARD13-AS 5.669603 3.88E-05 
ENSG00000267199 
 
5.658803 0.00133 
ENSG00000093010 COMT 5.646451 2.56E-05 
ENSG00000159189 C1QC 5.644668 9.43E-06 
ENSG00000280222 
 
5.598552 9.92E-05 
ENSG00000278206 
 
5.580433 0.000367 
ENSG00000239665 
 
5.565917 0.000161 
ENSG00000197093 GAL3ST4 5.41126 0.000249 
ENSG00000074964 ARHGEF10L 5.406619 0.000181 
ENSG00000274877 NA 5.38718 6.84E-05 
ENSG00000255874 LINC00346 5.343534 0.000189 
ENSG00000141338 ABCA8 5.317973 0.000807 
ENSG00000127980 PEX1 5.303836 0.000221 
ENSG00000125818 PSMF1 5.254467 0.000509 
ENSG00000092068 SLC7A8 5.231992 0.000197 
ENSG00000021355 SERPINB1 5.206477 0.006276 
ENSG00000229036 VDAC1P8 5.204373 0.00093 
ENSG00000271605 MILR1 5.171967 0.001723 
ENSG00000279433 
 
5.00273 6.56E-05 
ENSG00000100600 LGMN 4.990873 0.002326 
ENSG00000268364 SMC5-AS1 4.964322 0.030741 
ENSG00000238133 MAP3K20-AS1 4.957368 0.004526 
Table 34: Top 40 significantly upregulated genes in the CD206+CD163+ subset 
versus the double negative subset in RA patients sorted by log2 fold change. P 
values were adjusted using the Benjamini-Hochberg method. 
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It is often informative to use gene set enrichment analysis (GSEA) to facilitate the 
investigation of the functions of genes in known pathways as opposed to 
considering genes on a one-by-one basis. The Broad Institute molecular 
signatures database contains many gene sets designed for use in GSEA. 
Replicate genes in DE gene lists would result in false-positives during the 
enrichment tests as each occurrence of a gene is counted as a member of a gene 
set. To prevent this all GSEA and GO category or KEGG pathway analysis 
completed was run on a dataset in which only single occurrences of either primary 
assembly or non-primary assembly genes, with a preference for primary 
assembly genes, were included and which had been re-tested for differential 
gene expression before enrichment analysis. Using collection 2 of the molecular 
signatures database for GSEA, which consists of curated gene sets such as 
REACTOME pathways, the DE genes between the CD206+CD163+ and DN 
subsets in RA patients showed enrichment in 27 gene sets at a false discovery 
rate of less than 0.05. Further evidence as to the macrophage phenotype of the 
CD206+CD163+ subset was provided in the form of enrichment of genes in the 
gene sets REACTOME creation of C4 and C2 activators and REACTOME 
trafficking and processing of endosomal TLR pathways although the number of 
DE genes in these gene sets was small (Table 35). 
 
Using the molecular signatures database collection 7, which focuses on 
immunological gene sets generated from published microarray data, also found 
enrichment in a single gene set for the CD206+CD163+ subset (Table 36) 
(Subramanian et al., 2005). The enriched gene set in the CD206+CD163+ subset, 
GSE24634 Treg vs Tconv post day10 IL4 conversion DN (genes which are 
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downregulated in CD25+ regulatory T cells compared to CD25- T cells after 10 
days of IL-4 treatment of both cell types), did not help to elucidate the phenotype 
of the macrophage subset however a large number of DE genes were in the gene 
set and showed a considerable enrichment.
  
 
2
4
2
 
Gene set Number of DE 
genes in set 
Direction of 
enrichment 
FDR 
BIOCARTA_TCYTOTOXIC_PATHWAY 12 Down 4.201710e-05 
BIOCARTA_CTL_PATHWAY 12 Down 2.943158e-04 
REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS 5 Up 3.594883e-03 
BIOCARTA_TCAPOPTOSIS_PATHWAY 9 Down 5.832759e-03 
BIOCARTA_TCRA_PATHWAY 11 Down 1.061436e-02 
BIOCARTA_IL17_PATHWAY 11 Down 1.061436e-02 
BIOCARTA_CLASSIC_PATHWAY 10 Up 1.589149e-02 
BIOCARTA_THELPER_PATHWAY 12 Down 1.598335e-02 
REACTOME_TRAFFICKING_AND_PROCESSING_OF_ENDOSOMAL_TLR 10 Up 2.624318e-02 
BIOCARTA_NO2IL12_PATHWAY 13 Down 2.792765e-02 
Table 35: Results of gene set enrichment in the differentially expressed genes between the CD206+CD163+ and double negative 
subsets in RA patients using the Broad institute MSigDB C2 curated databases. Results displayed are REACTOME and BIOCARTA 
pathways which have a false discovery rate (FDR) less than 0.05%. 
 
Gene set Number of DE genes in 
set 
Direction of 
enrichment 
FDR 
GSE24634_TREG_VS_TCONV_POST_DAY10_IL4_CONV
ERSION_DN 
167 Up 0.007136543 
Table 36: Results of gene set enrichment in the differentially expressed genes between the CD206+CD163+ and double negative 
subsets in RA patients using the Broad institute MSigDB C7 curated databases. Results displayed are pathways which have a 
false discovery rate (FDR) less than 0.05%. 
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Figure 66: Barcode plot of the gene-set GSE24634 Treg vs Tconv post day10 IL4 
conversion DN  showing the log2 fold change of genes in the gene set and the 
relative enrichment score of this gene set in the CD206+CD163+ compared to the 
double negative subset. The x-axis represents log2 fold-change. 
 
A known issue with the detection of differentially expressed genes that may affect 
GSEA and gene ontology (GO) term enrichment in particular in RNA sequencing 
data is that the length of genes affects the number of reads generated with longer 
genes generating more reads (Oshlack and Wakefield, 2009). Using the goseq 
R package one can estimate bias from gene length and adjust the results of GO 
term enrichment and KEGG pathway enrichment to account for gene length bias. 
Using this approached the CD206+CD163+ subset was found to be enriched for 
genes in 51 GO terms for biological processes (Benjamin-Hochberg corrected p 
value less than 0.05). These GO terms included immune response, complement 
activation, and myeloid leukocyte activation indicating a myeloid phagocyte 
phenotype in this subset as expected from the flow cytometry data, however 
terms such as neutrophil activation and immunoglobulin humoral immune 
response were also enriched possibly due to the DE genes being members of 
several gene sets (Table 37). Using the same approach but instead testing for 
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enrichment in KEGG pathways found one significantly enriched pathway, 
complement and coagulation cascades (Benjamini-Hochberg adjusted p value 
0.01091599). 
 
GO category Number 
of DE 
genes in 
category 
Number 
of genes 
in 
category 
GO term Adjusted p 
value 
GO:0002376 60 1016 immune system process 2.442099e-08 
GO:0002443 33 340 leukocyte mediated 
immunity 
2.442099e-08 
GO:0006955 49 714 immune response 2.442099e-08 
GO:0002252 38 466 immune effector process 5.494062e-08 
GO:0045055 33 373 regulated exocytosis 1.343676e-07 
GO:0016192 51 867 vesicle-mediated 
transport 
6.335515e-07 
GO:0006887 33 409 exocytosis 1.317868e-06 
GO:0043299 27 282 leukocyte degranulation 1.629336e-06 
GO:0002275 27 284 myeloid cell activation 
involved in immune 
response 
1.685625e-06 
GO:0002444 27 285 myeloid leukocyte 
mediated immunity 
1.685625e-06 
GO:0002274 28 311 myeloid leukocyte 
activation 
2.216773e-06 
GO:0002283 25 262 neutrophil activation 
involved in immune 
response 
4.833798e-06 
GO:0043312 25 262 neutrophil degranulation 4.833798e-06 
GO:0042119 25 263 neutrophil activation 4.833798e-06 
GO:0002446 25 266 neutrophil mediated 
immunity 
5.852180e-06 
GO:0036230 25 267 granulocyte activation 5.852180e-06 
GO:0032940 38 583 secretion by cell 8.136843e-06 
GO:0046903 39 616 secretion 9.616950e-06 
GO:0002263 27 319 cell activation involved in 
immune response 
9.616950e-06 
GO:0002366 27 319 leukocyte activation 
involved in immune 
response 
9.616950e-06 
GO:0001775 36 538 cell activation 1.248697e-05 
GO:1902578 59 1248 single-organism 
localization 
2.464135e-05 
GO:0044765 57 1186 single-organism 
transport 
2.598041e-05 
GO:0045321 33 481 leukocyte activation 2.877428e-05 
GO:0051179 87 2317 localization 8.526574e-05 
GO:0006810 75 1884 transport 1.894815e-04 
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GO:0006898 15 138 receptor-mediated 
endocytosis 
4.050583e-04 
GO:0050896 98 2856 response to stimulus 4.580411e-04 
GO:0051234 75 1933 establishment of 
localization 
5.095624e-04 
GO:0072376 8 34 protein activation 
cascade 
6.856729e-04 
GO:0006956 7 27 complement activation 1.454987e-03 
GO:0002682 30 506 regulation of immune 
system process 
1.903319e-03 
GO:0006897 21 312 endocytosis 5.548695e-03 
GO:0006958 5 14 complement activation, 
classical pathway 
5.636344e-03 
GO:0032501 78 2227 multicellular organismal 
process 
8.096762e-03 
GO:0045087 20 285 innate immune response 8.096762e-03 
GO:0006952 29 517 defense response 8.096762e-03 
GO:0006950 55 1343 response to stress 8.096762e-03 
GO:0002455 5 16 humoral immune 
response mediated by 
circulating 
immunoglobulin 
1.059326e-02 
GO:0050776 22 344 regulation of immune 
response 
1.168618e-02 
GO:0002576 8 56 platelet degranulation 2.006748e-02 
GO:0071402 4 10 cellular response to 
lipoprotein particle 
stimulus 
2.179581e-02 
GO:0006959 8 56 humoral immune 
response 
2.620322e-02 
GO:0040011 31 645 locomotion 2.751136e-02 
GO:0050866 8 60 negative regulation of 
cell activation 
2.904154e-02 
GO:0043277 5 21 apoptotic cell clearance 3.167408e-02 
GO:0048870 28 562 cell motility 3.263271e-02 
GO:0051674 28 562 localization of cell 3.263271e-02 
GO:0044707 71 2055 single-multicellular 
organism process 
3.284563e-02 
GO:0051239 42 1011 regulation of multicellular 
organismal process 
3.594518e-02 
GO:0055094 4 12 response to lipoprotein 
particle 
4.038486e-02 
Table 37: GO biological process categories enriched for in the upregulated genes 
in the CD206+CD163+ subset versus the double negative subset in RA patients. 
Benjamin-Hochberg adjusted p value cutoff <0.05.  
 
In addition to investigating the genes that are upregulated in the CD206+CD163+ 
subset compared to the DN it was also of interest to investigate genes which are 
downregulated and hence expressed at higher levels in the DN subset than the 
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double positive. In the differential expression analysis comparing the two subsets 
in RA, 318 of the 537 significantly DE genes were found at higher levels in the 
DN subset than in the double positive, however the genes expressed were 
difficult to interpret as the NK cell marker NKG7 was highly expressed compared 
to the CD206+CD163+ subset as were T cell markers such as CD8A (log2 fold 
(log2FC) change of 6.50874), CD3G (log2FC 3.499673276), CD3E (log2FC 
4.692273633), and CD3D (log2FC 5.001018657) and B cell genes such as 
JCHAIN (log2FC 5.335226216), IGHG3 (log2FC 5.160072371), and IGHM 
(log2FC 4.752540244) (Table 38). The lack of obvious macrophage associated 
genes and expression of mixed lymphocyte genes indicated that the DN 
population may consist of several CD45+HLA-DR+ cell types rather than a single 
population. The results of the previous GSEA (Table 35) found several 
BIOCARTA pathways which were enriched in the DN subset rather than the 
CD206+CD163+ subset many of which are related to T cell biology such as the 
BIOCARTA T cytotoxic pathway (Figure 67), BIOCARTA T helper pathway, the 
BIOCARTA IL-17 (signalling) pathway, and the BIOCARTA TCRA pathway 
providing further evidence that the DN population contained a T lymphocyte 
population. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000009694 TENM1 -7.9085 2.19E-11 
ENSG00000240535 
 
-7.87094 3.32E-13 
ENSG00000267369 
 
-7.52547 7.47E-14 
ENSG00000206028 
 
-7.51196 5.35E-05 
ENSG00000105374 NKG7 -7.4614 4.83E-16 
ENSG00000215039 CD27-AS1 -7.1479 6.40E-11 
ENSG00000257957 QRSL1P3 -7.04593 6.39E-07 
ENSG00000132464 ENAM -7.01797 4.16E-10 
ENSG00000177272 KCNA3 -7.0163 2.70E-06 
ENSG00000245164 LINC00861 -6.85897 7.28E-08 
ENSG00000211895 IGHA1 -6.84059 8.91E-06 
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ENSG00000276849 TRBC2 -6.78075 6.49E-10 
ENSG00000267784 
 
-6.71705 6.59E-06 
ENSG00000107742 SPOCK2 -6.67499 3.63E-09 
ENSG00000162892 IL24 -6.66409 2.66E-08 
ENSG00000213262 VDAC2P3 -6.63303 1.09E-08 
ENSG00000280348 
 
-6.54324 1.36E-06 
ENSG00000153563 CD8A -6.50874 7.82E-10 
ENSG00000279149 
 
-6.39622 6.14E-10 
ENSG00000259326 
 
-6.38794 6.92E-09 
ENSG00000280014 
 
-6.36654 4.18E-11 
ENSG00000270574 
 
-6.35042 8.85E-06 
ENSG00000183508 FAM46C -6.32771 2.66E-08 
ENSG00000267046 E2F3P1 -6.32226 7.47E-14 
ENSG00000261054 
 
-6.31559 0.000203 
ENSG00000182463 TSHZ2 -6.13248 3.17E-06 
ENSG00000266413 NA -5.98241 4.52E-09 
ENSG00000173598 NUDT4 -5.98143 5.49E-06 
ENSG00000261346 
 
-5.97113 2.69E-06 
ENSG00000120875 DUSP4 -5.94401 3.83E-06 
ENSG00000235300 
 
-5.9211 8.78E-09 
ENSG00000237286 
 
-5.90329 0.000862 
ENSG00000115661 STK16 -5.90014 7.85E-05 
ENSG00000231858 
 
-5.86973 3.04E-06 
ENSG00000270956 
 
-5.72055 2.07E-07 
ENSG00000227217 
 
-5.69132 2.66E-10 
ENSG00000231799 PA2G4P6 -5.64528 3.39E-06 
ENSG00000245648 
 
-5.64314 0.000259 
ENSG00000250751 
 
-5.63939 0.000203 
Table 38: Top 40 significantly downregulated genes in the CD206+CD163+ subset 
versus the double negative subset in RA patients sorted by log2 fold change. P 
values were adjusted using the Benjamini-Hochberg method. 
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Figure 67: Barcode plots showing the log2 fold change of genes in the gene sets 
BIOCARTA Tcytotoxic pathway and GSE22886 IL17 pathway and the relative 
enrichment score of these gene sets in the CD206+CD163+ compared to the double 
negative subset. The x-axis represents log2 fold-change. 
 
Examining enrichment in GO biological process categories as before but 
substituting the list of DE genes for those higher in the DN subset revealed 65 
significantly enriched GO categories (Table 39). Of the enriched GO categories 
12 were specific for aspects of T cell biology with no other specific immune cell 
type explicitly stated in the remaining GO category titles. The remaining GO 
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categories were aspects of leukocyte and lymphocyte biology such as 
lymphocyte costimulation, lymphocyte activation, and leukocyte cell-cell 
adhesion. Using the same approach but instead testing for enrichment in KEGG 
pathways found four pathways enriched for in the DN upregulated genes, the T 
cell receptor signalling pathway (adjusted p value 0.0001147660), Natural Killer 
cell mediated cytotoxicity (adjusted p value 0.0004553556), primary 
immunodeficiency (adjusted p value 0.0004553556), and hematopoietic cell 
lineage (adjusted p value 0.0024522829). 
 
GO category Number 
of DE 
genes in 
category 
Number 
of genes 
in 
category 
GO term Adjusted p 
value 
GO:0042110 26 181 T cell activation 7.307012e-07 
GO:0031294 10 22 lymphocyte costimulation 2.242512e-06 
GO:0031295 10 22 T cell costimulation 2.242512e-06 
GO:0046649 28 239 lymphocyte activation 4.607952e-06 
GO:0006955 45 552 immune response 6.519748e-06 
GO:0007159 19 123 leukocyte cell-cell 
adhesion 
2.033754e-05 
GO:1903037 18 113 regulation of leukocyte 
cell-cell adhesion 
3.000701e-05 
GO:1903039 15 79 positive regulation of 
leukocyte cell-cell 
adhesion 
3.881554e-05 
GO:0030217 16 96 T cell differentiation 5.451514e-05 
GO:0050863 17 109 regulation of T cell 
activation 
7.349036e-05 
GO:0022409 15 85 positive regulation of cell-
cell adhesion 
7.349036e-05 
GO:0050870 14 75 positive regulation of T 
cell activation 
1.026148e-04 
GO:0051249 19 143 regulation of lymphocyte 
activation 
1.355637e-04 
GO:0022407 18 130 regulation of cell-cell 
adhesion 
1.355637e-04 
GO:0045321 31 353 leukocyte activation 1.730469e-04 
GO:0030098 17 124 lymphocyte 
differentiation 
1.993927e-04 
GO:0002376 52 800 immune system process 2.182536e-04 
GO:0045785 17 125 positive regulation of cell 
adhesion 
2.955877e-04 
GO:0002696 15 99 positive regulation of 3.640167e-04 
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leukocyte activation 
GO:0002694 19 157 regulation of leukocyte 
activation 
3.640167e-04 
GO:0050867 15 102 positive regulation of cell 
activation 
4.930454e-04 
GO:0050865 19 164 regulation of cell 
activation 
6.216705e-04 
GO:0002682 33 416 regulation of immune 
system process 
6.216705e-04 
GO:0051251 14 93 positive regulation of 
lymphocyte activation 
7.993189e-04 
GO:0001775 31 394 cell activation 1.076730e-03 
GO:0016337 19 172 single organismal cell-
cell adhesion 
1.076730e-03 
GO:0050776 25 277 regulation of immune 
response 
1.441857e-03 
GO:0002684 26 298 positive regulation of 
immune system process 
1.441857e-03 
GO:0002521 18 164 leukocyte differentiation 1.441857e-03 
GO:0006952 31 398 defense response 1.486300e-03 
GO:0045058 7 23 T cell selection 1.854097e-03 
GO:0032944 11 63 regulation of 
mononuclear cell 
proliferation 
1.916041e-03 
GO:0046631 10 54 alpha-beta T cell 
activation 
1.985408e-03 
GO:0098602 19 185 single organism cell 
adhesion 
2.512251e-03 
GO:0070663 11 65 regulation of leukocyte 
proliferation 
2.751957e-03 
GO:0030155 20 208 regulation of cell 
adhesion 
3.797050e-03 
GO:0030097 22 248 hemopoiesis 3.797050e-03 
GO:0045087 21 235 innate immune response 6.978579e-03 
GO:0032943 12 86 mononuclear cell 
proliferation 
6.978579e-03 
GO:0042129 9 48 regulation of T cell 
proliferation 
7.065498e-03 
GO:0098609 20 222 cell-cell adhesion 7.073226e-03 
GO:0045061 5 12 thymic T cell selection 7.073226e-03 
GO:0048534 22 260 hematopoietic or 
lymphoid organ 
development 
7.246462e-03 
GO:0050670 10 62 regulation of lymphocyte 
proliferation 
7.934753e-03 
GO:0050851 12 89 antigen receptor-
mediated signaling 
pathway 
8.168410e-03 
GO:0070661 12 88 leukocyte proliferation 8.293147e-03 
GO:0050852 11 76 T cell receptor signaling 
pathway 
8.856201e-03 
GO:0046632 8 43 alpha-beta T cell 
differentiation 
1.054236e-02 
GO:0042098 10 64 T cell proliferation 1.054236e-02 
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GO:0032609 8 42 interferon-gamma 
production 
1.410477e-02 
GO:0002757 16 160 immune response-
activating signal 
transduction 
1.533023e-02 
GO:0002250 14 128 adaptive immune 
response 
1.538536e-02 
GO:0002520 22 276 immune system 
development 
1.625446e-02 
GO:0018108 12 102 peptidyl-tyrosine 
phosphorylation 
1.692419e-02 
GO:0018212 12 102 peptidyl-tyrosine 
modification 
1.692419e-02 
GO:0050778 19 218 positive regulation of 
immune response 
2.015974e-02 
GO:0046651 11 85 lymphocyte proliferation 2.160840e-02 
GO:0032946 8 46 positive regulation of 
mononuclear cell 
proliferation 
2.212807e-02 
GO:0002253 16 169 activation of immune 
response 
2.550103e-02 
GO:0070665 8 47 positive regulation of 
leukocyte proliferation 
2.550103e-02 
GO:0002429 13 119 immune response-
activating cell surface 
receptor signaling 
pathway 
2.550103e-02 
GO:0042102 7 35 positive regulation of T 
cell proliferation 
2.618942e-02 
GO:0002764 16 171 immune response-
regulating signaling 
pathway 
2.750859e-02 
GO:0032729 6 27 positive regulation of 
interferon-gamma 
production 
4.677034e-02 
GO:0046641 3 5 positive regulation of 
alpha-beta T cell 
proliferation 
4.874571e-02 
Table 39: GO biological process categories enriched for in the downregulated 
genes in the CD206+CD163+ subset versus the double negative subset in RA 
patients. Benjamin-Hochberg adjusted p value cutoff <0.05. 
 
The results of this analysis indicated that the CD206+CD163+ subset was a 
macrophage population with a possible scavenger phenotype as opposed to an 
overtly pro-inflammatory phenotype as evidence by the enrichment in GO 
categories such as apoptotic cell clearance. In contrast the identity of the DN 
subset was unclear with significantly higher expression of T cell, B cell, and NK 
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cell genes in this subset compared to the CD206+CD163+ subset. When testing 
for enrichment in gene-sets, GO categories, and KEGG pathways, T cell related 
pathways were abundant indicating that the DN population consisted 
predominantly of T lymphocytes. 
 
5.3.4 Stromal subsets demonstrate differential gene expression 
Using the approach demonstrated in the previous section the differences 
between fibroblast subsets appeared less profound than those between the 
macrophage subsets. Principal component analysis found some separation 
between fibroblast subsets when examining the second and third components 
however the clusters overlap between 95% confidence interval ellipses (Figure 
68). However the CD34+ and CD90-GP38+ subsets showed a larger degree of 
separation than that of either subset with the CD34- samples. The fibroblast 
subset groups also clustered together loosely indicating higher heterogeneity 
between samples than was found between the macrophage samples. A feature 
that was not seen in the macrophage data was the presence of an experimental 
batch effect dependent on the digestion batch of samples with possible clusters 
visible (Figure 69). Due to careful experimental design this batch effect was not 
confounded with the disease groupings and so the effects on the analysis could 
be minimised with batch correction techniques if required. 
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Figure 68: Principal component analysis of the RNA sequencing data generated 
from the fibroblast samples only. The data is coloured according to the fibroblast 
subset from which the sample was generated. Ellipses show the 95% confidence 
interval for each group. Although clusters could be defined the samples within 
each group clustered loosely and a large amount of overlap was present between 
ellipses indicating high variation within groups and only small differences 
between clusters.  
 
 
Figure 69: Principal component analysis of the RNA sequencing data generated 
from the fibroblast samples only. The data is coloured according to the 
experimental batch in which the biopsy was digested and the sample generated. 
The presence of a small batch effect could be seen between the experimental 
batches. 
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Figure 70: Principal component analysis of the RNA sequencing data generated 
from the fibroblast samples only. The data is coloured according to the sex of the 
donor from which the sample was generated. There was some segregation 
according to sex apparent, although the contribution to the overall variance in the 
dataset was less than that of the fibroblast subset which the samples belong to. 
 
Hierarchical clustering of the fibroblast subsets using Pearson’s correlation 
distance between samples confirmed the findings of the PCA (Figure 71). Three 
broad clusters could be seen; a predominantly CD34+ cluster, a mixed CD34+ and 
CD34- cluster, and a predominantly CD90-GP38+ cluster. These clusters 
consisted of samples from all clinical outcome groups, indicating a higher 
contribution of the fibroblast subset to the variation in the data than the clinical 
outcome group, although some clustering according to clinical outcome could be 
found within the three subset clusters. As with the macrophage dataset, in some 
cases samples could be seen clustering with other samples from the same donor 
which could be explained by high homogeneity between subset samples, which 
seems unlikely given the ability of PCA and hierarchical clustering to find subset 
clusters, or more likely by a contribution of donor-specific variation to the dataset 
(Figure 72). 
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Figure 71: Complete linkage hierarchical clustering using Pearson’s correlation 
distance of the top 400 most variable genes of the fibroblast data subset. Three 
general clusters could be found; one mostly consisting of the CD34+ sample 
subset, one consisting of a mixed set of subset samples but broadly containing 
CD34+ and CD34- samples, and one mostly consisting of the CD90-GP38+ subset.  
 
 
Figure 72: Complete linkage hierarchical clustering using Pearson’s correlation 
distance of the top 400 most variable genes of the fibroblast data subset as in 
Figure 71 but using patient labels as opposed to diagnosis and population labels. 
As with the macrophage samples some samples clustered with other samples 
from the same donor indicating either small differences between these subsets or 
significant inter-donor variability. 
 
The number of differentially expressed genes between fibroblast subsets were 
smaller than those between the macrophage subsets with the greatest number 
of DE genes found between the CD34+ and the CD90-GP38+ subsets in all clinical 
outcome groups, as expected from the PCA (Table 40, mean of 108 DE genes). 
In the RA and anti-PD1 subset comparisons the CD34+ and CD34- subsets had 
the second largest number of DE genes, 60 and 23 respectively, with the lowest 
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numbers found between the CD34- and the CD90-GP38+ subsets. The treated 
RA samples were different in that the number of DE genes between the CD34- 
and CD90-GP38+ subsets, 19, was larger than that between the CD34+ and the 
CD34- subsets, 12. 
 
RA Treated 
RA 
Anti-
PD1 
CD34+ vs. CD34- 60 12 23 
CD34+ vs. CD90-
GP38+ 
98 148 78 
CD34- vs. CD90-
GP38+ 
16 19 10 
Table 40: The number of significantly DE genes, both up- and down-regulated, 
between fibroblast subsets in each disease group. Detected using linear 
modelling, significance is <0.05 Benjamini-Hochberg adjusted p-value.  
 
To simplify the analysis of the fibroblast subset data only the comparisons 
between RA subsets were considered, although the comparisons between 
subsets in the other disease states are obviously also of interest. When 
examining DE genes between the CD34+ and the CD34- subsets in RA MMP1 
and S100A10 were highly upregulated in the CD34- subset compared to the 
CD34+ (Table 41). The CD34+ subset expressed significantly higher levels of the 
genes FUT2 and FUT11 which both encode fucosyltransferases, a family of 
enzymes of which members have been implicated in the proliferation of synovial 
fibroblasts, angiogenesis, and in other inflammatory disorders such as Crohn’s 
disease and Behçet's disease (Isozaki et al., 2014a; Isozaki et al., 2014b; 
Mcgovern et al., 2010; Tsou et al., 2013; Xavier et al., 2015). 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000157570 TSPAN18 6.29528 0.00153 
ENSG00000223949 ROR1-AS1 5.59664 0.00295 
ENSG00000176920 FUT2 5.51965 0.03444 
ENSG00000198522 GPN1 5.41003 0.04565 
ENSG00000066422 ZBTB11 5.4 0.01885 
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ENSG00000270300 PHACTR2P1 5.29583 0.04565 
ENSG00000196968 FUT11 5.02206 0.01885 
ENSG00000224468 
 
4.98012 4.18E-06 
ENSG00000144476 ACKR3 4.90388 0.03444 
ENSG00000104611 SH2D4A 4.83396 0.04416 
ENSG00000135437 RDH5 4.79762 0.04529 
ENSG00000136816 TOR1B 4.62085 0.03943 
ENSG00000166226 CCT2 4.57854 0.03196 
ENSG00000140848 CPNE2 4.52478 0.04565 
ENSG00000170473 PYM1 4.51695 0.03674 
ENSG00000149646 CNBD2 4.17163 0.02571 
ENSG00000237413 
 
3.98405 0.02827 
ENSG00000229702 NA 3.82248 0.00153 
ENSG00000244171 PBX2P1 3.08492 0.04416 
ENSG00000239823 
 
2.86532 0.04219 
ENSG00000254102 
 
-3.22256 0.04219 
ENSG00000130707 ASS1 -4.36006 0.03444 
ENSG00000105856 HBP1 -4.49571 0.03444 
ENSG00000160991 ORAI2 -4.5482 0.03444 
ENSG00000131116 ZNF428 -4.55606 0.03943 
ENSG00000275871 
 
-4.62341 0.04219 
ENSG00000246174 KCTD21-
AS1 
-4.6509 0.03943 
ENSG00000249176 
 
-4.82239 0.02779 
ENSG00000166579 NDEL1 -4.97747 0.01956 
ENSG00000226706 
 
-4.98732 0.04565 
ENSG00000258648 UBE2CP1 -5.05178 0.04565 
ENSG00000261222 
 
-5.16108 0.01885 
ENSG00000066654 THUMPD1 -5.16355 0.03943 
ENSG00000197747 S100A10 -5.181 0.01885 
ENSG00000259627 
 
-5.18938 0.03666 
ENSG00000255164 
 
-5.2016 0.03157 
ENSG00000269480 
 
-5.22547 0.01885 
ENSG00000251593 MSNP1 -5.24033 0.02276 
ENSG00000197982 C1orf122 -5.29129 0.03302 
ENSG00000267139 
 
-5.30723 0.01514 
ENSG00000267439 
 
-5.43019 0.0192 
ENSG00000249971 
 
-5.43441 0.01885 
ENSG00000226152 
 
-5.483 0.00153 
ENSG00000228490 
 
-5.483 0.00153 
ENSG00000144747 TMF1 -5.51962 0.02453 
ENSG00000229781 
 
-5.5442 0.04435 
ENSG00000229044 
 
-5.57602 0.03786 
ENSG00000166171 DPCD -5.62691 0.01527 
ENSG00000100036 SLC35E4 -5.6297 0.01148 
ENSG00000279649 
 
-5.70367 0.01956 
ENSG00000213839 TMX2P1 -5.7482 0.01956 
ENSG00000255959 
 
-5.79059 0.03943 
ENSG00000279364 
 
-5.88565 0.01527 
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ENSG00000226736 
 
-5.95942 6.46E-05 
ENSG00000231197 
 
-5.95942 6.46E-05 
ENSG00000028839 TBPL1 -6.0775 0.00762 
ENSG00000224721 
 
-6.30773 0.0003 
ENSG00000267776 
 
-6.58257 0.00153 
ENSG00000255282 WTAPP1 -6.73487 0.01106 
ENSG00000196611 MMP1 -7.13899 0.00013 
Table 41: Significantly differentially expressed genes between the CD34+ subset 
and the CD34- subset in RA patients sorted by log2 fold change. P values adjusted 
using the Benjamini-Hochberg method. 
 
Investigating the genes which were DE between the CD34+ and the CD90-GP38+ 
subsets found some genes in common with those DE between the CD34+ and 
CD34- subset such as MMP1 and NDEL1 with higher expression of both in the 
CD90-GP38+ subset again indicating a downregulation of these genes in the 
CD34+ subset (Table 42). The CD34+ subset expressed higher levels of IGF1. 
Interestingly, the levels of CAV1, the gene encoding caveolin-1, were significantly 
lower in CD34+ than CD90-GP38+ synovial fibroblasts and CTSK, encoding 
cathepsin K, was also detected as DE between the two subsets with higher 
expression in the CD90-GP38+ subset which could be important given the 
degradative nature of cathepsins. 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000017427 IGF1 7.657472 3.14E-07 
ENSG00000181800 CELF2-AS1 7.278109 1.72E-06 
ENSG00000159596 TMEM69 6.134911 0.005201 
ENSG00000277401 TJP1 6.052997 0.000327 
ENSG00000183562 
 
5.9672 0.006424 
ENSG00000255565 
 
5.922744 0.010009 
ENSG00000254122 PCDHGB7 5.77401 0.022256 
ENSG00000254192 
 
5.719499 0.002031 
ENSG00000234338 
 
5.623439 0.016066 
ENSG00000213222 
 
5.610919 0.001388 
ENSG00000215277 RNF212B 5.420674 0.005201 
ENSG00000270300 PHACTR2P1 5.418524 0.025784 
ENSG00000248254 
 
5.212413 0.015669 
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ENSG00000104067 TJP1 5.211505 0.002092 
ENSG00000011465 DCN 5.1122 0.010487 
ENSG00000151748 SAV1 5.102822 0.014444 
ENSG00000196396 PTPN1 5.077432 0.012993 
ENSG00000076053 RBM7 4.961398 0.005201 
ENSG00000260111 
 
4.929137 0.044998 
ENSG00000205323 SARNP 4.920461 0.044059 
ENSG00000255390 
 
4.917876 0.034117 
ENSG00000230552 
 
4.826452 0.040382 
ENSG00000223949 ROR1-AS1 4.810049 0.009115 
ENSG00000116729 WLS 4.745186 0.022256 
ENSG00000233682 
 
4.743805 0.003225 
ENSG00000224468 
 
4.743153 5.27E-06 
ENSG00000107175 CREB3 4.693984 0.016405 
ENSG00000143387 CTSK 4.676193 0.044699 
ENSG00000235033 
 
4.646065 0.024828 
ENSG00000166025 AMOTL1 4.632639 0.042987 
ENSG00000136816 TOR1B 4.618524 0.026483 
ENSG00000232284 GNG12-AS1 4.615269 0.044059 
ENSG00000254418 SPON1-AS1 4.513102 0.03054 
ENSG00000258114 
 
4.487902 0.017735 
ENSG00000270607 
 
4.460797 0.025784 
ENSG00000108010 GLRX3 4.45456 0.044699 
ENSG00000269950 
 
4.418677 0.025457 
ENSG00000174348 PODN 4.344878 0.022256 
ENSG00000272235 
 
4.309307 0.032152 
ENSG00000196586 MYO6 4.300711 0.043001 
ENSG00000149646 CNBD2 4.298336 0.013373 
ENSG00000134574 DDB2 4.258815 0.033452 
ENSG00000242888 
 
4.233996 0.049981 
ENSG00000277288 C10orf142 4.224141 0.014444 
ENSG00000229702 NA 4.147683 0.000145 
ENSG00000229996 
 
4.022207 0.030313 
ENSG00000234557 
 
3.894989 0.045816 
ENSG00000237413 
 
3.88366 0.024828 
ENSG00000273656 
 
3.638532 0.025457 
ENSG00000254634 SMG1P6 3.541354 0.032152 
ENSG00000244171 PBX2P1 3.082589 0.030313 
ENSG00000138135 CH25H 3.038581 0.036013 
ENSG00000239823 
 
2.862988 0.029142 
ENSG00000079462 PAFAH1B3 -3.85193 0.048117 
ENSG00000267563 
 
-4.1701 0.040382 
ENSG00000253523 
 
-4.28097 0.044059 
ENSG00000112640 PPP2R5D -4.29059 0.044699 
ENSG00000105974 CAV1 -4.36605 0.025457 
ENSG00000226627 SHANK2-
AS1 
-4.44459 0.026059 
ENSG00000104325 DECR1 -4.4609 0.031188 
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ENSG00000246174 KCTD21-
AS1 
-4.49705 0.049643 
ENSG00000232406 
 
-4.64444 0.026059 
ENSG00000107736 CDH23 -4.64875 0.034117 
ENSG00000226152 
 
-4.7475 0.022256 
ENSG00000228490 
 
-4.7475 0.022256 
ENSG00000197046 SIGLEC15 -4.85683 0.034117 
ENSG00000039319 ZFYVE16 -4.92921 0.024828 
ENSG00000111276 CDKN1B -5.00785 0.025457 
ENSG00000271454 
 
-5.00822 0.017735 
ENSG00000089693 MLF2 -5.022 0.044059 
ENSG00000107164 FUBP3 -5.06468 0.039549 
ENSG00000196182 STK40 -5.14848 0.023132 
ENSG00000155265 GOLGA7B -5.14905 0.036279 
ENSG00000078795 PKD2L2 -5.15751 0.037115 
ENSG00000109323 MANBA -5.15951 0.026059 
ENSG00000134532 SOX5 -5.18668 0.022256 
ENSG00000261546 
 
-5.18779 0.025457 
ENSG00000166579 NDEL1 -5.22231 0.012916 
ENSG00000267139 
 
-5.27995 0.015669 
ENSG00000229127 
 
-5.29722 0.017735 
ENSG00000142634 EFHD2 -5.3097 0.026098 
ENSG00000272078 
 
-5.47999 0.010487 
ENSG00000267439 
 
-5.51407 0.015669 
ENSG00000140157 NIPA2 -5.53436 0.030313 
ENSG00000101126 ADNP -5.55212 0.025457 
ENSG00000196611 MMP1 -5.60814 0.042925 
ENSG00000119760 SUPT7L -5.68738 0.002851 
ENSG00000272072 
 
-5.71974 0.029142 
ENSG00000226736 
 
-5.80288 0.000169 
ENSG00000231197 
 
-5.80288 0.000169 
ENSG00000177409 SAMD9L -5.83618 0.007714 
ENSG00000257150 PGAM1P5 -5.96012 0.00127 
ENSG00000232682 
 
-6.26042 0.014922 
ENSG00000279083 
 
-6.32014 0.005538 
ENSG00000165480 SKA3 -6.33485 0.013783 
ENSG00000104154 SLC30A4 -6.91767 0.00292 
ENSG00000028839 TBPL1 -7.47584 7.38E-05 
ENSG00000224721 
 
-7.56903 3.14E-07 
Table 42: Significantly differentially expressed genes between the CD34+ subset 
and the CD90-GP38+ subset in RA patients sorted by log2 fold change. P values 
adjusted using the Benjamini-Hochberg method. 
 
The number of DE genes between the CD34- and the CD90-GP38- subsets was 
relatively small, as a result of direct similarity, or as a result of higher 
heterogeneity between subjects in these subsets influencing the results of the 
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linear model. Of the genes detected CDKN1B was significantly upregulated in the 
CD90-GP38+ subset which is of interest as this gene has been shown to inhibit 
fibroblast proliferation and was expressed at lower levels in the peripheral blood 
of RA patients who have not been treated with methotrexate compared to healthy 
controls and methotrexate treatment increased CDKN1B RNA levels in the 
peripheral blood of RA patients (Spurlock et al., 2012; Yang et al., 2013) (Table 
43). Of the genes expressed at higher levels in the CD34- subset CDSN is thought 
to be a risk allele for the development of RA (Sun et al., 2013). 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000263873 
 
6.457526 0.049351 
ENSG00000126861 OMG 6.24403 0.047604 
ENSG00000107223 EDF1 5.832043 0.047604 
ENSG00000279333 
 
5.789325 0.049351 
ENSG00000100036 SLC35E4 5.608836 0.047604 
ENSG00000263823 
 
5.566868 0.049351 
ENSG00000213222 
 
5.503838 0.047604 
ENSG00000275871 
 
5.174837 0.047604 
ENSG00000270412 
 
5.001844 0.049351 
ENSG00000204539 CDSN 4.358396 0.047604 
ENSG00000219790 OSTCP6 -4.53676 0.049351 
ENSG00000108639 SYNGR2 -5.34299 0.049351 
ENSG00000111276 CDKN1B -5.44997 0.047604 
ENSG00000142634 EFHD2 -5.74409 0.049351 
ENSG00000163875 MEAF6 -6.27948 0.047604 
ENSG00000279083 
 
-6.32197 0.047604 
Table 43: Significantly differentially expressed genes between the CD34- subset 
and the CD90-GP38- subset in RA patients sorted by log2 fold change. P values 
adjusted using the Benjamini-Hochberg method. 
 
As with the macrophage subsets it was of interest to test if the DE genes between 
fibroblast subsets were found in certain gene sets and if any enrichment in certain 
biological functions could be ascribed to the fibroblast subsets. GSEA and KEGG 
pathway or GO term enrichment was run on all of the DE genes between 
comparisons to determine if any enrichment was present, but no enrichment was 
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found. The detection of several genes which have previously been shown to be 
DE between RA synovial fibroblasts/synovial tissue and control samples 
indicates that the findings of these studies may be due to the expansion of or 
upregulation of these genes in specific subsets rather than a general upregulation 
in all fibroblast populations. This opens up avenues for targeted treatment of 
specific fibroblast subsets depending on the role they play in the disease. 
 
 
5.3.5 Stromal and macrophage populations show differences between 
clinical outcome group 
The previous two sections focused on the differences between fibroblast and 
macrophage subsets within untreated RA samples. It is of great interest to 
investigate how these subsets vary between diseases as this could possibly allow 
deconvolution of the complex interactions occurring in these pathologies. 
 
5.3.5.1 Macrophage subsets and clinical outcome groups 
Clusters representing the clinical outcome groups of the samples were found 
when examining the fourth and fifth principal components of the macrophage 
dataset (Figure 73). Interestingly the RA and anti-PD1 samples formed clear 
spatially separated clusters with some overlap of the 95% confidence intervals, 
however the treated RA samples showed much more variation across the 
principal components. The treated RA samples could be seen both in and out the 
RA and anti-PD1 clusters whereas the samples in these clusters were almost 
completely separated from each other.  
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Figure 73: Principal component analysis of the RNA sequencing data generated 
from the macrophage samples only. The data are coloured according to the 
clinical outcome group from which each sample was generated. Ellipses are 95% 
confidence interval ellipses for each group. The RA and anti-PD1 groups formed 
clear spatial separated clusters with a small amount of overlap in 95% confidence 
interval ellipses whereas the treated RA cluster was much more variable with the 
samples spread in and out of the other clusters. 
 
5.3.5.1.1 CD206+CD163+ population 
When considering the number of DE genes between the same macrophage 
subset in different disease groups it was apparent that the differences between 
them are less than those seen between subsets from the same clinical outcome 
group (Table 44). The CD206+CD163+ subset showed the smallest differences in 
all disease comparisons (mean of 5 DE genes) whereas the DN subset showed 
the greatest (mean of 43.67 DE genes) and the CD206+CD163- subset an 
intermediate number of DE genes (mean of 15.67). The fact that the largest 
numbers of DE genes were detected in the DN subset could be a reflection of the 
unclear origin of this subset with multiple possible sources of variation being 
included. 
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CD206+CD163+ CD206+CD163- Double 
negative 
RA vs Treated 
RA 
3 10 82 
RA vs Anti-PD1 6 11 10 
Anti-PD1 vs 
Treated RA 
6 26 39 
Table 44: The number of significantly DE genes, both up- and down-regulated, 
between the same macrophage subset in different disease groups. Detected using 
linear modelling, significance is <0.05 Benjamini-Hochberg adjusted p-value. 
 
Of the 3 downregulated genes in the RA CD206+CD163+ subset compared to the 
same subset in treated RA patients, two genes were uncharacterised and the 
remaining gene, TMEM218, encodes transmembrane protein 218 (Table 45). 
The comparison of the same subset between the RA and the anti-PD1 samples 
showed four genes upregulated, of which one gene was uncharacterised, and 
two genes downregulated in the RA samples (Table 46). The final comparison of 
the double positive macrophage subset, anti-PD1 patients versus treated RA 
patients, found six significantly DE genes at higher levels in the treated RA 
patients three of which were uncharacterised (Table 47). No GO term or KEGG 
pathway enrichment was found in any of the comparisons. 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000279758 -4.53573 0.031289 
ENSG00000262412 -5.61484 1.63E-05 
ENSG00000150433 TMEM218 -6.74268 5.21E-05 
Table 45: Significantly differentially expressed genes in the CD206+CD163+ subset 
in the RA patients compared to the treated RA patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
 
 
 
 
 265 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000104154 SLC30A4 5.793852 0.029687 
ENSG00000131503 ANKHD1 5.643881 0.00324 
ENSG00000165660 FAM175B 4.747566 0.01203 
ENSG00000228863 4.56843 0.022915 
ENSG00000260027 HOXB7 -3.84983 0.022915 
ENSG00000166250 CLMP -4.52859 0.008838 
Table 46: Significantly differentially expressed genes in the CD206+CD163+ subset 
in the RA patients compared to the anti-PD1 patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000279758 -4.53695 0.028925 
ENSG00000262412 -5.12532 0.003807 
ENSG00000140265 ZSCAN29 -5.53273 0.022914 
ENSG00000233485 -5.55673 0.006375 
ENSG00000131503 ANKHD1 -5.6599 0.006375 
ENSG00000225796 MTND4P23 -6.14558 0.000547 
Table 47: Significantly differentially expressed genes in the CD206+CD163+ subset 
in the anti-PD1 patients compared to the treated RA patients sorted by log2 fold 
change. P values adjusted using the Benjamini-Hochberg method. 
 
5.3.5.1.2 CD206+CD163- population 
The number of DE genes between the CD206+CD163- subset in different disease 
groupings was slightly higher than that of the CD206+CD163+ subset in the same 
comparisons. Between the single positive subset in RA patients and treated RA 
patients there were eight genes upregulated in the RA samples and two 
upregulated in the treated RA (Table 48). No GO category or KEGG pathway 
enrichment was found. 
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Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000211895 IGHA1 5.674698 0.008564 
ENSG00000230325 5.612619 0.00842 
ENSG00000204922 UQCC3 4.849422 0.014902 
ENSG00000277874 NA 3.915545 0.046671 
ENSG00000171860 C3AR1 3.83263 0.019804 
ENSG00000277336 CCL3L1 3.262052 0.008564 
ENSG00000277796 CCL3L1 3.261793 0.008564 
ENSG00000277768 CCL3L1 3.185079 0.014902 
ENSG00000104408 EIF3E -4.28629 0.014889 
ENSG00000236824 BCYRN1 -4.86716 0.017267 
Table 48: Significantly differentially expressed genes in the CD206+CD163- subset 
in the RA patients compared to the treated RA patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
Continuing with the comparisons of the CD206+CD163- subset across diseases 
found 6 genes upregulated in the RA samples compared to the anti-PD1 samples 
and 5 downregulated with no detectable GO category or KEGG pathway 
enrichment (Table 49). 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000232062 HLA-DQA1 4.76201 0.048233 
ENSG00000105851 PIK3CG 4.444169 0.007808 
ENSG00000231286 HLA-DQB1 4.334007 0.048233 
ENSG00000166501 PRKCB 4.299499 0.048233 
ENSG00000170088 TMEM192 4.255366 0.048233 
ENSG00000163734 CXCL3 3.943253 0.033567 
ENSG00000225496 -3.28804 0.007808 
ENSG00000251632 LINC02172 -3.66572 0.048233 
ENSG00000163815 CLEC3B -4.78911 0.013582 
ENSG00000028839 TBPL1 -4.87909 0.042892 
ENSG00000235033 -5.51636 0.000997 
Table 49: Significantly differentially expressed genes in the CD206+CD163- subset 
in the RA patients compared to the anti-PD1 patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
The comparison of the CD206+CD163- subset between the anti-PD1 samples and 
the treated RA samples detected 20 genes upregulated and six genes 
downregulated in the anti-PD1 subset again with no GO category or KEGG 
pathway enrichment (Table 50). 
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Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000137880 GCHFR 5.973088 0.000206 
ENSG00000278879 5.325296 0.018367 
ENSG00000198756 COLGALT2 5.253338 0.048806 
ENSG00000277287 5.182031 0.020276 
ENSG00000168612 ZSWIM1 5.087848 0.036794 
ENSG00000235033 4.994644 0.013461 
ENSG00000126895 AVPR2 4.963598 0.011044 
ENSG00000241043 GVQW1 4.960956 0.043906 
ENSG00000119729 RHOQ 4.678253 0.037364 
ENSG00000142046 TMEM91 4.539908 0.043906 
ENSG00000230733 4.515823 0.045574 
ENSG00000179598 PLD6 4.479462 0.036794 
ENSG00000246174 KCTD21-AS1 4.422779 0.013461 
ENSG00000245522 4.107623 0.048806 
ENSG00000255441 3.993933 0.048806 
ENSG00000183798 EMILIN3 3.892043 0.048806 
ENSG00000158869 FCER1G 3.857084 0.036794 
ENSG00000137393 RNF144B 3.396949 0.048806 
ENSG00000064601 CTSA 3.053456 0.04918 
ENSG00000225496 3.025847 0.018367 
ENSG00000279687 -3.22937 0.048806 
ENSG00000105373 NOP53 -4.34447 0.036794 
ENSG00000145907 G3BP1 -4.36424 0.048806 
ENSG00000240350 -4.54109 0.048806 
ENSG00000117115 PADI2 -4.60171 0.025721 
ENSG00000237989 LINC01679 -4.96256 0.000206 
Table 50: Significantly differentially expressed genes in the CD206+CD163- subset 
in the anti-PD1 patients compared to the treated RA patients sorted by log2 fold 
change. P values adjusted using the Benjamini-Hochberg method. 
 
5.3.5.1.3 CD206-CD163- population 
Moving on to the DN subset compared between RA and treated RA 62 genes 
were found to be upregulated and 20 down in the RA samples with 16 GO 
categories enriched for in the upregulated genes (Table 51, Table 52). As in the 
comparison of CD206+CD163- subset between RA and treated RA patients 
IGHA1 was the top upregulated gene in the RA samples which could have several 
interpretations including (a) similarities between the CD206+CD163- subset and 
the DN subset, or (b) the possibility that the markers used for the sorting strategy 
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did not isolate pure populations. Using the results of the GO category enrichment 
to guide the interpretation of the DE genes revealed that several GO categories 
for NK cytotoxicity and cell cytotoxicity were enriched for in the genes upregulated 
in the RA samples compared to the treated RA. The presence of several solute 
carrier genes (e.g. SLC25A47) in the DE gene lists suggested that the treatment 
of RA could modulate metabolic pathways within this subset. 
 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000211895 IGHA1 6.974043 0.001877 
ENSG00000213262 VDAC2P3 6.553248 9.63E-06 
ENSG00000280348 6.076781 0.001447 
ENSG00000250295 RDH10-AS1 6.023984 0.026024 
ENSG00000231858 5.982128 0.000378 
ENSG00000167987 VPS37C 5.536398 0.000319 
ENSG00000132464 ENAM 5.518767 0.004158 
ENSG00000101084 C20orf24 5.439185 3.70E-07 
ENSG00000241043 GVQW1 5.428825 0.04139 
ENSG00000186020 ZNF529 5.416118 0.027787 
ENSG00000279232 5.256478 0.026024 
ENSG00000267046 E2F3P1 5.196253 7.43E-06 
ENSG00000011590 ZBTB32 5.101131 0.04139 
ENSG00000140107 SLC25A47 5.026169 0.04356 
ENSG00000120875 DUSP4 5.005842 0.014427 
ENSG00000109943 CRTAM 4.922803 0.000458 
ENSG00000164402 SEPT8 4.898939 0.03063 
ENSG00000257284 4.811731 0.000228 
ENSG00000116685 KIAA2013 4.808939 0.043038 
ENSG00000270956 4.776992 0.004412 
ENSG00000265008 4.708816 0.037796 
ENSG00000076924 XAB2 4.626947 0.029587 
ENSG00000237798 4.62062 0.038523 
ENSG00000228274 4.616442 0.043962 
ENSG00000213445 SIPA1 4.610195 0.017539 
ENSG00000253980 4.540726 0.017539 
ENSG00000111276 CDKN1B 4.527756 0.043758 
ENSG00000089692 LAG3 4.436409 0.000228 
ENSG00000106952 TNFSF8 4.402801 0.036652 
ENSG00000105639 JAK3 4.375774 0.018687 
ENSG00000258869 LINC02312 4.339381 0.001447 
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ENSG00000174255 ZNF80 4.331375 0.036652 
ENSG00000272765 NDUFA6 4.25523 0.020706 
ENSG00000229757 4.176823 4.21E-05 
ENSG00000184983 NDUFA6 4.148222 0.038523 
ENSG00000235300 4.116512 0.034411 
ENSG00000211959 IGHV4-39 4.10428 0.04139 
ENSG00000277365 NDUFA6 4.057473 0.008208 
ENSG00000273397 NDUFA6 4.057473 0.008208 
ENSG00000179256 SMCO3 3.986879 0.014427 
ENSG00000100453 GZMB 3.938109 0.033589 
ENSG00000241511 3.916206 0.034998 
ENSG00000267394 3.886087 0.037796 
ENSG00000111371 SLC38A1 3.810471 0.04139 
ENSG00000231621 3.791735 0.017591 
ENSG00000276410 HIST1H2BB 3.778707 0.001445 
ENSG00000213809 KLRK1 3.755903 0.043758 
ENSG00000267289 3.726481 0.01997 
ENSG00000256705 3.695339 0.012903 
ENSG00000280014 3.639581 0.038523 
ENSG00000250214 3.573027 0.0072 
ENSG00000261188 3.532596 0.004158 
ENSG00000249713 3.460803 0.045842 
ENSG00000213049 HNRNPA1P34 3.318779 0.001357 
ENSG00000253690 3.313296 0.007675 
ENSG00000276173 IGHA2 3.118938 0.025499 
ENSG00000138684 IL21 3.004527 0.003952 
ENSG00000211890 IGHA2 2.963678 0.024684 
ENSG00000267349 2.903838 0.026122 
ENSG00000227777 2.87414 0.010244 
ENSG00000266075 RN7SL574P 2.821571 0.008843 
ENSG00000260810 2.724308 0.034998 
ENSG00000224397 SMIM25 -3.74895 0.037796 
ENSG00000079819 EPB41L2 -3.88235 0.038982 
ENSG00000125355 TMEM255A -3.93978 0.04139 
ENSG00000230729 -3.97282 0.023515 
ENSG00000171700 RGS19 -4.00507 0.043962 
ENSG00000154237 LRRK1 -4.07276 0.026024 
ENSG00000150782 IL18 -4.102 0.035053 
ENSG00000259687 LINC01220 -4.10503 0.021092 
ENSG00000115266 APC2 -4.33038 0.037796 
ENSG00000184014 DENND5A -4.35715 0.04791 
ENSG00000169682 SPNS1 -4.41657 0.014427 
ENSG00000256803 -4.44183 0.020771 
ENSG00000197208 SLC22A4 -4.55919 0.023515 
ENSG00000079691 CARMIL1 -4.63509 0.04139 
ENSG00000182685 BRICD5 -4.66069 0.014427 
ENSG00000101166 PRELID3B -4.84251 0.014427 
ENSG00000091106 NLRC4 -5.1076 0.012261 
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ENSG00000260918 -5.16476 0.004412 
ENSG00000237166 LINC01792 -5.18256 0.000272 
ENSG00000073756 PTGS2 -5.23397 0.004158 
Table 51: Significantly differentially expressed genes in the double negative 
subset in the RA patients compared to the treated RA patients sorted by log2 fold 
change. P values adjusted using the Benjamini-Hochberg method. 
 
GO 
category 
Number 
of DE 
genes in 
category 
Number of 
genes in 
category 
GO term Adjusted p 
value 
GO:0002228 5 24 natural killer cell 
mediated immunity 
0.0004472571 
GO:0045954 4 11 positive regulation of 
natural killer cell 
mediated cytotoxicity 
0.0006305874 
GO:0002717 4 12 positive regulation of 
natural killer cell 
mediated immunity 
0.0007599665 
GO:0001909 5 32 leukocyte mediated 
cytotoxicity 
0.0009850166 
GO:0042269 4 15 regulation of natural 
killer cell mediated 
cytotoxicity 
0.0012826535 
GO:0002715 4 16 regulation of natural 
killer cell mediated 
immunity 
0.0012826535 
GO:0001906 5 36 cell killing 0.0012826535 
GO:0001912 4 16 positive regulation of 
leukocyte mediated 
cytotoxicity 
0.0014491686 
GO:0031343 4 18 positive regulation of 
cell killing 
0.0025256920 
GO:0001910 4 21 regulation of 
leukocyte mediated 
cytotoxicity 
0.0034940440 
GO:0031341 4 23 regulation of cell 
killing 
0.0053411435 
GO:0002703 5 61 regulation of 
leukocyte mediated 
immunity 
0.0089071018 
GO:0002708 4 33 positive regulation of 
lymphocyte 
mediated immunity 
0.0150655636 
GO:0002705 4 36 positive regulation of 
leukocyte mediated 
immunity 
0.0191917170 
GO:0002449 5 87 lymphocyte 
mediated immunity 
0.0398879453 
Table 52: GO biological process categories enriched for in the upregulated genes 
in the double negative subset in RA patients versus treated RA patients. Benjamin-
Hochberg adjusted p value cutoff <0.05. 
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In the comparison of DE genes between the DN subset in RA versus anti-PD1 
arthritis eight genes were detected as upregulated and four as downregulated in 
the RA samples with no GO or KEGG enrichment when Ensembl IDs not from 
the primary genome assembly were excluded (Table 53). Of interest is that the 
genes NDUFA6, IL21, RN7SL574P, and HIST1H2BB were all upregulated in the 
RA samples compared to the anti-PD1 samples. 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000071073 MGAT4A 4.736999 0.012503 
ENSG00000272765 NDUFA6 4.206793 0.041975 
ENSG00000277365 NDUFA6 4.05435 0.012503 
ENSG00000273397 NDUFA6 4.05435 0.012503 
ENSG00000276410 HIST1H2BB 3.81668 0.004999 
ENSG00000150045 KLRF1 3.67763 0.012503 
ENSG00000138684 IL21 2.892027 0.012503 
ENSG00000266075 RN7SL574P 2.824856 0.015266 
ENSG00000237011 -2.43368 0.049778 
ENSG00000232759 -3.13133 0.045849 
ENSG00000227191 TRGC2 -3.71764 0.049778 
ENSG00000065534 MYLK -5.14206 0.041975 
Table 53: Significantly differentially expressed genes in the double negative 
subset in the RA patients compared to the anti-PD1 patients sorted by log2 fold 
change. P values adjusted using the Benjamini-Hochberg method. 
 
In the final comparison of the macrophage subsets, the DN subset in anti-PD1 
arthritis versus treated RA, 31 genes were detected as upregulated and 8 as 
downregulated in the anti-PD1 samples with no GO or KEGG enrichment (Table 
54). Several genes known to be involved in T cell function and regulation were 
found in the upregulated genes such as JAK3, LAG3, TRGC2, and TRGV8, 
however genes such as JAK3 and LAG3 are also expressed by other cell types 
such as NK cells (Huard et al., 1994; Johnston et al., 1994; Kisielow et al., 2005; 
Leonard and O'shea, 1998; Triebel et al., 1990; Workman et al., 2009). With 
regards to the genes higher in the treated RA samples, HAVCR2 could be of 
 272 
 
interest due to its role as an immune checkpoint receptor expressed in T cells 
and cells of the monocyte/macrophage lineage (Anderson, 2014; Hou et al., 
2016; Wang et al., 2017; Yi et al., 2017). 
 
 
 
Ensembl ID HGNC 
symbol 
Log2 fold change Adjusted P value 
ENSG00000279232 6.946044 0.00024 
ENSG00000076770 MBNL3 5.620846 0.032983 
ENSG00000259224 SLC35G6 5.188346 0.049746 
ENSG00000103260 METRN 5.02167 0.038415 
ENSG00000267046 E2F3P1 5.017611 9.29E-05 
ENSG00000111716 LDHB 4.977277 0.049746 
ENSG00000140650 PMM2 4.924903 0.012571 
ENSG00000255220 DDX18P5 4.922501 0.026005 
ENSG00000271774 4.860723 0.048751 
ENSG00000117868 ESYT2 4.82757 0.049746 
ENSG00000235300 4.759529 0.011411 
ENSG00000139626 ITGB7 4.716255 0.034727 
ENSG00000236521 NPAP1P4 4.686774 0.000461 
ENSG00000174255 ZNF80 4.581415 0.034727 
ENSG00000147138 GPR174 4.563711 0.002007 
ENSG00000121989 ACVR2A 4.538956 0.047257 
ENSG00000223965 ZNF587P1 4.524749 0.030015 
ENSG00000047579 DTNBP1 4.422963 0.023003 
ENSG00000105639 JAK3 4.360885 0.037392 
ENSG00000237914 SIRPG-AS1 4.314272 0.037392 
ENSG00000177494 ZBED2 4.239018 0.012063 
ENSG00000258268 4.210758 0.013209 
ENSG00000255518 4.083287 0.000584 
ENSG00000227191 TRGC2 3.993991 0.009495 
ENSG00000258869 LINC02312 3.8239 0.024947 
ENSG00000253690 3.647497 0.004206 
ENSG00000267349 3.586344 0.004206 
ENSG00000089692 LAG3 3.37021 0.037392 
ENSG00000259078 PTBP1P 2.764817 0.041476 
ENSG00000237011 2.43046 0.034727 
ENSG00000211696 TRGV8 2.278121 0.049746 
ENSG00000224397 SMIM25 -3.98236 0.013898 
ENSG00000230729 -4.04974 0.02388 
ENSG00000259687 LINC01220 -4.11006 0.022933 
ENSG00000139146 FAM60A -4.15515 0.049746 
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ENSG00000135077 HAVCR2 -4.32968 0.009495 
ENSG00000118689 FOXO3 -4.44538 0.037392 
ENSG00000118263 KLF7 -4.71123 0.049746 
ENSG00000125355 TMEM255A -4.72355 0.002007 
Table 54: Significantly differentially expressed genes in the double negative 
subset in the anti-PD1 patients compared to the treated RA patients sorted by log2 
fold change. P values adjusted using the Benjamini-Hochberg method. 
 
5.3.5.2 Fibroblast subsets and clinical outcome groups 
The differences between fibroblast subsets across clinical outcome groups were 
of a similar magnitude to those found in the macrophage. The number of 
differentially expressed genes in each comparison can be found in Table 55 with 
the comparison with the largest number of DE genes detected varying depending 
on the fibroblast subset under investigation. CD34+ fibroblasts showed the most 
DE genes between RA and anti-PD1 samples, CD34- between anti-PD1 and 
treated RA samples (although the all comparisons had similar numbers of DE 
genes in this subset), and the CD90-GP38+ subset between the RA and treated 
RA samples. PCA did not find any clear separation of samples according to 
disease grouping in any of the principal components indicating that the variance 
imparted by the disease upon the fibroblast subsets is less distinct than the 
impact upon the macrophage subsets. 
 
CD34+ CD34- CD90-GP38+ 
RA vs Treated RA 42 16 42 
RA vs Anti-PD1 63 20 14 
Anti-PD1 vs Treated RA 12 21 7 
Table 55: Differentially expressed genes between the same fibroblast population 
between different disease stages 
 
5.3.5.2.1 CD34+ population 
Beginning with the comparison of the CD34+ fibroblast subset between RA and 
treated RA samples an interesting pattern could be seen in the upregulated genes 
(Table 56). Both WARS, encoding tryptophanyl-tRNA synthetase, and CH25H, 
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encoding cholesterol 25-hydroxylase, were upregulated in the RA samples and 
are interferon-inducible genes indicating cytokines in the interferon family may 
play an important role in modulating fibroblast gene expression in RA (Buwitt, 
Flohr and Bottger, 1992; Chen et al., 2014; Fleckner, Rasmussen and Justesen, 
1991; Park and Scott, 2010). Of interest is the higher expression of TGFB3-AS1 
in the treated RA CD34+ cells as antisense transcripts have been found to 
negatively regulate the translation of the complementary sense transcript of the 
gene from which they are transcribed through the pairing of the two transcripts 
(Mizuno, Chou and Inouye, 1984; Weiss, Davidkova and Zhou, 1999). No 
enrichment of GO categories or KEGG pathways was found in the eight up- or 34 
down-regulated genes. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000140105 WARS 5.710392 0.010438 
ENSG00000151929 BAG3 5.239385 0.018512 
ENSG00000224468 4.808992 6.00E-06 
ENSG00000227262 HCG4B 4.484109 0.007721 
ENSG00000166226 CCT2 4.442182 0.03524 
ENSG00000236708 4.309059 0.012061 
ENSG00000229702 NA 3.890329 0.000473 
ENSG00000138135 CH25H 3.041684 0.048838 
ENSG00000239882 CYP21A1P -3.18092 0.018456 
ENSG00000231759 CYP21A1P -3.25631 0.007721 
ENSG00000227597 WASF1P1 -3.50633 0.021188 
ENSG00000131116 ZNF428 -4.08139 0.018512 
ENSG00000272140 -4.0906 0.040608 
ENSG00000246627 CACNA1C-AS1 -4.33133 0.048227 
ENSG00000267139 -4.34565 0.021188 
ENSG00000227056 RPL6P2 -4.44317 0.003144 
ENSG00000205056 LINC02397 -4.4467 0.01848 
ENSG00000267226 -4.45933 0.03524 
ENSG00000248138 -4.48368 0.012061 
ENSG00000105583 WDR83OS -4.51596 0.049096 
ENSG00000235397 EPN2-AS1 -4.60567 0.018533 
ENSG00000143473 KCNH1 -4.66878 0.007546 
ENSG00000212443 SNORA53 -4.67212 0.03524 
ENSG00000228170 -4.70031 0.043562 
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ENSG00000197747 S100A10 -4.73344 0.00552 
ENSG00000103550 KNOP1 -4.80978 0.040608 
ENSG00000214688 C10orf105 -4.85536 0.040608 
ENSG00000028116 VRK2 -4.86701 0.007341 
ENSG00000123240 OPTN -4.90493 0.00646 
ENSG00000235079 ZRANB2-AS1 -4.9142 0.049096 
ENSG00000180658 OR2A4 -4.94809 0.000829 
ENSG00000267439 -4.95693 0.006247 
ENSG00000159200 RCAN1 -4.98667 0.00646 
ENSG00000089234 BRAP -5.32195 0.006794 
ENSG00000243896 OR2A7 -5.32928 0.000338 
ENSG00000258876 TGFB3-AS1 -5.41749 0.002008 
ENSG00000255959 -5.45498 0.01848 
ENSG00000224721 -5.49143 0.000219 
ENSG00000166974 MAPRE2 -5.57152 0.000219 
ENSG00000237070 -5.72333 0.00044 
ENSG00000267776 -5.75136 0.002012 
ENSG00000152217 SETBP1 -6.30935 0.000174 
Table 56: Significantly differentially expressed genes in the CD34+ subset in the 
RA patients compared to the treated RA patients sorted by log2 fold change. P 
values adjusted using the Benjamini-Hochberg method.  
 
Comparing the CD34+ subset between RA samples and anti-PD1 patients 15 
genes were found to be upregulated in the RA samples and 48 in the anti-PD1 
samples with no GO/KEGG enrichment in either group. Differential expression of 
genes related to the regulation of extracellular matrix and synovial fluid was 
apparent (Table 57). A key finding from the DE genes in this comparison that is 
of importance to the entire RNA-sequencing dataset and its analysis was the 
higher expression of ZFY; encoding zinc finger protein, y linked; in the RA 
samples and the higher expression of X-inactive specific transcript (XIST), 
encoding X inactive specific transcript, in the anti-PD1 samples. ZFY is located 
on the Y chromosome and hence is a male sex specific gene whereas XIST is 
located on the X chromosome and is critical for inactivation of one of the X 
chromosomes in females and hence can be considered a female sex specific 
gene (Herzing et al., 1997). When comparing the expression of ZFY and XIST in 
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both macrophage and fibroblast samples segregated according to sex this 
pattern could clearly be seen in this dataset (Figure 74). The detected differential 
expression of these genes in the CD34+ RA versus anti-PD1 comparison 
indicated an imbalance in the sex of donors in each disease grouping contributed 
to the variance in the dataset and hence affected analysis of the data. Of the five 
anti-PD1 donors remaining after the sequencing dataset had been cleaned and 
filtered, four were from females whereas of the 11 RA donors three were female 
and eight were male meaning any comparison of any subset between these 
disease groups was confounded by sex specific differences (Table 58). The 
balance of sexes in the treated RA samples was better (three female and two 
male) but the comparison with other disease states will still have been impacted 
due to the relative imbalance in the other states. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000215277 RNF212B 6.09392 0.000362 
ENSG00000223949 ROR1-AS1 5.243877 0.001214 
ENSG00000162231 NXF1 5.077689 0.003668 
ENSG00000224468 4.977171 1.13E-06 
ENSG00000147457 CHMP7 4.722635 0.03345 
ENSG00000236708 4.63318 0.004379 
ENSG00000141644 MBD1 4.582734 0.025356 
ENSG00000273445 4.424191 0.036043 
ENSG00000272430 4.395145 0.01035 
ENSG00000229702 NA 4.147064 0.000198 
ENSG00000171502 COL24A1 4.109887 0.036043 
ENSG00000149646 CNBD2 3.838423 0.036043 
ENSG00000273656 3.556563 0.030381 
ENSG00000067646 ZFY 3.34045 0.031522 
ENSG00000244171 PBX2P1 3.08197 0.030381 
ENSG00000006042 TMEM98 -2.8245 0.024013 
ENSG00000257022 -3.78552 0.006615 
ENSG00000231197 -3.97092 0.034925 
ENSG00000226736 -4.00911 0.031587 
ENSG00000271049 -4.23902 0.045844 
ENSG00000112640 PPP2R5D -4.28978 0.018287 
ENSG00000266094 RASSF5 -4.31797 0.036043 
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ENSG00000267287 -4.42468 0.006615 
ENSG00000101182 PSMA7 -4.53958 0.041507 
ENSG00000107281 NPDC1 -4.56466 0.03345 
ENSG00000139239 -4.57776 0.01035 
ENSG00000131116 ZNF428 -4.58696 0.01035 
ENSG00000261546 -4.66385 0.031587 
ENSG00000237070 -4.69816 0.048001 
ENSG00000246774 ZCCHC23 -4.74936 0.000198 
ENSG00000106511 MEOX2 -4.75829 0.001885 
ENSG00000184162 NR2C2AP -4.77045 0.019001 
ENSG00000214650 -4.77789 0.031326 
ENSG00000268894 PLCE1-AS1 -4.78033 0.031326 
ENSG00000205056 LINC02397 -4.79083 0.018287 
ENSG00000255301 -4.79552 0.024013 
ENSG00000183535 COL18A1-AS1 -4.81706 0.027628 
ENSG00000106665 CLIP2 -4.84624 0.036043 
ENSG00000267139 -4.84634 0.01233 
ENSG00000231606 -4.85901 0.000878 
ENSG00000068912 ERLEC1 -4.86135 0.027628 
ENSG00000259627 -5.04022 0.023695 
ENSG00000237990 CNTN4-AS1 -5.07734 0.006615 
ENSG00000278899 -5.17621 0.031326 
ENSG00000214688 C10orf105 -5.29493 0.018287 
ENSG00000277277 -5.29545 0.00281 
ENSG00000222018 C21orf140 -5.29545 0.00281 
ENSG00000279649 -5.31598 0.023962 
ENSG00000250902 SMAD1-AS1 -5.51104 0.00281 
ENSG00000152217 SETBP1 -5.53329 0.006221 
ENSG00000160716 CHRNB2 -5.54799 0.006887 
ENSG00000115474 KCNJ13 -5.66035 0.018287 
ENSG00000170961 HAS2 -5.72222 0.000198 
ENSG00000260892 -5.75064 0.036043 
ENSG00000078795 PKD2L2 -5.82622 0.001104 
ENSG00000112851 ERBIN -5.82641 0.00281 
ENSG00000248138 -5.86026 0.000198 
ENSG00000212443 SNORA53 -5.97818 0.001214 
ENSG00000279989 -6.04146 0.00281 
ENSG00000227844 NA -6.05468 0.000198 
ENSG00000279364 -6.19595 0.001085 
ENSG00000267776 -6.29024 0.000915 
ENSG00000229807 XIST -7.78495 0.005775 
Table 57: Significantly differentially expressed genes in the CD34+ subset in the 
RA patients compared to the anti-PD1 patients sorted by log2 fold change. P 
values adjusted using the Benjamini-Hochberg method. 
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Figure 74: Log2 counts per million of the ZFY and XIST genes in the macrophage, 
fibroblast, and sequencing control samples grouped according to biological sex. 
Clear differences in expression depending on the sex of the patient were found in 
the expression of these sex specific genes as expected. The sequencing controls 
showed an intermediate level of expression possibly reflecting a mixed donor 
source used to generate the controls. 
 
 Female Male 
RA 3 8 
Treated RA 3 2 
Anti-PD1 4 1 
Table 58: Number of patients of each sex by disease group from which biopsies 
were collected 
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Of the four genes upregulated and the eight genes downregulated in the 
comparison of the CD34+ subset between anti-PD1 and treated RA samples three 
genes were uncharacterised (Table 59). The remaining genes gave an unclear 
view of the differences between disease states. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000150995 ITPR1 5.315765 0.034378 
ENSG00000246774 ZCCHC23 4.709045 0.001332 
ENSG00000267287 4.640226 0.009334 
ENSG00000257022 3.770372 0.028522 
ENSG00000128951 DUT -3.88263 0.028522 
ENSG00000240163 -4.34741 0.046176 
ENSG00000159445 THEM4 -4.39501 0.028522 
ENSG00000227056 RPL6P2 -4.44205 0.009334 
ENSG00000182197 EXT1 -4.79869 0.028522 
ENSG00000154188 ANGPT1 -4.86355 0.009334 
ENSG00000162231 NXF1 -4.89618 0.009334 
ENSG00000100439 ABHD4 -4.93659 0.009334 
Table 59: Significantly differentially expressed genes in the CD34+ subset in the 
anti-PD1 patients compared to the treated RA patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
5.3.5.2.2 CD34- population 
The comparison of the CD34- subset between RA and treated RA samples also 
found a smaller number of DE genes, four genes upregulated in RA samples and 
12 upregulated in treated RA samples of which seven genes were 
uncharacterised (Table 60). As with many of the previous comparisons several 
pseudogenes were detected such as TSPY26P and RPSAP44 and one 
antisense transcript, MTUS2-AS1, was also detected. No GO/KEGG enrichment 
was found in the DE genes and the remaining genes did not appear to have a 
clear disease-related role. In the comparison of the same fibroblast subset 
between RA and anti-PD1 samples 12 genes were detected as upregulated and 
eight as downregulated (Table 61). XIST was once again detected as expressed 
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at higher levels in the anti-PD1 patients reflecting the sex imbalance between the 
two disease groups. The final comparison of CD34- fibroblasts, anti-PD1 samples 
versus treated RA, found 10 genes upregulated and 11 downregulated with no 
GO/KEGG enrichment and a similar lack of apparent immunological genes (Table 
62). The pseudogene TSPY26P was of interest as it was expressed at higher 
levels in the treated RA samples than in the anti-PD1 and also at higher levels 
than the RA samples indicating expression could have been elevated as a result 
of the treatment regime. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000275871 5.176225 0.029009 
ENSG00000261222 5.134074 0.040076 
ENSG00000071282 LMCD1 4.934517 0.033687 
ENSG00000248367 4.016469 0.041791 
ENSG00000235217 TSPY26P -3.59175 0.024403 
ENSG00000204186 ZDBF2 -4.70051 0.027551 
ENSG00000179141 MTUS2-AS1 -4.75304 0.029009 
ENSG00000169826 CSGALNACT2 -4.88309 0.044592 
ENSG00000220773 RPSAP44 -5.18702 0.000924 
ENSG00000163959 SLC51A -5.26855 0.029009 
ENSG00000280239 -5.36272 0.033687 
ENSG00000179909 ZNF154 -5.60247 0.027551 
ENSG00000267610 -5.64299 6.92E-05 
ENSG00000248881 -5.69882 0.029009 
ENSG00000250424 -5.73807 6.92E-05 
ENSG00000166546 BEAN1 -6.19486 0.029009 
Table 60: Significantly differentially expressed genes in the CD34- subset in the 
RA patients compared to the treated RA patients sorted by log2 fold change. P 
values adjusted using the Benjamini-Hochberg method. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000259201 6.6854 0.01393 
ENSG00000196611 MMP1 6.37126 0.01393 
ENSG00000246422 6.1071 0.02152 
ENSG00000119661 DNAL1 5.839298 0.01393 
ENSG00000167291 TBC1D16 5.63874 0.01393 
ENSG00000231340 ACTG1P10 5.593199 0.01393 
ENSG00000213222 5.502951 0.01393 
ENSG00000166848 TERF2IP 5.27065 0.01393 
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ENSG00000270412 5.235594 0.014671 
ENSG00000261222 5.159689 0.02539 
ENSG00000184863 RBM33 4.662555 0.01393 
ENSG00000248367 4.014194 0.027866 
ENSG00000125841 NRSN2 -4.58679 0.01393 
ENSG00000272381 -4.61862 0.02539 
ENSG00000179029 TMEM107 -4.90325 0.035133 
ENSG00000196968 FUT11 -5.16166 0.016876 
ENSG00000233728 -5.26956 0.01393 
ENSG00000279291 NA -5.9103 0.01393 
ENSG00000232630 PRPS1P2 -5.91216 0.017643 
ENSG00000229807 XIST -7.64655 0.027866 
Table 61: Significantly differentially expressed genes in the CD34- subset in the 
RA patients compared to the anti-PD1 patients sorted by log2 fold change. P 
values adjusted using the Benjamini-Hochberg method. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000232630 PRPS1P2 5.838366 0.016858 
ENSG00000101558 VAPA 5.628758 0.003034 
ENSG00000235784 HNRNPA1P29 5.477071 0.002234 
ENSG00000164708 PGAM2 5.409667 0.012965 
ENSG00000233728 5.268614 0.011854 
ENSG00000101109 STK4 5.255165 0.007151 
ENSG00000129562 DAD1 4.599511 0.033735 
ENSG00000205108 FAM205A 4.345098 0.012004 
ENSG00000170265 ZNF282 4.26553 0.020164 
ENSG00000279891 3.651538 0.044487 
ENSG00000235217 TSPY26P -3.59335 0.007151 
ENSG00000231084 -3.61279 0.033735 
ENSG00000020129 NCDN -4.18743 0.035143 
ENSG00000243230 -4.27197 0.007151 
ENSG00000264714 -4.67001 0.016858 
ENSG00000204186 ZDBF2 -4.99886 0.012004 
ENSG00000267610 -5.05299 0.000681 
ENSG00000263179 HNRNPCP4 -5.09903 0.033735 
ENSG00000246731 -5.21062 0.035424 
ENSG00000178988 MRFAP1L1 -6.01414 0.000241 
ENSG00000254898 -6.399 0.000798 
Table 62: Significantly differentially expressed genes in the CD34- subset in the 
anti-PD1 patients compared to the treated RA patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
 
 282 
 
5.3.5.2.3 CD90-GP38+ population 
Investigation of the final subset, CD90-GP38+, in RA compared to anti-PD1 found 
five upregulated and nine downregulated genes with no GO/KEGG enrichment. 
The gene KHK, encoding ketohexofructose/fructokinase, was expressed at 
higher levels in the anti-PD1 samples than the RA in this subset indicating a 
difference in the fructolysis pathway may have been elicited by either disease 
state. Differences in the metabolism of glucose could also be present between 
RA and the anti-PD1 arthritis samples as RRAD has been shown to inhibit 
glucose uptake and was expressed at higher levels in the RA samples 
(Bustamante et al., 2017; Garcia-Carbonell et al., 2016). The increase in RRAD 
expression was also found in the comparison of the CD90-GP38+ subset between 
RA and treated RA patients with higher levels in the RA samples again (Table 
64). In this comparison 11 genes were found to be upregulated in the RA samples 
and 31 upregulated in the treated RA samples. An important finding of this 
comparison was the increased expression of TNFRSF10B, encoding 
TRAILR2/Death Receptor 5 (DR5), in the treated RA samples. A final DE gene 
of interest found at higher levels the treated RA samples was NDUT6. NDUT6 is 
transcribed from the antisense strand of the FGF2 gene and therefore may 
actually be involved in the downregulation of FGF2 protein expression which has 
been demonstrated as detrimental in arthritides (Manabe et al., 1999; Nakano et 
al., 2004; Yamashita et al., 2002). 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000107551 RASSF4 6.38104 0.000558 
ENSG00000279465 5.648922 0.04831 
ENSG00000177409 SAMD9L 5.462681 0.04831 
ENSG00000140391 TSPAN3 5.335383 0.04831 
ENSG00000166592 RRAD 5.177511 0.03631 
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ENSG00000138030 KHK -4.24968 0.04831 
ENSG00000227660 UST-AS1 -4.31555 0.03631 
ENSG00000204186 ZDBF2 -4.32309 0.04831 
ENSG00000076053 RBM7 -4.47211 0.03631 
ENSG00000247728 -4.8814 0.04831 
ENSG00000173113 TRMT112 -4.98429 0.031455 
ENSG00000254693 -5.21715 0.031455 
ENSG00000235347 -5.24634 0.04831 
ENSG00000273747 -6.07678 0.009519 
Table 63: Significantly differentially expressed genes in the CD90-GP38+ subset in 
the RA patients compared to the anti-PD1 patients sorted by log2 fold change. P 
values adjusted using the Benjamini-Hochberg method. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000019582 CD74 5.809231 0.019917 
ENSG00000186283 TOR3A 5.704267 0.029681 
ENSG00000279465 5.608922 0.024836 
ENSG00000131746 TNS4 5.534926 0.024836 
ENSG00000109323 MANBA 5.515379 0.019917 
ENSG00000115282 TTC31 5.335068 0.036245 
ENSG00000256928 5.179047 0.036245 
ENSG00000166592 RRAD 5.112516 0.018782 
ENSG00000104325 DECR1 5.050201 0.011237 
ENSG00000171067 C11orf24 4.616714 0.035995 
ENSG00000137992 DBT 4.276096 0.034103 
ENSG00000176490 DIRAS1 -3.01715 0.024633 
ENSG00000237207 RBM17P3 -3.50673 0.011237 
ENSG00000212747 RTL8B -3.58364 0.017821 
ENSG00000203778 FAM229B -3.74214 0.024836 
ENSG00000274547 -3.84599 0.000624 
ENSG00000036672 USP2 -3.8655 0.032039 
ENSG00000262558 -3.91177 0.024836 
ENSG00000166780 C16orf45 -4.01378 0.030371 
ENSG00000114698 PLSCR4 -4.12779 0.047509 
ENSG00000104067 TJP1 -4.13242 0.034103 
ENSG00000226430 USP17L7 -4.15655 0.024836 
ENSG00000273611 ZNHIT3 -4.16221 0.024836 
ENSG00000274415 -4.20084 0.015406 
ENSG00000245060 LINC00847 -4.25868 0.017821 
ENSG00000250424 -4.26814 0.029196 
ENSG00000278574 ZNHIT3 -4.30119 0.019917 
ENSG00000123243 ITIH5 -4.33992 0.024836 
ENSG00000106341 PPP1R17 -4.40834 0.024836 
ENSG00000277401 TJP1 -4.44113 0.041702 
ENSG00000173511 VEGFB -4.4705 0.024836 
ENSG00000237070 -4.54554 0.039511 
ENSG00000103024 NME3 -4.6088 0.011237 
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ENSG00000236287 ZBED5 -4.70481 0.028914 
ENSG00000143570 SLC39A1 -4.73114 0.011237 
ENSG00000120889 TNFRSF10B -4.87225 0.009013 
ENSG00000248664 -5.15086 0.044061 
ENSG00000151743 AMN1 -5.20813 0.004862 
ENSG00000097033 SH3GLB1 -5.32562 0.005828 
ENSG00000091317 CMTM6 -5.35686 0.004335 
ENSG00000254693 -5.65329 0.00254 
ENSG00000170917 NUDT6 -6.09343 0.000361 
Table 64: Significantly differentially expressed genes in the CD90-GP38+ subset in 
the RA patients compared to the treated RA patients sorted by log2 fold change. 
P values adjusted using the Benjamini-Hochberg method. 
 
The final comparison of fibroblast subsets was of the CD90-GP38+ subset in anti-
PD1 arthritis patients compared to treated RA patients. In this comparison two 
genes were upregulated, both of which were uncharacterised, in the anti-PD1 
samples and five genes were upregulated in the treated RA samples (Table 65). 
Of the five genes higher in the treated RA samples four were characterised, 
however, with the exception of the aforementioned NDUT6 (FGF2 antisense) the 
interpretation of these genes in the context of this work was unclear. 
 
Ensembl ID HGNC symbol Log2 fold change Adjusted P value 
ENSG00000273747 6.077605 0.004314 
ENSG00000258012 5.292796 0.027492 
ENSG00000176490 DIRAS1 -3.02651 0.029015 
ENSG00000267986 -3.80091 0.029015 
ENSG00000189320 FAM180A -3.93847 0.007624 
ENSG00000170917 NUDT6 -5.25461 0.024516 
ENSG00000135299 ANKRD6 -5.42767 0.020564 
Table 65: Significantly differentially expressed genes in the CD90-GP38+ subset in 
the anti-PD1 patients compared to the treated RA patients sorted by log2 fold 
change. P values adjusted using the Benjamini-Hochberg method. 
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5.4 Discussion 
In the work in this chapter samples from untreated RA patients, RA patients with 
inadequate responses to methotrexate, and cancer patients treated with anti-PD1 
agents who had subsequently developed arthritis were collected and 
cryopreserved before digesting the samples, cell sorting fibroblast and 
macrophage populations, and isolating the RNA from the populations. It is 
important to remember that all of these samples were taken from patients with 
actively inflamed joints, and a significant degree of global disease activity; there 
is therefore no “uninflamed” control, and it is possible that subtle differences 
between disease groups, for instance, could be obscured by genes involved in 
the inflammatory response. To some extent this is unavoidable as biopsy of 
minimally inflamed joints is a developing technique. The proportions of stromal 
populations, in particular the CD34- subset, correlated with ESR and synovial 
hypertrophy. RNA-sequencing of fibroblast populations found few clear 
differences in function between subsets or disease group, however it did discover 
differences of possible interest between disease groups. Sequencing of 
macrophage populations identified a CD206+CD163+/- subset and a CD206-
CD163- mixed lymphocyte population. 
 
Investigating the genes expressed at higher levels in the CD206+CD163+ subset 
than the DN subset confirmed the suspected macrophage identity of the subset 
with complement genes such as C1QB, C2, and C1QA, scavenger receptor 
genes such as COLEC12 and MARCO, and other genes such as SIGLEC1, 
CD14, MERTK, and TGFB1 all significantly higher in this subset (Baeten et al., 
2000; Baeten et al., 2004; Canton, Neculai and Grinstein, 2013; De Ceulaer, 
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Papazoglou and Whaley, 1980; Hartnell et al., 2001; Hartung and Hadding, 
1983). The finding of significant expression of MERTK is of interest in the context 
of work that suggested expression of MERTK can be used to discriminate 
macrophages from dendritic cells and identify tissue-resident macrophage 
populations (Gautier et al., 2012; Xue et al., 2014a).  
 
Investigation of the genes upregulated in the DN subset compared to the double 
positive indicated the cells are heterogeneous and displayed little evidence of a 
macrophage phenotype. The genes alluded towards the presence of two main 
cell populations within the CD45+HLA-DR+CD206-CD163- group with the 
expression of NGK7, CD8A, CD3G, CD3E, and CD3D all hinting at a cytotoxic T 
lymphocyte identity (Alarcon et al., 1988; Hidalgo et al., 2008; Turman et al., 
1993). The other cell type present in the population seemed to be B lymphocytes 
identified by the expression of the immunoglobulin genes IGHG3 and IGHM and 
the gene JCHAIN which encodes a protein involved in IgM secretion (Johansen, 
Braathen and Brandtzaeg, 2000). Two interesting points can be made from the 
expression of these genes, (1) the expression of IGHG3 suggested that IgG3 is 
being produced by these cells and production of this isotype is known to be 
stimulated by IFNγ suggesting this cytokine is involved in RA, and (2) the 
expression of IGHM and JCHAIN suggested that IgM is being secreted which is 
of importance given the dominance of this isotype in the pool of rheumatoid factor 
antibodies present in RA patients (Gioud-Paquet et al., 1987; Snapper et al., 
1992). 
 
The expression of a gene well known in the cancer field, CAV1 encoding the 
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caveolin-1 protein, was higher in the CD90-GP38+ fibroblast subset than in the 
CD34+ cells as was the expression of CTSK, encoding cathepsin K. Caveolin-1 
is used as a biomarker in the study of many cancers as downregulation of the 
protein in tumour stroma is associated with a poor prognosis (Simpkins et al., 
2012; Sloan et al., 2009; Sotgia et al., 2011; Witkiewicz et al., 2009). Cathepsin 
K could clearly be involved in the pathogenesis of RA given the degradative 
nature of the enzyme and is elevated in the serum of RA patients, is correlated 
with radiological progression, and genetic knockout of the gene in a murine 
arthritis model improves inflammation, bone erosion, and cell infiltration (Hao et 
al., 2015; Skoumal et al., 2004). When comparing the CD34+ subset between RA 
and anti-PD1 samples it was apparent that the regulation of extracellular matrix 
and synovial fluid constituents was different between the disease states either as 
a result of the anti-PD1 treatment or due to differences in the pathogenesis of the 
ailments. COL24A1, COL18A1-AS1, and HAS2 were all differentially expressed 
in this comparison with the first gene higher in the RA samples and the second 
and third higher in the anti-PD1 samples.  
 
Investigating subset differences it appeared that the CD90-GP38+ subset may 
have a more degradative role than the other two subsets, particularly the CD34+ 
subset. Recent work identifying stromal subsets in RA and OA patients provides 
somewhat similar results to the findings here. Mizoguchi et al. (2017) found that 
CD34-CD90- synovial fibroblasts had higher MMP1 production in response to 
TNFα stimulation than the other subsets, a finding similar with to the work above 
except the CD34- population in this thesis was defined as CD90+. The study also 
found that the CD34+ stromal cells expressed higher levels of IL-6 and CXCL12 
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when stimulated with TNFα and that the CD34+CD90+ subset, which would match 
the population in this thesis, had higher levels of RANKL expression than the 
other subsets. 
 
An important issue with the RNA-sequencing dataset was highlighted by the 
detection of differential expression of the sex-linked genes ZFY and XIST 
between the CD34+ subset in the RA and anti-PD1 samples. The ratio of female 
to male samples in the anti-PD1 samples was skewed towards female with only 
one of the five anti-PD1 patients being male. This influenced the findings of 
comparisons with these samples as the differences being detected could actually 
have been due to sex rather than due to the disease states. Although several 
computational methods exist to correct for unwanted variation in large datasets 
the viability of using a method on data with such a severe bias and relatively low 
replicates is questionable and may affect the validity of the results in other ways 
(Johnson, Li and Rabinovic, 2007; Leek, 2014; Leek and Storey, 2007; 2008). 
Therefore it is important to keep in mind that some of the differentially expressed 
genes detected in the analysis are probably due to sex differences. 
 
Although the findings in this chapter show some interesting differences in gene 
expression both between fibroblast or macrophage subsets and within subsets 
between disease groups improvements could be made to greatly increase the 
robustness and possibly the number of significant findings in the RNA-
sequencing dataset. To improve the utility of the dataset more samples would 
need to be sequenced both to increase the number of samples in each disease 
group but also aid in the balancing or even computational removal of sex 
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differences to reduce the impact of this on variation in the data. An larger number 
of samples were not sequenced to begin with for two reasons; (1) time constraints 
and the need to develop a digestion protocol prior to sample collection limited the 
number of samples that could be collected, and (2) RNA-sequencing is costly and 
although Novartis completed the sequencing resources were still transferred to 
facilitate this. 
 
As sequencing control samples were included in the sequencing then, so long as 
the sequencing controls were included in any subsequent sequencing batches, 
batch correction would be possible to allow merging of the experiments. The 
inclusion of more samples would improve the power of statistical analyses, a 
necessary improvement as the number of samples in the final analysis was low. 
A larger sample number in each group would allow the use of algorithms such as 
comBat or surrogate-variable analysis to correct for unwanted sources of 
variation (Johnson, Li and Rabinovic, 2007). Another improvement to the dataset 
would be to add a ‘normal’, uninflamed control to the dataset so comparisons can 
be made to a non-diseased sample group. 
 
For many of the comparisons small numbers of DE genes were detected with 
many genes being non-protein coding or uncharacterised. This casts doubt upon 
the robustness of these findings, particularly given the low number of samples in 
each group. If the differential expression of these genes was successfully 
validated then the biological significance would still be unclear as it is not possible 
to assign gross functional differences on the basis of such a small number of 
genes. In addition changes in the expression of genes does not always correlate 
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with changes in protein expression due to numerous post-transcriptional and 
post-translational regulatory mechanisms. 
 
For the identification of cellular subsets, in particular the macrophage subsets, it 
could be argued that a targeted approach using pre-defined markers is a naïve 
method to identify the full spectrum of subsets. Given enough funds and time, 
bar-coded single-cell sequencing using platforms such as 10x could have been 
a better approach to address this due to the unbiased nature of the technique 
and would not only allow identification of macrophage subsets but also 
investigation of the genes expressed in each subset as attempted in this work. 
One issue consistently encountered during the establishment of a suitable panel 
of cell surface markers for sorting was the limited number of channels available. 
This was confounded by the small quantity of synovial biopsy tissue collected 
which prevented the use of the material in two separate sorts with more 
expansive stromal or macrophage panels. Using single cell sequencing one could 
sort broad populations such as CD45-CD235a-CD326- stromal cells and CD45+ 
hematopoietic cells and use unsupervised cluster analysis to identify the sub-
populations. 
 
Finally, whilst the investigation of synovial cellular population data using the flow 
cytometry uncovered interesting correlations and differences it was all tested 
using proportions of cells rather than cell counts. This can make the interpretation 
of the data complex as changes in the proportion of one cell type will obviously 
affect the proportions of others whereas in reality it could be changes in the 
number of cells of one or more populations eliciting this effect. To account for this 
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effect further data should be collected whilst also noting the weight of tissue prior 
to digestion and also using counting beads to obtain accurate cell counts from 
flow cytometry data. This would allow the calculation of normalised cell counts 
which in turn would allow clearer interpretation of the results. 
 
In summary synovial fibroblast and macrophage populations were identified by 
immunofluorescent staining of tissue sections and synovial cell suspensions. A 
protocol was established to allow uniform cryopreservation and digestion of 
synovial tissue across sites which facilitates comparisons between results. The 
protocol allowed the isolation of both fibroblast and macrophage populations. 
Fibroblast populations showed dynamic changes and appeared to expand with 
inflammation and immune cell infiltration into the synovium. Macrophages and a 
mixed lymphocyte population changed in proportion in different disease stages 
with RA having a higher proportion of the lymphocyte population than anti-PD1 
induced arthritis patients and the opposite relationship displayed for 
CD206+CD163+ macrophages. The isolation of these populations from synovial 
biopsy material provided enough material for bulk RNA-sequencing. The findings 
of the RNA-sequencing dataset revealed that the CD206+CD163+ macrophage 
population had a scavenging phenotype, the CD206-CD163- population in RA 
appeared to be enriched for cytotoxic T cells and IgM secreting B cells, and 
synovial fibroblasts displayed differences in phenotype both between subsets 
and between disease stages however the magnitude and relevance of the 
differences in both cases was not large. 
 
The work in this chapter only partially addressed the third aim in section 1.9 that 
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different fibroblast and macrophage subsets exist within the synovium with 
distinct functions. The presence of different fibroblast subsets was demonstrated 
by staining of synovial tissue sections and cell suspensions and the subsequent 
RNA-sequencing data, however no clear functions could be assigned to the 
subsets using this dataset. Although 3 putative macrophage populations were 
identified in the synovial cell suspensions only the CD206+CD163- and 
CD206+CD163+ populations appeared to be macrophages and very few 
differences were detected between these populations meaning they may actually 
represent a very similar, if not identical, population which fails to prove that 
different macrophage populations exist in the synovium. 
 
The finding of MERTK expression in the CD206+CD163+ macrophage population, 
along with the expression of macrophage markers CD14 and SIGLEC1, adds 
further evidence to the postulated tissue-resident macrophage identity of these 
cells as suggested by the flow cytometry data in chapter 4. In addition, the 
expression of genes associated with scavenger functions (MARCO, COLEC12), 
and tissue remodelling (TGFB1) cast the CD206+CD163+ population as an anti-
inflammatory macrophage as hinted by the expression of CD206 and CD163. It 
is of particular interest that the CD206+CD163+ population constitutes a 
significantly higher proportion of the CD45+HLA-DR+ population in anti-PD1 
induced arthritis than in RA. Unfortunately it is not yet clear if anti-PD1 arthritis is 
an acute ailment or if it can develop into a chronic arthritis. If the former case is 
found true it is enticing to speculate that the higher proportion of tissue-resident 
macrophages may facilitate the resolution of inflammation whereas the number 
of tissue-resident macrophages is reduced in RA and as such results in 
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inadequate resolution. 
 
The finding that the stromal CD90+GP38+CD34- population significantly 
correlates with inflammation and synovial hyperplasia in the RA samples is 
particular incriminating. Using the immunofluorescence data to assign locations 
to these subsets leads to the CD90+GP38+CD34+/- subsets appearing to be 
sublining subsets whereas the CD90-GP38+ subset represents lining layer 
fibroblasts. The expression of the gene encoding the adhesion molecule CDH23 
at higher levels in the CD90-GP38+ subset provides further evidence that this 
population represents the lining layer, a region of the synovium which is tightly 
associated and dependent upon cadherin expression for this function (Kiener et 
al., 2009; Lee et al., 2007). It could be postulated that the sublining CD34- cells 
drive inflammation in the RA synovium given the correlations, however the gene 
expression data did not detect clear pro-inflammatory cytokines as being 
enriched in this subset. Both the sublining CD34- population and the lining layer 
population express MMP1 meaning both populations are capable of degrading 
collagen, a key pathological finding in RA. The CD34+ population shows signs of 
regulating cell infiltration into the synovium as these fibroblasts express higher 
levels of ACKR3 which is known to bind to CXCL12 and CXCL11 but it is not 
clear if this induces signalling or not (Burns et al., 2006). This may sequester 
available CXCL12 and CXCL11 inhibiting cell infiltration into the joint or 
alternatively generate a chemokine gradient to facilitate increased infiltration into 
the joint. Additionally the CD34+ subset expresses CTSK, an alternative matrix 
remodelling enzyme to MMP1 but one in which overexpression in murine models 
has been shown to result in joint damage and synovitis again demonstrating the 
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destructive capacity of the fibroblast subpopulations (Morko et al., 2005). Whilst 
the functions of fibroblast subsets appear somewhat overlapping there is 
evidence that the method by which these functions are achieved are differs in 
each subset. This would be relevant to therapeutics targeting fibroblast 
populations as targeting MMP1 expressing subsets for example may not 
successfully prevent joint destruction due to expression of CTSK by the CD34+ 
subset. 
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6 CONCLUDING REMARKS 
Three hypotheses were postulated and tested during this body of work. The first 
hypothesis, that fibroblasts isolated from different stages of RA progression 
differentially modulate monocyte or macrophage phenotype in vitro, was unable 
to be proven and as such the null hypothesis was accepted. Although the cultured 
fibroblast lines were unable to differentially modulate the phenotype of monocytes 
and macrophages according to the stage of RA from which the lines were isolated 
a coordinated modulation of cytokine production was elicited by co-culture of 
monocytes and fibroblasts regardless of disease stage (Figure 75). The 
modulation appeared to be a rapid event occurring within 24 hours of the initiation 
of co-culture, was cell contact in-dependent, and resulted in the regulation of 
cytokines and chemokines. Fibroblasts also appear to be able to influence to 
differentiation of monocytes into macrophages. This section of work confirmed 
published findings regarding fibroblast and monocyte interactions and contributes 
to the field by discovering that fibroblast disease stage does not affect the 
interactions. 
 
 
Figure 75: Co-culture of synovial fibroblasts and monocytes/macrophages does 
not result in differential modulation dependent upon the stage of RA from which 
the fibroblasts were isolated. However, co-culture does result in the modulation of 
the release of IL-6, CXCL10, VEGF, CCL2, CCL4, and CCL5 amongst others from 
the co-cultured cells. 
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The second hypothesis that different fibroblast and macrophage subsets exist 
within the synovium with distinct functions was partially proven although 
insufficient evidence was gathered to complete the testing of fibroblast and 
macrophage functions or to demonstrate the existence or lack of various synovial 
macrophage subsets. Using immunofluorescence staining both fibroblast and 
macrophage populations were identified in sections of synovial tissue with data 
generated by this work being included in and leading to publications (Choi et al., 
2017; Croft et al., 2016; Misharin et al., 2014). In order to further analyse these 
populations a digestion protocol for the isolation of cells from synovial biopsy 
material was established in collaboration with members of the NIH AMP 
consortium, and this collaborative work is now being developed into two 
manuscripts for publication, one in review following resubmission after comments 
with partial data in a pre-publication repository (Mizoguchi et al., 2017). The 
protocol was then used to identify the stromal and macrophage populations in the 
synovium and to sort cells and isolate RNA for RNA-sequencing. The flow 
cytometry data generated during the cell sorting process identified significant 
correlations of RA fibroblast populations with inflammatory markers and 
differences in the proportion of leukocyte cells between RA and other arthritic 
diseases. A significant portion of these data form part of the current submission 
under review (Mizoguchi et al., 2017). The RNA-sequencing process was 
challenging given the low number of cells isolated for each population but yielded 
data of adequate quality for analysis. Subset analysis found differentially 
expressed genes between fibroblast subsets but provided no clear picture of 
functional differences. In the macrophage populations two populations were very 
similar with regards to gene expression but one sorted cell population appeared 
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to be a mixed leukocyte population. Differences in subsets between disease 
groups were present but did not provide a clear idea of functional differences. 
This section of work significantly contributed to the discovery and examination of 
fibroblast subsets in the synovium both through the development of a unified 
digestion protocol and through initial studies of subset differences in RA and other 
diseases (Figure 76). Contributions were also made towards the study of synovial 
macrophage populations with the RNA-sequencing of a definitive macrophage 
population. 
 
 
Figure 76: Synovial fibroblasts can be separated into at least three subpopulations 
and synovial macrophages appear to exist as two subpopulations. Synovial cell 
subpopulations can be identified by flow cytometry and show significant 
differences in gene expression as measured by RNA-sequencing. 
 
Considerable evidence was found in support of the third hypothesis that 
fibroblasts isolated from different stages of RA progression maintain differential 
gene expression during in vitro co-culture and respond to stimuli in different ways. 
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Analysis of new microarray data, building on data generated by a previous 
student using fibroblast lines from different clinical outcome groups including 
different stages of RA progression with different stimuli and culture conditions 
found a large number of differentially expressed genes between disease stages 
in each treatment group. Differences in stromal subset markers were identified 
that validate the findings of flow cytometry and tissue staining data and 
highlighted a potential marker of very early RA that could be used alongside other 
novel biomarkers to stratify early disease. 
 
This body of work has considerably expanded the knowledge regarding synovial 
fibroblasts and macrophages in RA and has opened new avenues to search for 
therapeutics. It was known that fibroblasts from late stage RA possess an 
‘imprinted aggressor’ phenotype characterised by increased pro-inflammatory 
cytokine production and increased invasion and degredation of cartilage, 
however the point during RA progression at which the imprinting occurs is not 
known (Bottini and Firestein, 2013; Whitaker et al., 2013). The microarray data 
herein found that whilst fibroblasts cultured from the synovium of patients with 
resolving arthritis and very early RA both show differential gene expression when 
compared with fibroblasts from uninflamed joints there were no differentially 
expressed genes between the two groups, but differentially expressed genes 
were detected between the resolving arthritis and established RA or joint 
replacement RA groups. This indicates that the imprinted phenotype published in 
the literature may not occur during the intial stages of RA when symptoms first 
appear. This in turn may explain the therapeutic window seen whereby patients 
treated within the first three months of symptom onset have an improved disease 
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course with less joint destruction; it could be reasoned that the fibroblasts are 
more amenable to treatment during this early period before the imprinted 
phenotype is truly established. It would be pertinent to compare the differentially 
expressed genes between very early RA samples and the established RA and 
joint replacement RA samples and also between the resolving arthritis samples 
and the two later RA groups to assess if there are any genes common to the two 
lists that may explain the imprinted phenotype. 
 
The data obtained on fibroblast-monocyte/macrophage co-cultures found no 
statistically significant difference between co-cultures with fibroblasts from 
different stages of RA with regards to secreted factors or gene expression. 
Regardless co-cultures with either monocytes or differentiating macrophages 
influenced protein and gene expression in both cases demonstrating the 
capability of fibroblasts to regulate the immune response. Of particular interest 
was the ability of fibroblasts to downregulate TNF and IL10 expression in 
differentiating macrophages insinuating that synovial fibroblasts in the absence 
of exogenous factors elicit an anti-inflammatory phenotype from monocyte 
derived macrophages and can skew monocyte differentiation. This is somewhat 
suprising given the literature surrounding the pro-inflammatory phenotype of RA 
synovial fibroblasts. It may be that imprinted fibroblasts do not just drive 
aggressive disease mechanisms but still retain some features of maintaining 
homeostasis in the joint and the balance between the two has shifted in RA 
fibroblasts and is overwhelmed in inflamed joints. It was not investigated within 
this body of work but the interactions between fibroblasts and monocytes or 
macrophages in the presence of exogenous proinflammatory factors is of 
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significant interest, given the elements of regulation of inflammation displayed in 
the co-cultures it may be that in the presence of TNFα, for example, this vestige 
of regulation is lost and instead fibroblasts elicit an overtly inflammatory 
phenotype from monocytes and macrophages. Although no significant 
differences were found slight trends towards reduced inflammatory responses 
were seen in co-cultures with resolving fibroblasts. This should be further 
investigated as if proved true it would increase the resolution with which we can 
identify the point at which synovial fibroblasts become imprinted in RA which in 
turn could inform treatment regimes. 
 
The work in chapters 4 and 5 demonstrated the existence of separate fibroblast 
subsets within the synovium beyond the distinction between lining and sublining 
layer. Of particular interest was the finding that the CD34- sublining population 
was significantly positively correlated with both systemic inflammation but also 
synovial hyperplasia, indicating a large portion of the expansion of the synovium 
during RA may be due to this population. This is in contrast to previous findings 
indicating that the lining layer is expanded and responsible for joint destruction in 
RA (Kiener et al., 2006; Kiener et al., 2009; Lee et al., 2007). The evidence 
demonstrates a discord between joint damage and inflammation with one state 
not necessarily accompanying the other. This can be explained by the hypothesis 
that the different fibroblast subpopulations drive different aspects of RA, for 
example the CD34- subset may drive inflammation whereas the CD90-GP38+ 
subset is responsible for destruction of the joint architecture. It would be 
interesting to return to the literature identifying different subtypes of RA, such as 
fibroid, lymphoid, or myeloid, with fibroblast subsets in mind and quantify the size 
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and activity of each subset in each subtype (Dennis et al., 2014). This could lead 
to a stratified medicine approach in RA with the subtype identified dictating which 
fibroblast subpopulation will be targeted. 
 
In addition to the fibroblast subsets identified putative tissue-resident 
macrophages were identified in the synovium on the basis of CD206, CD163, and 
MerTK expression. It is not yet known if tissue-resident macrophages exist in the 
synovium however MerTK has been identified as a marker of tissue-resident 
macrophages and was expressed by the CD206+CD163+ macrophages identified 
herein (Gautier et al., 2012). Identifying tissue-resident macrophages in humans 
is difficult and as such the work is normally completed by fate-mapping in animal 
models, however one approach to confirm the residence and self-replenishing 
nature of the CD206+CD163+ population within the synovium could be to recruit 
patients who have undergone bone marrow transplants and through repeat 
biopsies and genetic typing measure the contribution of donor monocytes to the 
synovial macrophage pool. The genes expressed by the CD206+CD163+ 
population were indicative of an anti-inflammatory phenotype meaning this 
population could be responsible for maintaining homeostasis within the joint. 
Given the higher proportion of this population in the anti-PD1 induced arthritis 
patients than RA this may be one mechanism by which inflammation becomes 
chronic in RA, through a reduction in the number of tissue-resident macrophages 
in the synovium. In terms of therapeutics, targeting only monocytes and 
supporting tissue-resident macrophages may promote remission in RA patients 
as opposed to therapies targeting both cell types together. 
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In summary, this thesis has expanded knowledge of cellular subsets within the 
synovium in RA and on the phenotype of synovial fibroblasts during RA 
progression. Several avenues of investigation show promise as possible 
sources of new targets for therapeutics in RA and also may aid in the 
development of stratified treatments depending upon the subtype of RA with 
which patients present. 
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7 FUTURE WORK 
Although the work in this thesis has addressed most of the hypotheses postulated 
further work should be completed both to improve the integrity of the data and 
findings so far and to validate and expand upon the initial findings. Future work 
for the co-cultures includes: 
 Assess the impact of TNFα and IL-10, due to the clear pro- and anti-
inflammatory effects of these cytokines, upon fibroblast:monocyte co-
cultures. 
 Investigate fibroblast:monocyte co-cultures after 24 hours to test for 
disease specific differences in the temporality of cytokine/chemokine 
release. 
 Identify the sources of cytokines released during co-culture either through 
the using of secretion blocking agents such as Brefeldin A or through 
mRNA analysis. 
 Co-culture freshly sorted synovial fibroblast subsets or macrophages and 
assess IL-6 and MMP1 production. 
Future work for the synovial digestion and RNA-sequencing work: 
 The protocol optimisation work requires an increase in sample size 
particularly in the fresh versus frozen digestion comparisons. 
 Rather than using population proportions in the flow cytometry data for the 
protocol optimisation and the sample digestions for RNA-sequencing 
counting beads will be used to allow measurement of absolute cell count 
and normalising to tissue weight to be more accurate. 
 The sample size in all groups will be increased by sequencing more 
samples and correcting for batch effects using the sequencing controls. 
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This will increase the power of the statistical tests to detect differentially 
expressed genes and increase confidence in the current results. 
 Adding the BEACON cohort disease outcome groups to the RNA-
sequencing dataset will allow comparison of fibroblast and macrophage 
subsets across disease stages, a comparison not possible in the 
microarray dataset. 
 The results of the RNA-sequencing analysis requires validation by qRT-
PCR or by functional assays to determine if clear functional readouts can 
be assigned to the genes. To this end basal and stimulated MMP1 
production from fibroblast subsets will be measured and the metabolic 
state of fibroblast subsets from outcome groups will be measured using a 
Seahorse XF analyser. 
 Fibroblasts and macrophage subsets must be sorted and in vitro cultures 
established. This is to allow validation of the RNA-sequencing findings 
regarding gene expression and functional phenotype and to address the 
question of longevity of subsets i.e. do the subsets maintain gene and 
marker expression over several passages in culture or do they progress 
towards a single phenotype. The longevity of fibroblast subsets will be 
assessed using RNA-sequencing and flow cytometry analysis of the 
subsets at each passage. 
Future work for the microarray analysis: 
 As with the RNA-sequencing experiments the results of the microarray 
must be validated through qRT-PCR of gene expression of through 
functional assays. The expression of FOS family members in Jrep 
fibroblasts, histone H1 family members in the normal samples, and subset 
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markers CD34 and FAP in all outcome groups will be measured. 
 Present synovial fibroblast cultures generated from the BEACON cohort 
will be tested for the presence of subset markers using flow cytometry to 
address the questions raised by the microarray data regarding the homo-
/heterogeneity of cultured synovial fibroblast lines. 
Two first author publications will be generated using the work in this thesis: 
 The microarray data will be used to address the hypothesis that 
fibroblasts from different clinical outcome groups show transcriptional 
and functional differences. Briefly the DE genes detected between 
outcome groups that are associated with the matrisome will be 
validated using a combination of qRT-PCR, ELISA, and matrix 
degradation assays. The presence or absence of subsets of fibroblasts 
in the cultured fibroblast lines will be confirmed by flow cytometric 
analysis as will the persistence of subsets in in vitro culture using 
freshly sorted synovial fibroblasts. The pathogenic behaviour of 
fibroblast lines will be confirmed using the SCID mouse cartilage 
implantation model as in (Muller-Ladner et al., 1996). Investigation of 
the mechanism behind the maintained differential expression of genes 
will be investigated by assaying chromatin accessibility ATAC-seq or 
through assaying gene methylation status using bisulphite sequencing. 
 The current RNA-sequencing data and the associated flow cytometry 
data will be used to characterise the changes in synovial fibroblast 
subsets occurring during arthritis subsequent to anti-PD1 treatment 
and to investigate the effect of treatment upon cells in fibroblast 
subsets RA synovium. Briefly, the number of samples sequenced will 
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be increased and counting beads used during cell sorts to make the 
data more robust. The key differences in gene expression between 
subsets will be confirmed in RA samples and validated using qRT-
PCR, ELISA, matrix degradation assays, chemotaxis assays using 
conditioned media, and co-cultures with leukocytes. Differences in 
subset gene expression and function across disease groups will then 
be investigated and again confirmed using the above assays. 
Histological differences between the three disease groups will be 
investigated using hematoxylin and eosin and also immunofluorescent 
staining of synovial tissue sections. 
 
The overarching questions to address going forwards in this field are: 
1. How do synovial fibroblast subsets contribute to the pathology of RA? 
2. How do synovial fibroblast subsets differ in function and number during the 
progression of RA? 
3. Do fibroblasts from resolving arthritis demonstrate different interactions 
with monocytes and macrophages than those from RA? 
4. Does the CD206+CD163+ macrophage population represent a tissue-
resident population within the synovium and does this subset dampen 
inflammation? 
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8.2 In vitro monocyte:fibroblast luminex data 
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Figure 77: Results of all factors analysed in the multiplex analysis of 
supernatants harvested from unstimulated monocyte:fibroblast co-cultures. Bars 
show the median. 
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8.3 Synovial tissue digestion protocol 
1. Turn on the heating plate for the digestion. Warm serum-free RPMI-1640 
containing 0.97mM sodium orthopyruvate, 1.94mM glutamine, 97U/ml 
penicillin, 97μg/ml streptomycin, and [0.97x] MEM non-essential amino acids 
to 37oC in preparation for use in the digestion buffer. 
 
2. Drain media/saline from tissue using 100μm cell filter. 
 
3. Place tissue in Petri dish and cut into pieces 1mm3 using scalpels. Weigh 
tissue 
 
4. Divide tissue between 5ml FACS tubes at a max of 0.02g/tube. Add 
magnetic flea to tube. 
 
5. Make up digestion buffer.  
i. 10ml RPMI-1640 (serum free with additives as in step 1) 
ii. 200ul Liberase TM (50μg/ml final concentration) 
iii. 40ul DNase1 (40μg/ml final concentration) 
 
6. Add 1ml digestion buffer to each tube and digest at 37°C with a magnetic 
stirrer for 30 minutes. Stirrer revolutions set at 380rpm 
 
7. After 15 minutes of digestion agitate the tissue via repeated aspiration using 
a 14g needle. Continue digestion afterwards. 
 
8. Thoroughly resuspend/agitate digested suspensions and pass through 70m 
cell strainer. Rinse filter with 10ml RPMI 10% FBS (with NEAA, SOP, GPS). 
 
9. Spin down at 1400rpm for 6 minutes and continue with staining protocol 
 
Freezing tissue 
 
1. Pre-cool Mr Frosty to 4oC 
2. Collect tissues by biopsy needle. (Size of the tissue is about 16G diameter x 
1-10 mm length)  
3. Mince tissue with scalpels until pieces are approximately 1mm diameter 
4. Weigh tissue and place into 1ml cryovial with 1ml of Cryostor 10. Agitate vial 
to separate tissue pieces out. 
5. Put the tube on ice for 10 min. 
6. Put the tube into pre-chilled Mr Frosty and place into -80oC Freezer 
 
Thawing tissue 
1. Place cryovial into 37oC water bath to rapidly thaw vial 
2. As soon as sample has thawed decant tissue into a 70μm filter and rinse 
with 10ml serum-free RPMI-1640 
3. Transfer tissue into vessel for digestion and continue with usual digestion 
protocol 
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8.4 R script for the analysis of RNA-sequencing data from ex vivo 
synovial populations 
#Required packages 
library("BiocInstaller") 
library(Biobase) 
library(limma) 
library(edgeR) 
library(Glimma) 
library(gplots) 
library(org.Hs.eg.db) 
library(RColorBrewer) 
library("DESeq2") 
library("genefilter") 
library("ggplot2") 
library("ggfortify") 
 
# Reading in the data 
seqdata <- read.delim("NG00009.0-Ensembl-human-76-bowtie2-pe-gene-2.cnt", stringsAsFactors = FALSE) 
sampleinfo <- read.delim("SampleInfoCleaned2.txt", comment.char = "", stringsAsFactors = TRUE, fill=TRUE) 
sampleinfo$Group <- paste(sampleinfo$Diagnosis, sampleinfo$Population, sep = ".") 
head(seqdata) 
dim(seqdata) 
countdata <- seqdata[,-(1)] 
head(countdata) 
rownames(countdata) <- seqdata[,1] 
colnames(countdata) <- sampleinfo$Sample.Name 
table(colnames(countdata)==sampleinfo$Sample.Name) 
 
 
#removal of samples identified as outliers through several iterations of the normalisation and data preparatio
n 
sampleinfo <- sampleinfo[c(-2,-5,-6,-12,-14,-15,-16,-17,-18,-19,-20,-21,-25,-31,-72,-73,-74,-75,-76,-77,-79,-8
6,-99,-100,-108),] 
countdata <- countdata[,c(-2,-5,-6,-12,-14,-15,-16,-17,-18,-19,-20,-21,-25,-31,-72,-73,-74,-75,-76,-77,-79,-86
,-99,-100,-108)] 
rownames(sampleinfo) <- sampleinfo$Sample.Name 
 
#Remove genes not in any samples 
countdata2 <- countdata[rowSums(countdata)>0,] 
 
#Collection additional annotation information and adding the current annotation information 
library(biomaRt) 
ensembl = useMart(biomart = "ENSEMBL_MART_ENSEMBL",dataset="hsapiens_gene_ensembl", host="www.ensembl.org") 
Attributes <- listAttributes(ensembl) 
Filters <- listFilters(ensembl) 
BMimport =getBM(attributes= c("ensembl_gene_id", "hgnc_symbol", "entrezgene", "external_gene_name",  
                              "start_position", "end_position"), values= rownames(countdata),  
                filter="ensembl_gene_id", mart= ensembl) 
BMimport$gene_length <- (BMimport$end_position - BMimport$start_position) +1 
library("plyr") 
df <- data.frame(row.names = rownames(countdata2), stringsAsFactors=FALSE) 
df$ensembl_gene_id <- rownames(df) 
df2 <- join(df, BMimport, by="ensembl_gene_id", type="left", match="first") 
 
 
#Assessing log2 CPM to find where the boundry with noise lies 
logcounts <- cpm(countdata2,log=TRUE) 
plot(logcounts[,1],logcounts[,2]) 
 
# Create expression set, function provided by Sabina Pfister 
mr.analysis.get.eset <- function(x.data, x.annots, x.genes) 
{ 
  require(Biobase) 
  pData <- new("AnnotatedDataFrame",x.annots) 
  fData <- new("AnnotatedDataFrame", x.genes) 
  eset <- new("ExpressionSet", exprs = as.matrix(x.data), phenoData = pData, featureData= fData) 
  return(eset) 
} 
 
esetdata <- mr.analysis.get.eset(countdata2, sampleinfo, df2) 
 
 
# Filter read if intensity is at least 1 in 75% of the samples in at least one group 
# Yann Abraham code from Sabina Pfister 
mr.analysis.filter <- function(eset, groups, p=0.75, val=1, na.rm=TRUE) 
{ 
  require(genefilter) 
  require(edgeR) 
   
  cat(nrow(eset),'total identifiers\n') 
   
  ffun <- filterfun(pOverA(p=p,val,na.rm=na.rm)) 
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  fltr <- lapply( levels(groups), function(name)  
  { 
    sub <- cpm(eset[,groups==name],log=FALSE) 
    ft <- genefilter(sub, ffun) 
    return( ft ) 
  }) 
  fltr <- do.call('cbind',fltr) 
  fltr <- rowSums(fltr) 
   
  eset <- eset[fltr!=0,] 
  cat(nrow(eset),'identifiers passed filtering\n') 
  return(eset) 
} 
 
esetdataFilt <- mr.analysis.filter(esetdata,  
                                   groups = factor(sampleinfo$Group),  
                                   val= 1) 
 
#Voom transformation and quantile normalisation 
y <- DGEList(exprs(esetdataFilt), genes = fData(esetdataFilt)) 
barplot(y$samples$lib.size, ylab = "Library size", main = "Sample library sizes",names = colnames(y), las=2, c
ex.names = 0.75) 
y <- calcNormFactors(y) 
y$samples  
group <- factor(sampleinfo$Group) 
design <- model.matrix(~ 0 + group) 
colnames(design) <- levels(group) 
v <- voom(y,design,plot = TRUE, normalize.method = "quantile") 
 
par(mar=c(7,5,3,3)) 
boxplot(v$E, xlab="", ylab="Log2 counts per million",las=2,main="Voom transformed logCPM", cex.axis = 0.75) 
boxplot(cpm(y, log = TRUE), xlab="", ylab="Log2 counts per million",las=2,main="non-transformed logCPM",cex.ax
is = 0.75) 
 
#THIS CODE RUN AFTER INITIAL DE GENE ANALYSIS USING PREPARED DATA 
#PURPOSE IS MAKE DATA AMENABLE TO GSEA AND GO ENRICHMENT 
#USE THIS STEP TO PREPARE DATA FOR SECOND DEG ANALYSIS AND SUBSEQUENT GSEA AND GO ANALYSIS 
#Remove non-primary assembly genes and deprecated genes (using logic of higher ensembl ID are non-assembly for  
#duplicated genes and NA in external gene name are deprecated) 
dim(v) 
v <- v[!duplicated(v$genes$external_gene_name),] 
dim(v) 
v <- v[!is.na(v$genes$external_gene_name),] 
#END OF GSEA DATA PREP 
 
 
#Multidimensional scaling plots 
plotMDS(v) 
par(mfrow=c(3,2)) 
#Coloured according to variables 
#Diagnosis 
levels(sampleinfo$Diagnosis) 
col.dia <- c("purple","orange", "red", "blue")[sampleinfo$Diagnosis] 
data.frame(sampleinfo$Diagnosis,col.dia) 
plotMDS(v,col=col.dia, pch=16) 
legend("bottomleft",fill=c("purple","orange", "red", "blue"),legend=levels(sampleinfo$Diagnosis)) 
title("Diagnosis") 
#Cell type 
levels(sampleinfo$CellType) 
col.cell <- c("purple","orange", "red")[sampleinfo$CellType] 
data.frame(sampleinfo$CellType,col.cell) 
plotMDS(v,col=col.cell, pch=16) 
legend("bottomleft",fill=c("purple","orange", "red"),legend=levels(sampleinfo$CellType)) 
title("Cell type") 
#Population 
levels(sampleinfo$Population) 
col.pop <- c("purple","orange", "red", "blue", "green", "black", "brown", "grey")[sampleinfo$Population] 
data.frame(sampleinfo$Population,col.pop) 
plotMDS(v,col=col.pop, pch=16) 
legend("bottomleft",fill=c("purple","orange","red", "blue", "green", "black", "brown", "grey"),legend=levels(s
ampleinfo$Population)) 
title("Cell population") 
#Sex 
levels(sampleinfo$Sex) 
col.sex <- c("purple","orange", "red")[sampleinfo$Sex] 
data.frame(sampleinfo$Sex,col.sex) 
plotMDS(v,col=col.sex, pch=16) 
legend("bottomleft",fill=c("purple","orange", "red"),legend=levels(sampleinfo$Sex)) 
title("Sex") 
#Site 
levels(sampleinfo$Site) 
col.site <- c("purple","orange", "red", "blue")[sampleinfo$Site] 
data.frame(sampleinfo$Site,col.site) 
plotMDS(v,col=col.site, pch=16) 
legend("bottomleft",fill=c("purple","orange", "red", "blue"),legend=levels(sampleinfo$Site)) 
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title("Site") 
#Digest batch 
levels(sampleinfo$DigestBatch) 
col.digbat <- c("purple","orange", "red", "blue")[sampleinfo$DigestBatch] 
data.frame(sampleinfo$DigestBatch,col.digbat) 
plotMDS(v,col=col.digbat, pch=16) 
legend("bottomleft",fill=c("purple","orange", "red", "blue"),legend=levels(sampleinfo$DigestBatch)) 
title("Digest batch") 
 
 
#Checking batch vs diagnosis and diagnosis vs cell type 
par(mfrow=c(1,2)) 
char.batch <- c(1,2,3,4)[sampleinfo$DigestBatch] 
plotMDS(v,col=col.dia, pch=char.batch,cex=2) 
legend("topleft",fill=c("purple","orange", "red", "blue"),legend=levels(sampleinfo$Diagnosis)) 
legend("bottomright",legend=levels(sampleinfo$DigestBatch),pch=c(1,2,3,4)) 
 
char.cell <- c(1,2,3)[sampleinfo$CellType] 
plotMDS(y,col=col.dia, pch=char.cell, cex=2) 
legend("topleft",fill=c("purple","orange", "red", "blue"),legend=levels(sampleinfo$Diagnosis)) 
legend("bottomright",legend=levels(sampleinfo$CellType),pch=c(1,2,3)) 
 
#Interactive MDS plot with Glimma 
labels <- paste(sampleinfo$SampleName, sampleinfo$Diagnosis, sampleinfo$CellType, sampleinfo$Population, sampl
einfo$Sex, sampleinfo$Site) 
Group <- paste(sampleinfo$Diagnosis, sampleinfo$CellType, sampleinfo$Population, sampleinfo$Sex, sampleinfo$Si
te,sep=".") 
Group <- factor(Group) 
glMDSPlot(v, labels=sampleinfo$Sample.Name, groups=factor(sampleinfo$Diagnosis), folder="mdsVoomFirstdemul") 
 
#PCA 
pca <- prcomp(t(v$E), scale=TRUE, center = TRUE) 
autoplot(pca, data = sampleinfo, colour = 'Population', size = 2,  
         xlab="PC1: 17.2% of variance", ylab = "PC2: 4.3% of variance", 
         loadings = TRUE) 
 
#PCAs per subset 
vpca <- v 
#For macrophages 
vpca.mphage <- vpca[, grep("Macrophage", sampleinfo$CellType)] 
col.dia.mphage <- col.dia[grep("Macrophage", sampleinfo$CellType)] 
 
mp.pca <- prcomp(t(vpca.mphage$E), scale=TRUE, center = TRUE) 
autoplot(mp.pca, x= 2, y= 3, data = sampleinfo[grep("Macrophage", sampleinfo$CellType),], colour = 'Population
', size = 3, 
         frame = TRUE, frame.type = 'norm', xlab= "PC2: 7.23% of variance", ylab ="PC3: 3.97% of variance") 
#3D PCA 
library(ggbiplot) 
library(pca3d) 
pca3d(pca, components = 4:6, col = col.dia.mphage, axes.color = "grey", bg = "white", radius = 1, labels.col = 
"black",  
      show.axes = TRUE, group=factor(sampleinfo$Diagnosis[grep("Macrophage", sampleinfo$CellType)]), 
      show.axe.titles = TRUE,  show.plane = TRUE, 
      show.shapes = TRUE, show.centroids = FALSE, show.ellipses = FALSE, legend= "bottomleft") 
 
#Fibroblasts 
vpca.fibro <- vpca[, grep("Fibroblast", sampleinfo$CellType)] 
col.dia.fibro <- col.dia[grep("Fibroblast", sampleinfo$CellType)] 
col.pop.fibro <- col.pop[grep("Fibroblast", sampleinfo$CellType)] 
 
fb.pca <- prcomp(t(vpca.fibro$E), scale=TRUE, center = TRUE) 
 
autoplot(fb.pca, x= 2, y = 3, data = sampleinfo[grep("Fibroblast", sampleinfo$CellType),], colour = 'Populatio
n', size = 3, 
         frame = TRUE, frame.type = 'norm', xlab = "PC2: 4.24% of variance", ylab="PC3: 3.76% of variance") 
#3D PCA 
library(pca3d) 
pca3d(fb.pca, components = 1:3, col = col.dia.fibro, axes.color = "grey", bg = "white", radius = 1, labels.col 
= "black", 
      show.axes = TRUE, group=factor(sampleinfo$Diagnosis[grep("Fibroblast", sampleinfo$CellType)]), 
      legend = "bottomleft") 
pca2d(fb.pca, components = 2:3, col = col.pop.fibro, axes.color = "grey", bg = "white", radius = 1, labels.col 
= "black", 
      show.axes = TRUE, group=factor(sampleinfo$Population[grep("Fibroblast", sampleinfo$CellType)]), 
      legend = "bottomleft", biplot = TRUE) 
 
 
#tSNE 
library("Rtsne") 
Res.tSNE <- Rtsne(t(v$E), dims = 5, initial_dims = 15, perplexity = 20, 
      theta = 0.5, check_duplicates = TRUE, pca = TRUE, max_iter = 1000, 
      verbose = TRUE) 
plot(Res.tSNE$Y[,1], Res.tSNE$Y[,2], xlab="tSNE dim 1", ylab="tSNE dim 2", col=col.dia, pch=16) 
#CD34 colour gradient 
ggplot(Res.tSNE$Y, aes(Res.tSNE$Y[,1], Res.tSNE$Y[,2])) + 
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  geom_point(aes(colour = v$E["ENSG00000174059",])) + 
  scale_colour_gradient2(low = muted("black"), mid = "grey", high ="purple") + 
  theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank(), 
        panel.background = element_blank(), axis.line = element_line(colour = "black")) 
 
 
#Hierarchical clustering (Pearson's correlation distance of top 400 most variable genes across samples) 
#Macrophages 
var_genes <- apply(v[,grep("Macrophage", sampleinfo$CellType)], 1, var) 
head(var_genes) 
select_var <- names(sort(var_genes, decreasing=TRUE))[1:400] 
head(select_var) 
highly_variable_vmphage <- v$E[select_var, grep("Macrophage", sampleinfo$CellType)] 
dim(highly_variable_vmphage) 
head(highly_variable_vmphage) 
#Pearson correlation distance, labels changed if required 
hc <- hclust(as.dist(1-cor(highly_variable_vmphage))) 
plot(hc, labels = group[grep("Macrophage", sampleinfo$CellType)]) 
 
#Fibroblasts 
var_genes <- apply(v[,grep("Fibroblast", sampleinfo$CellType)], 1, var) 
head(var_genes) 
select_var <- names(sort(var_genes, decreasing=TRUE))[1:400] 
head(select_var) 
highly_variable_vfibro <- v$E[select_var, grep("Fibroblast", sampleinfo$CellType)] 
dim(highly_variable_vfibro) 
head(highly_variable_vfibro) 
#Pearson correlation distance, labels changed if required 
hc <- hclust(as.dist(1-cor(highly_variable_vfibro))) 
plot(hc, labels = group[grep("Fibroblast", sampleinfo$CellType)]) 
 
#Sanity checks on sorted markers 
par(mar=c(10,5,3,3)) 
sampleinfo$Population <- factor(sampleinfo$Population, c("DN", "206p163n", "206p163p", "34n", "34p", "90n38p", 
"Control")) 
boxplot(v$E["ENSG00000081237",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="PTPRC", col = c("red", "red", "red", "blue", "blue", "blue", "green4"))  
boxplot(v$E["ENSG00000261371",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="PECAM1", col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000154096",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="THY1", col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000162493",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="PDPN",  col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000174059",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="CD34", col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000204287",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="HLA-DRA",  col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000177575",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="CD163",  col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000260314",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="MRC1",  col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000126353",]~factor(sampleinfo$Population),vertical=TRUE,las=2, 
           ylab="log2CPM",main="CCR7",  col = c("red", "red", "red", "blue", "blue", "blue", "green4")) 
boxplot(v$E["ENSG00000188389",]~group,vertical=TRUE,las=2,cex.axis=0.8, 
           ylab="log2CPM",main="PDCD1" ) 
 
#Fit the linear model 
fit <- lmFit(v) 
names(fit) 
 
cont.matrix <- makeContrasts( 
  #Comparions of FLS to each other and mphages to each other within disease 
  RA.34pv34n=RA.34p - RA.34n, 
  RA.34pv90n38p=RA.34p - RA.90n38p, 
  RA.34nv90n38p=RA.34n - RA.90n38p, 
  RA.206p163pv206p163n=RA.206p163p - RA.206p163n, 
  RA.206p163pvDN=RA.206p163p - RA.DN, 
  RA.206p163nvDN=RA.206p163n - RA.DN, 
   
  PD1.34pv34n=PD1.34p - PD1.34n, 
  PD1.34pv90n38p=PD1.34p - PD1.90n38p, 
  PD1.34nv90n38p=PD1.34n - PD1.90n38p, 
  PD1.206p163pv206p163n=PD1.206p163p - PD1.206p163n, 
  PD1.206p163pvDN=PD1.206p163p - PD1.DN, 
  PD1.206p163nvDN=PD1.206p163n - PD1.DN, 
   
  TreatedRA.34pv34n=TreatedRA.34p - TreatedRA.34n, 
  TreatedRA.34pv90n38p=TreatedRA.34p - TreatedRA.90n38p, 
  TreatedRA.34nv90n38p=TreatedRA.34n - TreatedRA.90n38p, 
  TreatedRA.206p163pv206p163n=TreatedRA.206p163p - TreatedRA.206p163n, 
  TreatedRA.206p163pvDN=TreatedRA.206p163p - TreatedRA.DN, 
  TreatedRA.206p163nvDN=TreatedRA.206p163n - TreatedRA.DN, 
   
  #Comparison of populations across disease 
  RA.34pvPD1.34p=RA.34p - PD1.34p, 
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  RA.34pvTreatedRA.34p=RA.34p - TreatedRA.34p, 
  PD1.34pvTreatedRA.34p=PD1.34p - TreatedRA.34p, 
   
  RA.34nvPD1.34n=RA.34n - PD1.34n, 
  RA.34nvTreatedRA.34n=RA.34n - TreatedRA.34n, 
  PD1.34nvTreatedRA.34n=PD1.34n - TreatedRA.34n, 
   
  RA.90n38pvPD1.90n38p=RA.90n38p - PD1.90n38p, 
  RA.90n38pvTreatedRA.90n38p=RA.90n38p - TreatedRA.90n38p, 
  PD1.90n38pvTreatedRA.90n38p=PD1.90n38p - TreatedRA.90n38p, 
   
  RA.206p163pvPD1.206p163p=RA.206p163p - PD1.206p163p, 
  RA.206p163pvTreatedRA.206p163p=RA.206p163p - TreatedRA.206p163p, 
  PD1.206p163pvTreatedRA.206p163p=PD1.206p163p - TreatedRA.206p163p, 
   
  RA.206p163nvPD1.206p163n=RA.206p163n - PD1.206p163n, 
  RA.206p163nvTreatedRA.206p163n=RA.206p163n - TreatedRA.206p163n, 
  PD1.206p163nvTreatedRA.206p163n=PD1.206p163n - TreatedRA.206p163n, 
   
  RA.DNvPD1.DN=RA.DN - PD1.DN, 
  RA.DNvTreatedRA.DN=RA.DN - TreatedRA.DN, 
  PD1.DNvTreatedRA.DN=PD1.DN - TreatedRA.DN, 
 
  #INTERACTIONS TO ASSESS DIFFERENCES IN SUBSETS BETWEEN DISEASES I.E. 34NV90N38P IN RA V TREATEDRA 
  #34nv90n38p 
  RA.34nv90n38p.VS.TreatedRA.34nv90n38p=(RA.34n-RA.90n38p)-(TreatedRA.34n-TreatedRA.90n38p), 
  RA.34nv90n38p.VS.PD1.34nv90n38p=(RA.34n-RA.90n38p)-(PD1.34n-PD1.90n38p), 
  TreatedRA.34nv90n38p.VS.PD1.34n90n38p=(TreatedRA.34n-TreatedRA.90n38p)-(PD1.34n-PD1.90n38p), 
  #34pv90n38p 
  RA.34pv90n38p.VS.TreatedRA.34pv90n38p=(RA.34p-RA.90n38p)-(TreatedRA.34p-TreatedRA.90n38p), 
  RA.34pv90n38p.VS.PD1.34pv90n38p=(RA.34p-RA.90n38p)-(PD1.34p-PD1.90n38p), 
  TreatedRA.34pv90n38p.VS.PD1.34p90n38p=(TreatedRA.34p-TreatedRA.90n38p)-(PD1.34p-PD1.90n38p), 
  #34nv34p 
  RA.34nv34p.VS.TreatedRA.34nv34p=(RA.34n-RA.34p)-(TreatedRA.34n-TreatedRA.34p), 
  RA.34nv34p.VS.PD1.34nv34p=(RA.34n-RA.34p)-(PD1.34n-PD1.34p), 
  TreatedRA.34nv34p.VS.PD1.34n34p=(TreatedRA.34n-TreatedRA.34p)-(PD1.34n-PD1.34p), 
  #206p163pvDN 
  RA.206p163pv206p163n.VS.TreatedRA.206p163pv206p163n=(RA.206p163p-RA.206p163n)-(TreatedRA.206p163p-TreatedRA.
206p163n), 
  RA.206p163pv206p163n.VS.PD1.206p163pv206p163n=(RA.206p163p-RA.206p163n)-(PD1.206p163p-PD1.206p163n), 
  TreatedRA.206p163pv206p163n.VS.PD1.206p163p206p163n=(TreatedRA.206p163p-TreatedRA.206p163n)-(PD1.206p163p-PD
1.206p163n), 
  #206p163pvDN 
  RA.206p163pvDN.VS.TreatedRA.206p163pvDN=(RA.206p163p-RA.DN)-(TreatedRA.206p163p-TreatedRA.DN), 
  RA.206p163pvDN.VS.PD1.206p163pvDN=(RA.206p163p-RA.DN)-(PD1.206p163p-PD1.DN), 
  TreatedRA.206p163pvDN.VS.PD1.206p163pDN=(TreatedRA.206p163p-TreatedRA.DN)-(PD1.206p163p-PD1.DN), 
  #206p163nvDN 
  RA.206p163nvDN.VS.TreatedRA.206p163nvDN=(RA.206p163n-RA.DN)-(TreatedRA.206p163n-TreatedRA.DN), 
  RA.206p163nvDN.VS.PD1.206p163nvDN=(RA.206p163n-RA.DN)-(PD1.206p163n-PD1.DN), 
  TreatedRA.206p163nvDN.VS.PD1.206p163nDN=(TreatedRA.206p163n-TreatedRA.DN)-(PD1.206p163n-PD1.DN), 
   
  #Do the 206p163p and 206p163n differ from DN in the same way? 
  RA.206p163pvDN.VS.RA.206p163nvDN=(RA.206p163p-RA.DN)-(RA.206p163n-RA.DN), 
  TreatedRA.206p163pvDN.VS.TreatedRA.206p163nvDN=(TreatedRA.206p163p-TreatedRA.DN)-(TreatedRA.206p163n-Treated
RA.DN), 
  PD1.206p163pvDN.VS.PD1.206p163nvDN=(PD1.206p163p-PD1.DN)-(PD1.206p163n-PD1.DN), 
   
  #FLS v mphage test 
  RA.34n.v206p163p = RA.34n-RA.206p163p, 
 
  levels=design) 
 
fit.cont <- contrasts.fit(fit, cont.matrix) 
fit.cont <- eBayes(fit.cont) 
dim(fit.cont) 
summa.fit <- decideTests(fit.cont) 
summary(summa.fit) 
topTable(fit.cont,coef=1,sort.by="p") 
 
#Venn diagrams of DE genes 
#Within disease 
vennDiagram(summa.fit[,1:3], cex = 0.9) 
vennDiagram(summa.fit[,4:6], cex = 0.9) 
vennDiagram(summa.fit[,7:9], cex = 0.9) 
vennDiagram(summa.fit[,10:12], cex = 0.9) 
vennDiagram(summa.fit[,13:15], cex = 0.9) 
vennDiagram(summa.fit[,16:18], cex = 0.7) 
#Between disease 
vennDiagram(summa.fit[,19:21], cex = 0.7) 
vennDiagram(summa.fit[,22:24], cex = 0.7) 
vennDiagram(summa.fit[,25:27], cex = 0.7) 
vennDiagram(summa.fit[,28:30], cex = 0.7) 
vennDiagram(summa.fit[,31:33], cex = 0.7) 
vennDiagram(summa.fit[,34:36], cex = 0.7) 
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#Writing tables of DE genes for all comparisons 
write.table(x=topTable(fit.cont,coef=1,sort.by="p", n="Inf"), file = "RA.34pv34n.txt", row.names = FALSE, sep=
"\t") 
write.table(x=topTable(fit.cont,coef=2,sort.by="p", n="Inf"), file = "RA.34pv90n38p.txt", row.names=FALSE, sep
="\t") 
write.table(x=topTable(fit.cont,coef=3,sort.by="p", n="Inf"), file = "RA.34nv90n38p.txt", row.names=FALSE, sep
="\t") 
write.table(x=topTable(fit.cont,coef=4,sort.by="p", n="Inf"), file = "RA.206p163pv206p163n.txt", row.names=FAL
SE, sep="\t") 
write.table(x=topTable(fit.cont,coef=5,sort.by="p", n="Inf"), file = "RA.206p163pvDN.txt", row.names=FALSE, se
p="\t") 
write.table(x=topTable(fit.cont,coef=6,sort.by="p", n="Inf"), file = "RA.206p163nvDN.txt", row.names=FALSE, se
p="\t") 
write.table(x=topTable(fit.cont,coef=7,sort.by="p", n="Inf"), file = "PD1.34pv34n.txt", row.names=FALSE, sep="
\t") 
write.table(x=topTable(fit.cont,coef=8,sort.by="p", n="Inf"), file = "PD1.34pv90n38p.txt", row.names=FALSE, se
p="\t") 
write.table(x=topTable(fit.cont,coef=9,sort.by="p", n="Inf"), file = "PD1.34nv90n38p.txt", row.names=FALSE, se
p="\t") 
write.table(x=topTable(fit.cont,coef=10,sort.by="p", n="Inf"), file = "PD1.206p163pv206p163n.txt", row.names=F
ALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=11,sort.by="p", n="Inf"), file = "PD1.206p163pvDN.txt", row.names=FALSE, 
sep="\t") 
write.table(x=topTable(fit.cont,coef=12,sort.by="p", n="Inf"), file = "PD1.206p163nvDN.txt", row.names=FALSE, 
sep="\t") 
write.table(x=topTable(fit.cont,coef=13,sort.by="p", n="Inf"), file = "TreatedRA.34pv34n.txt", row.names=FALSE
, sep="\t") 
write.table(x=topTable(fit.cont,coef=14,sort.by="p", n="Inf"), file = "TreatedRA.34pv90n38p.txt", row.names=FA
LSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=15,sort.by="p", n="Inf"), file = "TreatedRA.34nv90n38p.txt", row.names=FA
LSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=16,sort.by="p", n="Inf"), file = "TreatedRA.206p163pv206p163n.txt", row.n
ames=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=17,sort.by="p", n="Inf"), file = "TreatedRA.206p163pvDN.txt", row.names=F
ALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=18,sort.by="p", n="Inf"), file = "TreatedRA.206p163nvDN.txt", row.names=F
ALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=19,sort.by="p", n="Inf"), file = "RA.34pvPD1.34p.txt", row.names=FALSE, s
ep="\t") 
write.table(x=topTable(fit.cont,coef=20,sort.by="p", n="Inf"), file = "RA.34pvTreatedRA.34p.txt", row.names=FA
LSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=21,sort.by="p", n="Inf"), file = "PD1.34pvTreatedRA.34p.txt", row.names=F
ALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=22,sort.by="p", n="Inf"), file = "RA.34nvPD1.34n.txt", row.names=FALSE, s
ep="\t") 
write.table(x=topTable(fit.cont,coef=23,sort.by="p", n="Inf"), file = "RA.34nvTreatedRA.34n.txt", row.names=FA
LSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=24,sort.by="p", n="Inf"), file = "PD1.34nvTreatedRA.34n.txt", row.names=F
ALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=25,sort.by="p", n="Inf"), file = "RA.90n38pvPD1.90n38p.txt", row.names=FA
LSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=26,sort.by="p", n="Inf"), file = "RA.90n38pvTreatedRA.90n38p.txt", row.na
mes=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=27,sort.by="p", n="Inf"), file = "PD1.90n38pvTreatedRA.90n38p.txt", row.n
ames=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=28,sort.by="p", n="Inf"), file = "RA.206p163pvPD1.206p163p.txt", row.name
s=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=29,sort.by="p", n="Inf"), file = "RA.206p163pvTreatedRA.206p163p.txt", ro
w.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=30,sort.by="p", n="Inf"), file = "PD1.206p163pvTreatedRA.206p163p.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=31,sort.by="p", n="Inf"), file = "RA.206p163nvPD1.206p163n.txt", row.name
s=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=32,sort.by="p", n="Inf"), file = "RA.206p163nvTreatedRA.206p163n.txt", ro
w.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=33,sort.by="p", n="Inf"), file = "PD1.206p163nvTreatedRA.206p163n.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=34,sort.by="p", n="Inf"), file = "RA.DNvPD1.DN.txt", row.names=FALSE, sep
="\t") 
write.table(x=topTable(fit.cont,coef=35,sort.by="p", n="Inf"), file = "RA.DNvTreatedRA.DN.txt", row.names=FALS
E, sep="\t") 
write.table(x=topTable(fit.cont,coef=36,sort.by="p", n="Inf"), file = "PD1.DNvTreatedRA.DN.txt", row.names=FAL
SE, sep="\t") 
write.table(x=topTable(fit.cont,coef=37,sort.by="p", n="Inf"), file = "RA.34nv90n38p.VS.TreatedRA.34nv90n38p.t
xt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=38,sort.by="p", n="Inf"), file = "RA.34nv90n38p.VS.PD1.34nv90n38p.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=39,sort.by="p", n="Inf"), file = "TreatedRA.34nv90n38p.VS.PD1.34n90n38p.t
xt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=40,sort.by="p", n="Inf"), file = "RA.34pv90n38p.VS.TreatedRA.34pv90n38p.t
xt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=41,sort.by="p", n="Inf"), file = "RA.34pv90n38p.VS.PD1.34pv90n38p.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=42,sort.by="p", n="Inf"), file = "TreatedRA.34pv90n38p.VS.PD1.34p90n38p.t
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xt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=43,sort.by="p", n="Inf"), file = "RA.34nv34p.VS.TreatedRA.34nv34p.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=44,sort.by="p", n="Inf"), file = "RA.34nv34p.VS.PD1.34nv34p.txt", row.nam
es=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=45,sort.by="p", n="Inf"), file = "TreatedRA.34nv34p.VS.PD1.34n34p.txt", r
ow.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=46,sort.by="p", n="Inf"), file = "RA.206p163pv206p163n.VS.TreatedRA.206p1
63pv206p163n.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=47,sort.by="p", n="Inf"), file = "RA.206p163pv206p163n.VS.PD1.206p163pv20
6p163n.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=48,sort.by="p", n="Inf"), file = "TreatedRA.206p163pv206p163n.VS.PD1.206p
163p206p163n.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=49,sort.by="p", n="Inf"), file = "RA.206p163pvDN.VS.TreatedRA.206p163pvDN
.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=50,sort.by="p", n="Inf"), file = "RA.206p163pvDN.VS.PD1.206p163pvDN.txt", 
row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=51,sort.by="p", n="Inf"), file = "TreatedRA.206p163pvDN.VS.PD1.206p163pDN
.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=52,sort.by="p", n="Inf"), file = "RA.206p163nvDN.VS.TreatedRA.206p163nvDN
.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=53,sort.by="p", n="Inf"), file = "RA.206p163nvDN.VS.PD1.206p163nvDN.txt", 
row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=54,sort.by="p", n="Inf"), file = "TreatedRA.206p163nvDN.VS.PD1.206p163nDN
.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=55,sort.by="p", n="Inf"), file = "RA.206p163pvDN.VS.RA.206p163nvDN.txt", 
row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=56,sort.by="p", n="Inf"), file = "TreatedRA.206p163pvDN.VS.TreatedRA.206p
163nvDN.txt", row.names=FALSE, sep="\t") 
write.table(x=topTable(fit.cont,coef=57,sort.by="p", n="Inf"), file = "PD1.206p163pvDN.VS.PD1.206p163nvDN.txt"
, row.names=FALSE, sep="\t") 
 
#Checking DE using plots 
par(mfrow=c(1,2)) 
plotMD(fit.cont,coef=1,status=summa.fit[,"RA.34pv34n"]) 
volcanoplot(fit.cont,coef=1,highlight=100,names=fit.cont$genes$hgnc_symbol) 
 
glXYPlot(x=fit.cont$coefficients[,1], y=fit.cont$lods[,1], 
         xlab="logFC", ylab="B", main="RA.34pv34n", 
         counts=y$counts, groups=group, status=summa.fit[,1], 
         anno=fit.cont$genes, side.main="ensembl_gene_id", folder="volcanoRA.34pv34n") 
 
 
glMDPlot(fit.cont, coef=1, counts=v$E, groups=group, 
         status=summa.fit, id.column="ensembl_gene_id", main="RA.34pv34n", 
         folder="mdRA.34pv34n") 
 
 
#GSEA 
#camera 
#Using msigdb gene sets 
load("human_H_v5p2.rdata")#Hallmark 
load("human_c2_v5p2.rdata")#Curated gene sets (Kegg etc) 
load("human_c5_v5p2.rdata")#GO 
load("human_c6_v5p2.rdata")#Oncogenic 
load("human_c7_v5p2.rdata")#Immunologic 
names(Hs.H)[1:5] 
length(Hs.c2) 
 
 
H.ind <- ids2indices(Hs.H, v$genes$entrezgene) 
gst.camera.H <- camera(v,index=H.ind,design=design,contrast = cont.matrix[,1],inter.gene.cor=0.05) 
gst.camera.H[1:5,] #Top 5 results 
table(gst.camera.H$FDR < 0.25) 
write.csv(gst.camera.H,file="gstcameraH_RA.34pv34n.csv") 
 
c2.ind <- ids2indices(Hs.c2, v$genes$entrezgene) 
gst.camera.c2 <- camera(v,index=c2.ind,design=design,contrast = cont.matrix[,1],inter.gene.cor=0.05) 
gst.camera.c2[1:5,] #Top 5 results 
table(gst.camera.c2$FDR < 0.25) 
write.csv(gst.camera.c2,file="gstcamerac2_RA.34pv34n.csv") 
 
c5.ind <- ids2indices(Hs.c5, v$genes$entrezgene) 
gst.camera.c5 <- camera(v,index=c5.ind,design=design,contrast = cont.matrix[,1],inter.gene.cor=0.05) 
gst.camera.c5[1:5,] #Top 5 results 
table(gst.camera.c5$FDR < 0.25) 
write.csv(gst.camera.c5,file="gstcamerac2_RA.34pv34n.csv") 
 
c6.ind <- ids2indices(Hs.c6, v$genes$entrezgene) 
gst.camera.c6 <- camera(v,index=c6.ind,design=design,contrast = cont.matrix[,1],inter.gene.cor=0.05) 
gst.camera.c6[1:5,] #Top 5 results 
table(gst.camera.c6$FDR < 0.25) 
write.csv(gst.camera.c6,file="gstcamerac6_RA.34pv34n.csv") 
 
c7.ind <- ids2indices(Hs.c7, v$genes$entrezgene) 
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gst.camera.c7 <- camera(v,index=c7.ind,design=design,contrast = cont.matrix[,1],inter.gene.cor=0.05) 
gst.camera.c7[1:5,] #Top 5 results 
table(gst.camera.c7$FDR < 0.25) 
write.csv(gst.camera.c7,file="gstcamerac6_RA.34pv34n.csv") 
 
#Plotting enrichment 
head(fit.cont$coefficients) 
head(fit.cont$t) 
par(mfrow=c(1,1)) 
# barcode plot with logFCs, edit gene set names as required 
barcodeplot(fit.cont$coeff[,1], index=c2.ind[["Gene set of interest"]], main="LogFC: Gene set name") #Edit nam
es as required 
# barcode plot using t-statistics, edit gene set names as required 
barcodeplot(fit.cont$t[,1], index=c2.ind[["Gene set of interest"]], main="T-statistic: Gene set name") #Edit n
ames as required 
 
#GO and Kegg enrichment with gene length bias correction, repeat for each comparison tested 
library(goseq) 
#Macrophage 
RA.206p163pvDN <- topTable(fit.cont,coef=5,sort.by="p", n="Inf") 
genes.up=as.integer(RA.206p163pvDN$adj.P.Val[RA.206p163pvDN$logFC>0]<.05) 
names(genes.up)=row.names(RA.206p163pvDN[RA.206p163pvDN$logFC>0,]) 
table(genes.up) 
pwf=nullp(genes.up,"hg19","ensGene") 
head(pwf) 
GO.BP=goseq(pwf,"hg19","ensGene",test.cats=c("GO:BP")) 
head(GO.BP) 
GO.BP$adj.over_represented_pvalue <- p.adjust(GO.BP$over_represented_pvalue, method="BH") 
GO.BP.sigover <- GO.BP[GO.BP$adj.over_represented_pvalue<0.05,] 
enriched.GO=GO.BP[p.adjust(GO.BP$over_represented_pvalue, method="BH")<.05,] 
head(enriched.GO) 
library(GO.db) 
for(go in enriched.GO[1:56, 1]){ 
  print(GOTERM[[go]]) 
  cat("--------------------------------------\n") 
  } 
 
KEGG=goseq(pwf,'hg19','ensGene',test.cats="KEGG") 
head(KEGG) 
KEGG$adj.over_represented_pvalue <- p.adjust(KEGG$over_represented_pvalue, method="BH") 
KEGG.sigover <- KEGG[KEGG$adj.over_represented_pvalue<0.05,] 
enriched.KEGG=KEGG$category[p.adjust(KEGG$over_represented_pvalue, method="BH")<.05] 
head(enriched.KEGG) 
 
genes.down=as.integer(RA.206p163pvDN$adj.P.Val[RA.206p163pvDN$logFC<0]<.05) 
names(genes.down)=row.names(RA.206p163pvDN[RA.206p163pvDN$logFC<0,]) 
table(genes.down) 
pwf=nullp(genes.down,"hg19","ensGene") 
head(pwf) 
GO.BP=goseq(pwf,"hg19","ensGene",test.cats=c("GO:BP")) 
head(GO.BP) 
GO.BP$adj.over_represented_pvalue <- p.adjust(GO.BP$over_represented_pvalue, method="BH") 
GO.BP.sigover <- GO.BP[GO.BP$adj.over_represented_pvalue<0.05,] 
enriched.GO=GO.BP$category[p.adjust(GO.BP$over_represented_pvalue, method="BH")<.05] 
head(enriched.GO) 
library(GO.db) 
for(go in enriched.GO[1:62]){ 
  print(GOTERM[[go]]) 
  cat("--------------------------------------\n") 
} 
 
#FLS 
RA.34pv34n <- topTable(fit.cont,coef=1,sort.by="p", n="Inf") 
RA.34pv90n38p <- topTable(fit.cont,coef=2,sort.by="p", n="Inf") 
RA.34nv90n38p <- topTable(fit.cont,coef=3,sort.by="p", n="Inf") 
genes.up=as.integer(RA.34nv90n38p$adj.P.Val[RA.34nv90n38p$logFC<0]<.05) 
names(genes.up)=row.names(RA.34nv90n38p[RA.34nv90n38p$logFC<0,]) 
table(genes.up) 
pwf=nullp(genes.up,"hg19","ensGene") 
head(pwf) 
GO.BP=goseq(pwf,"hg19","ensGene",test.cats=c("GO:BP")) 
head(GO.BP) 
GO.BP$adj.over_represented_pvalue <- p.adjust(GO.BP$over_represented_pvalue, method="BH") 
GO.BP.sigover <- GO.BP[GO.BP$adj.over_represented_pvalue<0.05,] 
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8.5 R script for the analysis of microarray data from fibroblast cultures 
library("BiocInstaller") 
library(Biobase) 
library("limma") 
library("genefilter") 
library("RColorBrewer") 
library("ggplot2") 
library("ggfortify") 
library("human.db0") 
library("AMADID039494.db") 
library("arrayQualityMetrics") 
library("Glimma") 
library("gplots") 
 
#Line below for loading data if saved during analysis and returned to 
load("MicroarrayAnalysis.RData") 
 
#Read in raw data from feature extraction files into red/green format 
targets <- readTargets(file="targets.txt") 
RG_allsample <- read.maimages(targets, path="All OGT Agilent fibroblast array raw data files", 
                              source="agilent") 
targets$Group <- paste(targets$Diagnosis, targets$Serum, targets$Stimulated, sep=".") 
targets$StimSerum <- paste(targets$Stimulated, targets$Serum, sep=".") 
 
#Swap colours for correct ratio calculation 
RG_allsampleRGSwap <- RG_allsample 
RG_allsampleRGSwap$G <- RG_allsample$R 
RG_allsampleRGSwap$Gb <- RG_allsample$Rb 
RG_allsampleRGSwap$Rb <- RG_allsample$Gb 
RG_allsampleRGSwap$R <- RG_allsample$G 
 
genelist <- RG_allsampleRGSwap$genes 
 
 
#Creating annotation database 
a <- genelist$ProbeName 
b <- genelist$SystematicName 
AgilentAMADID039494ID <- cbind(a, b) 
makeDBPackage("HUMANCHIP_DB", 
              affy=FALSE, 
              prefix="AMADID039494", 
              fileName="C:/Users/JDT366/Desktop/Agilent analysis WD/Annotationtest.txt", 
              baseMapType="gbNRef",  
              outputDir = "C:/Users/JDT366/Desktop/Agilent analysis WD/Annotation Test", 
              version="1.0.0", 
              manufacturer = "Agilent", 
              chipName = "agilent_sureprint_g3_ge_8x60k_v2", 
              manufacturerUrl = "http://www.agilent.co.uk") 
install.packages("D:/Jason's Folder/Microarray/Agilent analysis WD/Annotation Test/AMADID039494.
db ", repos=NULL, type="source") 
library("AMADID039494.db") 
 
#Diagnostic plots 
plotDensities(RG_allsampleRGSwap, main = "Red and Green channel densities for each array") 
imageplot(RG_allsampleRGSwap$R[,1], layout = RG_allsampleRGSwap$printer) 
 
#Normalising arrays, background correction, and log2 ratio calculation 
MA_allsampleRGSwap <- normalizeWithinArrays(RG_allsampleRGSwap, method="loess", bc.method="norme
xp", offset=50) 
plotMA(MA_allsampleRGSwap[,2]) 
plotDensities(MA_allsampleRGSwap) 
MA_RGSwapNorm <- normalizeBetweenArrays(MA_allsampleRGSwap, method="Gquantile") 
plotDensities(MA_RGSwapNorm) 
imageplot(MA_RGSwapNorm$M[,17], layout=MA_RGSwapNorm$printer) 
 
# Odd MA plots, 9, 17, 44, 67, 69, 73, 80, 145 
 
adf <- new("AnnotatedDataFrame", data=targets) 
adfgene <- new("AnnotatedDataFrame", data=genelist) 
experimentData <- new("MIAME", name="Maria Juarez, Jason Turner", lab="Andrew Filer", contact="a
.filer@bham.ac.uk", title="Gene expression in RA longitudinal synovial fibroblasts in response t
o TNF and/or Serum") 
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esetMA_RGSwapNorm <- new("ExpressionSet", exprs=MA_RGSwapNorm$M, phenoData= adf, experimentData=
experimentData, featureData=adfgene, annotation="AMADID039494") 
arrayQualityMetrics(esetMA_RGSwapNorm, outdir = "QC", intgroup = "StimSerum") 
 
#Arrayqualitymetrics outliers 30, 51, 52, 53, 67, 83, 129, 134, 135, 139, 140 
 
#Excluding manual MA plot checks and all ArrayQualityMetrics outliers 
dim(esetMA_RGSwapNorm) 
table(esetMA_RGSwapNorm$Group) 
esetMA_RGSwapNormClean <- esetMA_RGSwapNorm[,c(-9,-17,-30,-44,-51,-52,-53,-67,-69,-73,-80,-83,-1
29,-134, -139,-140,-145)] 
dim(esetMA_RGSwapNormClean) 
table(esetMA_RGSwapNormClean$Group) 
 
dim(MA_RGSwapNorm) 
MA_RGSwapNormClean <- MA_RGSwapNorm[,c(-9,-17,-30,-44,-51,-52,-53,-67,-69,-73,-80,-83,-129,-134, 
-139,-140,-145)] 
 
#Automated imageplotting for checking artefacts 
for(i in 1:132){ 
  imageplot(MA_RGSwapNormCleanCsex$M[,i], layout=MA_RGSwapNormCleanCsex$printer, main = i) 
  Sys.sleep(1.5) 
} 
#7,38, 55 
 
#Checking sample sex using XIST expression and removing samples which seemingly have incorrect s
ex info 
XISTexprs <- exprs(esetMA_RGSwapNormClean)[subsetting<-grep("XIST", esetMA_RGSwapNormClean@featu
reData$GeneName),] 
XISTexprsmean <- apply(XISTexprs, 2, mean) 
hist(XISTexprsmean) 
sex <- ifelse(XISTexprsmean>-1.2, "F", "M") 
CorrectSex <- as.matrix(esetMA_RGSwapNormClean$Gender == sex) 
table(CorrectSex) 
CorrectSex 
Csex <- grep("TRUE", CorrectSex) 
MA_RGSwapNormCleanCsex <- MA_RGSwapNormClean[,Csex] 
dim(MA_RGSwapNormCleanCsex) 
 
 
#Averaging replicate probes 
AvExprs<- avereps(MA_RGSwapNormCleanCsex$M, ID=MA_RGSwapNormCleanCsex$genes$ProbeUID) 
AvGenelist <- MA_RGSwapNormCleanCsex$genes[match(unique(MA_RGSwapNormCleanCsex$genes$ProbeName),  
                                                 MA_RGSwapNormCleanCsex$genes$ProbeName),] 
rownames(AvGenelist) <- AvGenelist$ProbeName 
rownames(AvExprs) <- rownames(AvGenelist) 
#Removing previous esets 
rm(esetMA_RGSwapNorm) 
rm(esetMA_RGSwapNormClean) 
 
#Generating new expression set 
adf <- new("AnnotatedDataFrame", data=MA_RGSwapNormCleanCsex$targets) 
adfgene <- new("AnnotatedDataFrame", data=AvGenelist) 
experimentData <- new("MIAME", name="Maria Juarez, Jason Turner", lab="Andrew Filer", contact="a
.filer@bham.ac.uk", title="Gene expression in RA longitudinal synovial fibroblasts in response t
o TNF and/or Serum") 
eset_RGSwap.Norm.Clean.Csex.AveRep <- new("ExpressionSet", exprs=AvExprs, phenoData= adf, experi
mentData=experimentData, featureData=adfgene, annotation="AMADID039494") 
dim(eset_RGSwap.Norm.Clean.Csex.AveRep) 
 
#Non-specific filtering 
eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt <- nsFilter(eset_RGSwap.Norm.Clean.Csex.AveRep, requir
e.entrez = FALSE, remove.dupEntrez = FALSE, var.func = sd, var.cutoff = 0.4) 
dim(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset) 
eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@phenoData$StimSerum <- paste(eset_RGSwap.Norm.Cle
an.Csex.AveRep.NSFilt$eset@phenoData$Stimulated, eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@
phenoData$Serum, sep=".") 
arrayQualityMetrics(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset, outdir = "QCEset", intgroup 
= "StimSerum") 
 
#---- End of data preparation 
 
 
#PCA, basic scripts but then modified to investigate other PCs 
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pca <- prcomp(t(exprs(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset))) 
autoplot(pca, x= 1, y= 2, data = pData(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset), 
         colour = 'StimSerum', size = 3, 
         frame = TRUE, frame.type = 'norm', xlab="PC1: 29.08% of variance", ylab="PC2: 11.01% of 
variance") 
 
#Subset data in treatment groups 
esetHigh <- eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset[,grep("High", eset_RGSwap.Norm.Clean.
Csex.AveRep.NSFilt$eset@phenoData$Serum)] 
table(esetHigh@phenoData$Serum) 
esetHighTNF <- esetHigh[,grep("TNF", esetHigh@phenoData$Stimulated)] 
table(esetHighTNF@phenoData$Stimulated) 
esetHighUnstim <- esetHigh[,grep("Unstim", esetHigh@phenoData$Stimulated)] 
table(esetHighUnstim@phenoData$Stimulated) 
esetLow <- eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset[,grep("Low", eset_RGSwap.Norm.Clean.Cs
ex.AveRep.NSFilt$eset@phenoData$Serum)] 
table(esetLow@phenoData$Serum) 
 
#PCA for individual treatment groups 
HiTNF.pca <- prcomp(t(exprs(esetHighTNF))) 
autoplot(HiTNF.pca, x= 1, y= 2, data = pData(esetHighTNF), 
         colour = 'Diagnosis', size = 3, 
         frame = TRUE, frame.type = 'norm') 
 
HiUnstim.pca <- prcomp(t(exprs(esetHighUnstim))) 
autoplot(HiUnstim.pca, x= 1, y= 2, data = pData(esetHighUnstim), 
         colour = 'Diagnosis', size = 3, 
         frame = TRUE, frame.type = 'norm') 
 
Low.pca <- prcomp(t(exprs(esetLow))) 
autoplot(Low.pca, x= 1, y= 2, data = pData(esetLow), 
         colour = 'Diagnosis', size = 3, 
         frame = TRUE, frame.type = 'norm') 
 
 
# 3D PCA plots for visualisation 
library(pca3d) 
pca3d(HiTNF.pca, components = 3:6, axes.color = "grey", bg = "white", radius = 1, labels.col = "
black", 
      show.axes = TRUE, group=factor(esetHighTNF@phenoData$Diagnosis), 
      show.axe.titles = TRUE,  show.plane = TRUE, 
      show.shapes = TRUE, show.centroids = TRUE, show.ellipses = TRUE, legend= "bottomleft") 
 
 
#Fitting a model to sex and sit then using residuals for second model fit to disease 
design <- model.matrix(~ 0 + eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@phenoData$Site 
                       + eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@phenoData$Gender) 
lmFitPatient <- lmFit(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset, design) 
resid <- residuals.MArrayLM(lmFitPatient, y= exprs(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$ese
t)) 
 
design <- model.matrix(~ 0 + eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@phenoData$Group) 
colnames(design) <- levels(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt$eset@phenoData$Group) 
 
eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt.Resid <-  new("ExpressionSet", exprs=resid,  
                                                        phenoData= new("AnnotatedDataFrame",  
                                                                       pData(eset_RGSwap.Norm.Cl
ean.Csex.AveRep.NSFilt$eset)),  
                                                        experimentData=experimentData,  
                                                        featureData=new("AnnotatedDataFrame",  
                                                                        fData(eset_RGSwap.Norm.C
lean.Csex.AveRep.NSFilt$eset)),  
                                                        annotation="AMADID039494") 
dim(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt.Resid) 
 
fitPatientremoved <- lmFit(eset_RGSwap.Norm.Clean.Csex.AveRep.NSFilt.Resid, design) 
 
#Contrast matrix 
cont.matrix <- makeContrasts( 
  #Within treatment comparisons (What is DE between outcomes treated the same) 
  TNFJrepvEstRA=Jrep.High.TNF-EstRA.High.TNF, 
  TNFJrepvEarly=Jrep.High.TNF-Early.High.TNF, 
  TNFJrepvRes=Jrep.High.TNF-Res.High.TNF, 
 323 
 
  TNFJrepvNorm=Jrep.High.TNF-Norm.High.TNF, 
  TNFEstRAvEarly=EstRA.High.TNF-Early.High.TNF, 
  TNFEstRAvRes=EstRA.High.TNF-Res.High.TNF, 
  TNFEstRAvNorm=EstRA.High.TNF-Norm.High.TNF, 
  TNFEarlyvRes=Early.High.TNF-Res.High.TNF, 
  TNFEarlyvNorm=Early.High.TNF-Norm.High.TNF, 
  TNFResvNorm=Res.High.TNF-Norm.High.TNF, 
   
  HighJrepvEstRA=Jrep.High.Unstim-EstRA.High.Unstim, 
  HighJrepvEarly=Jrep.High.Unstim-Early.High.Unstim, 
  HighJrepvRes=Jrep.High.Unstim-Res.High.Unstim, 
  HighJrepvNorm=Jrep.High.Unstim-Norm.High.Unstim, 
  HighEstRAvEarly=EstRA.High.Unstim-Early.High.Unstim, 
  HighEstRAvRes=EstRA.High.Unstim-Res.High.Unstim, 
  HighEstRAvNorm=EstRA.High.Unstim-Norm.High.Unstim, 
  HighEarlyvRes=Early.High.Unstim-Res.High.Unstim, 
  HighEarlyvNorm=Early.High.Unstim-Norm.High.Unstim, 
  HighResvNorm=Res.High.Unstim-Norm.High.Unstim, 
   
  LowJrepvEstRA=Jrep.Low.Unstim-EstRA.Low.Unstim, 
  LowJrepvEarly=Jrep.Low.Unstim-Early.Low.Unstim, 
  LowJrepvRes=Jrep.Low.Unstim-Res.Low.Unstim, 
  LowJrepvNorm=Jrep.Low.Unstim-Norm.Low.Unstim, 
  LowEstRAvEarly=EstRA.Low.Unstim-Early.Low.Unstim, 
  LowEstRAvRes=EstRA.Low.Unstim-Res.Low.Unstim, 
  LowEstRAvNorm=EstRA.Low.Unstim-Norm.Low.Unstim, 
  LowEarlyvRes=Early.Low.Unstim-Res.Low.Unstim, 
  LowEarlyvNorm=Early.Low.Unstim-Norm.Low.Unstim, 
  LowResvNorm=Res.Low.Unstim-Norm.Low.Unstim, 
   
  #Between treatment contrasts (How does treatment affect each outcome group) 
  JrepTNFvHigh=Jrep.High.TNF-Jrep.High.Unstim, 
  JrepHighvLow=Jrep.High.Unstim-Jrep.Low.Unstim, 
   
  EstRATNFvHigh=EstRA.High.TNF-EstRA.High.Unstim, 
  EstRAHighvLow=EstRA.High.Unstim-EstRA.Low.Unstim, 
   
  EarlyTNFvHigh=Early.High.TNF-Early.High.Unstim, 
  EarlyHighvLow=Early.High.Unstim-Early.Low.Unstim, 
   
  ResTNFvHigh=Res.High.TNF-Res.High.Unstim, 
  ResHighvLow=Res.High.Unstim-Res.Low.Unstim, 
   
  NormTNFvHigh=Norm.High.TNF-Norm.High.Unstim, 
  NormHighvLow=Norm.High.Unstim-Norm.Low.Unstim, 
   
  #Differences in TNF response from high serum samples between outcomes 
  #(What is different in the response to TNF between outcome groups in high serum) 
  JrepHighStimUnsvsEstRAHighStimUns=(Jrep.High.TNF-Jrep.High.Unstim)-(EstRA.High.TNF-EstRA.High.
Unstim), 
  JrepHighStimUnsvsEarlyHighStimUns=(Jrep.High.TNF-Jrep.High.Unstim)-(Early.High.TNF-Early.High.
Unstim), 
  JrepHighStimUnsvsResHighStimUns=(Jrep.High.TNF-Jrep.High.Unstim)-(Res.High.TNF-Res.High.Unstim
), 
  JrepHighStimUnsvsNormHighStimUns=(Jrep.High.TNF-Jrep.High.Unstim)-(Norm.High.TNF-Norm.High.Uns
tim), 
   
  EstRAHighStimUnsvsEarlyHighStimUns=(EstRA.High.TNF-EstRA.High.Unstim)-(Early.High.TNF-Early.Hi
gh.Unstim), 
  EstRAHighStimUnsvsResHighStimUns=(EstRA.High.TNF-EstRA.High.Unstim)-(Res.High.TNF-Res.High.Uns
tim), 
  EstRAHighStimUnsvsNormHighStimUns=(EstRA.High.TNF-EstRA.High.Unstim)-(Norm.High.TNF-Norm.High.
Unstim), 
   
  EarlyHighStimUnsvsResHighStimUns=(Early.High.TNF-Early.High.Unstim)-(Res.High.TNF-Res.High.Uns
tim), 
  EarlyHighStimUnsvsNormHighStimUns=(Early.High.TNF-Early.High.Unstim)-(Norm.High.TNF-Norm.High.
Unstim), 
   
  ResHighStimUnsvsNormHighStimUns=(Res.High.TNF-Res.High.Unstim)-(Norm.High.TNF-Norm.High.Unstim
), 
   
  #Differences in serum response between outcomes 
  #(What is different in the response to serum between outcome groups) 
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  JrepUnsHighLowvsEstRAUnsHighLow=(Jrep.High.Unstim-Jrep.Low.Unstim)-(EstRA.High.Unstim-EstRA.Lo
w.Unstim), 
  JrepUnsHighLowvsEarlyUnsHighLow=(Jrep.High.Unstim-Jrep.Low.Unstim)-(Early.High.Unstim-Early.Lo
w.Unstim), 
  JrepUnsHighLowvsResUnsHighLow=(Jrep.High.Unstim-Jrep.Low.Unstim)-(Res.High.Unstim-Res.Low.Unst
im), 
  JrepUnsHighLowvsNormUnsHighLow=(Jrep.High.Unstim-Jrep.Low.Unstim)-(Norm.High.Unstim-Norm.Low.U
nstim), 
   
  EstRAUnsHighLowvsEarlyUnsHighLow=(EstRA.High.Unstim-EstRA.Low.Unstim)-(Early.High.Unstim-Early
.Low.Unstim), 
  EstRAUnsHighLowvsResUnsHighLow=(EstRA.High.Unstim-EstRA.Low.Unstim)-(Res.High.Unstim-Res.Low.U
nstim), 
  EstRAUnsHighLowvsNormUnsHighLow=(EstRA.High.Unstim-EstRA.Low.Unstim)-(Norm.High.Unstim-Norm.Lo
w.Unstim), 
   
  EarlyUnsHighLowvsResUnsHighLow=(Early.High.Unstim-Early.Low.Unstim)-(Res.High.Unstim-Res.Low.U
nstim), 
  EarlyUnsHighLowvsNormUnsHighLow=(Early.High.Unstim-Early.Low.Unstim)-(Norm.High.Unstim-Norm.Lo
w.Unstim), 
   
  ResUnsHighLowvsNormUnsHighLow=(Res.High.Unstim-Res.Low.Unstim)-(Norm.High.Unstim-Norm.Low.Unst
im), 
   
  levels=design) 
 
fit.contPR <- contrasts.fit(fitPatientremoved, cont.matrix) 
fit.contPR <- eBayes(fit.contPR, trend = TRUE) 
summa.fitPR <- decideTests(fit.contPR) 
summary(summa.fitPR) 
 
#Generating tables of DE genes for assesment, functions modified to generate table for each comp
arison 
topTable(fit.contPR, coef = "LowJrepvEstRA", number = "inf", sort.by = "p") 
write.table(topTable(fit.contPR, coef = "TNFJrepvEstRA", number = "inf",  
                     sort.by = "p", p.value = 0.05), file= "TNFJrepvEstRA.txt", 
            row.names=FALSE, sep="\t") 
 
#After DE gene lists manually curated and specific genes selected the genes are imported as an i
ndex and used to  
#select only those genes in the comparisons 
IndexDups <- read.table(file="/DE genes after dual models one for donor variation/TNF/IndexwithD
ups.csv", sep = ",") 
Index <- IndexDups[!duplicated(IndexDups[,1]),1] 
Index <- read.table(file="DE genes after dual models one for donor variation/High/HighIndex.csv"
, sep = ",") 
Index <- Index[,1] 
Index <- read.table(file="DE genes after dual models one for donor variation/Low/LowIndex.csv", 
sep = ",") 
Index <- Index[,1] 
write.table(topTable(fit.contPR, coef = "LowResvNorm", number = "inf",  
                     sort.by = "p", p.value = 0.05)[which(topTable(fit.contPR, coef = "LowResvNo
rm", number = "inf",  
                                                                   sort.by = "p", p.value = 0.05
)$GeneName %in% Index),],  
            file= "LowResvNormIndexed.txt", 
            row.names=FALSE, sep="\t") 
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8.6 Differentially expressed gene lists from the TNF stimulated samples 
in the microarray experiments 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS3 NM_005329 1.054702895 0.036434211 
IL6 ENST00000420258 1.036563257 0.01672477 
COX1 ENST00000361624 1.002815221 0.020692944 
TSLP NM_033035 0.838692824 0.043702812 
IL4R NM_001008699 0.824232506 0.000207513 
IL34 NM_152456 0.649308856 0.020359111 
COQ10B NM_025147 0.577607612 0.028807291 
RASA2 NM_006506 0.469517126 0.026552842 
SERPINA4 NM_006215 -0.27276859 0.039570443 
COQ4 ENST00000372875 -0.291628217 0.013266841 
TFAP2B NM_003221 -0.310597678 0.022509149 
SYK NM_003177 -0.312360373 0.015280483 
SERPINA11 NM_001080451 -0.315908297 0.024683341 
COX6B2 NM_144613 -0.357205493 0.042127734 
PRODH2 NM_021232 -0.357826783 0.047409007 
IGSF1 NM_205833 -0.367907039 0.022412505 
SCARF2 NM_153334 -0.368129934 0.029150229 
LTB4R NM_181657 -0.369842067 0.044842034 
JAG2 NM_002226 -0.377159478 0.008659967 
NKAPP1 NR_027131 -0.381701206 0.03398931 
GZMM NM_005317 -0.388316219 0.047812223 
CARD14 NM_024110 -0.401338952 0.001675318 
SERPINB5 NM_002639 -0.404592656 0.031972296 
SERPINF2 NM_000934 -0.411482236 0.007020224 
HYAL4 NM_012269 -0.413309382 0.023995728 
ALDH1L1 NM_012190 -0.416419317 0.010569011 
PTPRC NM_002838 -0.435473418 0.009750039 
CCR2 NM_001123041 -0.440047841 0.035002169 
DUSP9 NM_001395 -0.442209666 0.021787886 
CD8B NM_172102 -0.452619432 0.018455135 
SOX10 NM_006941 -0.464535869 0.004956761 
CEBPD NM_005195 -0.479820555 0.009755944 
FGFR4 NM_213647 -0.490677476 0.002823283 
OSCAR NM_206818 -0.49149354 0.018022606 
CD3G NM_000073 -0.524078376 0.015664904 
IGSF1 NM_001555 -0.525779399 0.001542396 
ZAP70 NM_001079 -0.540821832 0.003781331 
FGA NM_021871 -0.585354185 0.000774919 
LCK NM_005356 -0.595633057 0.003621978 
SMAD1 NM_005900 -0.662092385 0.048686729 
RUNX1 NM_001001890 -0.702080226 0.026728522 
SERPINA3 NM_001085 -0.745231337 0.024683341 
ZFP36 NM_003407 -0.961766073 0.047528418 
COL7A1 NM_000094 -1.275588743 0.009791834 
CD86 NM_006889 -1.534046141 0.000774919 
MMP9 NM_004994 -1.550404411 0.03395765 
FOSB NM_006732 -2.020307681 0.01672477 
FOS NM_005252 -2.051984537 0.005459512 
Table 66: Selected significantly differentially expressed genes between JRep and EstRA fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS3 NM_005329 1.388361371 0.001314505 
CLEC3B NM_003278 0.882403683 0.014027336 
IL6 ENST00000420258 0.843053943 0.045422769 
FGFR1 NM_001174066 0.720790581 0.025589189 
TP53 NM_000546 0.473628873 0.001842865 
CDK8 NM_001260 0.461395358 0.030149868 
ADAM1 NR_036636 0.401599092 0.040740541 
TFAP2A ENST00000478375 0.27549022 0.037181421 
SOX13 ENST00000367203 0.275129638 0.033419206 
IKBKE NM_014002 -0.433752833 0.011167086 
RUNX1 NM_001122607 -0.467088011 0.016944944 
EGR4 NM_001965 -0.631455659 0.047512838 
ICAM4 NM_022377 -0.648142081 0.044741214 
BCL6 NM_001130845 -0.732160211 0.045440797 
SMAD1 NM_005900 -0.764398121 0.009307684 
HIST2H2BE NM_003528 -0.82659043 0.014068168 
RUNX1 NM_001122607 -1.065735825 0.001983654 
ZFP36 NM_003407 -1.220850599 0.003432037 
CLIC2 NM_001289 -1.225785884 0.034111787 
EGR1 NM_001964 -1.409174392 0.018170981 
FGF13 NM_004114 -1.827580743 0.017386367 
FOS NM_005252 -2.283156057 0.001127113 
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FOSB NM_006732 -2.491572913 0.001170927 
Table 67: Selected significantly differentially expressed genes between JRep and veRA fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS3 NM_005329 1.220568339 0.015890829 
IKBKE NM_014002 -0.440116965 0.018062278 
KMO NM_003679 -0.652033079 0.032306399 
TNF NM_000594 -0.786212456 0.024519039 
TLR3 NM_003265 -0.902515387 0.049960793 
ZFP36 NM_003407 -0.984824292 0.048576639 
CLIC2 NM_001289 -1.279694689 0.043166782 
FOSB NM_006732 -1.827600248 0.0389089 
FOS NM_005252 -1.852227398 0.016089606 
Table 68: Selected significantly differentially expressed genes between JRep and Res fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS2 NM_005328 1.6493715 0.031226592 
CDH13 NM_001257 1.609310774 0.049496744 
CDK6 NM_001259 1.442275755 0.00552671 
CD200 NM_001004196 1.416415032 0.001807355 
IRX1 NM_024337 1.391417635 0.01109573 
TAGLN NM_001001522 1.356057454 0.004544098 
LIMS2 NM_001161404 1.313388544 0.03874136 
IL6 ENST00000420258 1.247783845 0.000766548 
SERPINE1 NM_000602 1.242720696 0.030802221 
HAS3 NM_005329 1.235658372 0.004644338 
CDH13 NM_001220491 1.164016697 0.043781079 
HIST1H4L NM_003546 1.14053117 0.03755767 
HIST1H4C NM_003542 1.102695626 0.031591204 
TIMP3 NM_000362 1.058173824 0.002665742 
HIST1H4B NM_003544 1.047977395 0.04682513 
HMGB3 NM_005342 0.861838574 0.003304848 
TSLP NM_033035 0.852520582 0.021481896 
TRAIP NM_005879 0.842965855 0.046220202 
TAGLN NM_001001522 0.83759227 0.013915622 
LIMS2 NM_001161404 0.800592518 0.045026249 
SERPINA9 NM_175739 0.734939 0.015377522 
CD200 NM_001004196 0.715674783 0.020030768 
COL6A1 NM_001848 0.68740846 0.014888864 
CASP6 NM_001226 0.423294377 0.01574508 
OXSR1 NM_005109 0.407115297 0.044814047 
ILF3 NM_004516 0.406824919 0.045026249 
CCL17 NM_002987 -0.274552983 0.049766715 
CARD14 NM_024110 -0.288585323 0.019267016 
SGPP2 ENST00000321276 -0.293577187 0.023349752 
RUNX1 NM_001001890 -0.347789165 0.044939921 
HPGDS NM_014485 -0.383558214 0.001100795 
IL18BP NM_173042 -0.414382685 0.046810494 
IL17C NM_013278 -0.446974695 0.046105813 
IL15RA ENST00000379971 -0.453949707 0.027239622 
HSD17B7 NM_016371 -0.456440071 0.002406027 
STAT3 NM_213662 -0.488457338 0.026734798 
IFNAR1 NM_000629 -0.51884563 0.012192049 
KMO NM_003679 -0.528427282 0.002261617 
ZFP36L1 ENST00000408913 -0.53023163 0.009946613 
IL10RB NM_000628 -0.548664261 0.022957886 
NFKB1 NM_003998 -0.570133675 0.008605139 
ALDH6A1 NM_005589 -0.581385757 0.042162771 
HSD17B7 NM_016371 -0.597279098 0.00110405 
C1RL NM_016546 -0.602289744 0.001374465 
SGPP2 NM_152386 -0.60302848 0.002194067 
RUNX1 NM_001001890 -0.624297051 0.033746459 
IFNGR2 NM_005534 -0.634977189 0.014936099 
HSD17B7 NM_016371 -0.636658897 0.001457456 
IL13RA1 NM_001560 -0.652716092 0.024094389 
ZFP36L1 NM_004926 -0.65944701 0.044561829 
TGFA NM_003236 -0.66034474 0.028178336 
IFNAR2 NM_000874 -0.661848666 0.008913532 
OSMR NM_001168355 -0.665886636 0.002987967 
OSMR NM_003999 -0.689530989 0.007458511 
DUSP8 NM_004420 -0.703434358 0.017017269 
IL15RA NM_172200 -0.714050165 0.030377979 
JMJD7 NM_001114632 -0.715963215 0.001345267 
CD274 NM_014143 -0.735134724 0.003347188 
FOXP2 NM_148900 -0.740218665 0.009416389 
CD274 NM_014143 -0.768517611 0.000425461 
IFNAR2 NM_207585 -0.775137389 4.12E-05 
IRAK3 NM_007199 -0.778015073 0.003347188 
NFKBIE NM_004556 -0.838944803 0.000706544 
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CTSO NM_001334 -0.861289321 0.016867391 
CCL3L3 NM_001001437 -0.86287025 0.043562106 
SPHK1 NM_182965 -0.869544118 0.010158493 
BCL6 NM_001130845 -0.908790696 0.006944638 
C1RL NM_016546 -0.918542705 0.034086614 
TNF NM_000594 -0.923172673 0.001972305 
CD44 NM_001202557 -0.937638469 0.00968053 
SMAD1 NM_005900 -0.938082696 0.00071194 
LYVE1 NM_006691 -0.941841145 0.020505762 
CXCL10 NM_001565 -0.953793859 0.004921272 
IFI35 NM_005533 -0.964948123 0.00968053 
MMP2 NM_004530 -0.968656737 0.001089634 
ALDH2 NM_000690 -0.988034137 0.030698328 
DUSP1 NM_004417 -0.999226302 0.030698328 
IL15RA NM_001243539 -1.000799325 0.011020048 
TLR3 NM_003265 -1.026124493 0.008573067 
CD38 NM_001775 -1.053950124 0.009484482 
CSF3 NM_000759 -1.054566136 0.001682605 
SOCS2 NM_003877 -1.093477979 0.044179519 
C1QTNF5 NM_015645 -1.104644232 0.040394877 
CTSL1 NM_001912 -1.148471258 0.008229376 
HLA-F NM_001098478 -1.174982123 0.039154415 
PPARG NM_138711 -1.195556426 0.019516039 
CCL4 NM_002984 -1.200036135 0.009799091 
PPARG NM_138711 -1.205511203 0.040394877 
ZFP36 NM_003407 -1.213005913 0.003264632 
DUSP8 NM_004420 -1.227056592 0.000530288 
LBP NM_004139 -1.304005346 0.004500834 
CSF3 NM_000759 -1.337794611 0.011119258 
KMO NM_003679 -1.350190315 2.08E-08 
CCL4 NM_002984 -1.371833412 0.007458511 
IL36B NM_173178 -1.416273994 0.022957886 
CCL3L3 NM_001001437 -1.497368381 0.003771971 
PDGFRL NM_006207 -1.564402795 0.04368698 
CD34 NM_001773 -1.589703908 0.035779095 
CX3CL1 NM_002996 -1.595375062 3.89E-05 
CTSK NM_000396 -1.602221735 0.001126142 
NOD2 NM_022162 -1.658431646 7.18E-05 
CCL20 NM_004591 -1.783319571 0.009264125 
IDO1 NM_002164 -1.844872808 0.015106843 
LEF1 NM_016269 -1.978667398 1.84E-05 
MMP9 NM_004994 -2.062437596 0.000751947 
FOS NM_005252 -2.12843472 0.001100795 
CXCL9 NM_002416 -2.18179791 0.00334655 
CXCL11 NM_005409 -2.211024027 0.009815964 
FGF13 NM_004114 -2.233289418 0.001666051 
CXCL10 NM_001565 -2.239079297 0.000421839 
CLIC2 NM_001289 -2.345714422 1.74E-06 
CCL8 NM_005623 -2.605995483 1.96E-06 
IL23A NM_016584 -2.876867793 0.004167708 
Table 69: Selected significantly differentially expressed genes between JRep and Norm fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
CD86 NM_006889 1.691988908 1.28E-06 
HIST1H1D NM_005320 1.370161882 0.048339094 
HIST1H2AG NM_021064 0.909831741 0.038024279 
XIST NR_001564 0.781036032 0.003032042 
XIST NR_001564 0.77012738 0.002708592 
CLEC3B NM_003278 0.760223125 0.00864492 
SERPINA3 NM_001085 0.736809069 0.002201534 
XIST NR_001564 0.728273701 0.006557277 
FGA NM_021871 0.711047069 2.03E-07 
HIST1H2BF NM_003522 0.69768458 0.037913163 
CX3CR1 NM_001337 0.681183077 0.010977937 
CD3G NM_000073 0.633343327 5.10E-05 
HIF3A ENST00000457865 0.630607099 0.000137984 
LCK NM_005356 0.626589207 4.19E-05 
XIST NR_001564 0.612346772 0.002362684 
HAPLN2 NM_021817 0.608447078 0.011728367 
XIST NR_001564 0.585688384 0.028960163 
ADAM8 NM_001109 0.584218902 0.019632455 
PTPRC NM_002838 0.581900029 2.24E-06 
XIST NR_001564 0.572566779 0.00218547 
ADAMTS7 NM_014272 0.571086422 0.00056656 
FGA NM_021871 0.570498787 0.029496042 
CD69 ENST00000416624 0.552114648 3.96E-05 
CD8B NM_172102 0.546413516 6.80E-05 
C4BPB NM_000716 0.543892004 0.000337099 
ZFP36L1 ENST00000408913 0.531648189 0.000500841 
FGFR4 NM_213647 0.530368081 1.61E-05 
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TNFSF12 NM_003809 0.499036225 0.023950109 
SERPINA6 NM_001756 0.493966888 0.003901558 
IL2RG NM_000206 0.472615111 6.74E-05 
CCR2 NM_001123041 0.472546071 0.001457813 
SERPINB5 NM_002639 0.461032925 0.000545111 
SMAD5 NM_001001419 0.457758655 0.003535859 
ZAP70 NM_001079 0.453024816 0.001362799 
CD52 NM_001803 0.451231471 0.02980525 
PTPRC NM_002838 0.448590629 0.006506869 
LCK NM_005356 0.445543218 0.002427911 
PTPRC NM_002838 0.441392369 0.00531806 
TFAP2A ENST00000478375 0.438124734 7.13E-06 
KLB NM_175737 0.429161261 0.00034775 
PDPR NM_017990 0.420840653 0.00027076 
SERPINA7 NM_000354 0.415856591 0.001059914 
ADAM22 NM_021721 0.411186828 0.002002345 
SERPINC1 NM_000488 0.405037595 0.008920011 
HDAC10 NM_032019 0.403284537 0.00880644 
CD5 NM_014207 0.40212043 0.010897038 
PRODH2 NM_021232 0.397831018 0.001763908 
CD69 NM_001781 0.395857927 0.011573273 
CD247 NM_198053 0.389671489 0.003239389 
IGSF1 NM_205833 0.388551629 0.020041898 
CD33 NM_001772 0.383877957 0.019266639 
CASP2 NM_032982 0.383059396 0.004015127 
CD6 NM_006725 0.381438125 0.006879023 
SYK NM_003177 0.381433568 4.12E-05 
ALDH1L1 NM_012190 0.380645722 0.00158906 
JAG2 NM_002226 0.370181 0.000420857 
IGSF1 NM_001555 0.365763079 0.004782584 
SERPINA11 NM_001080451 0.364689486 0.000268538 
IGSF1 NM_205833 0.36211567 0.001868555 
COL11A2 NM_080680 0.360598939 0.009615331 
COL2A1 NM_001844 0.359664813 0.002988953 
COQ4 ENST00000372875 0.354794766 3.22E-05 
COL11A2 NM_080680 0.354765832 0.007253614 
MAPK4 NM_002747 0.354228566 0.016123701 
CDK3 NM_001258 0.349222949 0.002864536 
GZMM NM_005317 0.341028948 0.018935952 
SOX10 NM_006941 0.326774672 0.010697961 
CARD14 NM_024110 0.325154201 0.000838469 
CD8B NM_004931 0.320845322 0.033084139 
SOX13 ENST00000367203 0.313364698 0.001259891 
SERPINF2 NM_000934 0.308958109 0.007937836 
ADH6 NM_000672 0.285227063 0.007269505 
SERPINA4 NM_006215 0.283669087 0.00277543 
ICAM5 NM_003259 0.272813937 0.010977937 
MYB ENST00000528345 0.265743606 0.028484998 
TRAF3IP3 NM_025228 0.252138632 0.028733741 
ALOX5AP NM_001629 0.2340983 0.024922621 
IKBKB ENST00000517917 0.232276725 0.046353465 
HS3ST4 NM_006040 0.225007532 0.047861668 
SOX21 NM_007084 0.22119704 0.036847802 
ALOX5 NM_000698 0.220905386 0.018052175 
SSX2 NM_175698 0.216502857 0.028484998 
HSD17B7 ENST00000367915 0.20804293 0.039378397 
FGF14 NM_175929 -0.257522526 0.029001674 
HDAC2 NM_001527 -0.265998612 0.020405397 
SDHB NM_003000 -0.337718627 0.017233207 
EGFR NM_201282 -0.377178989 0.034524637 
IRF2 NM_002199 -0.382769818 0.035031078 
IKBKE NM_014002 -0.415870733 0.002300704 
COQ10B NM_025147 -0.416384555 0.026970803 
IRAK3 NM_007199 -0.512078496 0.02926486 
IL4R NM_001008699 -0.535459807 0.002098042 
EGR4 NM_001965 -0.540265742 0.036183372 
SOCS6 NM_004232 -0.576148706 0.003186845 
IFNE NM_176891 -0.60598381 0.041157673 
RUNX1 NM_001122607 -0.638687262 0.038938588 
COX1 ENST00000361624 -0.840009757 0.009253926 
CDH11 ENST00000394156 -0.859638518 0.006426459 
Table 70: Selected significantly differentially expressed genes between estRA and veRA fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
CD86 NM_006889 1.389353652 0.000110696 
SERPINA3 NM_001085 0.631049849 0.016910971 
FGA NM_021871 0.597545548 1.95E-05 
FGFR4 NM_213647 0.526193187 4.56E-05 
PTPRC NM_002838 0.517090051 5.43E-05 
HIF3A ENST00000457865 0.514604096 0.003998147 
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LCK NM_005356 0.489726667 0.00262486 
ADAMTS7 NM_014272 0.478062428 0.008058912 
CD3G NM_000073 0.456491408 0.007315394 
XIST NR_001564 0.454882468 0.049413966 
ZFP36L1 ENST00000408913 0.439942983 0.008279145 
CD69 ENST00000416624 0.41418873 0.004147856 
ZAP70 NM_001079 0.413148222 0.006511869 
TFAP2A ENST00000478375 0.402771447 5.91E-05 
IGSF1 NM_001555 0.393891505 0.003564809 
CD8B NM_172102 0.381374764 0.012388163 
CD6 NM_006725 0.360756503 0.017904322 
CARD14 NM_024110 0.344221985 0.00071852 
SERPINB5 NM_002639 0.340080032 0.024858009 
GZMM NM_005317 0.33880869 0.03003083 
KLB NM_175737 0.334828834 0.011502591 
IL2RG NM_000206 0.332472138 0.01141724 
JAG2 NM_002226 0.326914767 0.003691402 
COQ4 ENST00000372875 0.322244331 0.000274342 
IGSF1 NM_205833 0.318299758 0.011937787 
SERPINA11 NM_001080451 0.316737737 0.003055865 
CDK3 NM_001258 0.303960575 0.017996744 
ALDH1L1 NM_012190 0.2997419 0.027345873 
ICAM5 NM_003259 0.292426984 0.009031449 
SERPINA4 NM_006215 0.273377538 0.006720263 
IKBKB ENST00000517917 0.261226007 0.031079901 
SYK NM_003177 0.261037521 0.010663505 
SOX13 ENST00000367203 0.259644339 0.015159833 
IKBKE NM_014002 -0.422234866 0.003158306 
IL4R NM_001008699 -0.59549829 0.000887368 
COX1 ENST00000361624 -0.938249452 0.004908659 
CDH11 ENST00000394156 -0.971410631 0.002778639 
Table 71: Selected significantly differentially expressed genes between estRA and Res fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
CD86 NM_006889 1.563459581 0.000123487 
CDH13 NM_001257 1.537029867 0.037313916 
HAS2 NM_005328 1.502620566 0.03357635 
UBE2C NM_181803 1.489955088 0.027924586 
HMMR NM_012484 1.467669381 0.024310377 
HIST1H2AG NM_021064 1.335573456 0.00466954 
SERPINE1 NM_000602 1.16013258 0.028524381 
HIST1H4C NM_003542 1.125427058 0.016167988 
HIST1H4L NM_003546 1.108510183 0.026179302 
TRAIP NM_005879 1.085933188 0.003670476 
SERPINA3 NM_001085 1.070070001 0.025490247 
HIST1H4B NM_003544 0.994390986 0.037047428 
HMGB2 NM_002129 0.932994223 0.047323612 
SERPINA3 NM_001085 0.927220414 0.000863092 
HMGB3 NM_005342 0.911422971 0.001211103 
CD200 NM_001004196 0.910262838 0.044512677 
HIST1H2BF NM_003522 0.859317407 0.018699219 
HIST1H4L NM_003546 0.751531177 0.038554682 
COL6A1 NM_001848 0.709016063 0.007144767 
SERPINA9 NM_175739 0.707830572 0.012668494 
CD200 NM_001004196 0.68175105 0.017166993 
HMGB3 NM_005342 0.671335463 0.022557566 
XIST NR_001564 0.658895783 0.03321227 
CX3CR1 NM_001337 0.619154324 0.043721172 
XIST NR_001564 0.616633531 0.0411869 
IL24 NM_001185156 0.614822074 0.012573438 
MMP15 NM_002428 0.613820863 0.002400954 
ADAM8 NM_001109 0.612417674 0.028729551 
LCK NM_005356 0.584613629 0.001166384 
FGA NM_021871 0.557814954 0.000371438 
IGSF1 NM_001555 0.54567491 0.000187907 
TNFSF12 NM_003809 0.544674139 0.026622437 
CD3G NM_000073 0.541644498 0.003224028 
HIST1H2AC NM_003512 0.52565108 0.019338646 
HDAC10 NM_032019 0.509516579 0.003307606 
ZAP70 NM_001079 0.493057055 0.002555697 
XIST NR_001564 0.484847915 0.026872866 
CD8B NM_172102 0.483123053 0.002774021 
PTPRC NM_002838 0.478132549 0.000950172 
SOX10 NM_006941 0.454839192 0.001527243 
FGFR4 NM_213647 0.447820798 0.001932167 
SERPINA6 NM_001756 0.44604894 0.02532153 
IL2RG NM_000206 0.418665962 0.002666762 
LCK NM_005356 0.412883239 0.015733663 
ALDH1L1 NM_012190 0.400957983 0.004119238 
PRODH2 NM_021232 0.399089585 0.006910346 
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C4BPB NM_000716 0.397645789 0.028242353 
HYAL4 NM_012269 0.390610299 0.011115279 
ILF3 NM_012218 0.390018509 0.028242353 
SERPINF2 NM_000934 0.383232306 0.003575748 
CCR2 NM_001123041 0.383188797 0.028856134 
JAG2 NM_002226 0.378324734 0.002035801 
COQ4 ENST00000372875 0.377325398 0.000139996 
DUSP9 NM_001395 0.375589856 0.021701483 
SOCS4 NM_199421 0.374660478 0.009046961 
PDPR NM_017990 0.370248054 0.00665152 
IGSF1 NM_205833 0.365517775 0.006817367 
CD8B NM_004931 0.355195396 0.032318038 
CD6 NM_006725 0.354842673 0.029099309 
CDK3 NM_001258 0.348961865 0.010034215 
SERPINB5 NM_002639 0.34170054 0.032111992 
SERPINA11 NM_001080451 0.326307291 0.005795158 
COL11A2 NM_080680 0.321306573 0.044851662 
COX6B2 NM_144613 0.303749477 0.039307975 
NKAPP1 NR_027131 0.298702221 0.049673575 
HSD17B7 ENST00000367915 0.292236869 0.007183296 
SYK NM_003177 0.283521149 0.009882345 
SERPINA4 NM_006215 0.268678191 0.01454975 
TFAP2A ENST00000478375 0.24187981 0.039975867 
SMAD4 NM_005359 -0.297128508 0.04456685 
CCL17 NM_002987 -0.359780165 0.003487231 
RASA2 NM_006506 -0.376087841 0.037460651 
IFNAR1 NM_000629 -0.39556539 0.045615513 
HPGDS NM_014485 -0.422237447 0.000206038 
STAT5A NM_003152 -0.43525795 0.022187366 
EGFR NM_201282 -0.438639945 0.025092737 
JAK3 NM_000215 -0.443315153 0.003283529 
IL34 NM_152456 -0.473032387 0.048959135 
HSD17B7 NM_016371 -0.499442153 0.005742228 
JMJD7 NM_001114632 -0.507511918 0.022187366 
CD274 NM_014143 -0.512925039 0.037500662 
SGPP2 NM_152386 -0.531868185 0.005667209 
IL15RA ENST00000379971 -0.542748294 0.003670476 
CSF1 NM_000757 -0.544993197 0.022782128 
DUSP8 NM_004420 -0.555988187 0.046325536 
IL6ST NM_001190981 -0.56338086 0.036277051 
NFKBIE NM_004556 -0.585423163 0.017604695 
C1RL NM_016546 -0.593295161 0.001288624 
FGFR1 NM_001174066 -0.602380323 0.040371246 
STAG2 NM_001042749 -0.603627691 0.037134847 
HSD17B7 NM_016371 -0.616523976 0.001628698 
CD274 NM_014143 -0.620277999 0.00390128 
IFNAR2 NM_000874 -0.649999468 0.006516779 
BCL6 NM_001130845 -0.650485044 0.045267101 
TNF NM_000594 -0.658195698 0.025809434 
KMO NM_003679 -0.668476509 5.53E-05 
CSF3 NM_000759 -0.687700438 0.040647882 
NFKB1 NM_003998 -0.689712459 0.000720464 
CSF1 NM_172210 -0.704572097 0.013648841 
IL6ST NM_001190981 -0.720779249 0.007945021 
FOXP2 NM_148900 -0.722520878 0.007112283 
KGFLP1 NR_003674 -0.725823576 0.026622437 
IL13RA1 NM_001560 -0.751814579 0.00455215 
COQ10B NM_025147 -0.760028117 0.000532896 
COQ10B NM_025147 -0.762325861 0.000160722 
SERPING1 NM_000062 -0.763300222 0.041015229 
IFNAR2 NM_207585 -0.77373329 4.87E-05 
SPHK1 NM_182965 -0.804631376 0.01191349 
MMP2 NM_004530 -0.817274774 0.005083732 
IRAK3 NM_007199 -0.836042773 0.001091906 
IL15RA NM_172200 -0.871663288 0.003477945 
CD44 NM_001202557 -0.873522492 0.010761402 
CD55 NM_000574 -0.890591186 0.01162128 
C1RL NM_016546 -0.920338575 0.019751224 
NOD2 NM_022162 -0.958713101 0.024983953 
IL4R NM_001008699 -0.966299923 1.53E-06 
IL15RA NM_172200 -1.026469726 0.040051804 
DUSP8 NM_004420 -1.058484082 0.002349161 
PPARG NM_138711 -1.065016897 0.026532499 
IL15RA NM_001243539 -1.073430543 0.003669008 
CD34 NM_001025109 -1.090273073 0.044202978 
CX3CL1 NM_002996 -1.094933535 0.005795158 
PPARG NM_138711 -1.103628695 0.039339553 
SERPING1 NM_000062 -1.106394233 0.004161134 
KMO NM_003679 -1.106728426 8.68E-06 
COX1 ENST00000361624 -1.145758849 0.001603154 
CDH11 ENST00000394156 -1.195238996 0.000863092 
CTSK NM_000396 -1.220489213 0.012093237 
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CCL3L3 NM_001001437 -1.276810215 0.010630695 
LBP NM_004139 -1.27718058 0.003539003 
CCL4 NM_002984 -1.322453156 0.002380291 
CD34 NM_001773 -1.452648314 0.036549931 
PDGFRL NM_006207 -1.479308971 0.03538884 
CCL4 NM_002984 -1.500801871 0.001810964 
CCL8 NM_005623 -1.568682821 0.005667209 
LEF1 NM_016269 -1.572466135 0.000928608 
IDO1 NM_002164 -1.573766315 0.028556762 
CLIC2 NM_001289 -1.613207605 0.001364676 
TNFSF15 NM_005118 -1.896569213 0.019547678 
CCL20 NM_004591 -2.378568682 0.000181517 
Table 72: Selected significantly differentially expressed genes between estRA and Norm fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS2 NM_005328 1.863641497 0.00204622 
COL13A1 NM_080801 1.72684302 0.037177737 
PTGS1 NM_000962 1.409304409 0.033029992 
FOSB NM_006732 1.343806018 0.036857004 
UBE2C NM_181803 1.335970453 0.026327227 
HMMR NM_012484 1.224741004 0.034055678 
SERPINE1 NM_000602 1.056794368 0.024400147 
TAGLN NM_001001522 0.999164189 0.014197699 
CD200 NM_001004196 0.956394177 0.015450002 
TNFRSF10D NM_003840 0.949449963 0.044283301 
TMEM200A NM_052913 0.944867292 0.026327227 
HMGB3 NM_005342 0.880071025 0.000276546 
FGF1 NM_000800 0.772345017 0.044679721 
MAP4K4 NM_145686 0.763439786 0.009350926 
TRAIP NM_005879 0.714363828 0.034216507 
HSD17B1 NM_000413 0.680544224 0.027388898 
RUNX1 NM_001122607 0.667114716 0.026059734 
TIMP3 NM_000362 0.664234108 0.030809454 
HMGB3 NM_005342 0.634403347 0.014248049 
SERPINA9 NM_175739 0.616161287 0.01433844 
IL24 NM_001185156 0.539869397 0.013406659 
ICAM3 NM_002162 0.446429413 0.007732348 
NOSIP NM_015953 0.408351845 0.002140324 
MMP15 NM_002428 0.39081149 0.032790745 
HIST4H4 NM_175054 0.37619479 0.034238824 
SOCS4 NM_199421 0.356045743 0.004771034 
TP53I13 NM_138349 0.343579953 0.03702182 
ILF3 NM_012218 0.31470653 0.046986374 
SERPINB10 NM_005024 0.277537304 0.038934749 
HDAC2 NM_001527 0.26117545 0.03114751 
CARD14 NM_024110 -0.212400571 0.038542368 
SMAD4 NM_005359 -0.2963697 0.02308832 
LTB NM_002341 -0.313653098 0.022419105 
JMJD4 NM_023007 -0.322082112 0.028357646 
HPGDS NM_014485 -0.323542722 0.001230834 
JAK3 NM_000215 -0.326530066 0.015213878 
CCL17 NM_002987 -0.35099288 0.000984883 
LILRB4 NM_006847 -0.364234171 0.009443294 
HSD17B7 NM_016371 -0.366669266 0.00446769 
SGPP2 NM_152386 -0.367119936 0.033162086 
STAG2 NM_001042751 -0.372625466 0.047188095 
IL18BP NM_173042 -0.378076569 0.022880559 
ADAMTS7 NM_014272 -0.378895831 0.030722004 
SERPING1 NM_000062 -0.387860616 0.005691281 
C1R NM_001733 -0.389349052 0.027265707 
HLA-A NM_001242758 -0.390188008 0.029792002 
HLA-DOB NM_002120 -0.390437831 0.011633555 
TP53 NM_000546 -0.395200059 0.001895209 
C1RL NM_016546 -0.398276113 0.015377871 
JHDM1D NM_030647 -0.401245674 0.02632639 
IL15RA ENST00000379971 -0.40422517 0.015377871 
SOX13 NM_005686 -0.405867686 0.031784568 
ACADM NM_000016 -0.410137428 0.020400179 
CDK8 NM_001260 -0.416735566 0.012373031 
ISLR NM_005545 -0.428695732 0.007087651 
IL4R NM_001008699 -0.430840116 0.016195886 
CD274 NM_014143 -0.431198986 0.048700588 
HIF3A ENST00000457865 -0.442057111 0.01100384 
CSF1 NM_000757 -0.4445353 0.036588526 
ADAMTSL4 NM_025008 -0.445928287 0.029007361 
IFNAR2 NM_000874 -0.455881855 0.001030761 
JMJD7 NM_001114632 -0.45635453 0.019892739 
IFNGR2 NM_005534 -0.459795507 0.035908721 
FCGR2A NM_001136219 -0.464940197 0.042938344 
KLB NM_175737 -0.492938477 0.000832431 
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HSD17B7 NM_016371 -0.498084812 0.001464508 
IL6ST NM_001190981 -0.50219344 0.012311157 
FGFR1 NM_023110 -0.510639562 0.003004326 
CD79A NM_001783 -0.515974885 0.000838652 
IRF1 NM_002198 -0.518680395 0.044786146 
HAPLN2 NM_021817 -0.524492457 0.031598294 
KMO NM_003679 -0.532783957 0.000220658 
HLA-A NM_002116 -0.533825288 0.020409831 
HSD17B7 NM_016371 -0.536180663 0.001693074 
IL10RB NM_000628 -0.536729125 0.006109565 
HLA-C NM_001243042 -0.546105265 0.036639302 
TNFAIP8 NM_014350 -0.551703298 0.029461256 
HLA-F NM_018950 -0.564036422 0.040773292 
HLA-G NM_002127 -0.572558138 0.015349289 
CD274 NM_014143 -0.573820642 0.002226419 
NFKB1 NM_003998 -0.582967088 0.00096499 
IL15RA NM_172200 -0.590941415 0.028357646 
TGFA NM_003236 -0.59400367 0.014784937 
IL13RA1 NM_001560 -0.597456981 0.01115874 
HLA-E NM_005516 -0.61054245 0.009755457 
IL6ST NM_001190981 -0.61679541 0.010525634 
TNXB NM_032470 -0.622209606 0.031947739 
IFNAR2 NM_000874 -0.628383005 0.002509507 
KGFLP1 NR_003674 -0.628550613 0.030631377 
IFNAR2 NM_207585 -0.636583968 0.00011241 
TLR3 NM_003265 -0.662715456 0.046471537 
IFI35 NM_005533 -0.669130085 0.034216507 
TNXB NM_019105 -0.672502287 0.04601849 
STAT5A NM_003152 -0.690858809 1.07E-05 
CXCL10 NM_001565 -0.690933709 0.016992767 
MMP2 NM_004530 -0.691262894 0.007456799 
DUSP8 NM_004420 -0.724078434 0.002375228 
CD47 NM_198793 -0.725866484 0.014405172 
HIST1H4K NM_003541 -0.760585567 0.040696845 
CSF1 NM_172212 -0.777193589 0.014564613 
PDPN NM_198389 -0.800208524 0.017982015 
NFKBIE NM_004556 -0.804965437 0.000120562 
IRF7 NM_004031 -0.812004224 0.022715878 
CD55 NM_000574 -0.817286171 0.009022243 
SERPING1 NM_000062 -0.825026652 0.011276122 
IL15RA NM_001243539 -0.83107606 0.011629609 
C1RL NM_016546 -0.849596212 0.014618917 
CLEC3B NM_003278 -0.851926692 0.002923129 
APOL1 NM_145343 -0.881389901 0.006172614 
TLR2 NM_003264 -0.894884242 0.018032703 
CCL19 NM_006274 -0.908465024 0.034216507 
HLA-B NM_005514 -0.909949476 0.041417157 
PPARG NM_138711 -0.980284074 0.038060024 
FGFR1 NM_001174066 -1.001676322 3.81E-05 
SERPING1 NM_000062 -1.040922856 0.002011841 
HIST1H4J NM_021968 -1.044908184 0.036374972 
KMO NM_003679 -1.067345237 3.37E-07 
PPARG NM_138711 -1.106055931 0.008566536 
LBP NM_004139 -1.117578713 0.003857719 
CLIC2 NM_001289 -1.119928538 0.012610989 
CD38 NM_001775 -1.126813032 0.000618595 
TNFSF13B NM_006573 -1.148904249 0.041898051 
DUSP8 NM_004420 -1.149465612 0.000123137 
MMP9 NM_004994 -1.172035629 0.031620406 
CCL4 NM_002984 -1.185064648 0.001898973 
IL15RA NM_172200 -1.222057249 0.004638356 
CCL4 NM_002984 -1.24797393 0.003305644 
IFIT2 NM_001547 -1.305962888 0.042315859 
IDO1 NM_002164 -1.386307319 0.029811225 
CX3CL1 NM_002996 -1.413203702 2.01E-05 
CCL13 NM_005408 -1.456802722 0.045342654 
CXCL10 NM_001565 -1.464218854 0.008618722 
NOD2 NM_022162 -1.512045792 1.95E-05 
CFB NM_001710 -1.692376013 0.010839916 
CCL20 NM_004591 -1.797212689 0.001304004 
LEF1 NM_016269 -1.805530264 5.26E-06 
IL23A NM_016584 -1.95121438 0.024400147 
TNFSF15 NM_005118 -1.989979448 0.004945469 
CCL8 NM_005623 -2.013317151 2.08E-05 
Table 73: Selected significantly differentially expressed genes between veRA and Norm fibroblasts in the stimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
HAS2 NM_005328 1.605294626 0.010409256 
UBE2C NM_181803 1.329194691 0.030058911 
TAGLN NM_001001522 1.049471578 0.011148016 
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FGFBP1 NM_005130 0.948710761 0.018982322 
HIST1H4L NM_003546 0.944511567 0.037092556 
HIST1H4C NM_003542 0.895178248 0.036546782 
HMGB2 NM_002129 0.871309579 0.040442669 
FGF1 NM_000800 0.868388854 0.025578643 
TRAIP NM_005879 0.779456651 0.02291392 
HMGB3 NM_005342 0.769550947 0.00195089 
TIMP3 NM_000362 0.653506391 0.037801077 
TAGLN NM_001001522 0.648770904 0.025891105 
MAP4K4 NM_145686 0.613739929 0.045554189 
HMGB3 NM_005342 0.546944889 0.041402942 
HIST1H2AC NM_003512 0.472057105 0.019800478 
TP53I13 NM_138349 0.37672894 0.02436336 
MMP15 NM_002428 0.372893355 0.048470785 
TGFB1I1 NM_001042454 0.347825423 0.024291963 
CARD14 NM_024110 -0.231468356 0.026509582 
JAK3 NM_000215 -0.306742329 0.026801213 
SERPING1 NM_000062 -0.32284551 0.026655279 
HPGDS NM_014485 -0.35819454 0.00032274 
IL4R NM_001008699 -0.370801633 0.047629563 
FGFR1 NM_023110 -0.379921315 0.036076398 
ISLR NM_005545 -0.381155102 0.01991746 
LILRB4 NM_006847 -0.397552063 0.004503745 
JHDM1D NM_030647 -0.401366921 0.028724831 
CDK8 NM_001260 -0.402499248 0.018198402 
IFNAR2 NM_000874 -0.414044206 0.003607002 
JMJD7 NM_001114632 -0.415754388 0.039691302 
KMO NM_003679 -0.418442751 0.005233022 
IL10RB NM_000628 -0.425237954 0.037092556 
CD79A NM_001783 -0.427075748 0.007725523 
CD274 NM_014143 -0.429089132 0.030190164 
IL6ST NM_002184 -0.432606192 0.03039811 
HSD17B7 NM_016371 -0.433246887 0.007341888 
C1RL NM_016546 -0.448322734 0.006795621 
OSMR NM_001168355 -0.448883531 0.023110903 
HLA-DOB NM_002120 -0.452201724 0.003290349 
OSMR NM_003999 -0.457424277 0.04197604 
HSD17B7 NM_016371 -0.458236226 0.009710607 
IL6ST NM_001190981 -0.485227285 0.04768393 
STAT5A NM_003152 -0.487121897 0.003315244 
SGPP2 NM_152386 -0.488554967 0.003945037 
IL6ST NM_001190981 -0.506984705 0.013105508 
ADAMTSL4 NM_025008 -0.511974847 0.012590337 
TNFAIP8 NM_014350 -0.512318351 0.049841423 
IFNAR2 NM_000874 -0.538931074 0.012608272 
IFNAR2 NM_207585 -0.544091207 0.001239674 
FOXP2 NM_148900 -0.556215769 0.023170565 
ZFP36L1 NM_004926 -0.583732222 0.028681134 
FGFR1 NM_001174066 -0.592941746 0.02436336 
NFKB1 NM_003998 -0.601895751 0.000784427 
KGFLP1 NR_003674 -0.612671056 0.039559794 
IL6ST NM_001190981 -0.629640607 0.010066901 
IL13RA1 NM_001560 -0.645809245 0.00643236 
DUSP8 NM_004420 -0.64999648 0.008293007 
CXCL10 NM_001565 -0.658034135 0.02696493 
MMP2 NM_004530 -0.666500731 0.011555876 
NFKBIE NM_004556 -0.669463144 0.001878585 
SERPING1 NM_000062 -0.683084391 0.044154183 
KMO NM_003679 -0.698157236 0.001353739 
CD44 NM_001202557 -0.702391103 0.02436336 
CSF3 NM_000759 -0.703076504 0.018791106 
SERPING1 NM_000062 -0.78941791 0.025578643 
CTSF NM_003793 -0.894206088 0.015383848 
IL15RA NM_172200 -0.928109147 0.040152718 
C1RL NM_016546 -0.94549329 0.006932611 
PPARG NM_138711 -0.962782133 0.04838014 
CTSK NM_000396 -0.997434414 0.02436336 
NOD2 NM_022162 -1.004591972 0.00800878 
CCL3L3 NM_001001437 -1.007222885 0.027059477 
PPARG NM_138711 -1.013718064 0.018484087 
DUSP8 NM_004420 -1.031780566 0.000754751 
LBP NM_004139 -1.032863852 0.008988852 
CX3CL1 NM_002996 -1.051437269 0.002673 
CLIC2 NM_001289 -1.066019733 0.020485122 
TLR2 NM_003264 -1.098272277 0.003323617 
CCL4 NM_002984 -1.123349325 0.003708453 
CXCL10 NM_001565 -1.157012988 0.046904497 
CCL4 NM_002984 -1.226405852 0.004154838 
MMP9 NM_004994 -1.384140623 0.011604694 
CFB NM_001710 -1.438140773 0.036622789 
IDO1 NM_002164 -1.471665699 0.022970678 
TNFSF15 NM_005118 -1.669297347 0.023049545 
LEF1 NM_016269 -1.720464431 1.68E-05 
CCL20 NM_004591 -1.904819383 0.000739246 
CCL8 NM_005623 -2.278599649 8.38E-07 
Table 74: Selected significantly differentially expressed genes between Res and Norm fibroblasts in the stimulated high serum 
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treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
8.7 Differentially expressed gene lists from the unstimulated high 
samples in the microarray experiments 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
MOK NM_014226 1.212031885 0.031993944 
MOK NM_014226 0.985073433 0.006928529 
WNT16 NM_057168 0.911042236 0.02143313 
COX1 ENST00000361624 0.8426846 0.037000316 
WISP1 NM_080838 0.672212179 0.02570778 
IL4R NM_001008699 0.485301642 0.028275438 
LTK NM_002344 0.42508451 0.021139755 
IRF2BP1 NM_015649 0.419593023 0.019342288 
CDK10 NM_052987 0.381575367 0.043636672 
IL7 ENST00000379113 0.366623445 0.005031484 
WDR5B NM_019069 0.365800171 0.020916839 
CASP8 NM_033358 0.256434879 0.039460661 
COQ4 ENST00000372875 -0.243661756 0.027087867 
HSD17B7 ENST00000367915 -0.276134198 0.01955496 
SYK NM_003177 -0.277499833 0.02010976 
HSF1 NM_005526 -0.278693814 0.047857472 
SERPINA4 NM_006215 -0.30019578 0.010603827 
KLB NM_175737 -0.316874141 0.044758102 
BMS1P1 NR_026566 -0.321611718 0.048162082 
TRAF3IP3 NM_025228 -0.323060461 0.017750981 
BMP7 NM_001719 -0.336701939 0.040000247 
H3F3B NM_005324 -0.342043525 0.043980233 
CR2 NM_001006658 -0.351364089 0.039930204 
HYAL4 NM_012269 -0.356839297 0.035572628 
FGFR3 NM_000142 -0.358480697 0.015974075 
APOA1 NM_000039 -0.358632557 0.015903845 
PTPRC NM_002838 -0.367907797 0.019781181 
CELSR1 NM_014246 -0.370813748 0.026384121 
ITGAL NM_002209 -0.37376675 0.027605632 
RUNX3 NM_001031680 -0.373776493 0.043132022 
SERPINB5 NM_002639 -0.384661797 0.024943244 
BMP7 NM_001719 -0.411984721 0.000480334 
SERPINA7 NM_000354 -0.412257219 0.009125375 
ZAP70 NM_001079 -0.413709142 0.020916839 
CD8B NM_172102 -0.420678225 0.016852593 
APOA1 NM_000039 -0.422214291 0.020657089 
DUSP9 NM_001395 -0.425556829 0.01496303 
IGSF1 NM_205833 -0.425793227 0.002585343 
SERPINA11 NM_001080451 -0.426722593 0.000484185 
LCK NM_005356 -0.432791015 0.019342288 
FGFR4 NM_213647 -0.463874487 0.002289808 
SOX10 NM_006941 -0.470065562 0.001715966 
SDHC NM_003001 -0.482786437 0.000911182 
ZFP36L1 ENST00000408913 -0.499919821 0.017554638 
FGL1 NM_201553 -0.501189627 0.009974186 
IGSF1 NM_001555 -0.525041012 0.000669135 
SERPINA6 NM_001756 -0.54832397 0.008948615 
CD3G NM_000073 -0.57773592 0.002803615 
MMP15 NM_002428 -0.584013325 0.007155178 
FGA NM_021871 -0.599219859 0.000313193 
LCK NM_005356 -0.615547957 0.000920668 
EGR4 NM_001965 -0.621860784 0.045670072 
HYAL1 NM_007312 -0.621986201 0.034601897 
SOX2 NM_003106 -0.62783413 0.003399286 
CD52 NM_001803 -0.637320722 0.008341503 
XIST NR_001564 -0.646141136 0.048218978 
XIST NR_001564 -0.723883296 0.030889521 
XIST NR_001564 -0.75393362 0.019516672 
RUNX1 NM_001001890 -0.754022888 0.007868499 
CELSR1 NM_014246 -1.055475544 0.009042443 
FGB NM_005141 -1.15772556 0.000827724 
HIST2H2AA4 NM_001040874 -1.182713302 0.020594091 
EGR1 NM_001964 -1.269785502 0.032739875 
CD86 NM_006889 -1.514678902 0.000391181 
FOS NM_005252 -1.574686703 0.024943244 
FOSB NM_006732 -1.997930043 0.008839355 
RASIP1 NM_017805 -2.241809536 0.010603827 
Table 75: Selected significantly differentially expressed genes between JRep and estRA fibroblasts in the unstimulated high 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
INHBB NM_002193 1.716276642 0.018436135 
HAS3 NM_005329 1.422988857 0.000337483 
ITGA8 NM_003638 1.269949514 0.038020853 
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MOK NM_014226 1.126628239 0.041250473 
WNT16 NM_057168 0.789952652 0.044532502 
TNFRSF19 NM_018647 0.718280612 0.015976007 
CLEC3B NM_003278 0.703461198 0.047521126 
BCOR ENST00000501455 0.417180748 0.012991629 
MAPK8 ENST00000374189 0.396928964 0.011364137 
CD69 ENST00000416624 0.338302522 0.047521126 
CIDEC NM_022094 0.334484005 0.045801995 
TP53 NM_000546 0.32382432 0.038020853 
CD96 NM_198196 0.317535159 0.044098407 
PTPRC NM_002838 0.315997377 0.04370886 
KLRK1 NM_007360 0.301313506 0.048538186 
FGFR1 ENST00000496296 0.274771438 0.032238501 
IGSF11 NM_152538 0.256345709 0.022551316 
SS18L2 NM_016305 -0.28737696 0.014243734 
ISLR2 NM_020851 -0.365256552 0.038477353 
RB1 NM_000321 -0.433077435 0.038020853 
IGLL5 NM_001178126 -0.447365215 0.019603004 
ATF3 NM_001674 -0.909623962 0.048538186 
ATF3 NM_001040619 -1.007989254 0.044801141 
IER3 NM_003897 -1.268113304 0.033469761 
IER3 NM_003897 -1.387274556 0.045364062 
MME NM_007289 -1.456482769 0.043554892 
EGR1 NM_001964 -1.531252764 0.004543815 
ATF3 NM_001040619 -1.595787866 0.025567647 
FOS NM_005252 -1.616867706 0.014786755 
MME NM_007289 -1.646768285 0.044801141 
EGR2 NM_000399 -1.868377034 0.028098414 
FOSB NM_006732 -2.17854366 0.001754614 
Table 76: Selected significantly differentially expressed genes between JRep and veRA fibroblasts in the unstimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
MOK NM_014226 1.341542962 0.016654435 
HAS3 NM_005329 1.233692671 0.003190146 
MOK NM_014226 0.909270069 0.01360078 
NFATC4 NM_001136022 0.822747846 0.032651921 
PADI2 NM_007365 0.587461014 0.002648371 
Table 77: Selected significantly differentially expressed genes between JRep and Res fibroblasts in the unstimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
KRT34 NM_021013 2.561281789 0.010249823 
KRT19 NM_002276 2.426719483 5.11E-05 
KRT16 NM_005557 2.216353535 1.75E-06 
KRT19P2 NR_036685 2.109597555 0.001114972 
KRT16P2 NR_029392 2.089170757 0.000146855 
COL8A1 NM_001850 2.058805438 0.018209918 
KRT14 NM_000526 1.854161369 0.000995028 
CDH13 NM_001257 1.798675797 0.013296404 
MOK NM_014226 1.730986201 0.00051115 
SERPINE1 NM_000602 1.537731326 0.002725874 
HAS2 NM_005328 1.446352169 0.046667314 
KRT14 NM_000526 1.436596428 0.033976333 
KRT14 NM_000526 1.397571154 0.007636063 
TNC NM_002160 1.3070678 0.046665367 
CDH13 NM_001220491 1.300711577 0.011174189 
LOXL2 NM_002318 1.263120376 0.022905693 
MOK NM_014226 1.254579338 0.000118619 
HAS3 NM_005329 1.240530677 0.00246382 
ITGA3 NM_002204 0.843342081 0.03913778 
WISP1 NM_080838 0.819108665 0.002421392 
NFATC4 NM_001136022 0.787615257 0.021244107 
FGF5 NM_004464 0.772090975 0.036210115 
COL22A1 NM_152888 0.696580929 0.048976219 
IL27RA NM_004843 0.67504455 0.039547336 
LDHA NM_005566 0.656215996 0.048676461 
PADI2 NM_007365 0.611987758 0.001349021 
TGFB1 NM_000660 0.607095008 0.035482378 
FGF5 NM_033143 0.54449707 0.005785335 
ARG2 NM_001172 0.533966036 0.026793723 
CD3EAP NM_012099 0.532715807 0.021423199 
MOK ENST00000520252 0.523323529 0.005562866 
ITGA5 NM_002205 0.48814006 0.043635862 
MLF2 NM_005439 0.432042084 0.007668477 
STK24 NM_001032296 0.42315017 0.0022017 
STK24 NM_001032296 0.416977939 0.004275039 
CSK NM_004383 0.409472398 0.046898056 
ILF3 NM_004516 0.396858182 0.033289871 
WDR53 NM_182627 -0.244446295 0.037270247 
CCR3 NM_001837 -0.247132291 0.048522943 
SS18L2 NM_016305 -0.323191666 0.004107214 
HSD17B7 NM_016371 -0.337133292 0.024193337 
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COQ10A NM_144576 -0.33880253 0.047030593 
COL4A3BP NM_001130105 -0.372614769 0.044675826 
KLRG1 NM_005810 -0.420061607 0.010963434 
VEGFB NM_003377 -0.470658463 0.009932464 
IFNAR1 NM_000629 -0.506308795 0.008845084 
CTSA NM_000308 -0.511282007 0.049396774 
SOX13 NM_005686 -0.517805158 0.014265229 
IRAK3 NM_007199 -0.548544738 0.039428232 
HSD17B7 NM_016371 -0.558702561 0.004107214 
HSD17B7 NM_016371 -0.564816404 0.001355841 
DUSP8 NM_004420 -0.565025361 0.048976219 
ZFP36L1 ENST00000408913 -0.582676302 0.0022017 
HYAL1 NM_007312 -0.587148161 0.033289871 
ZFP36L1 NM_004926 -0.60382969 0.048137308 
MBP NM_001025101 -0.651595952 0.033581214 
ITM2B NM_021999 -0.666292511 0.039340596 
B2M NM_004048 -0.683491573 0.041804792 
HABP4 NM_014282 -0.711923103 0.02637757 
MMP2 NM_004530 -0.743333383 0.010676081 
ITM2B NM_021999 -0.763153632 0.005639895 
C1QTNF4 NM_031909 -0.801815856 0.010561496 
IL17RD NM_017563 -0.83844743 0.023313002 
S100B NM_006272 -0.968253225 0.049937442 
CARD6 NM_032587 -0.998731823 0.020548565 
LY96 NM_015364 -1.022549493 0.002055855 
IL1R1 NM_000877 -1.032728285 0.046545608 
ICAM1 NM_000201 -1.046967588 0.014770713 
SOX8 NM_014587 -1.137090382 0.004505171 
TLR5 NM_003268 -1.181659031 0.001372029 
EGR1 NM_001964 -1.307340463 0.016820741 
ITGB3 NM_000212 -1.345333403 0.013658454 
TNFAIP2 NM_006291 -1.39163094 0.005785335 
MME NM_007289 -1.483103059 0.031466982 
PDGFRL NM_006207 -1.545078197 0.029744914 
FOS NM_005252 -1.582120022 0.014265229 
FIGF NM_004469 -1.59026749 0.009119436 
CXCL14 NM_004887 -1.677358603 0.039325923 
CD34 NM_001025109 -1.684696548 0.00118431 
HS3ST1 NM_005114 -1.717329908 0.009650193 
CTSK NM_000396 -1.949735742 1.54E-05 
CD34 NM_001773 -2.127962454 0.001382946 
CTSH NM_004390 -2.37244439 0.01906409 
Table 78: Selected significantly differentially expressed genes between JRep and Norm fibroblasts in the unstimulated high 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
INHBB NM_002193 1.487890678 0.017010949 
CD86 NM_006889 1.399967653 4.64E-05 
FGB NM_005141 1.393160667 6.83E-07 
XIST NR_001564 0.786245615 0.001816541 
XIST NR_001564 0.77748283 0.002732686 
XIST NR_001564 0.770299567 0.003170536 
XIST NR_001564 0.748135407 0.002699061 
CLEC3B NM_003278 0.745513545 0.009243057 
CELSR1 NM_014246 0.719555642 0.038962113 
FGA NM_021871 0.71561975 8.62E-08 
CX3CR1 NM_001337 0.688899786 0.008849375 
PTPRC NM_002838 0.683905174 2.57E-08 
CD3G NM_000073 0.671539668 1.35E-05 
SOX2 NM_003106 0.656740042 0.000124041 
XIST NR_001564 0.653625874 0.007015909 
XIST NR_001564 0.652306468 0.000889356 
ITM2A NM_004867 0.648737371 0.020853834 
LCK NM_005356 0.609034082 5.27E-05 
C4BPB NM_000716 0.593115844 7.07E-05 
FYB NM_001465 0.588154605 0.001566101 
IL27RA NM_004843 0.58547962 0.044760618 
BMS1P1 NR_026566 0.5835468 1.65E-06 
FGA NM_021871 0.560545646 0.031003743 
CD69 ENST00000416624 0.557874805 2.41E-05 
SERPINA3 NM_001085 0.554754005 0.027784766 
FA2H NM_024306 0.554550586 0.000454189 
PDGFA NM_033023 0.547500634 0.010821429 
BMP7 NM_001719 0.532902712 2.89E-08 
CD8B NM_172102 0.530294641 9.64E-05 
XLOC_l2_014830 THC2583825 0.529957155 0.000422228 
LCK NM_005356 0.529287162 0.000203067 
HAPLN2 NM_021817 0.524093117 0.034541478 
SERPINB5 NM_002639 0.521226941 6.91E-05 
FCGR2A NM_001136219 0.519676422 0.023175855 
ZAP70 NM_001079 0.515066922 0.000185218 
DNMT3A NM_175629 0.514240974 0.011570765 
SERPINA7 NM_000354 0.511234195 3.82E-05 
COL4A6 NM_033641 0.511214206 0.001555705 
SERPINA6 NM_001756 0.509143299 0.002388778 
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PTPRC NM_002838 0.508447063 0.001378175 
CD247 NM_198053 0.507630009 6.71E-05 
TNFSF12 NM_003809 0.504761489 0.019922519 
CD69 NM_001781 0.49764473 0.000799468 
SERPINA11 NM_001080451 0.496660909 5.48E-07 
KLRK1 NM_007360 0.495966195 2.84E-05 
ADAMTS7 NM_014272 0.490866705 0.003272827 
MAPK4 NM_002747 0.487064861 0.000372136 
CDKN1B NM_004064 0.483293189 0.048982497 
XIST NR_001564 0.480774477 0.011321831 
CD52 NM_001803 0.480739392 0.016853212 
KLB NM_175737 0.480370185 4.83E-05 
STAG3 NM_012447 0.470596179 0.035555958 
PTPRC NM_002838 0.468056569 0.002447466 
BCOR ENST00000501455 0.464603192 0.000759932 
CD33 NM_001772 0.461611704 0.002828963 
FGL1 NM_201553 0.457518367 0.00329019 
CCR9 NM_031200 0.456181617 0.002439727 
IGSF1 NM_205833 0.454635989 5.55E-05 
C3AR1 NM_004054 0.453154221 0.009859316 
ADH4 NM_000670 0.440453414 0.013515688 
CCR2 NM_001123041 0.43916982 0.002969279 
LPL NM_000237 0.435352199 0.004814471 
LTB NM_002341 0.428748989 0.000883674 
CDK1 NM_001170406 0.425444799 0.000289346 
DUSP13 NM_001007271 0.422373316 0.000411105 
TFAP2A ENST00000478375 0.421369394 1.31E-05 
COL2A1 NM_001844 0.420327497 0.000323821 
SERPINA5 NM_000624 0.418819585 0.038864277 
IL10RA NM_001558 0.418405975 0.022221312 
CD5 NM_014207 0.418093652 0.006670375 
SOX10 NM_006941 0.411445868 0.000681585 
TRAF3IP3 ENST00000476050 0.411277535 0.003470093 
SERPINC1 NM_000488 0.410952836 0.006862587 
HIF3A ENST00000457865 0.409529776 0.019350732 
TRAF3IP3 NM_025228 0.402629649 0.011062 
IL2RG NM_000206 0.399643131 0.000715164 
FGG NM_000509 0.396850412 0.022027791 
CD6 NM_006725 0.388716014 0.004983758 
SYK NM_003177 0.388574444 2.18E-05 
CD46 NM_172350 0.388009659 0.015497876 
IGSF1 NM_001555 0.386699644 0.002262719 
CD28 NM_006139 0.385215027 0.001174158 
CR2 NM_001006658 0.384497989 0.003558295 
ITGAL NM_002209 0.382221166 0.004044319 
C4A NM_001252204 0.381475529 0.01850763 
BMS1P1 NR_026566 0.377859434 0.005031875 
COL11A2 NM_080680 0.375163747 0.003549019 
CDH3 NM_001793 0.372451994 0.022017955 
C1R NM_001733 0.366792502 0.042618033 
ZFP36L1 ENST00000408913 0.360853985 0.026408269 
APOB NM_000384 0.354652114 0.002559743 
PDPR NM_017990 0.353616947 0.002340278 
SOX3 NM_005634 0.351153373 0.012763739 
RUNX3 NM_001031680 0.345306885 0.001848102 
S100A1 NM_006271 0.345007172 0.006533316 
IGSF11 NM_152538 0.340811035 0.000140291 
CSF3R NM_156039 0.339299795 0.024377944 
ALDH1L1 NM_012190 0.334933896 0.005744704 
FGA NM_000508 0.331631604 0.044244797 
RUNX3 NM_001031680 0.328854301 0.028586782 
CDH1 NM_004360 0.322058218 0.04349493 
C8A NM_000562 0.319942664 0.025500708 
COL11A2 NM_080680 0.317723291 0.024969792 
MYB ENST00000528345 0.314279739 0.006031665 
HSD17B2 NM_002153 0.311560105 0.002323268 
CD1E NM_001042583 0.307505764 0.001174158 
CD8B NM_004931 0.307153303 0.041292581 
FGFR3 NM_000142 0.302532134 0.012326744 
S100Z NM_130772 0.299431446 0.010620545 
ICAM5 NM_003259 0.299148733 0.00390435 
SERPINA4 NM_006215 0.299104297 0.001250447 
BMP7 NM_001719 0.29842664 0.024893446 
FGFR4 NM_213647 0.296876698 0.023451648 
FBN3 NM_032447 0.29424809 0.008582602 
SOX13 ENST00000367203 0.29285275 0.00239905 
CD28 NM_006139 0.275956274 0.037291831 
TRAF3IP3 NM_025228 0.273708279 0.013549551 
TNFRSF19 ENST00000464735 0.270651264 0.035745641 
ALOX5 NM_000698 0.260773496 0.003263474 
CDK3 NM_001258 0.260501408 0.035216964 
XIST NR_001564 0.250684006 0.030179521 
TNFRSF13C NM_052945 0.245726179 0.040245869 
CTSG NM_001911 0.241970711 0.031175055 
CD3E NM_000733 0.237333058 0.040838797 
COQ4 ENST00000372875 0.232092671 0.008105473 
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PDPR NM_017990 0.231353441 0.036017693 
COL23A1 NM_173465 0.226253206 0.042838597 
HSD17B7 ENST00000367915 0.224734196 0.021033651 
CASP8 NM_033358 -0.218036256 0.033176237 
TRAF6 NM_145803 -0.275697768 0.026180046 
DUSP11 NM_003584 -0.299752221 0.037364778 
HSF1 NM_005526 -0.314683816 0.041553628 
MAPKAP1 NM_001006617 -0.37653558 0.034492646 
LTK NM_002344 -0.381200477 0.010249542 
ADAMTSL1 NM_001040272 -0.519168044 0.019555284 
IRAK3 NM_007199 -0.553194337 0.014530198 
COX1 ENST00000361624 -0.72731242 0.02753743 
Table 79: Selected significantly differentially expressed genes between estRA and veRA fibroblasts in the unstimulated high 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
RASIP1 NM_017805 1.63676332 0.024675231 
INHBB NM_002193 1.354470241 0.03154465 
KRT14 NM_000526 1.230862323 0.037520334 
FGB NM_005141 1.18335489 1.89E-05 
CD86 NM_006889 1.141605364 0.000898732 
XIST NR_001564 0.805622156 0.00118974 
FN1 NM_054034 0.784469446 0.00316798 
CELSR1 NM_014246 0.781936624 0.019506106 
FGA NM_021871 0.765784068 1.85E-08 
ITM2A NM_004867 0.749535586 0.005252757 
XIST NR_001564 0.733949954 0.004914706 
XIST NR_001564 0.721719707 0.005706403 
PTPRC NM_002838 0.646477237 8.06E-08 
LCK NM_005356 0.627970825 2.62E-05 
XIST NR_001564 0.61383618 0.017022459 
CD3G NM_000073 0.613830605 5.64E-05 
PDGFA NM_033023 0.602181443 0.003891648 
SOX2 NM_003106 0.58600697 0.000604195 
XIST NR_001564 0.578225701 0.018825563 
CX3CR1 NM_001337 0.574301294 0.034397621 
XIST NR_001564 0.571939394 0.003947076 
SERPINA6 NM_001756 0.571739347 0.00048264 
C4BPB NM_000716 0.535601046 0.000314538 
IGSF1 NM_205833 0.52959373 2.39E-06 
ADH4 NM_000670 0.517363702 0.002455152 
ZAP70 NM_001079 0.508818681 0.000195445 
FYB NM_001465 0.508616455 0.007195476 
SERPINA3 NM_001085 0.508066413 0.045429445 
XLOC_l2_014830 THC2583825 0.506721699 0.000702904 
CD52 NM_001803 0.502621977 0.010523776 
TNFSF12 NM_003809 0.492037703 0.022219393 
CD69 ENST00000416624 0.484762637 0.000218784 
BMS1P1 NR_026566 0.482705015 5.89E-05 
BMP7 NM_001719 0.472895938 5.70E-07 
IGSF1 NM_001555 0.46878698 0.000141362 
FCGR2A NM_001136219 0.465716239 0.04449413 
LCK NM_005356 0.463349217 0.001132027 
FGFR4 NM_213647 0.462659911 0.000127518 
MAPK4 NM_002747 0.457469943 0.000795667 
FA2H NM_024306 0.456406316 0.004677174 
S100A14 NM_020672 0.456203175 0.016125619 
SERPINA11 NM_001080451 0.455521078 3.45E-06 
CD8B NM_172102 0.451734574 0.000872443 
ADAMTS7 NM_014272 0.446566361 0.0079229 
KLRK1 NM_007360 0.44602982 0.000148791 
CD69 NM_001781 0.44464073 0.002891015 
SERPIND1 NM_000185 0.442753979 0.03542021 
FGL1 NM_201553 0.441882931 0.004432985 
CR2 NM_001006658 0.437560259 0.000665857 
COL2A1 NM_001844 0.431041181 0.000201329 
LPL NM_000237 0.428776745 0.005200617 
SERPINB5 NM_002639 0.423787828 0.001288637 
PTPRC NM_002838 0.422934756 0.009292428 
DNMT3A NM_175629 0.42009638 0.047229901 
CD5 NM_014207 0.417957782 0.006193604 
C3AR1 NM_004054 0.415426391 0.018825563 
CD247 NM_198053 0.411059482 0.001331955 
COL4A6 NM_033641 0.406431707 0.015132598 
SOX10 NM_006941 0.399467897 0.000904264 
KLB NM_175737 0.397448374 0.00076284 
COL11A2 NM_080680 0.385876183 0.00232196 
SERPINC1 NM_000488 0.383058302 0.012252796 
SOX3 NM_005634 0.379859297 0.005707849 
SERPINA7 NM_000354 0.377993935 0.002579068 
PTPRC NM_002838 0.377614764 0.018166892 
IL2RG NM_000206 0.375653632 0.001443823 
TFAP2A ENST00000478375 0.367821847 0.000123151 
ITGAL NM_002209 0.366309406 0.005742098 
IGSF1 NM_205833 0.364696961 0.026626925 
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CDK1 NM_001170406 0.361228581 0.00228372 
CCR9 NM_031200 0.358733421 0.022120312 
HIF3A ENST00000457865 0.357098811 0.045720892 
BMP7 NM_001719 0.349870323 0.005707849 
ZFP36L1 ENST00000408913 0.348702533 0.030910349 
C4A NM_001252204 0.346805404 0.033850497 
CCR2 NM_001123041 0.34524836 0.025138173 
S100A1 NM_006271 0.344668186 0.006111424 
BCOR ENST00000501455 0.343136897 0.017398604 
TRAF3IP3 NM_025228 0.341218984 0.036309902 
TRAF3IP3 NM_025228 0.338936149 0.001312646 
SYK NM_003177 0.338060062 0.000200579 
COL11A2 NM_080680 0.335356002 0.015106922 
TRAF3IP3 ENST00000476050 0.335323024 0.02101509 
FGA NM_000508 0.332787573 0.03915693 
ICAM5 NM_003259 0.331074843 0.001034185 
CD8B NM_004931 0.328673471 0.023618662 
DUSP9 NM_001395 0.326001223 0.023419725 
CSF3R NM_156039 0.322677537 0.031873117 
CD28 NM_006139 0.315811031 0.00945551 
ALDH1L1 NM_012190 0.312869907 0.010157806 
RUNX3 NM_001031680 0.306010969 0.006398498 
CDK3 NM_001258 0.302779 0.009869905 
HSD17B2 NM_002153 0.30210379 0.002987411 
APOB NM_000384 0.301171995 0.012409249 
SERPINA4 NM_006215 0.300911999 0.00101792 
LTB NM_002341 0.296550345 0.030935703 
BMS1P1 NR_026566 0.295646399 0.035851997 
PDPR NM_017990 0.293820483 0.013797241 
IL4 NM_000589 0.292525187 0.03542021 
CD6 NM_006725 0.290015633 0.047897935 
CELSR1 NM_014246 0.289972292 0.035185641 
S100Z NM_130772 0.282174472 0.01642312 
CD3E NM_000733 0.272426357 0.013443939 
SERPINF2 NM_000934 0.269176481 0.0214147 
DUSP13 NM_001007271 0.266818024 0.038529898 
CD28 NM_006139 0.26031926 0.048705249 
TNFRSF19 ENST00000464735 0.260260092 0.042062602 
TNFRSF13C NM_052945 0.257235816 0.026935309 
FGFR3 NM_000142 0.256764268 0.03890405 
FBN3 NM_032447 0.255438846 0.025503828 
SOX13 ENST00000367203 0.253979704 0.009772756 
APOA1 NM_000039 0.247464653 0.048757834 
CD4 NM_000616 0.245106255 0.036309902 
COL23A1 NM_173465 0.237349782 0.02855393 
HS3ST4 NM_006040 0.230952134 0.034603836 
IGSF11 NM_152538 0.224173136 0.017432898 
ALOX5 NM_000698 0.21634879 0.017590967 
IGSF3 NM_001542 0.199607414 0.03242972 
CASP8 NM_033358 -0.216537723 0.031653926 
COQ5 NM_032314 -0.254419817 0.032623367 
COQ3 NM_017421 -0.269364163 0.049220135 
DUSP11 NM_003584 -0.286353748 0.045411247 
WDR5B NM_019069 -0.323685978 0.010424637 
CDK10 NM_052987 -0.360905187 0.01534259 
LTK NM_002344 -0.364567701 0.013957759 
IL4R NM_001008699 -0.385069621 0.033929214 
IRAK3 NM_007199 -0.553635952 0.013493758 
COX1 ENST00000361624 -0.756005691 0.018763722 
CDH11 ENST00000394156 -0.876306051 0.004267432 
IL1RL1 NM_016232 -1.01924266 0.027421888 
Table 80: Selected significantly differentially expressed genes between estRA and Res fibroblasts in the unstimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
KRT14 NM_000526 2.18782001 0.000466137 
KRT19 NM_002276 2.048846792 0.00070572 
KRT19P2 NR_036685 1.824335547 0.003827506 
COL8A1 NM_001850 1.781949078 0.031519895 
CDH13 NM_001257 1.774000812 0.010473838 
ITGB2 NM_000211 1.698896857 0.036273983 
KRT16P2 NR_029392 1.65208547 0.002598368 
HAS2 NM_005328 1.506856423 0.024315716 
KRT14 NM_000526 1.381380857 0.012340073 
CLEC11A NM_002975 1.358567517 0.0012199 
CD86 NM_006889 1.317134679 0.00078387 
KRT16 NM_005557 1.267198321 0.005782468 
KRT14 NM_000526 1.193109911 0.018527012 
HIST1H3F NM_021018 1.158694665 0.027388927 
HIST1H3D NM_003530 1.153052852 0.025895415 
CTSZ NM_001336 1.126481426 0.040047523 
HIST1H3H NM_003536 1.097987097 0.022066074 
FGB NM_005141 1.059320242 0.000871688 
ITGA3 NM_002204 0.99582735 0.008098711 
HIST1H2AG NM_021064 0.93200215 0.042261826 
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CELSR1 NM_014246 0.923017787 0.010915795 
TGFB1 NM_000660 0.910093471 0.00061894 
HIST1H4C NM_003542 0.908960938 0.044297156 
VEGFC NM_005429 0.879230635 0.036198755 
IL27RA NM_004843 0.7341059 0.015004893 
CLEC18B NM_001011880 0.730892279 0.003354964 
HIST1H3G NM_003534 0.726346066 0.024756061 
HIST1H2BF NM_003522 0.696416323 0.048574629 
HIST2H2BF NM_001161334 0.678433808 0.030894638 
FGA NM_021871 0.651168156 2.43E-05 
ITM2A NM_004867 0.649147672 0.031749896 
SERPINA3 NM_001085 0.642135485 0.016156199 
XIST NR_001564 0.621802104 0.005141404 
XIST NR_001564 0.613145033 0.03753264 
RUNX1 NM_001001890 0.607721775 0.017029413 
PLOD1 NM_000302 0.6062584 0.028182629 
SOX2 NM_003106 0.605706387 0.002002709 
PDGFA NM_002607 0.596336406 0.031034245 
ARG2 NM_001172 0.596165199 0.008098711 
CD3G NM_000073 0.583874879 0.000894344 
XIST NR_001564 0.579060773 0.04459401 
MIF NM_002415 0.572487214 0.00826459 
PDGFA NM_033023 0.569450437 0.015164124 
LCK NM_005356 0.56816001 0.000951069 
ZAP70 NM_001079 0.563427873 0.000354397 
HIST1H3H NM_003536 0.554588894 0.031207703 
HIST2H3D NM_001123375 0.55369177 0.037529427 
TAGLN2 NM_003564 0.547504013 0.015654912 
IGSF1 NM_001555 0.542179632 0.000138703 
EGR4 NM_001965 0.535472046 0.048557952 
BMP7 NM_001719 0.527419821 3.37E-06 
PTPRC NM_002838 0.515239575 0.00020675 
S100P NM_005980 0.515183629 0.036190892 
LCK NM_005356 0.498712605 0.002170409 
SOX10 NM_006941 0.490448381 0.00038315 
SERPINA6 NM_001756 0.486617541 0.009777015 
LY86 NM_004271 0.485235719 0.027258562 
IGSF1 NM_205833 0.479991243 0.00020675 
JMJD6 NM_015167 0.47485814 0.023437741 
DUSP9 NM_001395 0.473397642 0.002206318 
ITGAL NM_002209 0.468937424 0.00146411 
CD3EAP NM_012099 0.466690035 0.033619138 
TRAF4 NM_004295 0.459762781 0.018264215 
RUNX3 NM_001031680 0.447501231 0.004554604 
C4BPB NM_000716 0.440301809 0.010061543 
CELSR1 NM_014246 0.437663994 0.002598368 
FGL1 NM_201553 0.430490339 0.013338196 
APOA1 NM_000039 0.423583888 0.008219187 
CDK1 NM_001170406 0.413828204 0.00205211 
CD8B NM_172102 0.409136643 0.008487134 
SERPINA11 NM_001080451 0.406789475 0.000317988 
SERPINB6 NM_004568 0.406373202 0.028472752 
PTPRC NM_002838 0.405125806 0.024910217 
APOA1 NM_000039 0.404348777 0.002095478 
ICAM3 NM_002162 0.403350903 0.026843708 
SERPINB5 NM_002639 0.399055598 0.007854629 
MLF2 NM_005439 0.383560741 0.014322879 
S100A1 NM_006271 0.382506038 0.029383089 
VWF NM_000552 0.382297297 0.042150663 
RUNX1 NM_001122607 0.37776294 0.02706205 
IGSF1 NM_205833 0.377701982 0.033577993 
MAP4K2 NM_004579 0.377258808 0.03271615 
COL11A2 NM_080680 0.375561677 0.012545969 
TRAF3IP3 NM_025228 0.374370562 0.00184359 
BMS1P1 NR_026566 0.373629382 0.007090595 
FGFR3 NM_000142 0.372608572 0.004411069 
IRF5 NM_001098627 0.37009359 0.038468333 
SERPINF2 NM_000934 0.367716701 0.003492405 
COL11A2 NM_080680 0.364429256 0.011090518 
ADAMTSL5 NM_213604 0.356959447 0.007932017 
DUSP15 NM_080611 0.354978882 0.00590183 
S100Z NM_130772 0.353679009 0.00557903 
BMP7 NM_001719 0.348404979 0.013709404 
FGFR4 NM_213647 0.347051332 0.012814052 
KLB NM_175737 0.344002616 0.011003689 
CCR2 NM_001123041 0.341217981 0.042150663 
CSF3R NM_156039 0.33674423 0.037226604 
SERPINA7 NM_000354 0.336453223 0.018098389 
HDAC10 NM_032019 0.335082191 0.048275522 
CR2 NM_001006658 0.334888589 0.023758771 
BCOR ENST00000501455 0.329143462 0.037722482 
ITGB2 ENST00000545414 0.329007232 0.03479601 
OGFR NM_007346 0.32774514 0.018198571 
IL2RG NM_000206 0.326628143 0.01508551 
SOX3 NM_005634 0.31996659 0.039036159 
COQ4 ENST00000372875 0.318679881 0.000889904 
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CD8B NM_004931 0.317026774 0.046076549 
DUS1L NM_022156 0.316204449 0.034874751 
CD6 NM_006725 0.314670004 0.043452594 
CD69 ENST00000416624 0.310779984 0.043051736 
HYAL4 NM_012269 0.310661815 0.036245104 
XIST NR_001564 0.309275374 0.010999758 
S100A1 NM_006271 0.303604829 0.031479719 
ALDH1L1 NM_012190 0.295978435 0.028329683 
CD3E NM_000733 0.293858715 0.01475548 
HYAL3 NM_003549 0.293675056 0.042108398 
COL2A1 NM_001844 0.290274313 0.031432323 
TLR9 NM_017442 0.287576316 0.049827066 
TNFRSF19 ENST00000464735 0.277553034 0.042321311 
SYK NM_003177 0.276488176 0.008356923 
STK24 NM_001032296 0.275214232 0.044297156 
RUNX3 NM_001031680 0.267407224 0.033676305 
COX8A NM_004074 0.263362973 0.028225773 
TNFRSF13C NM_052945 0.259457609 0.039348443 
CD4 NM_000616 0.257583347 0.040475175 
SERPINA4 NM_006215 0.251699401 0.016470209 
HSD17B2 NM_002153 0.231010656 0.048112599 
IGSF3 NM_001542 0.230518674 0.020696963 
HSD17B7 ENST00000367915 0.212382766 0.044439755 
EDF1 NM_153200 0.207028684 0.049510627 
WDR53 NM_182627 -0.216575164 0.049399844 
IL7 ENST00000379113 -0.254239979 0.032807382 
STK3 ENST00000424861 -0.261863767 0.032305966 
HDAC3 NM_003883 -0.271219544 0.048391636 
WDR5B NM_019069 -0.295940397 0.035352388 
TRAF6 NM_145803 -0.300743004 0.022614093 
CCR3 NM_001837 -0.30152348 0.00835685 
DUSP19 NM_080876 -0.324847496 0.011035235 
ZFX NM_003410 -0.331652265 0.032904079 
COQ5 NM_032314 -0.337826995 0.007585476 
MRFAP1L1 NM_203462 -0.338843035 0.010915795 
TP53 NM_000546 -0.359580571 0.010127931 
CASP8 NM_033358 -0.36803978 0.000586712 
C1RL NM_016546 -0.368341308 0.039822202 
COQ5 NM_032314 -0.369498191 0.002422323 
CASP8AP2 NM_012115 -0.370848314 0.035900648 
IRF2BP1 NM_015649 -0.382458574 0.015390496 
COQ10A NM_144576 -0.388542935 0.012863641 
MMP19 NM_002429 -0.389277398 0.044955217 
IFNAR1 NM_000629 -0.393904724 0.035900648 
SDHD NM_003002 -0.394055901 0.009999465 
TANK NM_004180 -0.395261286 0.023084674 
LTK NM_002344 -0.451062408 0.005267769 
IL6ST NM_002184 -0.460787651 0.028182629 
HEXB NM_000521 -0.473653992 0.048216691 
TANK NM_133484 -0.475037376 0.031262966 
EGFR NM_005228 -0.489088208 0.026827549 
CSF1 NM_000757 -0.503520148 0.027096026 
VEGFB NM_003377 -0.504630145 0.003855043 
NFKB1 NM_003998 -0.512759294 0.008859069 
IL4R NM_001008699 -0.527921367 0.006079353 
FGF16 NM_003868 -0.543628292 0.010642552 
HSD17B7 NM_016371 -0.565959578 0.000994163 
EGFR NM_201282 -0.578005894 0.001772152 
IL6ST NM_001190981 -0.586791354 0.020542856 
C1QTNF4 NM_031909 -0.637040108 0.035900648 
CD302 NM_014880 -0.642257917 0.031971681 
LY96 NM_015364 -0.653876879 0.047190042 
HSD17B7 NM_016371 -0.685616652 0.000281158 
FGFR1 NM_001174066 -0.689684237 0.012380576 
WNT16 NM_057168 -0.711772481 0.044004218 
DUSP8 NM_004420 -0.715862195 0.006188105 
CSF1 NM_172212 -0.735604032 0.033080896 
IL17RD NM_017563 -0.762314586 0.028834618 
SERPINF1 NM_002615 -0.770837353 0.043935366 
SERPING1 NM_000062 -0.77481374 0.028225773 
WARS2 NM_201263 -0.789939771 0.018198571 
IL6ST NM_001190981 -0.792841883 0.002227704 
HSD11B1 NM_181755 -0.795113663 0.016661893 
IRAK3 NM_007199 -0.815829948 0.000837308 
MMP2 NM_004530 -0.884713834 0.00146411 
C1S NM_201442 -0.895301832 0.011435542 
TLR5 NM_003268 -0.930755564 0.010062697 
CEBPA NM_004364 -0.935323864 0.018744202 
TGFBR3 NM_003243 -0.963083349 0.035517317 
IL1R1 NM_000877 -0.973405185 0.017542592 
TNFAIP2 NM_006291 -0.989078563 0.045498872 
CCL18 NM_002988 -0.989927163 0.042589861 
S100B NM_006272 -1.006830676 0.026484494 
COX1 ENST00000361624 -1.201795133 0.000554592 
SERPING1 NM_000062 -1.261808882 0.000635117 
CD34 NM_001025109 -1.462568414 0.003894013 
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FIGF NM_004469 -1.465115246 0.01235823 
CTSK NM_000396 -1.614271298 0.000482475 
CD34 NM_001773 -1.767836622 0.006537856 
CXCL14 NM_004887 -1.965472373 0.008544061 
TNFSF15 NM_005118 -2.446820772 0.001422026 
CTSH NM_004390 -2.465455782 0.009752533 
Table 81: Selected significantly differentially expressed genes between estRA and Norm fibroblasts in the unstimulated high 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
KRT19 NM_002276 2.189430413 3.99E-05 
KRT19P2 NR_036685 1.940385599 0.000407656 
MMP3 NM_002422 1.827997187 0.006693999 
HAS2 NM_005328 1.789285196 0.001480909 
HIST2H3A NM_001005464 1.685362715 0.003919487 
COL13A1 NM_080801 1.62669414 0.02876373 
KRT34 NM_021013 1.604795472 0.048381524 
KRT14 NM_000526 1.562681499 0.00314875 
KRT14 NM_000526 1.489560735 0.001433639 
CDH13 NM_001257 1.418059311 0.014711404 
SERPINE1 NM_000602 1.377489298 0.001139117 
HMMR NM_012484 1.327489833 0.010156929 
KRT16P2 NR_029392 1.292797676 0.005228299 
LIF NM_002309 1.255486032 0.019379977 
ITGA10 NM_003637 1.23185833 0.0130741 
KRT16 NM_005557 1.217348644 0.001761719 
KRT14 NM_000526 1.180138715 0.005449955 
IER3 NM_003897 1.169344158 0.023911901 
HS3ST3B1 ENST00000360954 1.144851692 0.004562995 
HIST1H3F NM_021018 1.13914114 0.009308184 
CDH2 NM_001792 1.132418694 0.03976666 
FGF2 NM_002006 1.124920521 0.01438476 
HIST1H4L NM_003546 1.118802026 0.004735409 
HIST1H3B NM_003537 1.104808731 0.030528908 
HIST1H3D NM_003530 1.092487539 0.011309103 
CDH13 NM_001220491 1.077322244 0.009083508 
COL4A1 NM_001845 1.076079436 0.012811628 
ADAMTS4 NM_005099 1.04372667 0.00474268 
HIST1H3H NM_003536 1.043429241 0.009279571 
IER3 NM_003897 1.022540587 0.023623605 
HIST1H4C NM_003542 1.022057226 0.00634607 
CLEC11A NM_002975 1.014251424 0.004501923 
CDK1 NM_001786 0.996648391 0.027989256 
MAPK13 NM_002754 0.969919802 0.014472881 
HIST1H4B NM_003544 0.89692495 0.01725275 
COL4A2 NM_001846 0.880828884 0.047541417 
TGFB1 NM_000660 0.87625039 0.000200112 
SOX9 NM_000346 0.827795139 0.022572237 
FGF5 NM_004464 0.751958228 0.008472839 
CTPS NM_001905 0.717834199 0.010323912 
ITGA3 NM_002204 0.694243394 0.028708223 
MAPK13 NM_002754 0.688882877 0.015409767 
PTPRB NM_002837 0.674420497 0.00198808 
JMJD6 NM_015167 0.618133726 0.00055147 
COL22A1 ENST00000522546 0.605288043 0.022754527 
HIF1A NM_181054 0.600684758 0.031276781 
IFNE NM_176891 0.587794191 0.022291213 
HIST1H3E NM_003532 0.581963799 0.042848394 
CDH4 NM_001794 0.573944523 0.018374224 
COL22A1 NM_152888 0.568403419 0.037699184 
HIST1H3G NM_003534 0.561804355 0.039146149 
HIST2H3D NM_001123375 0.561195838 0.011183396 
IGLL5 NM_001178126 0.546560306 0.000362893 
HIST2H2BF NM_001161334 0.543561557 0.039557566 
HIST1H2BE NM_003523 0.539579871 0.029636511 
P4HA2 NM_004199 0.539128029 0.021032893 
LIF NM_002309 0.518898513 0.016046527 
CTPS NM_001905 0.502366133 0.019456206 
WISP1 NM_080838 0.493922375 0.026587838 
HIST1H3H NM_003536 0.487328886 0.023626675 
S100P NM_005980 0.48646279 0.017760143 
MAPK12 NM_002969 0.483728638 0.010602695 
HIST1H2BB NM_021062 0.479511234 0.035576248 
CASP3 NM_004346 0.479139829 0.02692071 
ICAM3 NM_002162 0.476738714 0.001836711 
ADAMTS6 NM_197941 0.474134363 0.028379159 
CD3EAP NM_012099 0.461933843 0.011456968 
MIF NM_002415 0.461498398 0.011236929 
TGIF1 NM_170695 0.456820101 0.049874114 
ITGB1 NM_133376 0.448741617 0.03236398 
MLF2 NM_005439 0.447208728 0.000771277 
PLOD1 NM_000302 0.438760597 0.022243127 
CSK NM_004383 0.429708183 0.006664079 
TAGLN2 NM_003564 0.427965002 0.02510745 
HIST1H2BO NM_003527 0.427105713 0.030748857 
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CD99P1 NR_033381 0.417902985 0.033758005 
ITGA5 NM_002205 0.414729926 0.026788002 
TRAF4 NM_004295 0.411524965 0.011607931 
HIST1H2BJ NM_021058 0.408091466 0.043364553 
HIST1H2BH NM_003524 0.401033706 0.04670105 
STK24 NM_001032296 0.390500091 0.001080073 
STK24 NM_001032296 0.385180202 0.000771277 
IL17RE NM_153483 0.377673162 0.003750549 
HS3ST3B1 NM_006041 0.372470756 0.047281914 
ALDH4A1 NM_170726 0.368786031 0.022334293 
RB1 NM_000321 0.35794809 0.023252579 
HIST4H4 NM_175054 0.350552464 0.028105365 
COL17A1 NM_000494 0.342519841 0.042950103 
TBRG4 NM_030900 0.335408326 0.020683122 
VWF NM_000552 0.324811933 0.038579498 
MAP4K2 NM_004579 0.300208544 0.04320633 
COX8A NM_004074 0.299497699 0.002983065 
ISLR2 NM_020851 0.298337439 0.025409091 
CD8A NM_001145873 0.287896487 0.018142244 
HSF1 NM_005526 0.281727877 0.037780423 
ILF3 NM_012218 0.280727183 0.048784378 
DUSP15 NM_080611 0.260776143 0.016355341 
COX10 NM_001303 0.255349494 0.023140176 
RUNX1 NM_001001890 0.24643083 0.048956557 
ITGB7 NM_000889 0.246309898 0.023015171 
TRAF7 NM_032271 0.24178975 0.034893898 
ADAMTSL5 NM_213604 0.237075476 0.037216073 
SOX30 NM_178424 0.215369068 0.038177193 
TFAP2A ENST00000478375 -0.201671648 0.030458255 
SOX13 ENST00000367203 -0.204211082 0.025725872 
INHA NM_002191 -0.213977373 0.034801 
IGSF11 NM_152538 -0.221581122 0.010081613 
FBN3 NM_032447 -0.223505456 0.030874478 
SDHC NM_003001 -0.227047969 0.046242082 
HDAC3 NM_003883 -0.229775592 0.044642733 
MRFAP1L1 NM_203462 -0.230104863 0.041443182 
IL16 NM_001172128 -0.232712227 0.036106811 
CD99L2 NM_031462 -0.257241394 0.033743699 
COQ5 NM_032314 -0.263594723 0.010156929 
IFNAR2 NM_000874 -0.266939162 0.041030723 
HSD17B7 NM_016371 -0.269451016 0.022569051 
CCR3 NM_001837 -0.273080533 0.004646255 
CDH1 NM_004360 -0.276791487 0.04844452 
COX15 NM_078470 -0.290055547 0.009134035 
CD46 NM_172350 -0.291704254 0.046789339 
CD247 NM_198053 -0.300078855 0.014238982 
BCL9 NM_004326 -0.301649187 0.046175213 
FA2H NM_024306 -0.312191655 0.041283878 
ZFP36L1 ENST00000408913 -0.31453019 0.045915852 
FGG NM_000509 -0.318457965 0.0418904 
DUSP13 NM_001007271 -0.320542623 0.005199743 
IFNAR1 NM_000629 -0.32624008 0.038224047 
LTB NM_002341 -0.328482011 0.00757596 
CD81 NM_004356 -0.329909617 0.027685955 
KLRK1 NM_007360 -0.334254467 0.003608484 
COL6A6 NM_001102608 -0.334336072 0.039170871 
JMJD4 NM_023007 -0.337737888 0.010081613 
COL4A3BP NM_001130105 -0.34016734 0.041622859 
EGFR NM_201282 -0.340246268 0.029079764 
C1R NM_001733 -0.342904927 0.030086179 
KLRG1 NM_005810 -0.366614698 0.005922683 
ADAMTSL4 NM_025008 -0.368918756 0.044925904 
TANK NM_004180 -0.371751454 0.010499659 
ZFX NM_003410 -0.373125955 0.004238638 
SDHD NM_003002 -0.373628169 0.003882858 
MMP19 NM_002429 -0.37473214 0.020086567 
FGFR1 NM_023110 -0.378136509 0.017089095 
COQ10A NM_144576 -0.393478708 0.00284653 
TIMP2 NM_003255 -0.395938758 0.039221408 
ADAMTS7 NM_014272 -0.396746295 0.011236929 
HEXB NM_000521 -0.406911751 0.041360455 
CD33 NM_001772 -0.41005615 0.004871501 
NFKBIE NM_004556 -0.41408966 0.036795144 
ISLR NM_005545 -0.422733971 0.003688789 
FYB NM_001465 -0.429049026 0.014819547 
HIF3A ENST00000457865 -0.430299618 0.006374595 
SERPING1 NM_000062 -0.436854819 0.000756435 
IL6R NM_000565 -0.439768951 0.022728597 
XLOC_l2_014830 THC2583825 -0.440766155 0.002359484 
SRC NM_005417 -0.445894852 0.022431042 
CD79A NM_001783 -0.450236766 0.00186247 
IRF1 NM_002198 -0.459039357 0.048298168 
VEGFB NM_003377 -0.461774698 0.001836711 
HSD17B7 NM_016371 -0.468675404 0.001368289 
IL3RA NM_002183 -0.471487964 0.039026837 
SOX13 NM_005686 -0.486060177 0.004238638 
 344 
 
TANK NM_133484 -0.490904884 0.00757596 
CD248 NM_020404 -0.49412441 0.035624611 
IL34 NM_152456 -0.497337416 0.008605863 
FCGRT NM_004107 -0.499161307 0.006415354 
HLA-A NM_002116 -0.515631512 0.02876373 
NFKB1 NM_003998 -0.531629228 0.001391569 
TNFAIP8 NM_014350 -0.537547014 0.017754306 
HSD17B7 NM_016371 -0.544250835 0.000724018 
CD300A NM_007261 -0.549174049 0.012341706 
IL6ST NM_002184 -0.556535928 0.001630918 
IL6ST NM_001190981 -0.56140759 0.008027909 
HLA-A NM_002116 -0.564290364 0.00641976 
B2M NM_004048 -0.564892158 0.029866885 
TP53 NM_000546 -0.571058551 2.54E-06 
IL6ST NM_001190981 -0.571888797 0.00178201 
WNT16 NM_057168 -0.590682898 0.045347928 
STAT5A NM_003152 -0.60199831 0.000146006 
ADAMTSL4 NM_025008 -0.602557028 0.03706661 
HABP4 NM_014282 -0.606307275 0.015831113 
HAPLN2 NM_021817 -0.609525617 0.005208465 
C1S NM_201442 -0.611940404 0.041516119 
ITM2B NM_021999 -0.612407232 0.014091016 
HLA-J NR_024240 -0.626966478 0.036117481 
HLA-E NM_005516 -0.629206671 0.003486408 
CLEC3B NM_003278 -0.637542625 0.015409767 
HLA-F NM_018950 -0.637717689 0.00947685 
IL6ST NM_002184 -0.641183624 0.011896465 
ITM2B NM_021999 -0.646536604 0.00396943 
HLA-G NM_002127 -0.654875547 0.002318004 
TNFRSF19 NM_018647 -0.662161966 0.004522701 
MBP NM_001025101 -0.662859104 0.00544915 
TNXB NM_019105 -0.663687359 0.027618778 
CXCL16 NM_022059 -0.664207573 0.018268841 
C1RL NM_016546 -0.686031449 0.02973981 
IGSF10 NM_178822 -0.693404506 0.000689217 
CD55 NM_000574 -0.699364711 0.013325148 
PDGFRB NM_002609 -0.71335253 0.021788497 
IL6ST NM_001190981 -0.718578681 0.001092391 
C1QTNF4 NM_031909 -0.722830593 0.004484807 
CDKN1B NM_004064 -0.723230615 0.000756435 
TNXB NM_019105 -0.724207198 0.046434742 
DUSP8 NM_004420 -0.732458371 0.00098843 
MMP2 NM_004530 -0.744975505 0.001630918 
CCL28 NM_148672 -0.749833786 0.010769207 
C1S NM_001734 -0.766423582 0.013562522 
HLA-C M26429 -0.76955304 0.016695038 
IL17RD NM_017563 -0.781509573 0.007252692 
TNXB NM_019105 -0.787706494 0.020086567 
CD302 NM_014880 -0.787784734 0.001720166 
HSD11B1 NM_181755 -0.799860649 0.004338195 
CCL18 NM_002988 -0.806024488 0.048521774 
FGFR1 NM_001174066 -0.835534941 0.000457219 
CARD6 NM_032587 -0.851636177 0.012261966 
CSF1 NM_172212 -0.853422715 0.00314875 
IL15RA NM_172200 -0.873654131 0.027387919 
CTSF NM_003793 -0.875634554 0.007365432 
TGFBR3 NM_003243 -0.882754621 0.021039118 
TLR5 NM_003268 -0.891353432 0.003567363 
IL1R1 NM_000877 -0.892734652 0.025843516 
ICAM1 NM_000201 -0.896757871 0.008925009 
CXCL16 NM_001100812 -0.940704676 0.03079632 
SERPING1 NM_000062 -0.949968985 0.001410684 
SERPING1 NM_000062 -0.972915925 0.001892867 
SOX8 NM_014587 -0.997267448 0.00227453 
CEBPA NM_004364 -1.058895917 0.001630918 
PPAP2A NM_176895 -1.07111984 0.012809485 
IFI6 NM_022873 -1.140804558 0.027165255 
CD34 NM_001025109 -1.180240433 0.005824153 
CTSK NM_000396 -1.203166852 0.00218423 
CD14 NM_001174104 -1.268307047 0.011888954 
PDGFRL NM_006207 -1.290924312 0.020449063 
FGF9 NM_002010 -1.293298131 0.007176846 
C1R NM_001733 -1.325051515 0.011115066 
FIGF NM_004469 -1.333780281 0.006737687 
AHR NM_001621 -1.341253134 0.001930314 
AHR NM_001621 -1.342170198 0.004736242 
TNFAIP2 NM_006291 -1.433200695 0.000589664 
INHBB NM_002193 -1.500385674 0.007753531 
CD34 NM_001773 -1.516570755 0.005689158 
CXCL14 NM_004887 -1.648422153 0.008722197 
CCRL1 NM_178445 -1.750719297 0.018294532 
S100B NM_006272 -1.777244154 5.01E-06 
C3 NM_000064 -1.924817255 0.004225252 
TNFSF15 NM_005118 -2.024213571 0.00187624 
C3 NM_000064 -2.351077604 0.004972093 
CTSH NM_004390 -2.526888113 0.001738199 
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Table 82: Selected significantly differentially expressed genes between veRA and Norm fibroblasts in the unstimulated high 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
KRT19 NM_002276 2.047334531 9.18E-05 
MMP3 NM_002422 2.018429113 0.002682924 
KRT19P2 NR_036685 1.881864767 0.000594591 
HAS2 NM_005328 1.596286355 0.003797106 
HIST2H3A NM_001005464 1.435765945 0.01201747 
HS3ST3B1 ENST00000360954 1.239448628 0.001930996 
SERPINE1 NM_000602 1.21906278 0.003461711 
KRT16 NM_005557 1.210111808 0.001679199 
HMMR NM_012484 1.175656838 0.02122041 
ITGA10 NM_003637 1.132300721 0.021118066 
KRT14 NM_000526 1.115853709 0.014660786 
KRT16P2 NR_029392 1.093749498 0.01664042 
ADAMTS4 NM_005099 1.063785195 0.003594231 
HIST1H3B NM_003537 1.045823022 0.038294596 
FGF2 NM_002006 1.03740845 0.022634663 
CDH13 NM_001220491 1.010532539 0.012905526 
TNC NM_002160 1.000584288 0.045998211 
HIST1H3F NM_021018 0.993951307 0.021613185 
CDK1 NM_001786 0.991851284 0.026340432 
HIST1H4L NM_003546 0.972926646 0.012423182 
HIST1H3D NM_003530 0.95987386 0.024551792 
HIST1H3H NM_003536 0.954674799 0.015972925 
HIST1H4C NM_003542 0.931454641 0.011204044 
KRT14 NM_000526 0.926980337 0.027243403 
HIST1H4B NM_003544 0.825071508 0.026452876 
TGFB1 NM_000660 0.821645797 0.000341475 
MAPK13 NM_002754 0.781374991 0.048379629 
FGF1 NM_000800 0.773624931 0.022157629 
CTPS NM_001905 0.757814833 0.006000501 
CLEC11A NM_002975 0.723258585 0.04002402 
HIST1H2AI NM_003509 0.713470431 0.041634742 
VEGFC NM_005429 0.701183619 0.043125094 
ITGA3 NM_002204 0.662251123 0.034478237 
P4HA2 NM_004199 0.646702387 0.004840892 
LDHA NM_005566 0.616037173 0.01447501 
CTPS NM_001905 0.587062773 0.005438252 
HIF1A NM_181054 0.578991676 0.035596405 
FGF5 NM_004464 0.575226857 0.042759075 
WISP1 NM_080838 0.564518835 0.009437422 
HIST2H2BF NM_001161334 0.563320884 0.029707394 
MAPK13 NM_002754 0.557436504 0.049386941 
IFNE NM_176891 0.554626315 0.028756527 
CD3EAP NM_012099 0.542471002 0.002982706 
PLOD1 NM_000302 0.54233831 0.017096416 
JMJD6 NM_015167 0.542286385 0.001911257 
HIST1H3G NM_003534 0.538299535 0.044961252 
HIST1H2BE NM_003523 0.523776616 0.032503049 
HIST1H2AE NM_021052 0.507594767 0.03873044 
MIF NM_002415 0.502615719 0.005163134 
CASP3 NM_004346 0.499051318 0.018906721 
IFRD2 NM_006764 0.49354181 0.016302988 
HIST2H3D NM_001123375 0.490346494 0.025027181 
CSK NM_004383 0.462771477 0.003353746 
HIST1H3H NM_003536 0.459165769 0.030453607 
HIST1H2BB NM_021062 0.45710849 0.042255261 
HIST1H2BH NM_003524 0.438338033 0.026475862 
PLOD1 NM_000302 0.435667034 0.020979642 
TAGLN2 NM_003564 0.430912512 0.021734892 
S100P NM_005980 0.422233417 0.037521235 
ALDH4A1 NM_170726 0.421401854 0.007791741 
CDH15 NM_004933 0.418983324 0.032503049 
HIST1H2BO NM_003527 0.417071336 0.032515904 
TRAF4 NM_004295 0.416957802 0.009361588 
MAPKAP1 NM_001006618 0.416491784 0.028926409 
MAP4K2 NM_004579 0.412506598 0.004491357 
IGLL5 NM_001178126 0.409559577 0.00496458 
HIST1H2BD NM_021063 0.401755761 0.04695147 
STK24 NM_001032296 0.391736493 0.000707628 
STK24 NM_001032296 0.39101455 0.001046832 
ICAM3 NM_002162 0.390152147 0.009066335 
ITGA5 NM_002205 0.389728848 0.034837852 
MLF2 NM_005439 0.377715908 0.003746528 
COL17A1 NM_000494 0.377134984 0.022795194 
HS3ST3B1 NM_006041 0.364933101 0.048920256 
CSF1R NM_005211 0.356938191 0.048551731 
RUNX1 NM_001001890 0.350938765 0.004091494 
ILF3 NM_012218 0.341037712 0.047238055 
ISLR2 NM_020851 0.314674613 0.016374661 
H2AFY NM_138610 0.304963364 0.022817781 
SERBP1 NM_001018067 0.288756173 0.036318774 
COX8A NM_004074 0.28431829 0.004054495 
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ILF3 NM_004516 0.284173455 0.049348411 
DUS1L NM_022156 0.268757555 0.02948322 
DUS1L NM_022156 0.260774181 0.038509909 
COX5A NM_004255 0.254838794 0.027243403 
COX5A NM_004255 0.249911962 0.03586374 
COL5A1 ENST00000464187 0.242604379 0.034837852 
DUSP15 NM_080611 0.234375582 0.029126088 
COX10 NM_001303 0.226214478 0.041775149 
MMP25 NM_022468 0.225577746 0.025974129 
SDHA NM_004168 -0.200116024 0.049072951 
COQ5 NM_032314 -0.206182289 0.042962242 
MRFAP1L1 NM_203462 -0.22452493 0.043238224 
STK3 ENST00000424861 -0.230252571 0.022282778 
IL16 NM_001172128 -0.242451979 0.026269672 
IGBP1 NM_001551 -0.28424553 0.040104853 
KLRK1 NM_007360 -0.284318092 0.011190323 
S100A5 NM_002962 -0.290472249 0.026269672 
CD99L2 NM_031462 -0.293932377 0.013418062 
BCL9 NM_004326 -0.302344515 0.042211769 
CD81 NM_004356 -0.307622681 0.037735037 
CCR3 NM_001837 -0.325546109 0.000868697 
COL4A3BP NM_001130105 -0.326609765 0.020711014 
SERPING1 NM_000062 -0.32879833 0.009024133 
SDHD NM_003002 -0.336610595 0.007868495 
SOX13 NM_005686 -0.34695403 0.038493068 
FYB NM_001465 -0.349510876 0.046328841 
ADAMTS7 NM_014272 -0.35244595 0.022744046 
TP53 NM_000546 -0.354534845 0.002514867 
TANK NM_133484 -0.361739865 0.048192497 
HIF3A ENST00000457865 -0.377868653 0.015034889 
HSD17B7 NM_016371 -0.387229014 0.001063161 
EGFR NM_005228 -0.389757616 0.032745005 
CTSA NM_000308 -0.391707108 0.048943414 
IL6ST NM_002184 -0.399974798 0.0209413 
VEGFB NM_003377 -0.40106952 0.005735737 
IGBP1 NM_001551 -0.402519423 0.003609053 
ZFP36L1 ENST00000408913 -0.407906963 0.008003802 
COL4A3BP NM_001130105 -0.414123641 0.010951731 
NFKBIE NM_004556 -0.414599873 0.033579293 
FGF16 NM_003868 -0.414890297 0.018856271 
XLOC_l2_014830 THC2583825 -0.417530699 0.00346791 
ISLR NM_005545 -0.421685474 0.00341857 
ADAMTSL1 NM_001040272 -0.425575399 0.019444972 
TANK NM_004180 -0.439343404 0.002491602 
COQ10A NM_144576 -0.441387175 0.000891036 
IL34 NM_152456 -0.453073529 0.015331786 
IL6ST NM_001190981 -0.456696361 0.029539258 
CDKN1B NM_004064 -0.461736924 0.019090656 
IL6ST NM_001190981 -0.462416883 0.009485344 
CD79A NM_001783 -0.464203173 0.001292339 
TIMP2 NM_003255 -0.477737365 0.010710119 
HSD17B7 NM_016371 -0.484950352 0.000919765 
HAPLN2 NM_021817 -0.494981405 0.021532197 
NFKB1 NM_003998 -0.507172297 0.002018948 
IGSF10 NM_178822 -0.507461436 0.009946398 
FCGRT NM_004107 -0.508765009 0.00482355 
MMP19 NM_002429 -0.529848754 0.001046832 
ITM2B NM_021999 -0.53033219 0.032247889 
ADAMTSL4 NM_025008 -0.535020138 0.003198202 
HSD17B7 NM_016371 -0.537060039 0.00083748 
STAT5A NM_003152 -0.582817137 0.000167772 
HABP4 NM_014282 -0.597118367 0.016056846 
LY96 NM_015364 -0.601129637 0.025333527 
CD55 NM_000574 -0.603672573 0.031246006 
IL6ST NM_001190981 -0.615626577 0.004251092 
MBP NM_001025101 -0.638262753 0.006662972 
TNXB NM_019105 -0.640177949 0.031180623 
PDGFRB NM_002609 -0.649812111 0.034180186 
C1RL NM_016546 -0.653939924 0.036086863 
CDKN1B NM_004064 -0.66834713 0.001619918 
CSF1 NM_172212 -0.669320494 0.018308811 
ITM2B NM_021999 -0.671698527 0.00254402 
SERPINF1 NM_002615 -0.684649067 0.028926409 
MMP2 NM_004530 -0.689665736 0.003195805 
CD302 NM_014880 -0.7213299 0.003517454 
TNXB NM_019105 -0.733940787 0.031644171 
C1QTNF4 NM_031909 -0.736930586 0.003408916 
C1S NM_001734 -0.737708418 0.016302988 
ADAMTSL4 NM_025008 -0.747882775 0.008099988 
DUSP8 NM_004420 -0.749874147 0.000820339 
SERPING1 NM_000062 -0.752951532 0.009321448 
FGF9 NM_002010 -0.78992954 0.003777009 
TNXB NM_019105 -0.793983953 0.017047976 
TNXB NM_019105 -0.801587895 0.024431445 
IL1R1 NM_000877 -0.821758005 0.037521235 
SERPING1 NM_000062 -0.838574616 0.006268419 
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SOX8 NM_014587 -0.850123672 0.007868495 
PPAP2A NM_176895 -0.851090257 0.047366767 
TLR5 NM_003268 -0.878496644 0.003509155 
CARD6 NM_032587 -0.8990957 0.007444408 
CARD6 NM_032587 -0.909958278 0.006531218 
AHR NM_001621 -0.914099147 0.031844827 
IL17RD NM_017563 -0.926613824 0.001438242 
CEBPA NM_004364 -0.954942289 0.003777009 
TGFBR3 NM_003243 -1.023538968 0.006413539 
HS3ST1 NM_005114 -1.064625386 0.044932133 
CTSF NM_003793 -1.08076549 0.001046566 
COL14A1 NM_021110 -1.109826361 0.016821248 
MBP NM_001025100 -1.122017559 0.029049186 
CD14 NM_001174104 -1.155681702 0.02058822 
PDGFD NM_025208 -1.195125954 0.029539258 
PDGFRL NM_006207 -1.218453339 0.026277182 
C1R NM_001733 -1.226709758 0.017171372 
CDKN1C NM_000076 -1.233684271 0.033230212 
FIGF NM_004469 -1.27411166 0.008619174 
CTSK NM_000396 -1.296814752 0.001010483 
INHBB NM_002193 -1.366965237 0.013903843 
CXCL14 NM_004887 -1.377085922 0.026895624 
TNFAIP2 NM_006291 -1.438484749 0.000603516 
FGF9 NM_002010 -1.482823589 0.001968263 
CD34 NM_001025109 -1.509492961 0.000594591 
CD36 NM_001001547 -1.511082863 0.030167033 
S100B NM_006272 -1.546791482 6.34E-05 
CD34 NM_001773 -1.732455958 0.001544958 
C3 NM_000064 -1.879637878 0.004332559 
CCRL1 NM_178445 -1.990620448 0.006301474 
TNFSF15 NM_005118 -2.136303659 0.001046832 
C3 NM_000064 -2.282625996 0.005655134 
CTSH NM_004390 -2.446473497 0.002219418 
Table 83: Selected significantly differentially expressed genes between Res and Norm fibroblasts in the unstimulated high serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
8.8 Differentially expressed gene lists from the unstimulated low serum 
samples in the microarray experiments 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
ALDH3A2 NM_001031806 1.56734237 0.048275941 
SERPINE2 NM_006216 1.518726505 0.035960938 
TAGLN NM_001001522 1.509365466 0.03283886 
TAGLN NM_001001522 1.144203865 0.016734525 
ADH4 NM_000670 0.931777928 0.000333424 
POGZ ENST00000437847 0.560305661 0.00832172 
DUSP1 NM_004417 -1.384786331 0.03283886 
ADAM12 NM_003474 -1.802686277 0.035960938 
Table 84: Selected significantly differentially expressed genes between Jrep and estRA fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
INHBB NM_002193 1.90394431 0.006666342 
ALDH3A2 NM_000382 1.671966203 0.000335378 
ALDH3A2 NM_001031806 1.668092684 0.000566102 
MAPK10 NM_138980 1.290702139 0.001795459 
SERPINI1 NM_005025 1.25744147 0.008518211 
ALDH3A1 NM_001135168 1.244444239 2.07E-05 
TAGLN NM_001001522 1.229314657 0.007416524 
ALDH3A1 NM_000691 1.182079196 5.89E-05 
TAGLN NM_001001522 1.023381598 0.000872247 
IL16 NM_172217 1.005194553 0.00018112 
CDHR4 NM_001007540 0.918381004 0.004381714 
AHRR NM_020731 0.90801188 0.028035917 
IL16 NM_004513 0.907563497 0.002101519 
LTC4S NM_145867 0.864950958 0.012483713 
HLF NM_002126 0.86154971 0.023209213 
ADH4 NM_000670 0.859955388 7.87E-06 
COL9A3 NM_001853 0.848752473 0.049175173 
LSP1 NM_001013254 0.796417526 0.026762295 
LGI1 NM_005097 0.680432554 0.025462939 
XIST NR_001564 0.668653494 0.026486061 
XIST NR_001564 0.661652254 0.037733154 
POGZ ENST00000437847 0.657705393 1.96E-06 
XIST NR_001564 0.648945231 0.042781295 
RIIAD1 NM_001144956 0.612153773 0.018610847 
COX11 AK124809 0.557628502 0.000422741 
SERPINB1 NM_030666 0.510784758 0.010789715 
VWF NM_000552 0.42235587 0.023796776 
HDAC6 NM_006044 0.372579294 0.044060068 
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IL6R NM_001206866 0.347316626 0.023476767 
ZFAT ENST00000522974 0.29003749 0.02427553 
MMP11 NM_005940 -0.417029515 0.020020696 
COL4A3BP NM_001130105 -0.463290217 0.009827908 
MAPK12 NM_002969 -0.533152425 0.028569609 
JMJD6 NM_015167 -0.542083821 0.014564147 
CD276 NM_001024736 -0.554900142 0.047739687 
MAPK6 NM_002748 -0.562005639 0.001198541 
IGSF3 NM_001542 -0.573560847 0.031925704 
IER5 NM_016545 -0.58613413 0.027115432 
ADAMTS6 NM_197941 -0.59629777 0.040630281 
ADAMTS6 NM_197941 -0.602396967 0.029530116 
COQ10B NM_025147 -0.616508358 0.005054796 
IL1R2 NM_004633 -0.621442493 0.034813872 
TGFB1 NM_000660 -0.625815216 0.029621744 
CD276 NM_001024736 -0.632529072 0.009827908 
IRAK1 NM_001569 -0.640863242 0.003423184 
CTSA NM_001127695 -0.640935118 0.029455012 
IRAK1 NM_001569 -0.713782767 0.00205189 
BCL2 NM_000633 -0.722730239 0.043102922 
CD164 NM_006016 -0.778736748 0.006532227 
SOX30 NM_007017 -0.798928899 0.040723891 
MAPK6 NM_002748 -0.810530257 1.13E-05 
ZFP36 NM_003407 -0.838247894 0.045239978 
DUSP14 NM_007026 -0.861332572 0.002840002 
JUN NM_002228 -0.963175308 0.015370867 
DUSP2 NM_004418 -1.14916995 0.01162803 
ATF3 NM_001674 -1.160016517 0.006931131 
COL4A1 NM_001845 -1.190971414 0.033859171 
BMP2 NM_001200 -1.22242828 0.016829038 
DUSP5 NM_004419 -1.225991169 0.026063976 
FAP NM_004460 -1.288443373 0.017241072 
CXCL2 NM_002089 -1.32356235 0.038394835 
ATF3 NM_001040619 -1.394853971 0.002176527 
ADAM12 NM_003474 -1.487703792 0.007650797 
MME NM_007289 -1.495042886 0.030286342 
FOS NM_005252 -1.573048744 0.016549859 
COL4A2 NM_001846 -1.625229126 0.002522366 
DUSP1 NM_004417 -1.657100399 2.65E-05 
EGR1 NM_001964 -1.785919272 0.000566102 
MME NM_007289 -1.794213622 0.020861032 
MYC NM_002467 -1.851574417 2.13E-05 
MME NM_007289 -1.862144536 0.011009178 
IER3 NM_003897 -1.992504148 0.00018112 
EGR2 NM_000399 -2.070960425 0.011044416 
NFKBIZ NM_031419 -2.087211603 1.96E-06 
ATF3 NM_001040619 -2.105046969 0.001378265 
PTGS2 NM_000963 -2.176271809 0.01369418 
IER3 NM_003897 -2.220127414 0.000268428 
FOSB NM_006732 -2.293312419 0.000883401 
CXCL2 NM_002089 -2.781839154 0.003423184 
Table 85: Selected significantly differentially expressed genes between Jrep and veRA fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
INHBB NM_002193 2.096671364 0.002199433 
ALDH3A2 NM_000382 1.503319809 0.001468246 
ALDH3A2 NM_001031806 1.437083617 0.003853169 
SERPINE2 NM_006216 1.155894026 0.01623734 
ALDH3A1 NM_001135168 1.073366064 0.000312449 
ALDH3A1 NM_000691 1.056700458 0.000364906 
SERPINI1 NM_005025 1.007642761 0.046083117 
IL16 NM_172217 1.005578304 0.000180079 
AHRR NM_020731 1.001762444 0.012911774 
IL16 NM_004513 0.981158369 0.000635411 
ADH4 NM_000670 0.919956556 4.15E-07 
IGFBP3 NM_001013398 0.821850406 0.047262991 
LTC4S NM_145867 0.81309832 0.020243105 
CDHR4 NM_001007540 0.757335654 0.024679147 
TAGLN NM_001001522 0.670268733 0.049401089 
POGZ ENST00000437847 0.619511706 4.16E-06 
COL4A5 NM_033380 0.57076289 0.044118034 
COX11 AK124809 0.398680844 0.019004971 
ZFAT ENST00000522974 0.314426909 0.01249894 
MMP11 NM_005940 -0.374635966 0.044859807 
COL4A3BP NM_001130105 -0.380877033 0.044118034 
IRAK1 NM_001569 -0.522970408 0.02300501 
MAPK6 NM_002748 -0.584066683 0.002199433 
IRAK1 NM_001569 -0.624373215 0.008332486 
DUSP14 NM_007026 -0.696513766 0.021396681 
CTSA NM_001127695 -0.789372428 0.00498065 
BCL2 NM_000633 -0.819288785 0.018898426 
JUN NM_002228 -0.904927545 0.025218145 
ICAM1 NM_000201 -1.031154979 0.018278848 
DUSP1 NM_004417 -1.084599717 0.010032025 
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EGR1 NM_001964 -1.265911753 0.023505824 
MYC NM_002467 -1.318129973 0.003995484 
NFKBIZ NM_031419 -1.384646922 0.002208265 
COL4A2 NM_001846 -1.400173682 0.010779314 
ATF3 NM_001040619 -1.468767449 0.042035215 
FIGF NM_004469 -1.550350067 0.01167747 
CXCL2 NM_002089 -2.168425817 0.032607725 
Table 86: Selected significantly differentially expressed genes between Jrep and Res fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
TAGLN NM_001001522 2.333200054 1.61E-07 
COL8A1 NM_001850 2.141182109 0.024460067 
SERPINE2 NM_006216 1.979583476 3.05E-05 
ITGA10 NM_003637 1.913507668 0.003300872 
TAGLN NM_001001522 1.898278629 8.73E-10 
CDH13 NM_001257 1.847248441 0.020467002 
MAPK10 NM_138980 1.2021 0.007960021 
LTC4S NM_145867 1.187771969 0.000645619 
AHRR NM_020731 1.187288697 0.005223668 
IGFBP3 NM_001013398 1.168547262 0.004381821 
SERPINI1 NM_005025 1.163722257 0.028179184 
ADAMTS4 NM_005099 1.136163009 0.026015709 
CDH11 NM_001797 1.023945909 0.032692945 
MAP3K5 NM_005923 0.968565045 0.04589645 
PDGFC NM_016205 0.942501786 0.040728128 
IL16 NM_004513 0.928901763 0.003536073 
ITGA4 NM_000885 0.901742066 0.036154693 
ALDH3A1 NM_000691 0.887078725 0.007796841 
IL16 NM_172217 0.885027284 0.002854544 
COL6A1 NM_001848 0.878440109 0.001287536 
ALDH3A1 NM_001135168 0.812243282 0.017057309 
ADH4 NM_000670 0.771661992 0.000171219 
IL1RAP NM_002182 0.761741345 0.026744124 
MAP3K5 NM_005923 0.752732322 0.033895809 
PDGFA NM_002607 0.667950681 0.040368113 
SYNGR1 NM_145731 0.640880551 0.047361325 
POGZ ENST00000437847 0.619747607 3.05E-05 
IL1RAP NM_134470 0.573344482 0.036628258 
IRF2BPL NM_024496 0.571998076 0.006555971 
COX11 AK124809 0.452435564 0.011407861 
ZFAT ENST00000522974 0.3416579 0.011528001 
DUSP16 NM_030640 -0.370878056 0.033895809 
COL4A3BP NM_001130105 -0.447453797 0.022680341 
VEGFB NM_003377 -0.549880171 0.00445237 
CTSA NM_000308 -0.602683271 0.030324267 
ZAK NM_016653 -0.614034768 0.00258847 
CD44 NM_000610 -0.629713508 0.014048041 
MAPK6 NM_002748 -0.638264518 0.001648396 
CTSA NM_001127695 -0.665559861 0.039699706 
ZAK NM_016653 -0.753596567 0.002672441 
MMP2 NM_004530 -0.763734165 0.016565824 
DUSP8 NM_004420 -0.777123232 0.007893328 
IRAK1 NM_001569 -0.831310285 0.000607322 
IRAK1 NM_001569 -0.842629288 0.000182746 
SOX30 NM_007017 -0.87162515 0.038962645 
DUSP14 NM_007026 -0.896146625 0.00373103 
BCL2 NM_000657 -0.961378995 0.001569513 
NFKBIZ NM_031419 -1.06375703 0.044196282 
BCL2 NM_000633 -1.248076917 0.000309651 
CTSK NM_000396 -1.264099578 0.017107967 
EGR1 NM_001964 -1.401876999 0.017858101 
CCL18 NM_002988 -1.461682047 0.006348621 
CILP NM_003613 -1.599474994 0.048854546 
CTSH NM_004390 -3.226650996 0.001838196 
FIGF NM_004469 -3.314412236 2.91E-08 
Table 87: Selected significantly differentially expressed genes between Jrep and Norm fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
LGI1 NM_005097 -1.096769962 0.018868119 
FIGF NM_004469 -2.735315848 0.000308702 
Table 88: Selected significantly differentially expressed genes between estRA and Norm fibroblasts in the unstimulated low 
serum treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
RIIAD1 NM_001144956 -0.72606679 0.023453095 
Table 89: Selected significantly differentially expressed genes between veRA and Res fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
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HGNC symbol Database ID Log2 fold-change Adjusted P Value 
PTGS2 NM_000963 2.30601602 0.012021238 
IL6 NM_000600 2.238818238 0.021768154 
ITGA10 NM_003637 1.915065416 0.003775361 
ID1 NM_002165 1.674500883 0.007348784 
LIF NM_002309 1.485265582 0.045249235 
SERPINE1 NM_000602 1.434020996 0.009224673 
IER3 NM_003897 1.427687886 0.045849919 
ADAMTS4 NM_005099 1.32955867 0.005912306 
TNFRSF12A NM_016639 1.169537578 0.005296758 
CDH11 NM_001797 1.147989536 0.010721839 
HS3ST3B1 ENST00000360954 1.14074101 0.038958069 
SERPINE2 NM_006216 1.133342825 0.028412968 
MYC NM_002467 1.128207399 0.026733655 
TAGLN NM_001001522 1.103885397 0.027851664 
NFKBIZ NM_031419 1.023454573 0.049322907 
HIF1A NM_181054 0.983023676 0.010987424 
TAGLN NM_001001522 0.874897031 0.009224673 
RUNX1 NM_001122607 0.746054464 0.044119169 
SMAD7 NM_005904 0.721509262 0.034542581 
CD164 NM_006016 0.659625523 0.036785184 
CLEC2D NM_001004419 0.535847596 0.022791438 
CLEC2D NM_001004419 0.524617779 0.033749409 
JMJD6 NM_015167 0.516459498 0.031491725 
COQ10B NM_025147 0.478153868 0.034542581 
VEGFB NM_003377 -0.426106709 0.034542581 
HLA-A NM_002116 -0.581916574 0.041671712 
DUSP8 NM_004420 -0.641171448 0.034473059 
HLA-A NM_002116 -0.70743281 0.02710327 
HLA-G NM_002127 -0.710891751 0.011590118 
SMAD3 NM_005902 -0.741503221 0.040597208 
IL17RD NM_017563 -0.855038006 0.032366949 
TLR5 NM_003268 -0.863934157 0.038958069 
LGI1 NM_005097 -1.031103743 0.000836877 
CD34 NM_001025109 -1.244265529 0.034500725 
FGF9 NM_002010 -1.396302674 0.034542581 
INHBB NM_002193 -1.549186416 0.048633353 
CD34 NM_001773 -1.70662611 0.020924614 
FIGF NM_004469 -2.137874139 0.000836877 
C3 NM_000064 -2.341739161 0.043160544 
CTSH NM_004390 -2.646091674 0.012521152 
Table 90: Selected significantly differentially expressed genes between veRA and Norm fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
 
HGNC symbol Database ID Log2 fold-change Adjusted P Value 
TAGLN NM_001001522 1.482312554 0.002273658 
TAGLN NM_001001522 1.228009896 2.43E-05 
CDH11 NM_001797 1.13999156 0.031375864 
LGI1 NM_005097 -0.907878903 0.006115137 
INHBB NM_002193 -1.741913471 0.049320232 
FIGF NM_004469 -1.76406217 0.010757188 
Table 91: Selected significantly differentially expressed genes between Res and Norm fibroblasts in the unstimulated low serum 
treatment group sorted by log2 fold change. P values adjusted using the Benjamini-Hochberg method. 
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